ࡱ> Z\QRSTUVWXY^_`abcdef~ y bjbj 3{{v DDd```"`(!X(V7(~7~77DB~d       $#& VD|D DD~77 """ D<~77 " "" |7 ƮRb  0(!('('('?T"  ֵL(!(' : Contents  HYPERLINK \l "gastrointestinal" 1. Gastro-intestinal system  HYPERLINK \l "antacids" Antacids  HYPERLINK \l "antispasmodics" Antispasmodics  HYPERLINK \l "motility" Motility stimulants  HYPERLINK \l "ulcer" Ulcer healing drugs  HYPERLINK \l "h2" H2 antagonists  HYPERLINK \l "proton" Proton pump inhibitors  HYPERLINK \l "antidiarrhoeals" Antidiarrhoeals  HYPERLINK \l "chronicbowel" Chronic Bowel Disorders  HYPERLINK \l "laxatives" Laxatives  HYPERLINK \l "bulkforming" Bulk forming  HYPERLINK \l "stimulant" Stimulant  HYPERLINK \l "faecal" Faecal softeners  HYPERLINK \l "osmotic" Osmotic laxatives  HYPERLINK \l "bowelcleansing" Bowel cleansing solutions  HYPERLINK \l "laxativepolicy" Laxative policy  HYPERLINK \l "managementimpacted"  Management of impacted faeces  HYPERLINK \l "haemorrhoid" Haemorrhoid preparations  HYPERLINK \l "intestinal" Intestinal secretions HYPERLINK \l "_CARDIOVASCULAR_SYSTEM"2. Cardiovascular System  HYPERLINK \l "positiveinotropes" Positive inotropes  HYPERLINK \l "dieuretics" Diuretics  HYPERLINK \l "thiazides" Thiazides  HYPERLINK \l "loopdieuretics" Loop diuretics  HYPERLINK \l "potassiumsparing" Potassium sparing diuretics  HYPERLINK \l "combinationdieuretics" Combination diuretics  HYPERLINK \l "osmoticdieuretics" Osmotic diuretics  HYPERLINK \l "antiarrhythmics" Anti-arrhythmics  HYPERLINK \l "betablockers" Beta-blockers  HYPERLINK \l "drugsaffectingrenin" Drugs affecting the renin-angiotensin system and other antihypertensives HYPERLINK \l "vasodilator"Vasodilator antihypertensives  HYPERLINK \l "centrallyacting" Centrally acting antihypertensives  HYPERLINK \l "alphablockers" Alpha-blockers  HYPERLINK \l "angiotensin" ACE inhibitors  HYPERLINK \l "antiotensinII" Angiotensin II receptor antagonists  HYPERLINK \l "nitrates" Nitrates  HYPERLINK \l "calciumchannelblockers" Calcium channel blockers HYPERLINK \l "Ivabradine"Ivabradine  HYPERLINK \l "potassiumchannel" Potassium channel activators  HYPERLINK \l "sympathomimetics" Sympathomimetics  HYPERLINK \l "anticoagulants" Anticoagulants HYPERLINK \l "antiplateletdrugs"Antiplatelet drugs HYPERLINK \l "clopidogrelprescribing"Clopidogrel prescribing guidelines HYPERLINK \l "Fibrinolyticdrugs"Fibrinolytic drugs HYPERLINK \l "Antifibrinolyticdrugs"Antifibrinolytic drugs  HYPERLINK \l "lipidlowering" Lipid lowering drugs HYPERLINK \l "Anionexchange"Anion-exchange resins HYPERLINK \l "Fibrates"Fibrates HYPERLINK \l "Statins"Statins HYPERLINK \l "Guidelinesforstatins"Guidelines for prescribing cholesterol lowering agents HYPERLINK \l "fishoils"Fish oils HYPERLINK \l "otheragents"Other agents  HYPERLINK \l "respiratorysystem" 3. Respiratory System  HYPERLINK \l "bronchodilators" Bronchodilators  HYPERLINK \l "selectivebeta2" Selective Beta2 agonist HYPERLINK \l "antimuscarinics2"antimuscarinics2  HYPERLINK \l "Theophylline" Theophylline  HYPERLINK \l "combinationbronchodilators" Combination bronchodilators  HYPERLINK \l "inhalerdevices" Inhaler devices  HYPERLINK \l "inhaledcorticosteroids" Inhaled Corticosteroids HYPERLINK \l "Leukotriencereceptor"Leukotriene receptor antagonists HYPERLINK \l "managementacuteasthma2"Management of acute severe asthma in adults HYPERLINK \l "managementofcopd"Management of COPD:pharmacological therapy of stable COPD and Hospital management of severe exacerbations of COPD  HYPERLINK \l "solutionsnebulisation" Solutions for nebulisation  HYPERLINK \l "antihistamines2" Antihistamines   HYPERLINK \l "respiratorystimulants" Respiratory stimulants  HYPERLINK \l "oxygen" Oxygen  HYPERLINK \l "mucolytics" Mucolytics  HYPERLINK \l "aromaticinhalations" Aromatic Inhalations  HYPERLINK \l "coughpreparations" Cough preparations  HYPERLINK \l "centralnervoussystem" 4. Central Nervous System  HYPERLINK \l "hypnotics" Hypnotics and anxiolytics  HYPERLINK \l "drugspsychoses" Drugs used in psychoses  HYPERLINK \l "antidepressants" Antidepressant drugs  HYPERLINK \l "nauseavertigo" Nausea and vertigo  HYPERLINK \l "algorithmnausea" Algorithm for the management of post-operative nausea and  HYPERLINK \l "algorithmnausea" vomiting  HYPERLINK \l "analgesics" Analgesics  HYPERLINK \l "Painladder" Pain Ladder Please refer to before prescribing.  HYPERLINK \l "nonopoid" Non-opioid analgesics  HYPERLINK \l "opoid" Opioid analgesics HYPERLINK \l "prophylaxismigraine"Prophylaxis of migraine  HYPERLINK \l "antiepileptics" Antiepileptics   HYPERLINK \l "parkinsonism" Parkinsonism and related disorders  HYPERLINK \l "dopaminergics" Dopaminergics  HYPERLINK \l "antimuscarinics" Antimuscarinics  HYPERLINK \l "reliefhiccup" Relief of intractable hiccup  HYPERLINK \l "drugssubstancedependence" Drugs used in substance dependence  HYPERLINK \l "managenentalcohol" Management of alcohol withdrawal  HYPERLINK \l "infections" 5. Infections -  HYPERLINK "http://ctcnt20/policy/81/Antimicrobial%20Current%20February%202010.pdf" Refer to Antimicrobial Policy   HYPERLINK \l "endocrine" 6. Endocrine system  HYPERLINK \l "drugsdiabetes" Drugs used in diabetes  HYPERLINK \l "insulins" Insulins  HYPERLINK \l "oralantibiotic" Oral antidiabetic drugs -  HYPERLINK \l "hypoglycaemia" Hypoglycaemia  HYPERLINK \l "thyroid" Thyroid and antithyroid drugs  HYPERLINK \l "corticosteroids2" Corticosteroids  HYPERLINK \l "pituitaryhormones" Pituitary hormones  HYPERLINK \l "drugsbone" Drugs affecting bone metabolism  HYPERLINK \l "urinarytract" 7. Urinary tract disorders  HYPERLINK \l "vaginalantiinfective" Vaginal anti-infective drugs  HYPERLINK \l "genitourinary" Genito-urinary disorders  HYPERLINK \l "malignantdiseaseimmunosuppression" 8. Malignant disease and immunosupression  HYPERLINK \l "cytotoxic" Cytotoxic drugs  HYPERLINK \l "immunosuppressants" Immunosupressants  HYPERLINK \l "sexhormones" Sex hormones and hormone antagonists  HYPERLINK \l "nutritionblood" 9. Nutrition and blood  HYPERLINK \l "anaemias" Anaemias  HYPERLINK \l "fluidselectrolyes" Fluids and electrolytes  HYPERLINK \l "intravenousnutrition" Intravenous nutrition  HYPERLINK \l "enteralnutrition" Enteral nutrition  HYPERLINK \l "minerals" Minerals  HYPERLINK \l "vitamins" Vitamins  HYPERLINK \l "musculoskeletal" 10. Musculoskeletal and joint diseases  HYPERLINK \l "drugsrheumatic" Drugs used in rheumatic diseases and gout  HYPERLINK \l "nsaids" NSAIDS  HYPERLINK \l "corticosteroidinjections" Corticosteroid injections  HYPERLINK \l "drugsgout" Drugs used in gout  HYPERLINK \l "neuromusculardisorders" Neuromuscular disorders  HYPERLINK \l "drugsenhanceneuromuscular" Drugs which enhance neuromuscular transmission  HYPERLINK \l "skeletelmusclerelaxants" Skeletal muscle relaxants  HYPERLINK \l "nocturnallegcramps" Nocturnal leg cramps  HYPERLINK \l "topicalantirheumatics" Topical antirheumatics  HYPERLINK \l "drugsactingeye" 11. Drugs acting on the eye  HYPERLINK \l "antiinfective" Anti-infective preparations  HYPERLINK \l "corticosteroids3" Corticosteroids  HYPERLINK \l "mydriatics" Mydriatics  HYPERLINK \l "glaucoma" Treatment of glaucoma  HYPERLINK \l "misc" Miscellaneous  HYPERLINK \l "teardeficiency" Tear deficiency  HYPERLINK \l "earnose" 12. Ear, nose and oropharynx  HYPERLINK \l "drugsear" Drugs acting on the ear  HYPERLINK \l "antiinflam" Anti-inflammatory and anti-infective preparations  HYPERLINK \l "removalwax" Removal of ear wax  HYPERLINK \l "drugsnose" Drugs acting on the nose  HYPERLINK \l "nasalallergu" Nasal allergy  HYPERLINK \l "nasalstaphy" Nasal staphylococci  HYPERLINK \l "drigsoropharynx" Drugs acting on the oropharynx  HYPERLINK \l "ulceration" Ulceration and inflammation  HYPERLINK \l "fungalinfections" Fungal infections  HYPERLINK \l "oralhygiene" Oral hygiene  HYPERLINK \l "drymouth" Dry mouth  HYPERLINK \l "skin" 13. Skin  HYPERLINK \l "emollient" Emollient and barrier preparations  HYPERLINK \l "topicalantipruritics" Topical antipruritics  HYPERLINK \l "topicalcorticosteroids" Topical corticosteroids  HYPERLINK \l "sunscreens" Sunscreens  HYPERLINK \l "scalp" Scalp preparations  HYPERLINK \l "antiinfectiveskin" Anti-infective skin preparations  HYPERLINK \l "antibacterials" Antibacterials  HYPERLINK \l "antifungals2" Antifungals  HYPERLINK \l "antivirals2" Antivirals  HYPERLINK \l "scableslice" Scabies and lice  HYPERLINK \l "disinfectants" Disinfectants and cleansers  HYPERLINK \l "woundmanagement" Wound management HYPERLINK \l "_14._IMMUNOLOGICAL_PRODUCTS_AND VACC"14. Immunological products and vaccines   HYPERLINK \l "_15._ANAESTHESIA" 15. Anaesthesia  HYPERLINK \l "intravenousanaesthesia" Intravenous anaesthesia  HYPERLINK \l "inhalationalanaesthesia" Inhalation anaesthesia   HYPERLINK \l "antimuscarinics2" Antimuscarinics  HYPERLINK \l "sedative" Sedative and analgesic peri-operative drugs  HYPERLINK \l "anxiolytics" Anxiolytics and neuroleptics   HYPERLINK \l "nonopoidanalgesics" Non-opioid analgesics  HYPERLINK \l "opoidanalgesics" Opioid analgesics  HYPERLINK \l "musclerelaxants" Muscle relaxants  HYPERLINK \l "anticholinesterases" Anticholinesterases  HYPERLINK \l "antanonists" Antagonists for central and respiratory depression  HYPERLINK \l "malignanthyperthermia" Malignant hyperthermia  HYPERLINK \l "localanaesthetics" Local anaesthetics Appendix 8. Wound management refer to HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/library/departments/support_services/pharmacy/woundcareformulary/wound%20dressing%20formulary%20july%202011.xls"Wound formulary 1. GASTRO-INTESTINAL SYSTEM Antacids Magnesium trisilicate mixture Gaviscon Antispasmodics Mebeverine Hyoscine butylbromide Peppermint water Motility stimulants Metoclopramide (Maximum of 5 days treatment only as per  HYPERLINK "http://www.mhra.gov.uk/PrintPreview/DSUArticlePage/CON300404?DynamicListQuery=dDocType%20%3cmatches%3e%20%60Publication%60%20%20%3cAND%3e%20%20xSecondLevel%20%3cmatches%3e%20%60Safety%20Guidance%60%20%20%3cAND%3e%20%20xThirdLevel%20%3cmatches%3e%20%60Medicines%60%20%20%3cAND%3e%20%20xFourthLevel%20%3cmatches%3e%20%60Drug%20Safety%20Update%60%20%3cand%3e%20%20xNHSNetOnly%20%3cmatches%3e%20%60No%60" MHRA restrictions) Domperidone ( HYPERLINK "https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=101896" Restricted to Cystic Fibrosis and Palliative Care use only) Erythromycin (unlicensed indication. IV and oral) Ulcer healing drugs H2 antagonists Ranitidine Proton pump inhibitors Lansoprazole (see below for dosing and duration of therapy) IndicationDose of LansoprazoleDuration of TherapySurgical prophylaxis30mg daily (unlicensed indication)4 weeksNSAID GI prophylaxis30mg daily (unlicensed indication)  HYPERLINK "http://www.npc.nhs.uk/merec/pain/musculo/merec_extra_no30.php#GIR" http://www.npc.nhs.uk/merec/pain/musculo/merec_extra_no30.php#GIR Duration of NSAID therapyBenign gastric ulcer30mg daily8 weeksDuodenal ulcer30mg daily for 4 weeks then 15mg maintenance therapyContinuous (15mg daily)GORD30mg daily for 4 weeks, continued for a further 4 weeks if not fully healed then maintenance dose of 15-30mg dailyContinuousNSAID associated duodenal or gastric ulcerAs for GORD aboveContinuousZollinger-Ellison syndrome60mg daily adjusted according to response (up to 120 mg in divided doses).ContinuousEradication of H PyloriConsult antimicrobial guidelines1 weekCough associated with GORD15-30mg twice a day before meals (unlicensed dose)  HYPERLINK "http://www.brit-thoracic.org.uk/Portals/0/Guidelines/Cough/Guidelines/coughguidelinesaugust06.pdf" http://www.brit-thoracic.org.uk/Portals/0/Guidelines/Cough/Guidelines/coughguidelinesaugust06.pdf 8 weeks and then review Omeprazole (IV only) for use Where IV therapy is required at a dose of 40mg daily Prophylaxis of acid aspiration during general anaesthesia at a dose of 40mg on the evening before surgery then 40mg 2-6 hours before surgery. Dose should be converted to oral lansoprazole if therapy at earliest opportunity if treatment is to continue Discharge prescriptions MUST state duration of therapy for Proton Pump inhibitors. Consideration should be given to the possible long term side effects of proton pump inhibitors including hypomagnesaemia HYPERLINK "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON149774" http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON149774 and hip fracture risk  HYPERLINK "http://www.bmj.com/content/344/bmj.e372.pdf%2Bhtml" http://www.bmj.com/content/344/bmj.e372.pdf%2Bhtml. Antidiarrhoeals Codeine Phosphate Loperamide Chronic bowel disorders Consult gastroenterologist Laxatives Bulk forming Fybogel Stimulant Senna Glycerine suppositories Docusate sodium Dantron (present in co-danthramer capsules and suspension) Terminal care only. Faecal softeners Arachis oil enema Osmotic laxatives Lactulose Gastrografin (CF use only unlicensed) Macrogol 3350 sachets Sodium Citrate enema Phosphate enema Bowel cleansing solutions Klean Prep Picolax 5HT4 Receptor Agonists Prucalopride 2mg tablets for use in chronic constipation in CF unresponsive to other treatments. (For CF consultant use only).  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13284/52078/52078.pdf" NICE TA211 Chronic constipation in women  Laxative Guidelines Surgical Treatment/Prophylaxis in patients on opioids: Senna 15mg at night Lactulose 15ml bd initially and adjusted according to response Consider changing lactulose to Macrogol 3350 One sachet bd where lactulose is ineffective or a more rapid response is required Other points to consider Consider increasing fluid intake and mobility and reviewing other potentially constipating medication (e.g. NSAIDs) in all cases where possible. All laxatives are contraindicated in bowel obstruction. Lactulose may take up to 48 hours to have an effect and is therefore not suitable for prn administration or short term use. Distal Intestinal Obstruction Syndrome in CF (See policy - Nursing a patient with DIOS in CF) Initially give oral Gastrografin 100ml prn up to 500ml (unlicensed) with adequate fluid intake (1 litre of fluid is recommended per 100ml dose) If this fails to resolve blockage then commence Klean-Prep - one sachet in 1 litre of water every hour orally or via naso-gastric/PEG tube until blockage has resolved (unlicensed) plus Metoclopramide IV 10mg tds. Consider IV paracetamol 1g qds for pain relief (avoid opioid analgesia) Haemorrhoid preparations Anusol (suppositories or cream) Intestinal secretions Ursodeoxycholic acid Creon Pancrease CARDIOVASCULAR SYSTEM Positive inotropes Digoxin Enoximone Diuretics Thiazides Indapamide Chlortalidone Bendroflumethiazide Metolazone (unlicensed). Consider using bendroflumethiazide instead. Patients requiring metoloazone for discharge will need to obtain on going supplies from LHCH pharmacy (typically as an outpatient) Loop diuretics Furosemide Bumetanide Potassium sparing diuretics Amiloride Aldosterone antagonists/Mineralocorticoid receptor antagonists (MRA) Spironolactone Eplerenone Consultant use only for: Patients intolerant of spironolactone in heart failure NYHA II and LVEF less than 30% or Heart failure post MI with LVEF less than 40% Combination diuretics Co-amilofruse Osmotic diuretics Mannitol Anti-arrhythmics Adenosine Amiodarone Disopyramide Flecainide Lidocaine Mexiletine (unlicensed use) Propafenone Quinidine (unlicensed use) Verapamil Dronedarone (  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13115/50469/50469.pdf" Dronedarone for the treatment of non-permanent atrial fibrillation NICE TA197 Beta blockers IndicationPreferred drugOther optionsSecondary prevention after myocardial infarctionbisoprololpropanolol, metoprolol Anginabisoprololatenolol, metoprolol, propanololHypertension (uncomplicated)Not indicated for first line use. In combination therapy: atenolol, bisoprolol, propanolol. For intravenous treatment after aortic dissection use labetolol Heart failurebisoprololcarvedilol, metoprolol, nebivololTreatment of SVTmetoprololesmololProphylaxis of SVTmetoprololpropanolol, bisoprolol (unlicensed indication), atenolol, sotalol (seek consultant advice) Life-threatening arrhythmias/ Recurrent ICD shocksBisoprolol (unlicensed indication)Esmolol (unlicensed indication)Prophylaxis of AF post CABG bisoprololTreatment of AF post CABGAmiodarone 1st line (this should be reviewed at OPD and if patient still in AF consider alternative treatment options due to adverse side effect profile) Sotalol 80mg BD See also  HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Heart%20Failure%20Guideline%20Current%20March%202009.pdf" Chronic Heart Failure guidelines on Trust Intranet Drugs affecting the renin-angiotensin system and other antihypertensives Vasodilator antihypertensives Sodium nitroprusside Hydralazine Diazoxide Sildenafil Patients with pulmonary arterial hypertension should normally be referred to the regional specialist centre (Sheffield). Any intention to treat a patient locally should be discussed with the chief pharmacist/cardiology pharmacist. This drug is outside of tariff and therefore agreement for recharge must be obtained from the relevant CCG before prescribing. Centrally acting antihypertensives Methyldopa Moxonidine Alpha blockers Doxazosin Phentolamine Phenoxybenzamine Angiotensin Converting Enzyme (ACE) inhibitors Ramipril Perindopril Angiotensin II receptor antagonists IndicationPreferred DrugOther DrugsHypertensionTelmisartanLosartan , CandesartanLeft Ventricular dysfunction (when ACE-inhibitor not tolerated because of cough)CandesartanLeft Ventricular Function ( in addition to ACE-inhibitor)*Candesartan (Seek consultant advice) *Recent ESC guidance suggests mineralocorticoid receptor antagonist (MRA) should be added to an ACE-inhibitor not an angiotensin II receptor antagonist (ARA). Dual use of ACEi/ARA should be reserved for patients intolerant to MRAs. Renin Inhibitors Aliskiren (Treatment of essential hypertension as a 3 or 4th line agent) Nitrates Isosorbide mononitrate (10mg tabs, 20mg tabs, 60mg slow release preparations only) Glyceryl trinitrate (Buccal preparation is unlicensed) 2.6.2 Calcium channel blockers Amlodipine Diltiazem (as Tildiem LA capsules) Verapamil 2.6.3 Ivabradine). Antianginal- for the treatment of stable angina pectoris for patients in sinus rhythm who have contraindication or intolerance of beta blockers Heart failure  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13970/61620/61620.pdf" (Ivabradine for treating chronic heart failure NICE TA267) 2.6.3 Other anti-anginal drugs Nicorandil Ranolazine (consultant use only for the treatment of stable angina pectoris) Sympathomimetics Adrenaline Dobutamine Dopamine Dopexamine (Consultant anaesthetists only) Isoprenaline (unlicensed use) Noradrenaline Phenylephrine Anticoagulants (oral) HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Anticoagulation%20Policy%20Version%205%200%20Mar%202013.pdf"See Anticoagulation Policy and  HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/EP%20Anticoagulation%20Guidelines%20Mar%202013.pdf" EP anticoagulation policy Warfarin Acenocoumarol Phenindione Dabigatran ( HYPERLINK "http://www.nice.org.uk/nicemedia/live/13677/58470/58470.pdf" Dabigatran etexilate for stroke prevention in atrial fibrillation NICE TA249) Rivaroxaban ( HYPERLINK "http://www.nice.org.uk/nicemedia/live/13746/59295/59295.pdf" Rivaroxaban for stroke prevention in atrial fibrillation NICE TA256) ( HYPERLINK "http://www.nice.org.uk/nicemedia/live/13805/60040/60040.pdf" Rivaroxaban for treatment and prevention of venous thromboembolism NICE TA261) Apixaban ( HYPERLINK "http://www.nice.org.uk/nicemedia/live/14086/62874/62874.pdf" Apixaban for stroke prevention in atrial fibrillation NICE TA275) 2.8.1 Anticoagulants (parenteral) HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Anticoagulation%20Policy%20Version%205%200%20Mar%202013.pdf"See Anticoagulation Policy and HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/EP%20Anticoagulation%20Guidelines%20Mar%202013.pdf"EP anticoagulation policy Heparin (unfractionated) Enoxaparin (Low Molecular Weight Heparin) Danaparoid Sodium (in place of heparin where heparin induced thrombocytopenia suspected-refer to Trust HITT policy) Bivalirudin For patients undergoing primary PCI for ST-elevation Myocardial Infarction ( HYPERLINK "http://www.nice.org.uk/nicemedia/live/13513/55411/55411.pdf" Bivalirudin for the treatment of Myocardial Infarction (persistent ST-segment elevation) NICE TA230)  Antiplatelet drugs Aspirin Clopidogrel (see below) Prasugrel  HYPERLINK "http://www.nice.org.uk/nicemedia/live/12324/45849/45849.pdf" (Prasugrel for the treatment of acute coronary syndrome NICE TA182). This appraisal was based on a health economic model using Plavix. Subsequently, generic clopidogrel has become available at a substantially lower acquisition cost. The cost effectiveness of prasugrel relative to generic clopidogrel is now uncertain. A review of this guidance is currently being undertaken by NICE. The Trust will review accordingly. Ticagrelor  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13588/56819/56819.pdf" Ticagrelor for the treatment of acute coronary syndromes NICE TA236 For more detailed information on antiplatelet use: In NSTEMI refer to CMSCN guidelines- HYPERLINK "http://www.cmcsn.nhs.uk//fileuploads/NSTEACS_Guidelines.pdf" http://www.cmcsn.nhs.uk//fileuploads/NSTEACS_Guidelines.pdf In STEMI refer to LHCH PPCI protocol- Abciximab Eptifibatide Tirofiban The current guidelines for the use of clopidogrel within the Trust are as follows 75mg once daily post PCI with stent insertion.. Treatment for one year is generally recommended, but may be reduced, at the operators discretion, in patients treated with bare-metal stents for stable angina (e.g. to 4 weeks) or in ACS patients with a higher bleeding risk dependant on stent type And/or concurrent anticoagulant therapy Antiplatelet treatment indicated, but definite proven allergy to aspirin Gastrointestinal intolerance of aspirin where symptoms persist in spite of the use of low dose (75mg) aspirin and H2 antagonists or Proton-pump-inhibitors. 75mg once daily for one month following percutaneous closure of PFO, ASD and VSD (+ aspirin 300mg daily for 6 months) e) In combination with aspirin following CABG f) Medical management following acute myocardial infarction (STEMI) in combination with aspirin, for at least 4 weeks g) Option to prevent occlusive vascular events (clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events NICE TA210) Fibrinolytic drugs Tenecteplase (TNK-tpa) Administer over 5-10 seconds according to weight; Weight (kg) Dose (mL) <60 6 60-69 7 70-79 8 80-89 9 90+ 10 Co-therapy: IV heparin (minimum of 48hrs) Weight <67 kg -4000 IU bolus then 800 IU/hr infusion (0.8ml/h of 1000 units/ml) Weight > 67kg -5000 IU bolus then 1000 IU/hr infusion (1ml/h of 1000 units/ml) Target APTT: 50-75s (1.5-2.5 times control) Alteplase (reserved use for pulmonary embolism only) Please note alteplase is recommended by NICE in acute ischaemic stroke (NICE TA 264). Alteplase is not approved for use for this indication at LHCH as all patients presenting with acute ischaemic stroke must be transferred to their local specialist centre for thrombolysis Antifibrinolytic drugs Aprotinin Etamsylate Tranexamic acid NB. IV is unlicensed Lipid lowering drugs Anion-exchange resins Colestyramine Fibrates Bezafibrate MR Fenofibrate Statins Simvastatin Atorvastatin Rosuvastatin (consultant/SpR use only) Guidance removed pending review Fish oils Omega-3-acid ethyl esters (Omacor) Other agents Ezetimibe (consultant/SpR use only) 3. RESPIRATORY SYSTEM 3.1 Bronchodilators 3.1.1 Selective beta2 agonists Short acting beta2 agonists DrugFormulationStrengthUsual dose AsthmaUsual dose COPDSalbutamolGeneric CFC free MDI Ventolin Accuhaler Salamol Easibreathe breath activated MDI Salbutamol easyhaler Salbutamol nebules Salbutamol injection 100mcg 200mcg 100mcg 200mcg 2.5mg, 5mg 500mcg/ml 200mcg prn 2.5-5mg qds Consult chest physician200mcg qds and prn 2.5-5mg qds Consult chest physicianTerbutalineBricanyl turbohaler Bricanyl nebules Bricanyl injection500mcg 5 mg 500mcg/ml500mcg prn 5-10mg qds Consult chest physician500mcg qds and prn 5-10mg qds Consult chest physician  Long acting beta2 agonists (see also combination steroid inhalers) DrugFormulationStrengthUsual dose AsthmaUsual dose COPDSalmeterolSalmeterol CFC free MDI Serevent Accuhaler25mcg 50mcg 50mcg bd (only in combination with steroid inhaler)50mcg bdFormeterolOxis Turbohaler6mg, 12mg12mcg bd (only in combination with steroid inhaler)12mcg bdIndacaterolOnbrez Breezhaler150mcg, 300mcgUnlicensed150-300mcg od Oral beta2 agonists DrugFormulationStrengthUsual dose AsthmaUsual dose COPDBambuterolTablets10mgConsult chest physicianConsult chest physician 3.1.2 Antimuscarinics (anticholinergics) DrugFormulationStrengthUsual dose AsthmaUsual dose COPDIpratropiumAtrovent MDI Ipratropium nebules20mcg 250mcg, 500mcgNot routinely used 250-500mcg qds 20-40mcg qds 250-500mcg qdsTiotropium Spiriva handihaler plus inhalant capsule Spiriva Respimat metered inhaler18mcg 2.5mgNot licensed for treatment of asthma18mcg od 5mg odAclidinium Bromide (Eklira Genuair) Inhalation Powder400mcg400mcg inhaled TWICE daily. For maintenance treatment of chronic obstructive pulmonary disease.Glycopyrronium Bromide (Seebri Breeshaler)Inhalation powder, hard capsule.50mcg50mcg ONCE daily. Second line maintenance treatment of chronic obstructive pulmonary disease. 3.1.3 Theophylline DrugFormulationStrengthUsual dose AsthmaUsual dose COPDTheophylline Aminophylline (multiply by 0.8 for equivalent theophylline dose)Uniphyllin continus M/R tablets Injection for IV infusion Phyllocontin tablets 200mg, 300mg, 400mg 25mg/ml 225mg 200-400mg bd See notes below 225-450mg bd200-400mg bd See notes below 225-450mg bd Dose of Aminophylline intravenous infusion: Loading dose (only if not previously treated with oral theophylline): 250-500mg (5mg/kg) over 20 minutes Maintenance dose (if on oral theophylline check levels first) 0.5mg/kg/hr adjusted according to plasma concentration Higher doses may be used in Cystic Fibrosis Therapeutic drug level monitoring of theophylline/aminophyline:- Therapeutic range: 10-20mg/l Time to steady state: Usually 24-48 hrs (unless loading dose given or previously on oral). Levels should not be taken before 48hours unless an IV loading dose has been given or previously on oral in which case 24hours is sufficient. Oral theophylline levels (usual range 10-20mg/l) should be monitored 4 to 7 days after starting therapy. Levels should ideally be taken immediately before the next dose. The theophylline dose should be reduced if macrolide or fluroquinolone antibiotics (or other drugs known to interact) are prescribed for an exacerbation (contact pharmacy for advice) 3.1.4 Combination bronchodilators (To aid compliance only) DrugFormulationStrengthUsual dose AsthmaUsual dose COPDIpratropium and salbutamol nebulesCombivent nebules 500mcg/2.5mgNot licensed for treatment of asthmaOne nebule qds 3.1.5 Inhaler devices Both Volumatic (for use with Flixotide, Seretide and salbutamol MDIs) and Aerochamber (for use with all MDI inhalers) spacer devices are available from pharmacy to assist drug delivery. Patients should be advised to clean their spacer monthly with detergent and allow to air dry. Spacers should be replaced at least every 12 months. Haleraids are available from pharmacy for patients who have impaired hand strength and are prescribed an MDI. These patients should initially be assessed by the respiratory specialist nurse to ensure that an MDI is the most appropriate device. 3.2 Inhaled Corticosteroids (prescribe by brand) DrugFormulationStrengthUsual dose AsthmaUsual dose COPDBeclometasoneQvar CFC free MDI Qvar CFC free autohaler Qvar 50mcg is equivalent to 100mcg Clenil CFC free MDI (non formulary)50mcg, 100mcg, 250mcg100-400mcg bdNot normally used.FluticasoneFlixotide evohaler (MDI) Flixotide accuhaler50mcg, 125mcg, 250mcg 50mcg, 100mcg, 250mcg, 500mcg100-1000mcg bdSee SeretideBudesonidePulmicort turbohaler Pulmicort MDI Easyhaler100mcg, 200mcg, 400mcg 200mcg 200mcg100-800mcg bdSee Symbicort Patients receiving high dose inhaled steroids (800mcg of beclometasone or equivalent) via a metered dose inhaler should also be prescribed an appropriate spacer device (Volumatic/aerochamber) to prevent oropharyngeal side effects. Consult the respiratory specialist nurse or pharmacy for advice on appropriate inhaler devices for individual patients. Combination steroid plus long acting beta2 agonist inhalers (prescribe by brand) DrugFormulationStrengthUsual dose AsthmaUsual dose COPDFluticasone plus salmeterol Budesonide plus formeterol Beclometasone plus formeterolSeretide CFC free evohaler (MDI) Seretide Accuhaler Symbicort turbohaler Fostair MDI 50/25mcg, 125/25mcg, 100/50mcg, 250/50mcg, 500/50mcg 100/6, 200/6, 400/12 100/62 puffs bd One blister bd 100/6 bd to 800/24 bd 1-4 puffs bdNot licensed in COPD 500/50 (one blister) bd 400/12 bd Not licensed in COPD Seretide 250/25mcg evohaler has been removed from the hospital formulary as it is expensive and not licensed in COPD. Any new prescriptions for this will be queried by pharmacy and only supplied if there is no other device the patient can tolerate as determined by the respiratory specialist nurse. Equivalent doses of inhaled steroids (adapted from British Thoracic Society Asthma Guidelines May 2011) CorticosteroidEquivalent dose to non-formulary Clenil 400mcg (beclomethasone)Beclometasone Qvar MDI/Autohaler Fostair MDI 200-300mcg 200mcgBudesonide Pulmicort MDI/turbohaler Easyhaler Symbicort turbohaler 400mcg 400mcg 400mcgFluticasone Flixotide evohaler/Accuhaler Seretide evohaler/Accuhaler  200mcg 200mcg 3.3 Leukotriene Receptor Antagonists DrugFormulationStrengthUsual dose AsthmaUsual dose COPDMontelukast tablets10mg10mg in the eveningNot licensed in COPD MANAGEMENT OF ACUTE SEVERE ASTHMA IN ADULTS Patients with acute severe asthma will not normally present at LHCH. If further guidance is required please refer to the BNF. STEPWISE MANAGEMENT OF CHRONIC ASTHMA IN ADULTS (Adapted from British Thoracic Society Guidelines, Thorax 2008 revised May 2011  HYPERLINK "http://www.brit-thoracic.org.uk" www.brit-thoracic.org.uk) Start at the step most appropriate to initial severity of disease. Check compliance and inhaler technique prior to stepping up therapy. STEP ONE Mild Intermittent AsthmaInhaled short acting 2 agonist as required (up to once daily) Move to step 2 if 2 agonist needed more than once dailySTEP TWO Regular Preventer TherapyAdd regular inhaled steroid (200-800*mcg/day of beclometasone dipropionate [BDP] or equivalent) Start at dose of inhaled steroid appropriate to severity of disease. A dose of 400mcg/day is appropriate for most patients.STEP THREE Add on TherapyAdd regular inhaled long acting 2 agonist (LABA) Assess asthma control: Good response to LABA continue Benefit from LABA but control still inadequate continue LABA and increase dose of inhaled steroid (up to 800mcg/day BDP or equivalent). No response to LABA stop LABA, increase dose of inhaled steroid as above. If control still inadequate, trial of other therapies eg leukotriene receptor antagonist or slow release theophylline NB Addition of anticholinergics is generally of no valueSTEP FOUR Persistent Poor ControlConsider trials of Increase dose of inhaled steroid (up to 2000micrograms/day* BDP or equivalent) Addition of fourth drug e.g. leukotriene receptor antagonist, slow release theophylline or slow release oral 2 agonist. If trial is of no benefit then stop the drug or in the case of inhaled steroid, reduce to the original dose.STEP FIVE Continuous or frequent use of oral steroidsUse oral steroid once daily in the lowest dose possible to provide adequate control. Maintain high dose inhaled steroids. Consider other treatments to minimize dose of oral steroids.  STEPPING DOWN Once asthma is controlled then stepping down of treatment is recommended. When deciding which drug to step down first consider benefits of treatment, side effects and patient preferences. Inhaled steroids should be maintained at the lowest possible dose. The dose should be reduced slowly at a rate of approximately 25-50% every three months. *Doses of BDP refer to the BDP-HFA product Clenil which is non formulary. When prescribing Qvar these dosages shold be halved. See table in section 3.2 : Equivalent doses of inhaled steroids (adapted from British Thoracic Society Asthma Guidelines May 2011) to determine the equivalent doses for other inhaled steroids. Prescribers should note the contents of HYPERLINK "http://www.nice.org.uk/nicemedia/live/11945/40099/40099.pdf"NICE TA138 Inhaled corticosteroids for the treatment of chronic asthma in adults and children over 12 years before prescribing Pharmacological therapy of stable COPD Adapted from NICE Guidelines June 2010  HYPERLINK "http://www.nice.org.uk" www.nice.org.uk Smoking All COPD patients still smoking should be referred to the Smoking Cessation Advisor for appropriate support and advice regarding quitting. Nicotine replacement therapies and varenicline are available for prescribing.  HYPERLINK "http://www.nice.org.uk/nicemedia/live/11809/35940/35940.pdf" NICE TA123 Inhaled bronchodilator therapy (from NICE COPD Guidelines June 2010)  _ Choose a drug based on the persons symptomatic response and preference, the drugs side effects, potential to reduce exacerbations and cost. _ Do not use oral corticosteroid reversibility tests to identify patients who will benefit from inhaled corticosteroids. _ Be aware of the potential risk of developing side effects (including non-fatal pneumonia) in people with COPD treated with inhaled corticosteroids and be prepared to discuss this with patients. SABA = Short Acting Beta2 Agonists SAMA = Short Acting Muscarinic Antagonist (Antimuscarinics/anticholinergics) LABA = Long Acting Beta2 Agonists LAMA = Long Acting Muscarinic Antagonist (Antimuscarinics/anticholinergics) Nebulised bronchodilator therapy in stable COPD Nebulised bronchodilator therapy should only be considered in patients with distressing or disabling breathlessness despite maximal inhaler therapy and should not be continued unless there is a perceived benefit. Assess individual and/or carers ability to use the nebuliser before prescribing. Patients should be referred to the respiratory specialist nurses for further support. Patients commencing ipratropium nebules should have all anticholinergic inhaler therapy (eg tiotropium) stopped since there is no additional benefit. Oral corticosteroids Maintenance oral corticosteroid therapy is not normally recommended and should only be prescribed in advanced COPD in patients whose treatment cannot be stopped after an exacerbation. The dose should be kept as low as possible and osteoporosis prophylaxis therapy considered. Theophylline Only offer after trials of short- and long-acting bronchodilators or to patients who cannot use inhaled therapy (see section 3.1.3) Mucolytics Mucolytics (Carbocisteine) can be considered for patients with chronic productive cough Roflumilast Roflumilast is not currently recommended for use at LHCH.  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13649/57889/57889.pdf" NICE TA244 COPD Roflumilast recommends roflumilast for use in severe COPD in the context of a clinical trial and at present no trials are available at LHCH. Should a clinical trial become available the use of roflumilast will be reconsidered. Hospital Management of Severe Exacerbations of COPD Assess severity of symptoms (x-ray, blood gases, ECG, FBC, U & Es, sputum microscopy and culture if purulent). Check theophylline level if on theophylline therapy on admission Administer controlled oxygen therapy if necessary - see below. (Repeat blood gases after 30 minutes). Oxygen must be prescribed on EPMA and the paper the drug chart. Bronchodilators Increase dose or frequency consider giving via nebuliser (air driven if the patient is hypercapnic (PaCO2 > 6.0Kpa)) Combine 2-agonists and anticholinergics. Consider adding IV aminophylline if inadequate response to nebulised bronchodilators. Monitor levels within 24 hours of starting therapy Add oral corticosteroids prednisolone 30mg daily for 7-14 days (if NBM consider IV hydrocortisone 100mg BD ). Give antibiotics if sputum purulent or clinical signs of pneumonia (see Trust Antimicrobial policy) Consider non-invasive mechanical ventilation. At all times: - Monitor fluid balance and nutrition. Consider subcutaneous low molecular weight heparin (enoxaparin 40mg od). Identify and treat associated conditions (eg heart failure, arrhythmias). Closely monitor condition of the patient. Change nebulisers back to handheld inhalers as soon as their condition has stabilised. SOLUTIONS FOR NEBULISATION Patients with COPD and carbon dioxide retention (PaCO2 > 6.0Kpa) should have their nebuliser therapy driven via an air cylinder or a nebuliser compressor. If the hypercapnic patient is so hypoxic that they need continuous oxygen then this should be administered via nasal cannula and the nebuliser driven from an air cylinder or compressor concurrently. Patients without CO2 retention can use either air or oxygen safely (unless the patient has acute asthma in which case oxygen must be used) but oxygen as a driving gas should be discontinued immediately after medication is nebulised. (See nebulisation guidelines for further information on preparations and administration) Patients not previously using nebulised therapy should only be discharged on such treatment on the advice of a respiratory physician or the Respiratory Nurse Specialist. 3.4 Antihistamines DrugFormulationStrengthDoseChlorphenamine CetirizineTablets Oral solution Tablets 4mg 2mg/5ml 10mg4mg 4-6hourly. Max 24mg in 24 hours 10mg daily  3.5 Respiratory stimulants Doxapram - Consult SPC for dosing details. For use on consultant recommendation only. 3.6 Oxygen Oxygen is one of the most widely used drugs and as such must be prescribed on an inpatient prescription chart. Oxygen should be signed for by nursing staff on the drug chart initially. On subsequent drug rounds it is the responsibility of the nursing staff to ensure that the prescription is still correct and should be crossed off once oxygen is discontinued. Oxygen therapy will be adjusted to achieve target saturations rather than giving a fixed dose to all patients with the same disease in accordance with the new Emergency Oxygen Guideline (2008), which can be reviewed on the British Thoracic Society website. In general, oxygen should be prescribed to achieve a target saturation of 94 - 98 % for most acutely unwell patients or 88 93 % for those at risk of hypercapnic respiratory failure. If the patient is critically ill / peri arrest situation Commence treatment with reservoir mask (non rebreath mask) at 15L/mt. Seek urgent medical advice. Once the patient is stable reduce the oxygen dose and aim for target saturations of 94 98 %. Patients with COPD and other risk factors for hypercapnia (see below for risk factors of hypercapnia) who develop critical illness should have the same initial target saturations as other critically ill patients pending results of urgent blood gas measurements after which patients may need controlled oxygen therapy or supported ventilation (NIV or IPPV) For hypoxemic patients who are not at risk of hypercapnic respiratory failure Initial oxygen therapy is nasal cannula at 2 6 L/mt or Venturi mask 28 % to up to 60 % and aim oxygen saturations of 94 98 %. Obtain ABG. If the oxygen saturation is less than 85 % use reservoir mask at 15 L/mt and seek urgent medical advice. For hypoxemic patients who are at risk of hypercapnic respiratory failure (moderate or severe COPD, moderate or severe bronchiectasis, those on long term oxygen therapy, morbid obesity, chest wall deformities or neuromuscular disorders) Aim for target saturations of 88 92 %, start with 24 28 % Venturi mask or nasal cannula at 1- 2 L/mt. Obtain ABG and consult respiratory physician for further advice. Any increase in oxygen therapy must be followed by repeat ABG in 30 60 minutes or sooner if conscious level deteriorates. Mucolytics DrugFormulationStrengthDoseDornase Alfa Sodium Chloride Carbocisteine Mannitol ErdosteinePulmozyme nebulisation solution Nebusal nebules Capsules Syrup Inhalation powder, hard capsules Capsules2.5mg 7% 375mg 250mg/5ml 40mg 300mg2.5mg daily (Cystic Fibrosis only) 4mL up to twice daily 375-750mg tds 400mg twice daily (Cystic Fibrosis only)  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13969/61603/61603.pdf" NICE TAG 266 Mannitol dry powder for inhalation for treating cystic fibrosis 300mg TWICE daily for up to 10 days.  Aromatic inhalations Menthol and eucalyptus inhalation Cough preparations Simple linctus Codeine 15mg/5ml linctus 4. CENTRAL NERVOUS SYSTEM Hypnotics and anxiolytics Benzodiazepines and other hypnotics should not be routinely prescribed for anxiety or night sedation. If treatment is considered necessary then they should be prescribed on a prn basis only and be reviewed regularly. Owing to the possibility of addiction, patients not previously taking benzodiazepines prior to admission should not receive them on discharge. Hypnotics Zopiclone - licensed for short term use only. Follow advice as for benzodiazepines above Temazepam (controlled drug) Anxiolytics Diazepam Lorazepam Chlordiazepoxide (alcohol withdrawal see below) Drugs used in psychoses Antipsychotic drugs Consult appropriate psychiatric specialist Antimanic drugs Lithium (Priadel) (HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Lithium%20Therapy%20Protocol%20Current%20June%202011.pdf"Click here to view Lithium therapy policy) Antidepressants Amitriptyline Fluoxetine Sertraline General Guidance for Management of Depression at LHCH In accordance with NICE recommendations, patients with significant physical illness causing disability e.g. Heart failure, COPD should be screened for depression. Screening for depression should include the use of at least two questions concerning mood and interest, such as: During the last month, have you often been bothered by feeling down, depressed or hopeless? and During the last month, have you often been bothered by having little interest or pleasure in doing things? Severity must be assessed using the ICD-10 definitions as described below. Patients should be referred to their G.P. for management in all cases of mild depression and where symptoms are diagnosed in the outpatient setting. In-patients diagnosed with depression will most likely be categorised as moderately depressed due to co-morbidities. In moderate depression, antidepressant medication should be routinely offered to all patients before psychological interventions. A selective serotonin reuptake inhibitor (SSRI) should be considered first line therapy. When initiating treatment in a patient with a recent myocardial infarction or unstable angina, sertraline is the treatment of choice as it has the most evidence for safe use in this situation. Sertraline is a well-tolerated SSRI but is more likely to be associated with upwards dosage titration during treatment than the other SSRIs. In most other circumstances, fluoxetine is a reasonable choice because it is associated with fewer continuation/withdrawal symptoms than other SSRIs. However, it has a high propensity for drug interactions through hepatic enzyme inhibition. Sertraline is less problematic in this regard although enzyme inhibition is dose-related. Where there are concerns regarding drug interactions with SSRIs, pharmacy should be consulted for further advice. All patients commenced on antidepressants at LHCH should be referred back to their GP within 2 weeks of commencing treatment for continued care and dosage titration (particularly sertraline) if necessary. All healthcare professionals actively screening and treating depression at LHCH must familiarise themselves with NICE guidelines for the Management of Depression. ICD-10 Definitions A. Look for key Symptoms: Persistent sadness or low mood; and/or Loss of interests or pleasure Fatigue or low energy. At least one of these, most days, most of the time for at least 2 weeks. B. If any of above present, ask about associated symptoms: Disturbed sleep Poor concentration or indecisiveness Low self-confidence Poor or increased appetite Suicidal thoughts or acts Agitation or slowing of movements Guilt or self-blame. C. Then ask about past, family history, associated disability and availability of social support 1. Factors that favour general advice and watchful waiting: Four or fewer of the above symptoms No past or family history Social support available Symptoms intermittent, or less than 2 weeks duration Not actively suicidal Little associated disability. 2. Factors that favour more active treatment: Five or more symptoms Past history or family history of depression Low social support Suicidal thoughts Associated social disability. 3. Factors that favour referral to mental health professionals: Poor or incomplete response to two interventions Recurrent episode within 1 year of last one Patient or relatives request referral Self-neglect. 4. Factors that favour urgent referral to a psychiatrist: Actively suicidal ideas or plans Psychotic symptoms Severe agitation accompanying severe (more than 10) symptoms Severe self-neglect. ICD-10 definitions Mild depression: four symptoms Moderate depression: five or six symptoms Severe depression: seven or more symptoms, with or without psychotic features Adapted from NICE Guidelines for the Management of Depression in Primary and Secondary Care (Amended). April 2007 Nausea and vertigo Metoclopramide (Maximum of 5 days treatment only as per  HYPERLINK "http://www.mhra.gov.uk/PrintPreview/DSUArticlePage/CON300404?DynamicListQuery=dDocType%20%3cmatches%3e%20%60Publication%60%20%20%3cAND%3e%20%20xSecondLevel%20%3cmatches%3e%20%60Safety%20Guidance%60%20%20%3cAND%3e%20%20xThirdLevel%20%3cmatches%3e%20%60Medicines%60%20%20%3cAND%3e%20%20xFourthLevel%20%3cmatches%3e%20%60Drug%20Safety%20Update%60%20%3cand%3e%20%20xNHSNetOnly%20%3cmatches%3e%20%60No%60" MHRA restrictions) Cyclizine Prochlorperazine Betahistine Ondansetron (limited indications, post-operative nausea and vomiting only) Consult the following algorithm for the management of post-operative nausea and vomiting Algorithm for the management of post-operative nausea and vomiting  Analgesics Also see HYPERLINK "http://ctcnt20/policy/81/Acute%20Pain%20Current%20June%202011.pdf"Acute Pain Protocol Compound oral analgesics, such as paracetamol plus an opioid, should not be prescribed because of the inflexibility in the dosage of such products. Combinations with low doses of opioid have not been proven to provide more effective analgesia than paracetamol alone, yet still have opioid side effects. Combinations with higher doses of opioid result in dosage inflexibility and a greater incidence of side effects. If an opioid analgesic is considered necessary then a single ingredient preparation should be used, such as dihydrocodeine or codeine phosphate tablets. Consult the following Pain Ladder before prescribing Non-opioid analgesics Paracetamol Opioid analgesics Codeine phosphate Dihydrocodeine Diamorphine Morphine Fentanyl patch (palliative care) Tramadol (Consultant use only) Oxycodone (Anaesthetist use only and in accordance with cardiac surgery analgesia algorithm below)  Prophylaxis of migraine Pizotifen Antiepileptics Carbamazepine Phenytoin Sodium valproate Status epilepticus Diazepam Phenytoin Parkinsonism and related disorders Contact appropriate specialist in the management of Parkinsons disease and related disorders Relief of intractable hiccup Chlorpromazine Haloperidol Drugs used in substance dependence Methadone (Addicts must be registered with the Home Office) Nicotine (Various preparations available. Refer to smoking advisor)  HYPERLINK "http://www.nice.org.uk/nicemedia/live/11809/35940/35940.pdf" Varenicline NICE TA123 Management of alcohol withdrawal Step Dose of chlordiazepoxide (mg) Time of administration10:0014:0018:0022:001252525252252020253202020204202020520101061010107101081095 The severity of withdrawal symptoms will determine the initial dose of chlordiazepoxide. Steps 1 and 2 are usually reserved for patients with severe withdrawal symptoms such as confusion, seizures and hallucinations. Oxazepam may be used in place of chlordiazepoxide if there is severe liver failure. If the oral route is not available then use:- diazepam 10-20mg IV every 6 hours or lorazepam 4mg IV every 4 hours Thiamine deficiency Thiamine tablets 100mg bd plus Multivitamins one or two daily If neurological signs are present then - Vitamins B and C injection 2-3 pairs of ampoules IV every eight hours for up to two days. Then one pair daily for 5-7 days. 5. INFECTIONS Please refer to the HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Antimicrobial%20Policy%203.1%20April%202012.pdf"Antimicrobial Policy and  HYPERLINK "http://www.nice.org.uk/nicemedia/live/12060/42040/42040.pdf" NICE TA158 Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza and  HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/TA168fullguidance.pdf" TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza 6. ENDOCRINE SYSTEM Drugs used in diabetes 6.1.1 Insulins TypeDrugBrandNotesShort acting insulinsSoluble InsulinActrapidFor use in HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Insulin%20policy%20v%204%203%20Nov%202012.pdf"management of acutely ill or peri-procedural diabetic/non-diabetic patients requiring insulin only. Insulin Aspart Insulin Glulisine Insulin LisproNovorapid Apidra HumalogFor use in CF or Diabetes Specialist Nurse advice onlyLong acting insulinsInsulin Detemir Insulin Glargine  HYPERLINK "http://www.nice.org.uk/nicemedia/live/11482/32518/32518.pdf" NICE TA53Levemir LantusFor use in CF or Diabetes Specialist Nurse advice onlyIntermediate acting insulinsBiphasic Insulin Aspart Biphasic Insulin LisproNovoMix 30 Humalog Mix 25For use in CF or Diabetes Specialist Nurse advice only 6.1.2 Oral Diabetic Drugs TypeDrugs AvailableSulfonylureasGliclazideBiguanidesMetforminMetformin oral SolutionMetformin M/RDipeptidylpeptidope 4 inhibitorsSitagliptin 6.1.2.3 Other Antidiabetic Drugs Exenatide M/R 2mg s/c injection  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13670/58205/58205.pdf" NICE TA 248 Exenatide modified- release for the treatment of type 2 diabetes mellitus Liraglutide 6mg/mL s/c injection  HYPERLINK "http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf"  NICE TAG-TA203 Liraglutide for the treatment of type 2 diabetes mellitus For further information on the management of type 2 diabetes please consult NICE guidelines  HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf" NICE clinical Guideline 87 Hypoglycaemia Glucagon Thyroid and anti-thyroid drugs Thyroid hormones Levothyroxine (thyroxine) Liothyronine Antithyroid drugs Carbimazole Propylthiouracil Corticosteroids Prednisolone (not enteric coated*) Dexamethasone Hydrocortisone Methylprednisolone * There is currently no evidence to indicate that enteric coated prednisolone is less likely than uncoated prednisolone to cause peptic ulceration. The evidence that enteric coating is less likely to cause dyspepsia is unsatisfactory and there is no robust evidence to suggest that enteric coating of prednisolone confers gastrointestinal protection. There is however, evidence to suggest lack of disease control for some conditions in those taking enteric coated compared to uncoated prednisolone particularly in cystic fibrosis. Patients should not be commenced enteric coated prednisolone and those currently taking enteric coated should be advised to switch to ordinary tablet. The Pan Mersey Medicines Management committee does not support the use of enteric coated prednisolone in primary care. Pituitary hormones Tetracosactide Vasopressin Terlipressin Drugs affecting bone metabolism Disodium etidronate Disodium pamidronate 7. URINARY TRACT DISORDERS Vaginal anti-infective drugs Clotrimazole 500mg pessary 7.4 Genito-urinary disorders Urinary retention Indoramin Tamsulosin Urinary frequency Oxybutynin Urological pain Potassium citrate mixture 8. MALIGNANT DISEASE AND IMMUNOSUPPRESSION Cytotoxic drugs Bleomycin Immunosuppresants Azathioprine Ciclosporin (Neoral) Sex hormones and hormone antagonists Progestogens Medroxyprogesterone acetate Megestrol acetate Hormone antagonists Tamoxifen Octreotide 9. NUTRITION AND BLOOD Anaemias Ferrous sulphate Ferrous glycine sulphate syrup Ferrous Fumarate syrup Folic acid Hydroxocobalamin Erythropoetin beta (Neo-Recormon) (consultant only) Fluids and electrolytes Oral potassium Potassium effervescent (12mmol of K+) Potassium chloride syrup (1mmol/ml of K+) Potassium chloride MR* (8mmol of K+) *N.B. Absorption of MR is poor and should only be used where the patient cannot tolerate syrup or effervescent tablets Potassium removal Calcium Resonium Resonium A Oral sodium Sodium chloride MR (10mmol each of Na+and Cl-) Oral bicarbonate Sodium bicarbonate 600mg tablets Intravenous fluids and electrolytes Contact Pharmacy for availability of various solutions Plasma substitutes Pentastarch 10% Gelofusin Voluven Intravenous nutrition Contact Pharmacy for advice Enteral nutrition Contact dietitian for advice Minerals Calcium Calcium carbonate Calcium gluconate injection Calcium chloride injection Magnesium Magnesium sulphate injection 50% Phosphate Phosphate-Sandoz Potassium acid phosphate injection Zinc Zinc sulphate effervescent tabs Vitamins Vitamin B Thiamine (B1) Pyridoxine (Isoniazid neuropathy prophylaxis only) Vitamin B compound strong Vitamin B and C injection (Pabrinex) Vitamin C Ascorbic acid tablets Vitamin D Calcium and vitamin D tablets Alfacalcidol capsules Colecalciferol 50,000units capsules (unlicensed)- for CF patients only Vitamin E Vitamin E capsules 400 IU Vitamin K Menadiol (water soluble for use in fat malabsorption states) Phytomenadione Multivitamin preparations Multivitamins tabs/caps 10. MUSCULOSKELETAL AND JOINT DISEASES Drugs used in rheumatic diseases and gout Non-steroidal anti-inflammatory drugs Ibuprofen Diclofenac (PR only) NICE guidance (cyclo-oxygenase-2 selective inhibitors). NICE has recommended that cyclo-oxygenase-2 selective inhibitors (celecoxib, etodolac and meloxicam) should: not be used routinely in the management of patients with rheumatoid arthritis or osteoarthritis; be used in preference to standard NSAIDs only when clearly indicated (and in accordance with UK licensing), for patients with a history of gastroduodenal ulcer or perforation or gastro-intestinal bleedingin these patients even the use of cyclo-oxygenase-2 selective inhibitors should be considered very carefully; they should also be used in preference to standard NSAIDs for other patients at high risk of developing serious gastro-intestinal side-effects (e.g. those aged over 65 years, those who are taking other medicines which increase the risk of gastro-intestinal effects, those who are debilitated or those receiving long-term treatment with maximal doses of standard NSAIDs); not be used routinely in preference to standard NSAIDs for patients with cardiovascular disease; the benefit of cyclo-oxygenase-2 selective inhibitors is reduced in patients taking concomitant low-dose aspirin and this combination is not justified. There is no evidence to justify the simultaneous use of gastro-protective drugs with cyclo-oxygenase-2 selective inhibitors as a means of further reducing potential gastro-intestinal side-effects. Local corticosteroid injections Methylprednisolone Drugs used in gout Colchicine (acute attacks if need to avoid fluid retention) Allopurinol (long term control) Neuromuscular disorders Drugs which enhance neuromuscular transmission Pyridostigmine Edrophonium Skeletal muscle relaxants Dantrolene Baclofen Diazepam Nocturnal leg cramps Quinine sulphate 300mg tablets Topical antirheumatics Benzydamine 11. DRUGS ACTING ON THE EYE Anti-infective preparations Antibacterials Chloramphenicol (drops and ointment) Antivirals Aciclovir ointment Corticosteroids Betamethasone drops Prednisolone drops Mydriatics Tropicamide drops Treatment of glaucoma Contact Pharmacy for availability of specific treatments 11.8 Miscellaneous Tear deficiency Hypromellose drops 12. EAR, NOSE AND OROPHARYNX Drugs acting on the ear Anti-inflammatory and anti-infective preparations Betamethasone drops Gentamicin drops Removal of ear wax Sodium bicarbonate drops Drugs acting on the nose Nasal allergy Beclometasone nasal spray (Beconase) Fluticasone nasal spray (Flixonase) Nasal staphylococci Mupirocin Naseptin Drugs acting on the oropharynx Ulceration and inflammation Benzydamine mouthwash/spray (Difflam) Triamcinolone (Adcortyl) in Orabase Choline salicylate gel (Bonjela) Fungal infections Nystatin Oral hygiene Thymol (mouthwash tablets) Chlorhexidine gluconate Dry mouth Glandosane spray (Restricted use. Severe cases only) 13. SKIN See NPSA alert regarding fire hazard with products containing 100g or more of paraffin  HYPERLINK "http://www.nrls.npsa.nhs.uk/resources/?entryid45=59876" http://www.nrls.npsa.nhs.uk/resources/?entryid45=59876 Emollients White soft paraffin Hydromol ointment Oilatum bath additive Moisturisers E45 cream Diprobase Barrier preparations Metanium ointment Cavilon barrier cream and film spray Topical antipruritics Crotamiton cream (Eurax) Topical corticosteroids Hydrocortisone 1% Fucibet cream Fucidin H cream Sunscreens Uvistat factor 30 Anti-infective skin preparations Antibacterials Mupirocin Silver sulfadiazine Metronidazole gel Antifungals Clotrimazole Antivirals Aciclovir Scabies and lice Malathion Disinfectants and cleansers Chlorhexidine Povidone iodine Alcoholic iodine solution Hydrogen peroxide A8 WOUND MANAGEMENT  HYPERLINK "http://nww.staffintranet.lhch.nhs.uk/library/departments/support_services/pharmacy/wound_dressing_formulary_march_09.doc" See wound care formulary and guidelines 14. IMMUNOLOGICAL PRODUCTS AND VACCINES Tuberculin PPD (100units/ml) Hepatitis B vaccine Influenza vaccine Pneumococcal vaccine Tetanus Vaccine Adsorbed Tetanus immunoglobulin Normal immunoglobulin for IV use 15. ANAESTHESIA 15.1.1 Intravenous anaesthesia Thiopental Etomidate Propofol Ketamine 15.1.2 Inhalational anaesthesia Enflurane Sevoflurane Isoflurane 15.1.3 Antimuscarinics Atropine Glycopyrronium Hyoscine hydrobromide 15.1.4 Sedative and analgesic peri-operative drugs Anxiolytics and neuroleptics Diazepam Lorazepam Midazolam Non-opioid analgesics Ketorolac Dexmedetomidine (use only for post operative sedation/analgesia supplementation for patients after thoracoabdominal aortic aneurysm surgery) Opioid analgesics Alfentanil Fentanyl Remifentanil 15.1.5 Muscle relaxants Atracurium Mivacurium Pancuronium Rocuronium Suxamethonium Vecuronium 15.1.6 Anticholinesterases Neostigmine Edrophonium 15.1.6.1 Other drugs for reversal of neuromuscular blockade Sugammadex 15.1.7 Antagonists for central and respiratory depression Doxapram Flumazanil Naloxone 15.1.8 Malignant hyperthermia Dantrolene Local anaesthetics Lidocaine (lignocaine) Bupivacaine Cocaine Emla cream     Liverpool Heart and Chest Hospital NHS Foundation Trust Drug Formulary  PAGE 1  PAGE 1 POST OPERATIVE NAUSEA and VOMITING (PONV) ALGORITHM ASSESSMENT PONV: 0 No nausea or vomiting 1- Mild nausea/occasional vomiting 2- Moderate nausea and/or occasional vomiting 3- Severe nausea and/or frequent vomiting PONV : GENERAL ADVICE: Ensure adequate hydration. Do not discontinue PCA if patient in pain:-Administer anti-emetics as prescribed. Anti-emetics are more effective if used in combination. SATISFACTORY RESPONSE Continue cyclizine 25-50mg 8hrly IV PONV Score greater than 1: Give cyclizine 50 mg IV (reduce dose to 25 mg if over 70 yrs) Re-assess in one hour PONV Score greater than 1 Administer single dose Ondansetron 4 mg IV Re assess in one hour PONV Score greater than 1 Administer Dexamethasone 8 mg IV as single dose and re-assess in one hour Seek advice from pain nurse specialist or on-call anaesthetist KM/JC review date 02/11  EMBED PowerPoint.Show.8   >?@CS[\_`a{|}˷ب،m[Am-'h ChcZ0J5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJ#h ChKX!5CJOJQJ^JaJ,jh ChKX!5CJOJQJU^JaJhKX!hcZ5h ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch#0JOJQJ^J'jh ChOJQJU^Jh Ch.OJQJ^J!jh Ch.OJQJU^JhcZ#h Ch2>*CJOJQJ^JaJ _ B q * ] 0 t < { @ gd# 9gd C & FgdcZ & FgdcZgdcZ$a$gd2   # $ 鶜ȶnZ@2jh Ch.5CJOJQJU^JaJ'h ChKX!0J5CJOJQJ^JaJ2juh Ch.5CJOJQJU^JaJ'h ChcZ0J5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJ#h ChKX!5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhf]5CJOJQJ^JaJ,jh ChKX!5CJOJQJU^JaJ$ % 8 9 A B C W X Y Z [ g h p q r ƴq[՝ƴA՝ƴ2jh Ch.5CJOJQJU^JaJ*h ChcZ0J5CJH*OJQJ^JaJ2jUh Ch.5CJOJQJU^JaJ#h Ch@5CJOJQJ^JaJ,jh Ch@5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhf]5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh ChKX!5CJOJQJU^JaJ   ! " ) + , G H I R S \ ] ^ ׽隈n]隈C隈2j'h Ch.5CJOJQJU^JaJ!hf]0J5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhf]5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j+h Ch.5CJOJQJU^JaJ#h Ch,5CJOJQJ^JaJ,jh Ch,5CJOJQJU^JaJ^ { | } Ӽm^G5#h ChJc5CJOJQJ^JaJ,jh ChJc5CJOJQJU^JaJhv`5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJh C5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch,5CJOJQJU^JaJ2jh Ch.5CJOJQJU^JaJ#h Ch,5CJOJQJ^JaJ    ' ( / 0 1 Q ϻϩfR@1hf]5CJOJQJ^JaJ#hf]hcZ5CJOJQJ^JaJ'hf]hcZ0J5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJ#hf]hJc5CJOJQJ^JaJ,jhf]hJc5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh ChJc5CJOJQJU^JaJ2jh Ch.5CJOJQJU^JaJQ R S l m t u ϻϩfR@#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJ#h ChJc5CJOJQJ^JaJ,jh ChJc5CJOJQJU^JaJ#hf]hcZ5CJOJQJ^JaJ'hf]hcZ0J5CJOJQJ^JaJ,jhf]hJc5CJOJQJU^JaJ2jjh Ch.5CJOJQJU^JaJ    3 4 = > Z [ \ q r x z { ~  ϻϩϗ}ϻϩϗcϻϩ^R^M^ h C5hWghcZ5CJaJ hcZ52jhh Ch.5CJOJQJU^JaJ2jh Ch.5CJOJQJU^JaJ#h ChJc5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh ChJc5CJOJQJU^JaJ2jhh Ch.5CJOJQJU^JaJ    * |bN<|#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jn h Ch.5CJOJQJU^JaJ#h Ch%5CJOJQJ^JaJ,jh Ch%5CJOJQJU^JaJh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch#0JOJQJ^J'jh Ch!XOJQJU^Jh!XOJQJ^J!jh Ch.OJQJU^J* + , 5 6 @ A \ ] ^ g h q r ϻϩϗ}ϻϩϗcϻϩϗIϻϩϗ2j^ h Ch.5CJOJQJU^JaJ2j h Ch.5CJOJQJU^JaJ2jj h Ch.5CJOJQJU^JaJ#h Ch%5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch%5CJOJQJU^JaJ2j h Ch.5CJOJQJU^JaJ@ q :zd,c)[_:{gdigdcZ & FgdcZ23:;^_`qrz{ϻϩϗ}ϻϩfT:fffT2j h Ch.5CJOJQJU^JaJ#h Ch!y5CJOJQJ^JaJ,jh Ch!y5CJOJQJU^JaJ2jn h Ch.5CJOJQJU^JaJ#h Ch%5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch%5CJOJQJU^JaJ2j h Ch.5CJOJQJU^JaJabdeϻϩfK4,hWghWg5B*CJOJQJ^JaJph5jhWghD5B*CJOJQJU^JaJph2j h Ch.5CJOJQJU^JaJ#h ChD5CJOJQJ^JaJ,jh ChD5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch!y5CJOJQJU^JaJ2jt h Ch.5CJOJQJU^JaJƲƛufLu8u'hc hcZ0J5CJOJQJ^JaJ2jhc hYy5CJOJQJU^JaJhc 5CJOJQJ^JaJ&jhc 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ,hWghcZ5B*CJOJQJ^JaJph'hWghcZ0J5CJOJQJ^JaJ5jhWghD5B*CJOJQJU^JaJph;jxhWgh^5B*CJOJQJU^JaJph #$,-JKLZ[cd׽闀nTn:2jhh Ch.5CJOJQJU^JaJ2jh Ch.5CJOJQJU^JaJ#h Chq5CJOJQJ^JaJ,jh Chq5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jrh Ch.5CJOJQJU^JaJ#h ChD5CJOJQJ^JaJ,jh ChD5CJOJQJU^JaJ !"()*ǵLJǵmLJ[@5jh Ch5T5B*CJOJQJU^JaJph3f#h Ch5T5CJOJQJ^JaJ2jXh Ch.5CJOJQJU^JaJ'h ChcZ0J5CJOJQJ^JaJ2jh Ch.5CJOJQJU^JaJ#h Chq5CJOJQJ^JaJ,jh Chq5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ*DEFPQWZ[\~˰s\J0\2j^h Ch.5CJOJQJU^JaJ#h Chq5CJOJQJ^JaJ,jh Chq5CJOJQJU^JaJ#h Ch5T5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ0h Ch5T0J5B*CJOJQJ^JaJph3f5jh Ch5T5B*CJOJQJU^JaJph3f;jh ChT5B*CJOJQJU^JaJph3f,h Ch&5B*CJOJQJ^JaJph3f  ABCUV԰԰|eV_'j^h ChOJQJU^Jh Ch.OJQJ^J!jh Ch.OJQJU^J2jh Ch5CJOJQJU^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jrh Ch5CJOJQJU^JaJh5CJOJQJ^JaJ,jh Ch5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ9:;JKSTUuǽzfWH4W&jhW5CJOJQJU^JaJh=5CJOJQJ^JaJhW5CJOJQJ^JaJ'h Ch=0J5CJOJQJ^JaJ2jh Ch=5CJOJQJU^JaJ#h Ch=5CJOJQJ^JaJ,jh Ch=5CJOJQJU^JaJh=OJQJ^JhcZOJQJ^J!jh Ch.OJQJU^Jh ChcZ0JOJQJ^Jh Ch#0JOJQJ^Juvwղղ{ղgXAg,jfhlp5CJOJQJU^JaJhlp5CJOJQJ^JaJ&jhlp5CJOJQJU^JaJ!hW0J5CJOJQJ^JaJ,jhW5CJOJQJU^JaJh8uY5CJOJQJ^JaJhW5CJOJQJ^JaJ'hWh8uY0J5CJOJQJ^JaJ&jhW5CJOJQJU^JaJ,jdhW5CJOJQJU^JaJ  678STZ[\|}~ȹתȹת|ȹhY?h2jhih0_5CJOJQJU^JaJhi5CJOJQJ^JaJ&jhi5CJOJQJU^JaJ,jxhlp5CJOJQJU^JaJ,jhlp5CJOJQJU^JaJhlp5CJOJQJ^JaJh8uY5CJOJQJ^JaJhv`5CJOJQJ^JaJ&jhlp5CJOJQJU^JaJ'hlph8uY0J5CJOJQJ^JaJ()012XôeQD-,jh Cha5CJOJQJU^JaJh Ch=OJQJ^J'h Ch=0J5CJOJQJ^JaJ2jh ChR%5CJOJQJU^JaJhR%5CJOJQJ^JaJ,jh Ch=5CJOJQJU^JaJh=5CJOJQJ^JaJhlp5CJOJQJ^JaJ&jhi5CJOJQJU^JaJ'hih=0J5CJOJQJ^JaJ'hihlp0J5CJOJQJ^JaJXYZ,./0WϻϬϋqϻbSbD2#h Cha5CJOJQJ^JaJhFh#5CJOJQJ^JaJh45CJOJQJ^JaJh=5CJOJQJ^JaJ2jh ChR%5CJOJQJU^JaJhR%5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhlp5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Cha5CJOJQJU^JaJ2jh Chlp5CJOJQJU^JaJWXYst{|}ϻϬr^J^6'h ehcZ0J5CJOJQJ^JaJ'h eh e0J5CJOJQJ^JaJ'h eh=I0J5CJOJQJ^JaJ,jh e5CJOJQJU^JaJ&jh e5CJOJQJU^JaJh=I5CJOJQJ^JaJh e5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Cha5CJOJQJU^JaJ2j#h Ch.5CJOJQJU^JaJ%&01MNOYZdeĪ֖ևm֖S֖2j-!h Ch.5CJOJQJU^JaJ2j h Ch.5CJOJQJU^JaJh e5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j1 h Ch.5CJOJQJU^JaJ#h Cha5CJOJQJ^JaJ,jh Cha5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ0d6v9Y GK & FgdU^gd. & FgdcZgd#gdcZϻϬψnϻϬiXK7X'j"h ChOJQJU^Jh Ch.OJQJ^J!jh Ch.OJQJU^J hcZ52j-"h Ch.5CJOJQJU^JaJ#h Cha5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Cha5CJOJQJU^JaJ2j!h Ch.5CJOJQJU^JaJ-.67RSTmnuvwӼ|m[A|m[2j#h Ch.5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j=#h Ch.5CJOJQJU^JaJ#h Chw5CJOJQJ^JaJ,jh Chw5CJOJQJU^JaJh ChcZOJQJ^J!jh Ch.OJQJU^Jh Ch#0JOJQJ^J/089:[ϻϬψnϻϬ\E3#h Ch.5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ#h Chi5CJOJQJ^JaJ2j$h Ch.5CJOJQJU^JaJ#h Chw5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Chw5CJOJQJU^JaJ2j1$h Ch.5CJOJQJU^JaJ[\]ϻϬϚϻnnϚTϻnn2j1&h Ch.5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ2j%h Ch.5CJOJQJU^JaJ#h Ch.5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ2j/%h Ch.5CJOJQJU^JaJ"#$/0YZtuvݛo[L:#hUhv`5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j'h Ch.5CJOJQJU^JaJ#h Ch.5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ'hUhU0J5CJOJQJ^JaJ,j&hU5CJOJQJU^JaJhU5CJOJQJ^JaJ&jhU5CJOJQJU^JaJ   ,Ī֖ևufL֖ևu2j'h ChAi5CJOJQJU^JaJhAi5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j'h Ch.5CJOJQJU^JaJ#h Ch.5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ#hUhcZ5CJOJQJ^JaJ,-.=>FGHfghϻϬψnϻϬψTϻϬψ2j)h Ch.5CJOJQJU^JaJ2j)h Ch.5CJOJQJU^JaJ#h Ch.5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ2j(h Ch.5CJOJQJU^JaJ%&'CDJKLvwxϻϬψnϻϬψTϻEψh C5CJOJQJ^JaJ2j*h Ch.5CJOJQJU^JaJ2j*h Ch.5CJOJQJU^JaJ#h Ch.5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ2j)h Ch.5CJOJQJU^JaJ"ϻϬuhTuE6u,hvOJQJ^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^J'j,h ChOJQJU^Jh ChBOJQJ^J!jh ChBOJQJU^J hcZ5#h Ch5CJOJQJ^JaJhcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch.5CJOJQJU^JaJ2j+h Ch.5CJOJQJU^JaJ"#wxyĵ񨣒qbSDh ChcZ0JOJQJ^Jh Ch#0JOJQJ^Jh Ch.0JOJQJ^J'j-h ChOJQJU^Jh ChBOJQJ^J!jh ChBOJQJU^J hcZ5h ChcZOJQJ^Jh5hcZ0JOJQJ^Jh5hv0JOJQJ^J'j,h5hd?OJQJU^Jh5OJQJ^Jjh5OJQJU^J J !P!Q!R!!!!! "n"""#M###gdcZ^gda & FgdcZgd#gdcZgd#     6 7 8 @ A I J K k ׽隈q_Eqqq_2j.h Chsr 5CJOJQJU^JaJ#h Ch N5CJOJQJ^JaJ,jh Ch N5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j .h Chsr 5CJOJQJU^JaJ#h Ch j5CJOJQJ^JaJ,jh Ch j5CJOJQJU^JaJk l m ϻϬ|bϻPP|62j/h Chsr 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ2jy/h Chsr 5CJOJQJU^JaJ#h Ch N5CJOJQJ^JaJha5CJOJQJ^JaJhcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch N5CJOJQJU^JaJ2j.h Chsr 5CJOJQJU^JaJ ! !!!!!5!6!7!F!G!O!P!Q!R!S!v!³ԡxiZHԡ#h Ch5CJOJQJ^JaJh5CJOJQJ^JaJhcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ2jg0h Chsr 5CJOJQJU^JaJ#h Ch N5CJOJQJ^JaJh C5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ,jh Ch N5CJOJQJU^JaJ'h ChcZ0J5CJOJQJ^JaJv!w!x!!!!!!!!!!!!!!!!!!ϻϬψnϻϬidSF2'j1h ChOJQJU^Jh ChQOJQJ^J!jh ChQOJQJU^J hv5 h52jo1h Chsr 5CJOJQJU^JaJ#h Ch N5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch N5CJOJQJU^JaJ2j0h Chsr 5CJOJQJU^JaJ!!!"" "!"G"H"I"e"f"m"n"o"""""ìl]K1l2j2h Chsr 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j_2h Chsr 5CJOJQJU^JaJ#h Chi5CJOJQJ^JaJ,jh Chi5CJOJQJU^JaJh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^J!jh ChQOJQJU^J"""""""""#####2#3#4#µ’vlZ@2j 4h Chsr 5CJOJQJU^JaJ#h Chi5CJOJQJ^JaJh COJQJ^Jh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^J'jg3h ChOJQJU^Jh ChQOJQJ^J!jh ChQOJQJU^JhcZ#h ChcZ5CJOJQJ^JaJ,jh Chi5CJOJQJU^JaJ4#C#D#L#M#N#r#s#t###############±ԟvԟ\vWF!jh ChQOJQJU^J hcZ52j5h Chsr 5CJOJQJU^JaJhv`5CJOJQJ^JaJ2j4h Chsr 5CJOJQJU^JaJ#h Chi5CJOJQJ^JaJ h ChcZCJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ,jh Chi5CJOJQJU^JaJ'h ChcZ0J5CJOJQJ^JaJ##$N$$$%L%|%}%%"&M&&&'''(X(Y((($)X))) & FgdcZgd#gdgdQgdcZ####$$$$$9$:$;$C$D$M$N$O$οΣz`L=+#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j6h Chsr 5CJOJQJU^JaJ#h Ch5CJOJQJ^JaJ,jh Ch5CJOJQJU^JaJh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^J!jh ChQOJQJU^J'j5h ChOJQJU^Jh ChQOJQJ^JO$r$s$t$$$$$$$$$$$$$$$%%%%%%%7%ӼmS2j7h Chsr 5CJOJQJU^JaJ2j6h Chsr 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch5CJOJQJU^JaJ2js6h Chsr 5CJOJQJU^JaJ#h Ch5CJOJQJ^JaJ7%8%9%A%B%K%L%M%g%h%i%q%r%{%|%}%~%%ϻϬψnϻϬ_NAh ChQOJQJ^J!jh ChQOJQJU^Jh C5CJOJQJ^JaJ2jy8h Chsr 5CJOJQJU^JaJ#h Ch5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch5CJOJQJU^JaJ2j8h Chsr 5CJOJQJU^JaJ%%%%%%%%%%%%%%&˼ڠ}fT:f&'h ChcZ0J5CJOJQJ^JaJ2jm9h Chsr 5CJOJQJU^JaJ#h Chf5CJOJQJ^JaJ,jh Chf5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJ h ChcZCJOJQJ^JaJh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch#0JOJQJ^Jh Ch.0JOJQJ^J!jh ChQOJQJU^J'j8h ChOJQJU^J&&!&"&#&;&<&=&C&D&L&M&N&x&y&z&&&&&&&&&&&&&&&&鶜nT2j:h Chsr 5CJOJQJU^JaJ2j[:h Chsr 5CJOJQJU^JaJ'h ChcZ0J5CJOJQJ^JaJ2j9h Chsr 5CJOJQJU^JaJ#h Chf5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ,jh Chf5CJOJQJU^JaJ&&&'''' 'K'L'M'{'|'~'''''ϻϬqWHq.2j<h Chsr 5CJOJQJU^JaJh C5CJOJQJ^JaJ2j;h Chsr 5CJOJQJU^JaJ#h Ch6p 5CJOJQJ^JaJ,jh Ch6p 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Chf5CJOJQJU^JaJ2jc;h Chsr 5CJOJQJU^JaJ''''''''''(((((7(8(9(O(P(W(X(Y(Z(z(ƴ颈ƴnƴiXKh ChQOJQJ^J!jh ChQOJQJU^J hcZ52j=h Chsr 5CJOJQJU^JaJ2j=h Chsr 5CJOJQJU^JaJ#h Ch6p 5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch6p 5CJOJQJU^JaJz({(|((((((((((((( ) )ھ{gXF,2j(?h Chsr 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2j>h Chsr 5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJh ChcZOJQJ^Jh ChQ0JOJQJ^J!jh ChQOJQJU^J'j,>h ChOJQJU^J ) )))#)$)%)A)B)C)M)N)W)X)Y)s)t)u)))))))))))))))ƴ颈ƴnƴTƴ2j@h Chsr 5CJOJQJU^JaJ2j"@h Chsr 5CJOJQJU^JaJ2j?h Chsr 5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ))))))******8*9*A*B*\*ϻϬ|hYJ=+#h Ch 5CJOJQJ^JaJh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^J'jAh ChOJQJU^Jh ChQOJQJ^J!jh ChQOJQJU^J#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ2jAh Chsr 5CJOJQJU^JaJ))*A*~** +L+++ ,J,,,,,,-f----.c...!/ & Fgd gd ^gdgd#gdcZ & FgdcZ\*]*^*u*v*}*~*************++ + ++)+ϻϬψnϻϬψTϻϬψ2jBh Chsr 5CJOJQJU^JaJ2jcBh Chsr 5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ2jAh Chsr 5CJOJQJU^JaJ)+*+++C+D+K+L+M+k+l+m+z+{++++++++++++ϻϬψnϻϚψTϻϬ2jADh Chsr 5CJOJQJU^JaJ2jCh Chsr 5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ2jQCh Chsr 5CJOJQJU^JaJ+++++,,, , ,&,',(,C,D,J,K,m,n,o,,,,,,,׽隈nT隈2jEh Chsr 5CJOJQJU^JaJ2j;Eh Chsr 5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jDh Chsr 5CJOJQJU^JaJ#h Chsr 5CJOJQJ^JaJ,jh Chsr 5CJOJQJU^JaJ,,,,,,,,,,,,,,,,,,ϻϬy_ϻϬMH7!jh ChdOJQJU^J h5#hv`hcZ5CJOJQJ^JaJ2jFh Chsr 5CJOJQJU^JaJ#h Chsr 5CJOJQJ^JaJ#h Ch5CJOJQJ^JaJhcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Chsr 5CJOJQJU^JaJ2j5Fh Chsr 5CJOJQJU^JaJ,- - - - ------:-;-<-^-_-f-οΔ}kQ}=}+#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jGh Ch5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJh ChcZOJQJ^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^Jh Ch#0JOJQJ^J!jh ChdOJQJU^J'j!Gh ChOJQJU^Jh ChdOJQJ^Jf-g-----------------...".#.,.-...E.׽隈n隈T隈2jIh Ch5CJOJQJU^JaJ2jHh Ch5CJOJQJU^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ2jHh Ch5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJE.F.G.Y.Z.].b.c.d................. /ϻϩψnϻϚψTϻϚψ2jJh Ch5CJOJQJU^JaJ2jIh Ch5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJhv`5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ2jIh Ch5CJOJQJU^JaJ / / /// /!/"/?/@/A/K/L/T/U/V/s/t/u///////ϻϬψnϻϬψTϻϬψ2jKh Ch5CJOJQJU^JaJ2j~Kh Ch5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ2jKh Ch5CJOJQJU^JaJ!/U///000y0z0{001O111 2c222=333 4!4"44gdqWh^hgdcZgd Cgd#gdcZ & FgdcZ///////////0 000000I0J0K0ϻϬψnϻϬidSI5S'jnMh Ch^OJQJU^Jh COJQJ^J!jh ChdOJQJU^J h 5 hcZ52jLh Ch5CJOJQJU^JaJ#h Ch 5CJOJQJ^JaJ#h ChcZ5CJOJQJ^JaJhv`5CJOJQJ^JaJ'h ChcZ0J5CJOJQJ^JaJ,jh Ch 5CJOJQJU^JaJ2jpLh Ch5CJOJQJU^JaJK0O0t0u0w0x0y0z0{0|00000000fUD1%hWghcZB*OJQJ^JaJph hWghcZ0JOJQJ^JaJ hWgh C0JOJQJ^JaJ7jNhWgh^>*B*OJQJU^JaJph(hWgh C>*B*OJQJ^JaJph1jhWgh C>*B*OJQJU^JaJphh`hcZh ChcZ5h Ch ChcZOJQJ^J!jh ChdOJQJU^Jh ChcZ0JOJQJ^Jh Ch.0JOJQJ^J00000000111-1.1/1F1G1I1N1O1P1r1s1t1111111111111111ὸܨḽo_jPhW2h5Uj?PhW2h5UhW2hcZ0J5jOhW2h5U hW25jhW25Uj+Ohw;h5U hcZ5 hv`5hw;hcZ0J5jNhw;h5U hw;5jhw;5U(hWghcZ>*B*OJQJ^JaJph%11222 2!2E2F2G2\2]2b2c2d2222222222222222233 33343=3>3[3\3]33333333ݽݭݘ݈xjShW2h5Uj=ShW2h5UjRhW2h5U hE6v5j3RhW2h5UjQhW2h5Uj+QhW2h5U hW25 hcZ5 hv`5hW2hcZ0J5jhW25U/3333344444"4@4K4L4444444555555 5)5*5ƾ抃sleXS hZoq5hPZh]OJQJ^J h]5>* h]5>*hPZh]5>*OJQJ^J h#5>*hPZh#5>*OJQJ^J h5 hqWhh>ZhqW0JjTh =Uh>Zjh>ZU h>ZhqWhqWjCThW2h5U hW25 hcZ5jhW25UhW2hcZ0J5455555 5)5*5H5Q5R5a5b5m5555557R8888^`` & FgdcZh^hgdcZ*5Q5R5a55555577777777888O8P8Q8R88ĹĖ{p]{M{?hPZh2/;5OJQJ^Jh h 0J5OJQJ^J$jZh 5OJQJU^Jh 5OJQJ^Jjh 5OJQJU^Jh 5OJQJ^JhH8+h0J5OJQJ^J$jkVhH8+5OJQJU^JhH8+5OJQJ^JjhH8+5OJQJU^Jh5OJQJ^JhPZh]OJQJ^J h]5hPZh]5OJQJ^J8888888888888888888999N9O999񶲮zk[MIhvNhUhvN5OJQJ^JhUhvN5OJQJ^JaJhUhvNOJQJ^JaJhvNhvN5OJQJ^JaJhvN5OJQJ^JhV15OJQJ^JhV1hV15OJQJ^JhH8+hV1h]5OJQJ^JhPZh]5H*OJQJ^J h]5hPZh]OJQJ^JhPZh2/;5OJQJ^JhPZh]5OJQJ^J888888888999%9:9N9 $IfgdV1gdV1^N9O9d999riii $IfgdV1kdO[$$IflFL  t0    44 laytU999\:]:w:riiii $IfgdV1kd[$$IflFL  t0    44 laytU99::Z:[::::::;;u;v;;;;;;1<2<<<><M<U<V<v<w<}<<<<鵧ykghPhUhP5OJQJ^JhUh[56OJQJ^JhUh5CJOJQJ^JhUh[5OJQJ^JhUh5OJQJ^JhUhvN5OJQJ^J'hUhvN0J5CJOJQJ^JaJ#hUhvN5CJOJQJ^JaJ,jhUhvN5CJOJQJU^JaJ w:x::::riii $IfgdV1kdu\$$IflFL  t0    44 laytU:::::riii $IfgdV1kd]$$IflFL  t0    44 laytU::;v;;ri`` $IfgdV1 $Ifgd[kd]$$IflFL  t0    44 laytU;;;;;ri`` $IfgdV1 $Ifgd[kd.^$$IflFL  t0    44 laytU;;;2<=<ri`i $IfgdU $IfgdV1kd^$$IflFL  t0    44 laytU=<><V<w<~<riii $IfgdV1kdT_$$IflFL  t0    44 laytU~<<<<===riiiii $IfgdV1kd_$$IflFL  t0    44 laytU<<>=?===========\>>>>???C??ۻtfYL?hP5CJOJQJ^Jho5CJOJQJ^JhPZh]OJQJ^Jhoho5OJQJ^Jhoh[OJQJ^Jhoh[5OJQJ^JhV15OJQJ^Jho5OJQJ^Jh[5OJQJ^JhvN5OJQJ^JhUhP5OJQJ^J#hUhP0J5CJOJQJ^JhUhP5CJOJQJ^J(jhUhP5CJOJQJU^J====>>??AArmmeeecWRgdP $^a$gdo & F-gdogdV1kdz`$$IflFL  t0    44 laytU ???-@/@0@s@t@@@@@@@@AAAAA1AKALAfAgAhAiAtAuAvAAAAᲮ}oj`VhYOJQJ^Jh]OJQJ^J h]5h<h<5OJQJ^Jh<5OJQJ^JhP5OJQJ^Jh<h]5OJQJ^Jh<h]OJQJ^Jh]hV15CJOJQJ^J#h hP0J5CJOJQJ^JhPhP5CJOJQJ^JhP5CJOJQJ^J"jhP5CJOJQJU^J AAAA'A2A3AKALAgAhAiAtAuAAAAAAAAAA;B gd4<gdPgdP & F^AAA0B:B;B?B@BEBFBOB`BzBBBBBB3C_CzC{C}CCCCCCDDز؎wieiiZhP5OJQJ^Jh?h?h?5OJQJ^Jh?h?OJQJ^Jh?OJQJ^Jh?5OJQJ^Jh<h+&5OJQJ^Jh+&5OJQJ^Jh]5OJQJ^Jh]h<h4<OJQJ^Jh<OJQJ^Jh<h]5OJQJ^Jh<h]OJQJ^Jh<hYOJQJ^J;BFBGB`BzB{BBBBBC2C3CVCjC{C}CCCDDDDDDgdi^gdi`gdPgd? ^gd<DDbDcDdDDDDDDDDDDDEEEEEE_F²𮣕}rn`U`G9h+&h+&>*OJQJ^Jh<h]>*OJQJ^Jh+&5OJQJ^Jhihi5OJQJ^Jhih]>*OJQJ^Jhi>*OJQJ^Jh<h]OJQJ^Jh<h]5OJQJ^Jhi5OJQJ^Jh]h!ah?0J5OJQJ^Jh!ahP0J5OJQJ^J$j ah!a5OJQJU^Jh!a5OJQJ^Jjh!a5OJQJU^JDD/E0EEEEE`FaFFFGGGGGJG{G|G H=H+I,I.IGI & F^gd_ t & F.gd_ tgd+&`gdi_F`FaFGGGGHGIGJGOGXGzG{G|GKHsH*I+I,I-I.IGINIŴsddRMIM<h<h]OJQJ^Jh] h]5#h+&h_ t5CJOJQJ^JaJh_ t5CJOJQJ^JaJh]5CJOJQJ^JaJhzE85CJOJQJ^JaJh+&5CJOJQJ^JaJ&hzE8h+&5>*CJOJQJ^JaJ hzE85>*CJOJQJ^JaJ hY5CJ h]5CJh<h]5CJOJQJ^Jh<h]5OJQJ^Jh+&h]5OJQJ^JGIHIhIiIjIIIIIIIIIIIIIIIJJ JJ$Jgd5^gd5 & Fgd5gd5gd5 & F^NIgIhIiIjIIIIIIIIIII J JJ#J$JCJKKK&K'K(K̿㿫~q~dYYNhY5OJQJ^Jh55OJQJ^Jhfh5OJQJ^Jhu h5OJQJ^Jh5OJQJ^Jh<h5OJQJ^Jh<h55OJQJ^Jh<h]h5h<h]5>*OJQJ^Jh<h]OJQJ^Jh<hXzROJQJ^JhXzROJQJ^Jh<h]5OJQJ^Jh<h5OJQJ^J$J9JKKKK'K(K)K*K+KGKQKSKKKKLYLZLpL~LLLLgd.9 ^`gd.9gd.9gd5 ^`gd5(K)K*KGKQKSKKKKKKKKKL'L+LYLpL~LLLLLLLM3M5M6MgMhMiMvMwMxM˙˙˕˙˙˙˙wb(jh02B*CJOJQJU^Jphf%h_>h5B*CJOJQJ^Jphfh025OJQJ^Jh5h55OJQJ^Jh.9h<h.95OJQJ^Jh.9OJQJ^Jh.95OJQJ^Jh<h55OJQJ^Jh<h5OJQJ^Jh<hY5OJQJ^Jh!X5OJQJ^J#LLLLLMMM6MBM]MhMiMNNN"N#N/N>NLN $Ifgd6,gd5^gd5 & Fgd5 ^`gd5xMMMMNNNN"N#NLNMN~NNNNNNNNOOOOOOnPoPPPQ Q± un^Q^Q^n^n^n^n^n^n^n^Qh55OJQJ^JaJhjh55OJQJ^JaJ hjh5hjh5OJQJ^JaJh5h<h5OJQJ^Jh55OJQJ^J!h_>h5B*OJQJ^Jphf h02h50JCJOJQJ^J(jh02B*CJOJQJU^Jphf.jbh02B*CJOJQJU^Jphfh02B*CJOJQJ^JphfLNMN~NNN`WWW $Ifgd6,kdc$$IflF$   t06    44 lapyt6,NNNNN`WWW $Ifgd6,kdc$$IflF$   t06    44 lapyt6,NNNOO`WJW $If`gd6, $Ifgd6,kdSd$$IflF$   t06    44 lapyt6,OOOOOxooo $Ifgd6,kdd$$Ifl0$  t0644 lapyt6,OOOOO`WWW $Ifgd6,kde$$IflF$   t06    44 lapyt6,OOPPmPnP`WWWW $Ifgd6,kd)f$$IflF$   t06    44 lapyt6,nPoPPPP`WWW $Ifgd6,kdf$$IflF$   t06    44 lapyt6,PPQQQ`WWW $Ifgd6,kdmg$$IflF$   t06    44 lapyt6, QQQ*Q6Q8QQQQQQQrRsRtRRRRRRS*CJOJQJ^J hOhO0JCJOJQJ^J hOh50JCJOJQJ^J(jhOB*CJOJQJU^Jphf.jyxhOB*CJOJQJU^JphfhOB*CJOJQJ^Jphf!c"ckclcmccccccceee eiejeke벡둁qdO7O.j{zh\FB*CJOJQJU^Jphf(jh\FB*CJOJQJU^Jphfh55OJQJ^JaJhy h55OJQJ^JaJh\FB*CJOJQJ^Jphfh5B*CJOJQJ^Jphf h14Nh14N0JCJOJQJ^J h14Nh50JCJOJQJ^J.jzyh14NB*CJOJQJU^Jphfh14NB*CJOJQJ^Jphf(jh14NB*CJOJQJU^Jphfkeeeeeeef f fSfTffffffffffffgg.gCgFg[g\ggh h}hxiijͱ͜ͱzzm^^zzzzz^zhy h5OJQJ^JaJh\F5OJQJ^JaJhy h55OJQJ^JaJ#hu h50J5OJQJ^JaJ(jhu h55OJQJU^JaJhu h55OJQJ^JaJh5OJQJ^JaJh55OJQJ^JaJ(jh\FB*CJOJQJU^Jphf h\Fh50JCJOJQJ^J$f.g~hhdii jjkk3kLkMkkkkkklOliljll r ^gd2Z^gd5 & Fgd5^gd5`gd5 & F%gd5gd5j#jHjPjQjRjnjkkk k2k3kKkLkMkkkllhliljll3m4mmnnnnnnnnoo򶧘~njh5hy h2Z5OJQJ^JaJh2Z5OJQJ^JaJh\F5OJQJ^JaJh@h5OJQJ^JaJhy h5OJQJ^JaJh5OJQJ^JaJh%7,h55OJQJ^JaJh |h55OJQJ^JaJhy h55OJQJ^JaJh55OJQJ^JaJ$ll3m4m`mammmnnnnnnnnnooo.o*h_h#5>*OJQJ^J h\Fh9h]h5"hy h55H*OJQJ^JaJ(h5h55B*OJQJ^JaJph"h55B*OJQJ^JaJphh55OJQJ^JaJhy h5OJQJ^JaJhy h55OJQJ^JaJh kh55OJQJ^JaJUoaobojovoooooooop p1p2p4pJpKp_p`papppgd/ 0^`0gd/gd\F^gd5gd5^gd5Jp^p_p`pappppppp6q7q8qMqNqqqqqqrrrrrrrr>s|ssڿn]] hjh/CJOJQJ^JaJ#hjhn@x5CJOJQJ^JaJhn@x5CJOJQJ^JaJh5CJOJQJ^JaJh/5CJOJQJ^JaJ#hjh/5CJOJQJ^JaJhjh/OJQJ^JaJh/OJQJ^JaJhol$h/OJQJ^JaJh/OJQJ^Jhol$h/OJQJ^Jppppppp $Ifgd>wgd/ppkd|{$$Iflr B: `  t20J!44 lap2ytjpppq7q8qMqNqOqbqcqdqyqzqqqqqqqqqqqqqqqq $Ifgd>wqqqqqqqqqqqqqqrrrrrrrrrr,r $Ifgd>w,r-r9rMrNr2))) $Ifgd>wkd|$$Iflr B: ` t0J!44 lap2ytjNrOr`rartr{r|r}rrrrrrrrrrrrrrrr $Ifgd>wrrr>sCs2--$ $Ifgd>wgd/kd|}$$Iflr B: ` t0J!44 lap2ytjCsOsXsks{s $Ifgd>w{s|s kd[~$$Iflr ! pT  t20x!644 lap2ytj|ssssssssss $Ifgd>w ss tt#t.%%% $Ifgd>wkd$$Iflr ! pT t0x!644 lap2ytj#tWt`tatmt%kdk$$Iflr ! pT t0x!644 lap2ytj $Ifgd>wsWt`tatltmt~tttttttttttuu uuuDuEuLu[unuouŶŧŧŧŧŝucucucYLYLhol$h/OJQJ^Jh/OJQJ^J#hjhtCT5CJOJQJ^JaJhtCT5CJOJQJ^JaJhjhtCTOJQJ^JaJhtCTOJQJ^Jh\FOJQJ^Jh G5CJOJQJ^JaJhY5CJOJQJ^JaJ#hjhY5CJOJQJ^JaJ#hchY5CJOJQJ^JaJ,h`.hY5B*CJOJQJ^JaJphmttttt $Ifgd>wtttt.))gd/kdR$$Iflr ! pT t0x!644 lap2ytjtttttt $IfgdtQttkd9$$Iflr ! pT  t20x!644 lap2yttQtuuu+uCu $IfgdtCT $IfgdtQCuDuEuFuou0+++gd/kd]$$Iflr ! pT t0x!644 lap2yttQoutuuuuu $Ifgd>wuukd?$$Iflrq/ ! pT  t20x!644 lap2ytjouuBvvvvvvvvvvvv wwwwvwxwwwwwwww+x,x-x.x߷mmmmcYh9OJQJ^Jh/OJQJ^J#hjh!O5CJOJQJ^JaJ+hjh!O5CJOJQJ^JaJmHsH%h!O5CJOJQJ^JaJmHsHh!O5CJOJQJ^JaJ#h!Oh!O5CJOJQJ^JaJ+hjh/5CJOJQJ^JaJmHsH#hjh/5CJOJQJ^JaJhjh/OJQJ^JaJuuuuuuuuuuvvvv$v%v&v5v $Ifgd>w5v6vBvlvmv0''' $Ifgd>wkdc$$Iflrq/ ! pT t0x!644 lap2ytjmvvvvvvvvvvvvv $Ifgd>w vvvw0' $Ifgd>w $Ifgd!OkdE$$Iflrq/ ! pT t0x!644 lap2ytjwww2w3www $Ifgd>wwwxwww0' $Ifgd>w $Ifgd!Okd'$$Iflrq/ ! pT t0x!644 lap2ytjwwwww+x $Ifgd>w+x,x-x.xAx0+++gd/kd $$Iflrq/ ! pT t0x!644 lap2ytj.x3xAxxxxx"y#yByCykylyyyyyyyyyzzz˻˘ˉˉ}n}n}aQAhv9h/5OJQJ^JaJh9h\F5OJQJ^JaJh/5OJQJ^JaJhv9h/OJQJ^JaJh/OJQJ^JaJhB65CJOJQJ^JaJ+hjh/5CJOJQJ^JaJmHsHh5OJQJ^JaJhjh/5OJQJ^JaJ#hjh/5CJOJQJ^JaJhjh/OJQJ^JaJh/OJQJ^JhONOJQJ^JAxFxRx[xnx~x $Ifgd>w~xxkd$$IflrT !  t20x!44 lap2ytjxxxxxxxxx y y"y#y7y8y@yAyByCyIyJyWyXyYyZyjykylyyy $Ifgd>wyyyyyyyyyy $Ifgd>wyyyyy2---gd/kd$$IflrT ! t0x!44 lap2ytjyz@z~zzzz${B{{{/||||}}}}}}} $Ifgd# gdON ^ gd\F & F*gd/gd/`gd/ & F)gd\F & F)gd/ & F)gd/z{ {8{B{Y{e{k{{{{{{{||U}t}u}}}}}}} ~~ջȮȡȇ}p}paO#hjhON5CJOJQJ^JaJhjhONOJQJ^JaJhol$hONOJQJ^JhONOJQJ^JhON5OJQJ^JaJhv>5OJQJ^JaJh`F5OJQJ^JaJh!O5OJQJ^JaJh\F5OJQJ^JaJh/5OJQJ^JaJhh/5OJQJ^JaJh/OJQJ^JaJhh/OJQJ^JaJ} ~ $Ifgd#  ~ ~kdϊ$$Iflr ! pT  t20x!44 lap2yt#  ~0~B~C~P~u~~ $Ifgd# ~~~~~~2----gd/kd$$Iflr ! pT t0x!44 lap2yt# ~~~r|΀Rxy|ȂɂӹkUkFh/5CJOJQJ^JaJ+hjhRv5CJOJQJ^JaJmHsH+hjh/5CJOJQJ^JaJmHsH#hjh/5CJOJQJ^JaJhjh/OJQJ^JaJh/OJQJ^Jhfsh/OJQJ^Jh`FOJQJ^Jhchc5OJQJ^JaJhchON5OJQJ^JaJhchONOJQJ^JaJh95OJQJ^JaJ~%.AQ $Ifgd>wgd/ QRkdό$$Iflr !t  t20x!44 lap2ytjR`rҁ $Ifgd>w /02))) $Ifgd>wkd$$Iflr !t t0x!44 lap2ytj012F\]^| $Ifgd>w 2))) $Ifgd>wkd$$Iflr !t t0x!44 lap2ytjɂʂԂ  $Ifgd>w ɂӂԂƒڃyz{˄̄ م̰̽vl_P:+hjh/5CJOJQJ^JaJmHsHhjh/OJQJ^JaJhol$h/OJQJ^Jh/OJQJ^Jh/>*OJQJ^JaJh!Oh95OJQJ^JaJhh/5OJQJ^JaJh?k5OJQJ^JaJh/5OJQJ^JaJh/5CJOJQJ^JaJ#hjh/5CJOJQJ^JaJ#hjh' 5CJOJQJ^JaJh' 5CJOJQJ^JaJ2**$a$gd/kd$$Iflr !t t0x!44 lap2ytjz{̄ф݄ $Ifgd>wgd/$a$gd/$a$gd!O kdU$$Iflr !tT  t20x!644 lap2ytj &'()*+,GHIg…؅مڅ $Ifgd>wمڅ\ۇ܇݇/0EFQRxk[L[<[<[<[<[<hchq?5OJQJ^JaJhchcOJQJ^JaJhchc5OJQJ^JaJh/5OJQJ^JaJhchVT5OJQJ^JaJhVT5OJQJ^JaJh' 5OJQJ^Jhjh/5OJQJ^J#hjh/5CJOJQJ^JaJ+hNNh/5CJOJQJ^JaJmHsH+hjh/5CJOJQJ^JaJmHsH%h2i5CJOJQJ^JaJmHsH"#$%4567MNO\qrs $Ifgd>w܇݇0+++gdVTkdy$$Iflr !tT t0x!644 lap2ytj݇ET͈̈؈߈[kd[$$Ifl09   t0644 lapyttQ $IfgdVTgdVT ߈/07>E{{{{{{{{ $IfgdVT{kd$$Ifl09  t0644 layttQ EFRs{{{{{{ $IfgdVT{kdz$$Ifl09  t0644 layttQ͉Ήω QRSTĊ׊2µ~n¨^OOO@Ohol$hAOJQJ^JaJhol$h/OJQJ^JaJhol$h/>*OJQJ^JaJhjh/5OJQJ^JaJhjh/OJQJ^JaJhe/h/OJQJ^JaJh/OJQJ^JaJhA>*OJQJ^JaJh!O>*OJQJ^JaJh/>*OJQJ^JaJhVThc5OJQJ^JaJhchq?5OJQJ^JaJhchc5OJQJ^JaJΉωԉwwwwrriiii $Ifgd>wgd/$a$gd/gdVT{kd$$Ifl09  t0644 layttQ $Ifgd>w kdd$$Iflr !tT  t20x!644 lap2ytj "';P $Ifgd>wPQRS0++gd\Fkd$$Iflr !tT t0x!644 lap2ytjST2͋V_x$s&P#$/Ifgd\F$s&P#$/Ifgd\Fgd/$a$gdVTh^hgd/$a$gd/2opqʋˋ̋͋UW_wxñ≱weXH9H9hol$h\FOJQJ^JaJhol$h\F5OJQJ^JaJh\F5OJQJ^JaJ"hol$h/5>*OJQJ^JaJ#h"h/0J5OJQJ^JaJ.jxh"h/5OJQJU^JaJhih/5OJQJ^JaJ"jh/5OJQJU^JaJhVT5OJQJ^JaJhVT5OJQJ^J hih/h/5OJQJ^JaJhol$h/5OJQJ^JaJˌ̌3;<34[r{ȏɏ̏оППyeо'hol$h\F>*OJQJ^JaJmH sH *hol$h\F5>*OJQJ^JaJmH sH hyh\F5OJQJ^JaJh\F5OJQJ^JaJ"hol$h\F5>*OJQJ^JaJ"hol$h\F5H*OJQJ^JaJhol$h\F5OJQJ^JaJhol$h\FOJQJ^JaJhol$h\FH*OJQJ^JaJ!wqaQaaQQ$s&P#$/Ifgd\F$s&P#$/Ifgd\Fkdy$$Ifl_0n C!   6Ps 0!4 lap yt\FqaQQQa$s&P#$/Ifgd\F$s&P#$/Ifgd\Fkd3$$Ifl0n C!   6Ps 0!4 lap yt\FD[|ɏ$s&P#$/Ifgd\F & F h$s&P#$/If^gd\F & F $s&P#$/Ifgd\F ':qaQQaQ$s&P#$/Ifgd\F$s&P#$/Ifgd\Fkd$$IflU 0n C!   6Ps 0!4 lap yt\F &':^tunpz ]_`aoƓξwk\Lhh/5OJQJ^JaJhh/OJQJ^JaJhPOJQJ^JaJh/OJQJ^JaJ"hh\F5H*OJQJ^JaJh\F5OJQJ^JaJhyh\F5OJQJ^JaJh\FOJQJ^JaJhh\F>*OJQJ^JaJ"hh\F5>*OJQJ^JaJhh\FOJQJ^JaJhh\F5OJQJ^JaJ:opzJ:$s&P#$/Ifgd\Fkd$$Ifl4I0n C!   6Ps 0!4 laf4p yt\F$s&P#$/Ifgd\F & F($s&P#$/Ifgd\F ^_`ao+Ɠ^VVQLLgd/gd/$a$gd/kdg$$Ifl400n C!   6Ps 0!4 laf4p yt\F$s&P#$/Ifgd\FƓǓ '(×ė q| 7$8$H$gd+gdgdgd# gd/ƓǓޓ 56}~¶§l[O@hh?kOJQJ^JaJh/OJQJ^JaJ hFh?k0JOJQJ^JaJ%j'hCOJQJU^JaJhCOJQJ^JaJjhFOJQJU^JaJh?kOJQJ^JaJhh/OJQJ^JaJh\FOJQJ^JaJhch# OJQJ^JaJhchVTOJQJ^JaJhch/OJQJ^JaJhch/5OJQJ^JaJ(OPcrtuviklƶ۶Ƈ۶qV@+hch5>*B*OJQJ^JaJph4jhch5>*B*OJQJU^JaJph+hch5>*B*OJQJ^JaJph,hch0J5B*OJQJ^JaJph.j(hch5OJQJU^JaJhch5OJQJ^JaJ(jhch5OJQJU^JaJ"hch5>*OJQJ^JaJ#hch5CJOJQJ^JaJ—×ė ٙǵǟ{fT@,@,@,&h+5B*CJOJQJ^JaJph&h+B*CJOJQJ\^JaJphM"hDCB*CJOJQJ\^Jph(jhchDCCJOJQJU\^JhchOJQJ^JaJ(hch5B*OJQJ^JaJph+hch5>*B*OJQJ^JaJph#hchH0J5OJQJ^JaJ4jhch5>*B*OJQJU^JaJph:jhch5>*B*OJQJU^JaJph|ڙۙKm,-:ʞ"#/gd/gd/gdgdgd+ٙڙۙ^lj-:ʞ"/ǹ{k{k[k[k{K{9"hch?k5>*OJQJ^JaJhch/>*OJQJ^JaJhchoHr>*OJQJ^JaJhchoHr5OJQJ^JaJhch/5OJQJ^JaJhch5OJQJ^JaJhch5OJQJ^Jhch5OJQJ^JaJhch5OJQJ^Jhch>*OJQJ^JaJ(hh5B*OJQJ^JaJph%hhB*OJQJ^JaJph/Xhjkӟԟ՟ͷzk^N<"hh/5>*OJQJ^JaJhh/>*OJQJ^JaJh/>*OJQJ^JaJhh/OJQJ^JaJ#hh"0J5OJQJ^JaJ1jFh5B*OJQJU^JaJph"h5B*OJQJ^JaJph+jh5B*OJQJU^JaJph"h"5B*OJQJ^JaJphhch"5OJQJ^JaJhch?k5OJQJ^JaJ(ǡ+:et}HɥҳҔrbҔSA"hch5>*OJQJ^JaJhch/OJQJ^JaJhchv>5OJQJ^JaJ"hch5H*OJQJ^JaJhch5OJQJ^JaJhch5OJQJ^JaJhch&iOJQJ^JaJhch/OJQJ^JaJhch&i5OJQJ^JaJhch/5OJQJ^JaJh/5OJQJ^JaJhh/5OJQJ^JaJT;KtIwHrɥ4$a$gdgd & F( hh^hgd>w & F $ gd>w & Fgd/ & F gd & F gd/ & F gd & F gd/ & F gd/I\^mԧ0134978JKڵ}k[L@9 hh/h/OJQJ^JaJhh/OJQJ^JaJhh/5OJQJ^JaJ#hh/5CJOJQJ^JaJh/5CJOJQJ^JaJ+hh5>*B*OJQJ^JaJph%h5>*B*OJQJ^JaJph%h5>*B*OJQJ^JaJph"hch5>*OJQJ^JaJ"hch5>*OJQJ^JaJ%hch5>*H*OJQJ^JaJ478KLQ]fk $Ifgd>w^gd/gd/$a$gd/gd/ KLl bcdop۬ŻufVF6F6FhchV{5OJQJ^JaJhch/5OJQJ^JaJhh/5OJQJ^JaJhh/OJQJ^JaJh.Wh/OJQJ^JaJhh/5OJQJ^JaJhh/5OJQJ^JaJhh/OJQJ^Jh=IOJQJ^Jh/OJQJ^Jh\FOJQJ^Jh/hjh/5OJQJ^JaJhjh/OJQJ^JaJh/5OJQJ^JaJkl{|}-$$$ $Ifgd>wkdG$$Ifl\NQ !!   t(0x!644 lap(ytj}ީߩ $Ifgd>w HC//C & F hh^h`gd/gd/kd&H$$Ifl\NQ !! t0x!644 lap(ytj cdop٫ګ۬ܬݬϭЭE=>+RS^ & Fgd/^gd/$a$gd`F$a$gd/gd/$a$gd/gd/^gd/۬ܬݬ<\ϭE>+QRS^_ճՒՒՂscTD7Dh5OJQJ^JaJhjh/5OJQJ^JaJhjh/OJQJ^JaJhh/5OJQJ^JaJhh/OJQJ^JaJhch\F5OJQJ^JaJhch/OJQJ^JaJ#hch/5CJOJQJ^JaJ"hch/5OJQJ\^JaJhchB5OJQJ^JaJhch/5OJQJ^JaJhP5OJQJ^JaJh/5OJQJ^JaJ^_dpy~ $Ifgd>wgd/~-$$$ $Ifgd>wkdH$$Ifl\:0 !  t(0x!644 lap(ytjɳ ,-./8> $Ifgd>wȳɳ -78@ADETU]fg޴ߴ(ȸȸȸo_hvB*CJOJQJ^Jphf(jhvB*CJOJQJU^JphfhKO5OJQJ^JaJh/5OJQJ^JaJh5OJQJ^JaJh05OJQJ^JaJhjh/5OJQJ^JaJhjh!O5OJQJ^JaJh!O5OJQJ^JaJh#J5OJQJ^JaJhWiv5OJQJ^JaJ#>?@CDEKUVWX]^_`ag޴x $Ifgd>w()*6vwxyٵ 2±ӡqbRbRERERERE? h]CJh/5OJQJ^JaJhh/5OJQJ^JaJhh/OJQJ^JaJhjh/5OJQJ^JaJh!Oh!O5OJQJ^JaJh!OB*CJOJQJ^Jphfh#JB*CJOJQJ^Jphf hvh#J0JCJOJQJ^J hvh"0JCJOJQJ^J(jhvB*CJOJQJU^Jphf.jIhvB*CJOJQJU^Jphfxy?6^gd/kdJ$$Ifl\:0 ! t0x!644 lap(ytj $Ifgd>wٵڵ34NOPjkGַ׷$=Y^gd ^gd;$^ & F hgd.^^gd/gd/ & Fgd/2347NP{ַ׷ <=XYfĸŸ߸ $=ȻȻ̠̠v̻̻̻k`Vh>ZOJQJ^Jh^5OJQJ^Jh5OJQJ^Jhh\F5OJQJ^Jhh;$5OJQJ^Jhh]R5OJQJ^Jhh 5OJQJ^Jhh]ROJQJ^Jhh]OJQJ^Jh]hh]5OJQJ^Jhh.5>*OJQJ^J h]5h/h]5OJQJ^JaJ YZfoyĸŸٸ $(34567mn$a$gd9+^gd"` & F^=>?ιϹй(23456qcUJ?hP5OJQJ^Jh9+5OJQJ^Jhh/5OJQJ^Jhh"5OJQJ^JhhvD5OJQJ^Jhh]OJQJ^Jh>Zh>Z5OJQJ^Jhh]5OJQJ^Jhvh>Z5OJQJ^Jhvhv0J5OJQJ^J$jKh{5OJQJU^Jh{5OJQJ^Jjhv5OJQJU^Jhv5OJQJ^J67hlnJiFGQRbc4[\ʾʳʾʯʨʤʨʐ|o\UQh/ hh$hh9+B*OJQJ\^Jphhh9+B*\ph'hh5>*B*OJQJ^Jph'hh9+5>*B*OJQJ^JphhIF\ hh}h\Fhh9+CJaJhh9+5h}p hh9+hh}5>*OJQJ^Jhh9+5>*OJQJ^JhhP5OJQJ^Jn2,Rc4\z,Tk 7$8$H$gdIF\ gd\F gd\F gd 7$8$H$gd9+ 7$8$H$gd9+ & Fgd & Fgd/ gd & Fgd9+CDE\SX1!"#q˺ẑ~ẳqfq_qqX hh hh\Fhh9+OJQJhh9+OJQJ^J$hh9+B*OJQJ\^Jph'hh9+5B*OJQJ\^Jphhh9+B*\]ph hh9+!hh9+B*OJQJ^Jph*hh9+5B*OJQJ\]^Jph'hh9+B*OJQJ\]^Jph hhPh9+DE3SX & F#7$8$H$gd9+ & F"7$8$H$gd9+ 7$8$H$gd9+ & F!<7$8$H$gd9+ gd1Uk"#qr^ & Fgd9+gd9+ 7$8$H$gd9+ & F$7$8$H$gd9+ gdqr 45 ʼ~oj\XNAhhwWOJQJ^Jh IOJQJ^Jh]jh*UmHnHu h]>*jh]>*UmHnHuhjH5hjH50J5OJQJ^J$jFMhjH55OJQJU^JjhjH55OJQJU^JhjH55OJQJ^Jhh]5OJQJ^Jhh]OJQJ^J hP5 h]5)hh9+B*CJOJQJ^JaJphh9+OJQJ^JZ[{|} & Fgd Igd*^^ defyz{}/6@ʱآؕ}seWLWs>hh^#5OJQJ^JhU>*OJQJ^JhUhU>*OJQJ^JjhUUmHnHuhUOJQJ^Jh]OJQJ^Jhh]5OJQJ^Jhh]OJQJ^Jh IhwW0JOJQJ^J0jPh>Zh =B*OJQJU^Jphh>ZB*OJQJ^Jph*jh IhwWB*OJQJU^Jph!h IhWgB*OJQJ^Jph/AP\e +567^gd*-dhgd9`^ *5Fp:UW{EĶIJ㥡r㡥bWhX5OJQJ^JjhX5OJQJU^Jhh;85OJQJ^Jh5OJQJ^Jh;85OJQJ^Jh]5OJQJ^Jh]hh]OJQJ^Jh!)jh UmHnHuh7h8Hh$ h8H5hh8H5OJQJ^Jhh]5OJQJ^Jhh0f5OJQJ^J"7FGU_pq:IUVz{_`a^gd;8`^ & FEFGS]^_i %&(235?@BJKMSTV[]ͽݯ}}}}}}}}}}}}hh]OJQJ^J h]5h]hh]>*OJQJ^Jhh]5OJQJ^JhhqI5OJQJ^JhXhH0J5OJQJ^JhXhqI0J5OJQJ^JjhX5OJQJU^J$jQhX5OJQJU^J1ankdR$$Ifl0U04 la $$Ifa$ ~~~~ $$Ifa$$IfqkdS$$Ifl40U04 la f4TKKKKK $$Ifa$kdDT$$Ifl4r Q U04 la f4 WNNNNN $$Ifa$kd4U$$IflXr QU04 la  WNNNNN $$Ifa$kd V$$Iflr QU04 la "%WNNNNN $$Ifa$kdV$$Ifl-r QU04 la %&(+,/2WNNNNN $$Ifa$kdW$$Iflr QU04 la 23589<?WNNNNN $$Ifa$kdX$$Iflr QU04 la ?@BEFGJWNNNNN $$Ifa$kdgY$$Iflr QU04 la JKMNOPSWNNNNN $$Ifa$kd>Z$$Iflr QU04 la STVWXY[WNNNNN $$Ifa$kd[$$Ifl-r QU04 la [\]6WUPPPUUUU & Fkd[$$Iflr QU04 la "#ƸƪƟԀrdQFhP>*OJQJ^J$jhXhwW>*OJQJU^JhXhwW>*OJQJ^JhXhsl>*OJQJ^J!hh.56>*OJQJ^JhhIF\5OJQJ^Jh]5OJQJ^Jhhg:5OJQJ^JhhV5OJQJ^Jhh]5OJQJ^Jhh]OJQJ^Jhh]>*OJQJ^Jh]hch]OJQJ^J-2QR|   789gd1qgdX & FgdIF\gdsld-D9DM gdA`klqr׹|fTA).jhX>*B*OJQJU\^JaJph%hA>*B*OJQJ\^JaJph#h}phA0JOJQJ\^JaJ*h}phc0J5CJDOJQJ\^JaJDh}phW:0JOJQJ^J$jN^h}p>*OJQJU^Jh}p>*OJQJ^Jjh}p>*OJQJU^JhXhW:>*OJQJ^JhXhwW0J>*OJQJ^J$jhXhwW>*OJQJU^J*j\hXhP>*OJQJU^Jr  67ѹqaTG94G*h]OJQJ^J h]5hIF\h]5OJQJ^JhIF\h]OJQJ^JhIF\h.OJQJ^JhAhIF\5OJQJ^JaJhAh]5OJQJ^JaJ(hAhA>*B*OJQJ^JaJph hXhA0JOJQJ^JaJ#hXhA0JOJQJ\^JaJ.jhX>*B*OJQJU\^JaJph4jO_hX>*B*OJQJU\^JaJph%hX>*B*OJQJ\^JaJph789GHI_` ! 0;@ABƹ}o\ƹƹƹNjhxOJQJU^J$h&JhP5B*OJQJ^Jphh1qB*OJQJ^Jphh1qh1q0JOJQJ^J!j0ah{OJQJU^Jh{OJQJ^Jjh1qOJQJU^Jh1qhh1qOJQJ^Jh1qOJQJ^Jhvh1q5OJQJ^Jhvh1qOJQJ^Jh1q>*OJQJ^JhXOJQJ^J9HINSY_ $Ifgdgd1q@&gd1q_`v-$$$ $IfgdkdN`$$Ifl\9 TTTT  t(&&&&0644 lap(&&&&ytSkdb$$Ifl4\9 `TTTT t0644 layt $Ifgd 0AQkdc$$Ifl4\9 TTTT t0644 layt $Ifgd B-2:Cnt 1<=>_`׻rrhvh1q5OJQJ^Jhvh1qOJQJ^J$h&Jh1q5B*OJQJ^Jphh1qh1qOJQJ^Jhh1qOJQJ^JhhxOJQJ^Jhxhx0JOJQJ^JjhxOJQJU^J!jchxOJQJU^JhxOJQJ^J(-89:Skdd$$Ifln\9 TTTT t0644 layt $Ifgd :ISNNNNgd1qkd/e$$Ifl \9 TTTT t0644 layt $Ifgd`kde$$Ifl0:   t&&0644 lap&&yt $Ifgdyy $Ifgd}kddf$$Ifl20:  t0644 laytyy $Ifgd|kdf$$Ifl40: ` t0644 layt yy $Ifgd|kdfg$$Ifl40:  t0644 layt 1=yy $Ifgd|kdg$$Ifl40:  t0644 layt=>?`a+,-}w}w}}}}}}}rgdX@&gd1qgd1q}kdlh$$Ifl20:  t0644 layt )*+-NO훑yo^yOy<2h\FOJQJ^J$h+h1q5B*OJQJ^JphhXHh1q0JOJQJ^J!jihXHOJQJU^JhXHOJQJ^JjhXHOJQJU^Jh1qOJQJ^Jhy3OJQJ^J$hua!h1q5B*OJQJ^Jphhy3h1q0JOJQJ^Jhx0JOJQJ^J*jhhy3B*OJQJU^Jphhy3B*OJQJ^Jph$jhy3B*OJQJU^JphGH!4Qbcpտ㢑wibUGUGUGUBG hc5hIF\hc5OJQJ^JhIF\hcOJQJ^J h`h`hIF\h]5OJQJ^JhIF\h]OJQJ^JhIF\hAOJQJ^J!hy3h;B*OJQJ^Jphh1qB*OJQJ^Jphhxh1q0JOJQJ^J*jjhxB*OJQJU^JphhxB*OJQJ^Jph$jhxB*OJQJU^Jphh1qOJQJ^J!"4@QRbc`gdc^gdcgdc & Fgdcgd`gdcgdXHgdXp1N"*+.=efgklnprۄyue[h.h.5>*hIF\h.5>*OJQJ^Jh]h;5OJQJ^Jh\F5OJQJ^JhIF\hcOJQJ^JhchIF\hIF\OJQJ^Jh\Fhc5OJQJ^JhR5OJQJ^JhAhA5OJQJ^J hAhAhc5OJQJ^JhIF\hc5OJQJ^JhA5OJQJ^J =Qfghijklmn & Fh^hgdcgdc & Fgdc^gdc^gd\Fr +<OVWX[ 789Mabcg{|񓬆xshh\F5OJQJ^J h]5hIF\h]>*OJQJ^JhIF\hIF\OJQJ^Jh\Fh]5OJQJ^Jh]5OJQJ^Jh]hIF\h.5>*OJQJ^Jh~h]>*hIF\h!)5OJQJ^JhIF\h5OJQJ^JhIF\h]OJQJ^JhIF\h]5OJQJ^J&  +,<VWX & F`^ &89MWbc{| !"^gdR & F^gd\F`^ & F !:;Jmn:;<NW^_jklyععةة؞upbعةةعhIF\h 5OJQJ^J h]5hIF\h5H*OJQJ^Jh5OJQJ^JhIF\h5OJQJ^Jh]5OJQJ^JhIF\h]5H*OJQJ^JhIF\h]OJQJ^J"hIF\h 5H*OJQJ^JaJhIF\h]5OJQJ^JhIF\h/5OJQJ^Jh5OJQJ^J&":;Jq;<N`lmy89L]hgd^gd^` & F9LWXYfgopqr4?_`al|}Z[]^μ񱦘xx"hIF\h5H*OJQJ^JaJhIF\h/5OJQJ^JhIF\h\F5OJQJ^Jh\F5OJQJ^Jh]5OJQJ^J"hIF\h]5H*OJQJ^JaJ"hIF\hipz5H*OJQJ^JaJhIF\h]OJQJ^Jh]hIF\h]5OJQJ^J-hqr45?`abl~ & F^7]^h~ 67A~ 9r gdB`` & F^^h~ #%.67>Aĵyyyk]yPhIF\h.OJQJ^JhB`hIF\5OJQJ^JhIF\h5OJQJ^JhIF\h]OJQJ^Jhi5OJQJ^JaJhB`hB`5OJQJ^JaJ"hB`hB`5OJQJ\^JaJhB`5OJQJ\^JaJh]5OJQJ^JhIF\h]5OJQJ^J#hIF\h]5OJQJ^JmH sH hIF\h]OJQJ^JmH sH ;EZ[\] \|`x`x$a$gdIF\gdt^ & F^;OYZ[\]·wdSES2$hIF\h]5B*OJQJ^JphhIB*OJQJ^Jph!hIF\h]B*OJQJ^Jph%hIF\h]0JB*OJQJ^Jph(hIF\h]0J5B*OJQJ^Jph"h_0J5B*OJQJ^JphhIF\h\F5OJQJ^Jh\F5OJQJ^Jh]5OJQJ^Jh_5OJQJ^JhIF\h]5OJQJ^JhIF\h]OJQJ^JhIF\h]>*OJQJ^JhIF\OJQJ^J }ŴŤŴőŴŴ|nj]O]OhIF\h]5OJQJ^JhIF\h]OJQJ^Jh.zhIF\h!)5OJQJ^J(hIF\h]5B*CJOJQJ^Jph$hIF\ht5B*OJQJ^Jphh/5B*OJQJ^Jph!hIF\h]B*OJQJ^Jph$hIF\h]5B*OJQJ^Jph%hIF\h]0JB*OJQJ^Jph(hIF\h]0J5B*OJQJ^Jph|} 3RSTUVWXYpq}~gd\F^gd\Fx`x & F^}3RSUVWYpq|}~ EQd{ƹ壞~tphIF\h,OJQJ^JhIF\hIF\5>*OJQJ^JhIF\h.5>*OJQJ^J h.z5hIF\h.z5OJQJ^JhAh]hIF\h\FOJQJ^Jh\FOJQJ^Jh]OJQJ^Jh]5OJQJ^JhIF\h]5OJQJ^JhIF\h]OJQJ^J*~ 2EFQRde{|gd,^ & F &'Ym~%&x`x & F^ &'Y"#$%&;NOPpq $Wblm޽އއ޽yއއއއhIF\h/5OJQJ^J"hIF\h5H*OJQJ^JaJhIF\hA5OJQJ^JhA5OJQJ^Jh\F5OJQJ^Jh]5OJQJ^JhIF\h]OJQJ^Jh] h]5hIF\h]5OJQJ^JhIF\5OJQJ^Jh~h]>*-&';FPQpq $?WXb^gdRgdNt & Fx`x^mn>@AwxyzͽᲮvivZvPChIF\h]OJQJ^Jh]OJQJ^JhRhNt0JOJQJ^JhNthNtOJQJ^JhNtOJQJ^JjhNtOJQJU^J hNthNthR5OJQJ^JhNthNt5OJQJ^JhNth]5OJQJ^JhIF\hIF\5>*OJQJ^JhIF\h.5>*OJQJ^Jh]hIF\h]5OJQJ^JhIF\h]5OJQJ^JaJyz 01G`abc{^gdNt^gdNt^gdx`x^`gdNtgdNt^gd\F /0G`ab{ˬ}oءaThIF\hN8OJQJ^JhIF\hD65OJQJ^JhIF\h\F5OJQJ^Jh5OJQJ^JhIF\hNt5OJQJ^JhNt5OJQJ^Jh]5OJQJ^Jh65OJQJ^JhOJQJ^JhNtOJQJ^JhIF\h]OJQJ^JhIF\h]5OJQJ^JhIF\h5OJQJ^Jh5OJQJ^J01=JKV`ar|}x`x^gdN8^^gdNt`gdNt 0=KV`r|}~㾰r[H$h2*hg5B*OJQJ^Jph-jh2*hg5B*OJQJU^Jph$h2*h`+5B*OJQJ^Jphh,h]>*OJQJ^Jh,>*OJQJ^Jh,h,>*OJQJ^JhhIF\hIF\5OJQJ^Jh]5OJQJ^JhIF\hN8OJQJ^JhIF\h]OJQJ^JhIF\h]5OJQJ^JhIF\hN85OJQJ^J*@Zrgd^*1Z[8PlξΫrmr_rRrNrRrRrRrhE6vhIF\h]OJQJ^JhIF\h`m5OJQJ^J h]5hIF\h]5OJQJ^JhIF\hIF\5>*OJQJ^JhIF\h.5>*OJQJ^Jh] hh$h2*h]5B*OJQJ^Jphh2*h]0J5OJQJ^J-jh2*hg5B*OJQJU^Jph3jkh2*h~Z5B*OJQJU^Jph!-89PQ[k`l*+JKLMNPiǼҐwl^QhIF\hp>GOJQJ^JhIF\h/5OJQJ^JhD65OJQJ^Jh/5OJQJ^JhIF\hjB5OJQJ^Jh\F5OJQJ^J h]5hIF\hIF\5OJQJ^JhR`hR`5OJQJ^JhR`5OJQJ^Jh]5OJQJ^JhIF\h]OJQJ^Jh]hIF\h]5OJQJ^JhIF\hh5OJQJ^J #/>JKLMNijv^gdgd`gdR`(GTUVjk˾yqmqmqmqm\ hPZh CJOJQJ^JaJhrjhrUhIF\h`5OJQJ^JhIF\h5OJQJ^JhIF\hOJQJ^JhIF\hp>G5OJQJ^JhIF\h]5OJQJ^JhIF\h]OJQJ^Jh]hh5OJQJ^JhOJQJ^JhIF\hOJQJ^Jh5OJQJ^J!()GHTUijgd`X^Xgd`X^X & Fgd\F  PQb|*| 7$8$H$gd* $7$8$H$a$gd*h]h$a$gdPZ  Ű}hWhDh5hVGh CJOJQJ^J%h 0JCJOJQJ^JmHnHu hVGh 0JCJOJQJ^J)jhVGh 0JCJOJQJU^Jh5zh CJOJQJ^J%h2>0JCJOJQJ^JmHnHu h5zh 0JCJOJQJ^J)jh5zh 0JCJOJQJU^J h 0Jh #hPZh >*CJOJQJ^JaJ hPZh CJOJQJ^JaJh CJOJQJ^JaJOPQ[\b  %HKabcn{}~hijͺ溏ͺͺz)h\b|h B*CJOJQJ^JaJph.h\b|h 5>*B*CJOJQJ\^Jph%h 5B*CJOJQJ\^Jph%h\b|h B*CJOJQJ^Jphh )h\b|h B*CJOJQJ^JaJ$ph+h\b|h 5B*CJOJQJ\^Jphhr. JKbc~()hijgd` 7$8$H$gd*h]hrjOmh Uj@}T h UVh jh U(. A!"#$% (. A!"#$% +0A .!@"@#@$@% (. A!"#$% 10:p7A .!"#$% (. A!"#$% @=PfYHvufyfΜyy9llB@ddޱBT\ lj61$[d03gmQpChh@.4{C$j @aZH0\B-AKBl-)\9t&Hd|zAk"?Lkz;Ӧ~6a [ p"bo a8r@0CcaO_g=#ebkJٌmg}6ޙcJ} M䜤(w;UfU628OʕBlu!T }&XfB E]ț.Eeb5Xuo.W).ÿKRHY\kQ+R5R ۽l%R*ÔZ&t 8 ?e]Y3f=4ے̓Nfud}Ye>,y؀4mf`Н#BܓXGS|W-6j/¾ 3h佌MOo +K.CpCc ߘ}g*lYkکucFB~&\_7Q +ےKl18Τ9nrt@~ 2z T r\/}@dlX=e ʬ7^@jF;Qnk k uU U(k r̕ m\ʱ1i.4 NC|'ou-:όUU~:4CNl YtO?.!o,;iێMjSLM"J3&E6M}X|?ˀRV X;]gR1 1_9GcT.@Lv1̓i]ڱl֩.ҴcՀDc]9w-/VW@N99vʢ}Ի<ıл{>oww pCvbY;^5 (bWe(9%:dNG]JKJ|{e=AbxK˅K\zJ'ԫarʏqKZ1YN#b[O1\SwJO =N_Og^ȧڀj@ LG׀TߺA@8WtApey1њ%p͢.Tou:ԅ..ԢHR-M}]9לڢ3ѓͨ۩.ڃE ye+Y Olܹ(2} $MzK x-lwy.ĶXA$6ƾB,DC໱ߌf<֌Y9rM>PV'_xaG)1=܊{#l@=lW,I)NP. RǘGH>gWQom}SG6J&ܯΝZ?kC;~ZʷUi6 4Й}THzr|ض~x:w'bA无AǽPpCXN~@E` )}#-Cuˁ-&دJ@g_M_帢i!Ǘ4د&ȁc).o, /J}%P }\ ]b߄X^ F4iE'&J^#=܌h2zn.Bإڼ"p]6 {ygJ]eŻB @_Vr~]=vS%bol@$^v|ջ鏃nJ3i3Ҵ``E]+r|Is|ov9qR}/ѣ"E IƝy؞2{-t=< YQN2BE~3h;ěB/!!sw>e}o!Wko r̕ m嬎e8 ?R[>;mywA|ݒ_*me3T_f59l?A'Yf</.& ]}w^9) ! xͷ1/VFTwB0P`ig ш^ ΰdx kPlN|r8N~7|}?.f@*@^Ҝ_f{m]my9f>=i@4ߠC=q"ǐ $+qX  ~d8#=D !F>24?jQtuB_^5\;R,͹Lp^0i3m] '!+8+)[q\fypҗvaOg|_keCCbd󙖺|T:G; p蔜Rb_cd$P,t51:uʵ FĪNQԩNES:e-77E?ntoQ':Cfc2~>0Y8U|U@s_@~祶&k}[Q^?bs`<|Ȉ*Ɨ/ `sv=^;W13e 1f=lhw 9~Ef׃}[ -\΋l h!SWG"cg6ݠy q32Ǜ鵵FgFʷ`{<{C}{Mkkwdlsf߮@g?3ԗiA_{gcc W w~er g}4Ei}\ѽ>גr!F"@`@1;szrp^A嘒H mŘ/~lfs+kkW{խqo?!w?t~PUœc =# '=tx $8l6缿 U̫_^ ^{6'#ڭqu6?A<k忣aRNQ:oU߼~U'ڪaߌ@/'ޝ~wQ}=M<3{g=zVz>.NL&zwoyHϧ'Wb yVy7y89-j=垙 V-5K׵=itÛm=|{/ ,M jF`A5@@%pÐ:>Y?H{8Qzϻ1 h s +7_p?azM i k3V\U3(mE0W[<[<+xx#mU: V Vvx2m? |{W:'z'yWyW{xz*y*{<5bρ`C禆77Wp_1x7/81N{x{nw{u?t8t'kko17p;|6A u67q5i5v9gwi_έl-rϭ9%E8*]Z).8 cc19 }@8eL{gwlభad`]|{+ێﻳ7nͱFWAW8 0i473Eb"1aNZ-}ŠMMf T\_r/AmSu#}$ q0 2c,fR^ ~4ҴAՀD۳tcq1{s2tE6Q=1y jbwb ,c1'-lcc]=l:c$/f߽;1_Y5HۄL?VI9 +͈-!sQs:ނhg(]eQ/Iy.L-֑uImr|^K} ]¥{lE?>+s;XtXs+9 :kσgkQVVPX"SB}5~QG=6р QU9SON4멺z&xm_V>r3c9sę`}:U lbO,8P4*ƥ?ȩ236ps- elHg M@ &y4u- ?ýw٦s\+t򋀩H ҝo_, aG~Ԟ`j^y|G]4wh%h9Z69X޳[K gr`6 csm5?ÍA`{MΨz} !u ~y GaWü^8A7͑YYpXnSP"]݇s'`g>|3wo`L8؅}i_A\V"|O~i@4ѡ.AKCq2Dӥ~M}ƅQ;z}-tY](g p,tڑvWtdG87FnWq.Efg,dMf2䑞s]~7eF:SɇnYO흉>B}@4}T?Iv2H\.,5~QcQq%#s闳/;9vl hg?[Q3ҬG{ ;M9V?n35FԄݔ]wA `bw 6C+>Ѷ62Y럠.?8ԱqJ'cwf=) N r̘/njj`Ɵ %}j4y4nxɤ:\F7% k[rq앋'4 +dRͻ&~wB/Ⱦ IUR$oIu3>[Js-O?At2X 䍵Ͻ3TkiA|:u'hO(E ]9 0i/G}u -G >zՀЈ!U/~@ 2} 3j2iCTO^Cˑ~h@5 !N}lE,}l)o_.<u;4Н 뎆kGNW}lwguxk1}yO``Jw֢\9&9>nF|-l_̪_V>}3k9Oqy\N E].αJ /ʠ,.{̼9RT}qQAw_\$&Q8h a(v&h3񅓵Ԩ߅r\tx|Is4-5G; pP.#M 1 a"hO09d?dlO r\/}XdЭ[˰2CpU}tѴ*⣋&BUk 5/ ˙2WƏ24eRtM@wvْX9wݗƟd]hl_+*uM?~6 8LOAp'b3t|XF/NY?oY;LMC|G f>Gup`V/<φ"EL٪k\ 2¿ͯ.ǯ,4mCp@=" Hz|yJbcXc8p@3K:MVX?bt8t,tl^+u5:vї ׹lJqRBV ^[ lѿzŶ^uL3N$`^N@;m3_`J>극gN0YghHҪ=}}ꉴ9{=d:9 9t,mN#uV"ˈEL٪L͙:ؘsi3U̚ƒ96Ϭd/U[ҝ?[e7WAnhk'R?h7* ;4<:?Ll/cczޯQ^>Ъ}O} h Yw-JI'VbqM[k]}/ࣼ>; 8_iOfhKA\9ۜ}9JtVk⏴9s/@}*1y&6z"mޥ4 T"^mNi "lep| f,G?FzOQJ]Y…'_5^?OZO{]xߋ5KgO;;6E#E/./4b`cLzf>m3-c!hBKsfnxUyͦE9_R־j'U:_Ѫ?rLW]{yCYX̆o3^1P;!6Ft`e3B7gJǷn :.v>RZnk_3*Y#O#UL'4ꉴ934שΝ)MAX؜C?7l΅bN9؜ԗ }ŽaG_^0t/KR͑͑}͉|ߩϱ' 46up=);6 3ߛxxleX s̏jCs_w3?M;_s7Y i>wcy)Jfˬ5 ;I߆o.KoKĻ3Imm8e @OSg/t>[ܺ i++@2Po87i LEЬG[kfM}Fo6LGC ӃI?XV6k'6LKH` )}Fivg`|9 A]7~-O/.#Xfsn{gSq^ &?cwM^GʊUWdA7?.~!F̶#FAl l7L"nX6r,tr<y ω OAOz+2,g\lu,sf:p 3|]ͥ7hwާ]wK~uViu[Qi+:/ǜ򧼝4Yuh5 [ܬ6` gF !du#[ &;|2&M}g_@;s ~> ˕9F#NLufЭߦZ ໔+!؇!2i 27 04Js~s4mu ">xoN@xZ}6cSASYYVC^eOv[{]p}鬮m/u:vɽFUǒ*dur;^WJ]߿NqURbSv_^Sԥ'~nSgSkQvc8T| M?|*q>UU⏼_x>nzl'rt>3my6?/{n2A݊Ӹ}S{l2? zLy[(Dbp} I%?Q J؊~nym`h./^ c?8V]5˶j ݫEYXK~xd_2T bMvՒ @i2w4}@>o!H,1;Gr5gΝvexƴO'-E<yVgcР6"'O||$ޙiΧqi-MTi=mA½T&B)TKNriڔ6 HPEХ@}?X*..+j/*'ʺ-WXYW҄&3gfΜ}{dMܣs}g(tRIzݣ2+c?ʎI?zoMC[(rI;2ؒ^;sQۅ؞DȹAl9rqߜoASM3}^;!}ȅ[%~ownw>oܞeĉ9mZނ\ޛ|'(fr ;[}}ze1LBvbVwހwZ.Dk-ed=x;8F\ %ނgaن1:mVZ[=^z(-QUQ#;rREBrNS=t1ѧZݕQ VxK{Q]"0/;!-@@{<Ģ}Ǵhڄ{ uϵ9wLĚLW~܂M%T{뺺zo K8Xm#1XGVcO>߰ w/ :i[ep)3L ~Q~kJ磌я~]i;=b-?]o{u8yt{?vҒlmY7w5t3].+rXVJ[VrV>rnv;2]'^\CmW;9g>vm:v8X}xz]eVVvln^a^}xRR~zVd?Q}8V許:v;nxv>gKtY*Uvjove\cC>kNԹZ|и:lA8A yY?ee@^Ϝ74漮yso7:3[i---7-·Z[^qn]mu{ 1*Gۼz{ɾ?m[+|zgl*YKn>nͻ|wymxDoiwpb-MZ Li)4շ|#n9.(e5-oGytCsk$ tY YUNd:rOUIZ5pIG ҇=]%}TeQv\:eFzVhzV`dmiaη%'VO5S|qK%/Uǔl̄_<CpTOBݺW)vD>B;ԭ1V_5U5>F{_I}xKXJɸI8r!ox[ ~t'<өh{+9T9To3="[-:slV"yLLS{l[=[ۊ]֗S[Mw T[oD{ȱq b-ؿ8jVO𡻾 b+˛&![2 b'z茭-@WdFp%穿5W3W+̋_6כQך&g|@ژ|t"Jə2^z$%KMMf(~9NJ,N5(Ƙ 1fI㥥WJ/i4<ӽӟ_%}a2*M̗5/0M/i6V.7' IǟJ;IyNt⇜Kpft1f1RNJ\/VfbS\d)''pnL~9#j<;:*qp(b;Q2~:Z6F}xV6F[>MھT}C/F:ucձGqJd$9y]չ"rrsWr_Fgߔ:R9/Oy͹=3):ƺRR5y\S\g\$c?WQcu?u?s+~ٷxˋ7:77;+nhy,c$sAzt!T8t}i}i}쥦wm%ö u KJL3KJMJFbCLǥ|@7.%LKϚJM1RH*4+FXҦ]wKuH}H6KzX#%i`̕EzQT+]JR_ɔi{K\;W8fhdPqVyGY|nBΕ}m5seq~V{Z+m|ÚQR2J=X.W76p!0/;!-@+D w.Q \3ĞM4ɽgN-0܁oj.蛚 =(ęNK$#9؈s]c8nHV硔Kd뙎e#3Sq4e| iB]Ty:-y@(Y 4,/S¶*vnA$!OhHdĂcwIߔc{h4`_g{pHo wB ~*dR!4 $xV<_7"w KϹ*Ge0`=:ggJ_rڼc`U9w/}c]5; yw)"Dwg Հ{N2x [Yo%7Ctҩ$HqZf,EiSLp=9Dz\G]lC``X6\/$3(1:QU_?TKN. # G7\ensJ<Q(?*IG~cϿlg&nʙgbMN 3+e`C*݄/(8y2,CY_)3v pDb9Jnw[5Xs9Ss 93@'&DG>3g,d)l|Σ}d`_~}hYweVUʔ۝RNc9I'B{WfmglخŃs۵xp3 T֡1Boua_W}98>s_ӀK{@yo|Ƕmby 끩F잏.Ւ )fN :49%y> o)hX/3ӭVB~v'uOY16T|=XUgYGh'2WỸݙ>9iSӶgp?Y~.ɽ;~3q-D@m^jFyU&[wxr7yF}gJϳz簾~G2r3<wahr5Ը7F73TU>fVOAZUV:Pd q8kųk{*pwx Ud߫*O*?l'Z'XӬ_Z?O^`ZK ˭ X0xdh.6kpz{Նlr u_c` 6}a݋ M'W6rO6u_b * ==_-ɞImgxy k<ՀMrY qYxCyiyNlNNkVk= ziU6SNGmݟdX~?ʴ o샏ˬ+dY8d}?]I3/'3~GšZK&P"mu6Zh]=^;`~__j߫^`u೯#8UIKrz_g_>;BݷSW,b7!_T8!yFKm[VMo Z^Yg2J=X.󍷴O6NX kNH P$:搡)W#Htk܈򸑾tXFQ36BH'Oף: Dl! 2By qp xIR pK1nfߞ#yp`4gX73:eeB5]r }A<614E@\Q.8D ť~]*DLGx:u-8YlC.q| .\؝3p%^a=֍r_7r>uYp c)lԃeOru ڀ~0YnYwpmȱz>q >^P݊o[plP$ǎwqȭ}p:q ԓ22Zw/q6ř~rɲ9MЗsVM?G{urqcYe-^a^lw;**ǜJ}y Owt* ʱȿ:!/pv糮JŀE>sV[%b%<qyXXo Mw=k͘"@@P15s1vNicXwsƔ9)}O):ǔpiƔQւ8҈>oBr{vBuB2IĔzdNK7%UoE| h~lbaBł`}iԹw:cwNԍܱ o|ElC\䁧sǂcG;x>Δ;X`xyLߗ8:+89WCQ/s\fu̧o#XDޏ\&xhhDіx8`L"~pAi?kջg_g6.Zޫv"؎~aF[mȣ+Q6<}ME#qlXr[池+c)`^Z>^"U 8'fk }`D_ĸ6Anj0)}@pB+Y&J #"p)ݾuy0O`LD]u8_ XL/:+S@rXH ґI~/JNjQ`5A~PYTm|g LΕ!W ά ™(3X7qr)"9a4>'݀.Cv#1_0߯"=r`-\d.PscE'b|VK<&+PUY ,Ķ(*tmUԭtb-(iQ!fb*Ѿ*Q#/P\s1lOJ&!0ݔI+?@=0 0?:!KO|D|4>IcV«K'`Oi9lfűX7Q;抶 jge[`?*cU]SkٴT_grc+߸? |_+oA+-SQkhe?;(R lOiK)/C4|>Z4Xe#1>!;?lon' יe#Ko|N}Z){8㖫&,^ tWRPg[s:D`aY*Hxlo؁TZtBZ(5"bF2\S^sJUNֶP4Gmȵk!#s͂cwZϑ飴ϙv/4D 6AҶv\LeЧ:o;x]WtX'BQ'g)Q.!GK¥#Xc~ 2ȥ#GK;qp6uK.qKK\LWG|@qSP 9s _76s# ꃊٌIy)6#u_SjATaء勝}Kʘ @uQuQ.Dч|~Գg{S~t~+?,V{j 95 O ~Gr^:g瀭@X~d|2QlkDs;*IHz(lcBVw]1`h֍:ZqmI ~C[=e;_e +݀ KcU2]Qv"u_(c 8I1տOASBL) F!эu!$㚖kZ A=VckYyikN3hA=p}8 \?2_Xw卲ݨG+O{b3V\2[7c7(`v@@7Q; u]vVU9bm-N1hx+Zpj1Fӯȁz>w=m3NRNG ;Jtr| 4}S G~G0O{ҟ T/c2"3 AC6!ζol?>'x;:ۈd8NT9x;[xo >Uտ`V_^UEo]2y޴5uh\S<gs:5)׎ z m? \S?k pD9ts͝aw,зY wG,uĢ)׎SwBNJ'|'mľqlǥجRظ+>vJ=X?G ;~]חY?RԿf.']ͤSMޗ9$}bFxҶ_}R¶K wZnv+  rLvlQ3s6'%Ѩ/abe+織(-x<}:y[gL{^M~@$PZ,7¦9VWT:i΋pk FbkyzoUB,\L.|ON_еq[@?@`.LÀ!3$._}H<s}qLsɁ8WvQg,%^`lb.TGꃊ46Eu)ųlFŶk{CWٌi9YZ6iSOWLϡ)[|sh}sh}Ga2UlUSZ)mڤ]&զ=iPơ!|eDO@{qп^:3zh>(zOًˠgb{9?o^^~~M>L3QXPҾL/fڗ3_K{g_&2o ԱӾ<Ks]0I`P83p#|Ûx|w}݈ێA*u/:r]AuC? RNP / O!/XP̩40=< 1LxXaa<0?,yL_N?Maټ`>),o>˃<#˚N |hs a`Potc+@Ms)0 0#<}fl_|,ٰ?i`w4p戁Nz|hk v:h_ _f@, 3e9L6wo . ,>O`?|Ph|/# (3PL+@a:x0: <_F`:0te6k?>L^]^ol7ktpj^ܔS1Vڲ]pA֡=4 P#жnou=b=5-g 4=S;^t9怟 :Jgy*OryR0Pv 4n"Ai< :: #+dGP4A(9'j2ifW7$^(_1ԽefO+f?YUA~=` P ]w S*<]eUٛpAxM_o}N蠭  p vfD軭 iׁ/("ZVȆ)j KEuMIݐp _VuA^aIpgB> N1hAէx(P`:xNj={3;,PYN:G8D8EMV>(s5U9eIKw 哐Q>Be W13\vVn{=< :~dD䩨s /\LL|=F[/(,zʪgM-;޾7o޽$|NLv!_eߵKkn.Y"J\6;Q9#최2^I5IȰiS-Za 5D! '}h)f+ ̞n)\Y~]nx+YDe$V=]O'ЧY B&V,eV0/U| 'zaƌUIs0T1dB:Y A2 ⎖0~Lb>¼ӹh(68KYT^Q!vůGNnE E Vryw&-(ҩb7I`eSn{45W/\ֻo/½!CA;n-R+捗b)5?KKƄ}aigi Q\cB*5.ETL F ,FfΕWiP"JXH$fOW0VH/QJ*$ZoP\EguT*\VK'6P~^hfiQ^鎽\ٚhy(XiAG% TЙ +nZ>KuJ/-*pJU ]N^*ͥ$4Dt+f/95'MbPX@&XgϺ1PyN|0Lʷea!AaRWz"RVhTJ7</7 fQoٝueƍqZn>t8u߃" #**n9Œd##fޯ([Y!hZ֬H ejQSX24'u- }d8?pDZ{ 6'r]Is! ~{gZk$VÒ%_nҡX?mDJAx'Xh5442{Mhq35'$A2,+z؅G:#.VJ_tN5jkШrYa"i,BZXH^Vud׀\Iǿ9vRYO D")' |o;JĄ#B J^Y6JVI68 >5\띡ܡ,ʐ-X۔>wq4e</)Kk?MtU# -}=V枡R]]JNزp`<W-;Yɔ#rgyќ6gBO!;m"^LdQ}T's!O~{'Lj5/nts^-tz4 煉YJ lyb"RJ~Xn2=#ܗ(lX28s#xlKr yyl k9XV_Q/y_CW&sQZWlz{wXAe /+/lAr#l8C>sK;T/nWSCլVɞk,쎽=_uzD>GrF4ŕٻ&+'+d-(JθFm/?EZ,~I: NwJC,UK=rPVsDvkK8S=>z4Y:Ǧa z?몂l꼀Do*KG; hs;zT9.\.}3XexȫE84GaG~[`xYIɧK:6LO D4=ҦB]XHVj(7n: 4%~# |VV؇6fՃVPkTZTI-:<j-'#Z-ϜP\->&@5?./ fq^*8Oxs{p&8A qV}>NĪ.,R)( J QƉđ֔"p3T'XaZCWۗGݺ`RYvFK^ԤGsQ$}'=[A[66VotP(I9tNgH$B~2 J0ehl&yz]eeI+%3"`)ק+styF~ϕ ()$xQcqR]X[o rm sęT-[cl'倲n*:b<x^ɢARj4FlԢS_WsKrhꧭb 3-u (=84{ާx2UWe/15f/;*_~v gT"ѵiFNX-Aؿ莺bvj|G-p =֔hF2}mo9/-Zoy/Ծ>PҡM:MkZDsjcCNotםv{}Io9])ACw]^wuh],2 %np╋)=1bX%P|IO󃺤fo"j_&d\?yA듮EIԢEH,d-m7.Ie0J1L>Hc5*naɌOkV'yOm퍘0ak/c`۪Ghmj~+;q)G%og>@dmx@]Cz@$ʣU(Fm ^9?{ي S y«+1(ܞN,=9Z OJ S=?[GyWRV[o)QV0C|"E+ṛy0nfu1.s*.s :obrQ"\Ð,JKNkR)9 ({E"6sEm* Q@ 6O>PU|F6gU E{q[cÔ׮*gB57$q}"ī~;+ r9<ι? dl`Ѕmt޷׈uOKeH; "1nѭ{qQG2oۺȋ_w%NԧW>0 wz}h:Cˮ.ңK.Ē%IWBw{Mυ2O<~sL45EBR{b1ˉtQ+ 7蔓t=7"H**:fC/DIl_oa tC)zM^[%̏7v s:ta KYkbRٚ@8p4M]d*=aҩ+OGӍWp"]¢ji;Xv=5}ԟ e+mryY=!7G6tH3ń3x`zO{9qI(x,hP:3+5N'PD,Rz7m;u5 ^SwC7M/˱#̔#lomZ V.xPFRiZ_g:nmVVZ?:wC 10,5:M$xөyRRω) jMw#Tf"g']B`DOE-8r=w{P 7+Dr s>{bB"^LA] yČjFNR9 } ncYz"6I/ؖd'W%Ew]`ݲ;nzrs2K,C_[ b!3t'}>mfj =wޮsRݮ C[,W( xj-8YP1MZv~lxkI?-ݢf!uhǫU L)RGѯ?.fCH-?aGl`y9ɻo$GߪrWTA"yvꂞk4?Ԅ{tB}di/b6ޱ^6 0,t'vz9f;\<;|)7R hc&!lLMtz(',zT4 IEЭz G:6$ʏ/>  &SFmJ}r/KU[1yu+6j2x9T yKF|`vUzo_lKcȼ"woc>{G msp+]Sc!ͺ:4^-d²8$m?0Jz2޺sB0> -r}⁼ Y-}&Bc&Q Э]=Qs%d|ahfX9 '"cffGOvC*܎ުZ^pЦQ`஡H뱑GO=3Z(6W E\cq*-E`zɂ}d.3Eհ(;}:7aoZj+_*= ̛3Om˴}\МA u:fҋ*87!ń*7Ҩ7J&[kzdt>yW|1KZ#j/:wxiF 2B5>,ϰI13 _  RE!7 >J >x4-Vp|d,RLtrɝyWzG$%Lͫ T-;68<ځ ƑhekKnB"0\WR.:ቘud?i2bi1a"0Ҩ={"3K7rZy%%Җ#k"Wa|5{S4'F0Bܦ)frg_{\`n[ry~d١m"WA0X}vh HLJ}:ҋƔ/FPwyKѬshT .XsTt7Sv^W[g}dNCGZũ^r&ȆAqe?-`~]K,wkq))ܼbg+[6UٝŶͯ(4JNok y0Z R1%4xhd%DU>8Q`L[FD_6v-NzGynD/&,Q=,_z׌wC ,V4Ɏh: \ ؈29LnfsbҡuyGLfOQb´磮 29 5.v^e<2$hx(.}x?|<9׹s }U)7vSo7:ʲn%`~ څ݈ª0uhA`Ob7U[e9M ;_ƬF6Uh5V "BK-in+UQ|=8z慠f<7hGoㆅHldŕsT\9QPţcoڢD 1rje+yD UsbZ>qMbּu`m/<͌dur!Vlr1eB;E$m\2SʹZ?q'.QSHhOJ#-A&Ecv*x#dz!5-dCgK+6K .<4RMIb=$)J N6+À3=0@70V]d쵍y0\utl"!4ICBKCSX s8f[:Or7UcCدxΆăO]̪1fbsa"Pp5Ņj^dKX8Nr roWmIqM(? TBЋy<TKr>q_}}|m-!'Oy5\7PjODp=#2hA0,ϰwЦorg0≟_)n(ssh LA4Lgެ|ɕbL.9W725 4MyavzO&6~\ }NKR߷;`$=]oeύ".*M2o yr(#_Ȅ]C¨p@mȻ]m[861s*m|zlj,YY)g4}#wx\f ʯ/*ݡX[>«q%3UU( =%~vil#S?Ֆ+N,mn~دVrLSR,'&$lI\eFFi7rPv` J M%|8GNa^6{-1QЀ`eS}J]$QƔWM՟Sy LJ5#bgjH6,UxW^pV~5ttsp]L/Vg2F.;UX:{K1}_p?> 7gy}ƸvA딬"s5zPN.=9“qB,QT[G}[ܢ43{|:@?v{~@ayZ@nsm&F?斣 &p.K|Ü^֏>ynԍbCLHG-?&++4xSTmt?;䯋ՑV1ͮ_Dv6 1D2+|%gMsOfFF=lk ɾ1Uc@JS,2ɐv_ *nc}F}:c\.hmJ?`na* Ro0Xcye ӫj-oƚ8';,_?(tdQzV+C=c3vQQhF-Kea#OuKem0,&Rj|7>YyOȒL'o&)pXb'H)Ce8#wf$MT4tR![}ڭ떗x`/݋7n#"殘f+ޏ#f>tF|SlGS?.=ߪ>%zb<=Tlpɕ4oϺr#o~)^Z6d {&3&vh 9_~7G+}l H0탡Z[)a3X1vAg>v{Se,*彏ANb}'gO`R5̺;G)clGX9Z ٬jQ}a^;DnTIbzr hʊ{E̦s6vFYFu=X O NVSҾzY/ͯENZ@#n6vkoiG2wqB!=!Cm{p_$- ~m }I2mQ\DeVG0L3uXLc6;)=OI};iN@N˥p%)x) (")AC(~{#$#~&35v-|,}F8az҆B䢋{"r~տrΣ=\S5l^&ʣWe&clz14 f@=NSr_UƽYfÉvֻ8è;_, דV7yƒgS@<*'x|k˻9_,:H`s ]vȎ{ uH3-憳%d$>@iv [K(^YN^㋺HW[⏜=nܞK!=|A!p Fՠ؂z$"sSqC+0Uշ^R mǰ6Ce{W.;ȔUѮ1`x{ܠeӋa9G^Fr2y*K0@|}&2^N|!G(Wb-^ kJkZCu{i6ϙuԣ^R<k%#{qDҐ=+ܪu"s5?vFğ1th헿Jү 2nR-pe([ptvqB^g;b` voee! \MJU`~T'@֟ϊa\l.`\:8 Wk4[2L_S^j}iU< i!W ;BOWОDn$ŭ8nԿgp  r1]QjJ[]]+ 瞦KRJ+Xe#(ͪm9j֦AEA72v*DVp)IB/GإM(t689;\D/]_v]+Nb:*"|DM x+},\-W&3mj#^O h-9q iQo "Tq8U&[!׆8ѡU>heh:wǃ򜁊K RyG>n4#ǥ` A>j}׈h݆'Â̡֎>To(ˤnt)G#UxHC8 j.TvV`fBMmHsss49N|iOwC0`(q Tc6GpF4y{.o!K <'֨}ɰ`w`-OLN.i.F5Jй~yfpۙbZf.qۭȪW"aL^̑Imxl)$m%׍RKJ@)kEvf__$_1D >)~"+MA-`12^Ǵ.SOT;8IͲG"Xo OD#_pEɃÖsN4(ΣY4=8 RtZ<ɘ;ID׬-z6IcZ 7)-:e0_fޝ6@9 ÊU?(s]Ud$_Y_ASNyҲ-iḄ7%Tم"%1^nU+u1- B|9.B$q#"0MbJ3TCDy"=ny}ިԀa.r-b 0/w m3A{XD˜ki2OE @jIeJ```3Mw_@yy"߭3Qώ@沔)0`x'uNͿIőZ12 HTѽ[.<\Inʭ:ipŸRl! `,;0#ʖl_`iuqY^fLYr{xp)ð⟧4x2\Α z um1$t7a8,,Q1Cp.yђ E{/&Eflq1BLk2qQ.K*"!6nkn<L:当 [192ï8Kjy;(CC[.s5@V>gBbˠ&5ܚ} JkǩMpFspf-KU^`\CWuٲSfG؈[>ky$׮iUH k7tӱJѝZ3{I#gV .A zeUOђ{PK0o{>y?z DߣL2Kna0f@WBTH!.& Z, RM|rPVF}oJDQ ЅSҡl]lwcUoϮl+Y~v(v8b B LI6$Wٚ:Viή2N?n(7^,h| (Nr<@{-xUwkS $CMJTF?dQWqrX3S \r}I,{b^ Sl+:#l "OngK}`봽\ ;3lbA )ٴaL3E`>{$]uwHô[ 1/bܝzfL 2QnSa;/C8 9H-LrT< ko+xf5Έ3>|Q,a蟎S@6P tgcVM)o<$7vvBF׵(-+\! _,&b˙)sE2Qbj7٤PKH?S.Y8e ԽF_"#QkYt r>T|ΈN/aoro/3]n +twNWCqkmxU g@8̀+9؏utE%inc$)4rI_O}mSO&׶ČiiyxPFͫ h@< {,(ŴsO L?SwX8a>f4nr1V#۞C|52TyndU_ 1e{Dt1$Ae`H9V{s!Em񖻾S'b 9aw{k}47^HkSU`)~N7 (Spi<(2afB4 ԍMS2X':7(%yIu>~6oBNk B[i`C$Ǿ9:@t|6 h0 P t}id\J}Z$Z*uګvtɕ2Բ HF[LJ1X_TW[EЀjl~l8jwoYg,MBeMd2/§,"YǮl=#f$e2ň{?>??͌>>>~Nq%\/6s0_vJ݁x𡝠șO5 C\ި>pN&a p~3 1M@ӶNY3tԵkp$uMh2Xhd,/b.3qN˗KDz9UqYX)F8ZT:r2 -h ]k  x^˹ypQ^NkԖRʵ vnPj\ԜK!+(!pRVojM_}HX>k`^ LJHaeX7t>rw;sK޿-ZD3/Zfh.TSn=Wh<z 1} FmK\5<P^/{ ʃ!aBL1rx*mQJ I|X}򁘾ԋ% A}݋I>1eu +z= <%.7Wyb)!oVYЩ3aD W~?~2ct_F5Raio͂@G"DF{ sM:uǟھ?5C=ÎY!rj2[PQg?s!I.hCO /:&k· [-h3LѢ?~T2U?䖿gCSsG}{zqBxo整CC,dA<! SMɏ~$4ink7 7mwjמ.?ꂟ?Tx' #;ɷ0g8KB^"z̚8BBOlS{~#!r>ss*/oڮBw/s*ekFiN mi}Yp_rץ _/xmzPрW-#h7/y*,P>C 0RaÞe7maLa3_?ĪDuI>;#rFv.6h ѝ]z HCzS09nI_W;%9B?"lngz1-ma #d*  kz^W"5GFbk#EnP4+ DGaWUn5Kn}A\O:kן̩Eó͒P ja3BL!ɳ8ؼ;YԻ1 ^svyRGkl{%'?>ɩkF8sDYV1zRg!qeTiW|9<[lzy Q֍볥/{;s_c N }t`C|[%:I8^yǹyS>@^f"Ѐ -4:k?=N7UQ3ghӐ{#aaqLu@I@e2`L|=`PJ@ꖩXKL)U74"$ybiq2|K ]YA㈩p[e7 t?}I__I2ΚG;Z/!L?dlťX6{TA #O1jZ'͋ j;4JO7/zNxl X{g5ƙ]KShBy³Q<;Ŋ:}'+qͽD\D /h4{+NRaC_!'}{h7VRKh'wܴشAUntި x3Ah\s+?a3|5ĎUg\h?\c$2őC|o >Ig< (Lmݢ|^Ϛ7gαy.]gRW^t9': 4< ܯ[q<6ODi?/BZ䫤˹CuxSP{ 1= “ #]b7MdKbCԌ[ldgxsym'Kh*&9O('K<0yW\/WPSRw215)ޗOe-mS =Y0P}3d:?#%_ƬpXwئr-SȐ!2PG6%^ MP6yѿyBL1`z$ڢ mQ&`4z$Ѿ2͑"Nm(LWr2R#)rpDm/V>]RMl4&[DHDVC(G^Tj2L|jsg\rur_W]]>-.&8> {02Z 5 g]#,1 M ܨp")s$d|8=y\F"D_:\9S#PKYBB9jڰղVg/N! uW6̏ :<_=6a͕~@e r /9PTͥ)-3cOv!0C*ޯi>Sv79WtLIl~Kl40zK>D!#?{'@p_Ϛv۹ :m }5;@&6kl(?#Y!` j,HM]sD#vOiVr]Kh^l(\y&iF EҥzhH Ǧ-VD'xWAGCz^ =0ELk5օǭ,c DL}zZ@rSԱ1'LM~u~{ +ztj'χ5,@dق6Qj`B"Vh#uOθΓz.cN ʞ Hk+-f U>pCV?бkZ5! B b4Yᱛ #ɰ;tK+O q@ U^-sbBLva 9m't+s ` C0$kTpb  ́S*G(jwYj$am!ܑ &j }{}/>L)(Yc c.("vJYʭߛRN Sd$QK(LG3K/Y5@>>m C8@pOc[~ݫ0>+Og‰r^ZӰ5|O(1SsU9r D ;C,~E}8c)RFHMuwónW!S`kfG…]jc*mɜ|)Vr}h0~6BA!ɴP-~!:b <4D,c8@60#Fp++WraӫxV Zw64f CR+;L6_F#? / 8NX[a0 |5}EGA(}?6ڻ jtcekFj5~i" L3Np{6!5en aO6 `TQ134JXSh}Tp'n[F4j;*\ ma[_j8j|pL8FɎFDR3C@hKh=f2&"$ƹ .#R0?DQ3K;3K`q/UݮSӶg=+CJGS7(m~DZ֑#,2pb sZGNQLmoMs @SToH1N%*<%k5_!łs 3㥛6+Mn، d?:ՓrnEc}ꖢ f y(QoWs[za<[fGrxP@FD2((1Y|駇ybͅW=}|1SOnrlƳyɮvv𡎂i"TynInغl s귡>n^jbp<>M1S z`A׮].ӎ@[c~;TS{.\lxp YJrlATNMQq;g'e ODvy 3u6]r7E9G;rPU˞BlEJ.HU6YTBڶ`_J0c^G֞A=+CG!l~e{@,G.?*CH#;4'Hý#1-*Y] ½ଷ2/~AH2qrxsRU> 8F $Ѣ4-vY}%yf.uRX *?OLW̿^ aV0@(C}AMkgg@ A"Ԅzs$4X<ejD' LhB}3CѮ9Ҋkxcxa)5|G{gMv&@wfJő&NΜ[3~nCo[pzoʚ~>0e9$aT)'[j``,.:߱u9jX|PTw![&[As`18%wks?SBj)- $47#`Drɴ.&ږr^Hv?e=J>޽Or:pdqqdX,JSv a TŒ`?c+P|ݺWjl@^;90 ڸ^I/Z@"e)oΞok ){ PDE 쏰#[Ba^yEG"ΰPS&}RjR[ҲwTW=")=hz^&7O)d`$bf T|=uۆWH@cz0;٧]j{KI Ӷ/WkmS0}&ݼONҪG@ei+3N,N?M/YмP|!D-öz(\cTA<}W>O:ߏ]}?;cu_e)v6 e>;^ԓmh=>*] u MfY?L20~]PsdАčbe tûZ9~ƈ&OrIE)daeiHdX3èB gB0МTSnԀ{sVmύsu ul_FA O?ǖ9Dxtζϫ1gaAiTS xpV‰Sq@Eɋ_p~j!ZnjHE]2F0ht(eڿ_wl1IbzPM@7Zbb];znw%^)RB=.~oõ@AR#"t N+2ڳvu'x28 UgAL `ѮStMIV‹q"1_fH?z~\ "LIV+_@}Ƨ6,}~u E \ؤAW p󾦧Ar)0qJ~!CJK$Co68^^g?w='fԚroQvEAҖjVNI]5rPB~Ccܙ2P7taصuI82ldVY!!^j,o2dQP(ސMS]l>|pƪƺY힢i@^F6B "h SȄ1;*|g)+֫)fZĽKBta -ߜoq 2jK2 NCPѾ' rb)~RR9's.J[[0?b0::U󃱱V]j_:!0]v;~ҬcNULIS& 9cp- qdȎԡ}Hor{뱀}ȋFx28F'l&|~37ݑwer}i Kw,]x+$;: -n '&v`ic7nߋI;za!l(l9 LՎ:0\pّsZ7 fkLie+i5@T,ę'*h]sL9gH+yRhZ~`e)!Λi6+ {L?n#iA?('vC% NjbA[} ׿$F"gX4Jf0FS #a^tlj7UZ.D 8qlq,#`,=:VM+KO@z_he7㍲Fּ#eOwM+Qp$\b1ֿה\˱B=r(#Ql : Os=ļ$oM/+O4/ï'Vrg*OS/`3#®kb^#? \sdnQRَ: ;â!N3R6w'rSI]8nIږ&'?F>׵ޟys[%ɮ8[[b$cdSjnWeAZjSygֲ_6K.V}\S^ȭSĹ ?OJ4껱2!w C;!o4:=#7M]L-J^}@˕NsVo;f-+-g~z|,1=NYt\E" ^р6:I pLHP[~^t:gV&{vŻ=OLƾe&mo9y=i7s^7pqʨۣsU AYQݯDna{EؒIqW &eJܾ x7nxg]0}'KxW"|JJk|]/+}q*hw[Q sJvĴQj"~Q-~9~=z mߙե1!1^Y1::~ɣ yZȚ\s޶C'4W َf8Ĝ|L|Ȫo}q&xԌwx?EQA'.ߥոqCoZSF`/lqhl4.绔$ޕv3 ;ǔ D秐 9˦U7y;GG9=vƅf֘? K9fXݷrz]x?=C187O5;"3*}FgOKxaFɱ,nW<8zVA2ZoB4+ J?"~pP3?4|E"Wgxe wՕO~0Ҩ[y(UOs  dK _ ׬$Ys#>` /\5{ߏ6Էtn`qvv%e],t%s![Od4I$֥\-ֺ ^t,8I R<7gLkأ["z_tʀW7BPs NYkl2WORֽ_鐏OD,(in?>g=ԭVDw&޺{/Gxt@1|6ÍA:])ߚٲTPw쓷+=})\r1m? }15=&jxu|zݾ/v7O/Cd y pP)jljny>}*=%;;>bHg chi];u=,oYkoBdlʓ=ԗ߈V?]=<=7iv[Fq)>[Y,$$/؛CEeqz늢HInf .Ѭ21*׾nO kgb~4\*/=^nݢ-xGkb_vU?x?-q-lkiZlND% ﬈v8\,~fޒF.峭T|eWAǵ}Hov猞Njܬ2kA֊EA9;v]\[b{ۻJvw2[ֶjӦfDW|YfO/Ɋ =v|*mqj=*'rrݥĪ3yi܊vK5\,_eBE^#`F N|=ӄ^?ߓ`ٮ#Gn._eٲ369'tZ; _/zdcnn%L[G[!*هF(gNWvitF2s$ObuEk\'mCM= +Ӌg?眙sչs L?5|vɻc+N}Uτ|wA"]9lN5 W,qKF8ϭSql@+yKKn['}lUݭzerڵ/-&όQB_{rn?8%4ҶpS΢R_VĪ#slD ث,0s͐ZbDIӅ+ NV0dAo?]*}ͧsܗG5k򫂴 >?iY\NAuXS܄9r$܋Iy Zuy㄃&>ndnҺM17>2\ƪzKߑгfycX}[ccuppg /{ vҤ~*귬ހ#>_k]Ė x%׳wJ uUǏ֖|X<5oo}xtbqv2?Ưl91wPgfnWGF^9L>{Qb30Zsrx;6a`EB[gKQ ulveu}4{Y7'XDT^ܺeâ ss:UjH~"L͂ÎrWJhܧ3U#\ȘqDמ+.s.T4<^{xsg|m3;骻遴P /%3/:Ɲ8\*)~&/ouYWǽZtr=^ic r-`DqGAm=_$2LsRkZƯJ|876$ 6p!]m=Z֦^w=X潨$"yԵb\vlyK7WZovk .X\O;37պ}_岵&6x9>w; rpܦ^bU<3=" ןiǎ5Bj02PwׯqfhO$[QMc0&߿oyX0_P0X2Mw."ٔq۪wLײkم{%?d͹S6k倥K5=5[Z:vYmpnrG*R!ȭ}O/Rl`~-+ٕ28=G~^oz2 sFƷ\;5bCƯ 2)S֯QHVv0`BA8)gl&jJ["e"sW] nqkǹsYhqޜ;g/YC茢W/C3|j=5?/ Ot-Y5gYϷ%(m8co3O}rPF=U2,upm~~kݧS޾LTŨY!j~~ ,,ZD9`>=imٴ <*m'fw*+Jv,󭛼nҒ3}lm/~=xqf)S"V{R+nYUoGFϻ좸#Il8Kxt`ʉd^`_Aw Rl E#wWՖOSdYMᷦ붍Lj衄^Ԩ nف3l[WS-3v5Yř&X{xlNТ?6Rb9QlPϚ.-|prUI!}ݴObV *pXysoa)qi"=O.(8oF63PҒc Ѣ oŪ_WJܝ-}˶&f/ qw˳Q%Ol`S[D'Tـm\'L#I4:4jWz +#F4'''=O^ik;F=!rW@U~՞o;.SN_u-4 WSmlQG{Y Nu;xVW74cVhM JNaϸּkN轆O=:o6z_ZPUfIj<6vX|u}a;`SyO8O`w 4\AC=>Ejb{\_8Z ذ_'~> {X[18~mKlO(qWnh|M] 86z " " " " " jHI=" " "CD@D@D," " "1" " @;Y#D@D@Dc4D@D@vH@G" " h " " >ngD@D@@D@D@ }!" " H9 " "@:BD@D@>Fs@D@Dh'q; t " " }" " "Nv@D@D@D@D@D," " "1" " @;Y#D@ާ_~w]j__-9C  @X_*-q-u>˃sy2]|йV];ӹu:Wu}U_[Qk6g6}îu|bTFU:X]}RT~׽GU{*]X6jkf[uZVRWͱ?Ωʪ{sYeD@D782 4=kx4g:*uj5,׀nH3_u$wdK8 ~ K}}09!ؗQ h gU+<=U>xzV+50-3iNє``r!ϔ@?zFu heN+ԳtrpOmc4evGLoiwX'1:˜b1d`Cgs18mtl,<+;l>ǽ)ڞCK/-3toO |#E&ay3ʝ2c! ]uNOGZE9~0fock=ܷm0 h4GuݵV'[iۀNbt%a{{e:m*ظ1080c5]7 yv 7lfQݕ3k߱lPNLAA-T@ -!k :йQ_EFBJ"PlM}EC})]c>0J%>K~BH03tnַ[`}%h <9r ٴm_  Fָ,`td[0kϠbebшlJX7b}C!065L%6;⁇lC SbJVypg߮3|K'"1,!ǚb5r#|%P:U0A n-!XT9esc0^Pq(%FݡN 2N\B/[$ \cSBb0/bӟ(܅hڨal^FlbYA|1BaFc}JaW}}^|;ǑN,4@9l=bP Dc4D$~M8f#>پ(4eM==tuj}zfE&&\*q74=Ui2L<*fgKqM8)YYC'q#^YڣISJ1ʫzQ כTWW|OGw,Y#D塺.G;[R\_G{l lἍk8!"GFUmK 6Mx1ͱXK)^)}" !b`#$K=mVRB zxd46덄,8^`r+ }g0]CM%N;wlNjac $2].}%t>FD@9WN* ܾ.L;* !Uݤ)$B[9)4Hv}Ui1V*7pt%@B$%0γAB,$կ@,k,.ISh611Q)~"I|#16ϵT>idc llLSc~}ԇsgMXu(hq}`m|@a4I@(fQqwWjm̷)RhISwG_ g ^? Ӆ]3ǥ8?Vj] ~)l } k+XˠxlU0Q+(aɝD0ŚuRǺ}@@G clgϫzpb-EO@Ԇ8;fG3PJ_C^&\ ?nccLAloRׁ]ezKZ]ͱTDT1}JcCgքyȑ=؝RJ g_9Π a&Z$Ýu,(/#ď,1_`[}"7*#R `,֔ V: #v T1.SI6*˃U[e7S{*Y<j6Y+<cvWƥIb%8MM]B_Bِ&cJÔ`MH ѹYiiFCLX 1QjwGW>Uީg("\Lw 5z}̂)20l$8Ҿ*2܈A+`ͣT]W'0P[A6cBO|vU8Y5R_w-2_f99DC5':Ď;z1Jqa~4;Ǟx7 JcjBD=R,W{W݅31̤'ՈK z9>t])t3WE;h(3~0ȇsΤ Ƭ;֘٩Ku/'{cyE[1vQkt?$*U.|҆ďc&RĔKe}n$U>/'|', BU؎4,~(IV @Kޕ#a(D/ i؀1Df%;HF6b2HHwVfye@6/yIFޜ؆<7V;owk{llǛRkU:UuWOU=?2ٯH6`4TŖy`MߴZpHˁv(?μOVfvG~Qu-?f,x+hl"o^y>^홑H6^Iou6 ~\d?^GROJM_aYȺ~nHC3ju]Կ+-4)؏ q5经ǻh0@+qPuKò3[#;~{1gr^ǪWy+o}]ۄu`o5DBQȑG`\5ָX׵bO=:_8}|vkw)JZ>K>՘VAe?n\8:x`|-DWE˶YHZq;3PK>tCێ q-gi)mT0ڰ23,7﹭|_zb꺝3_{;˴`KUbLUpvB@Q}i騘 X.`tl?Y "SۃLKُo3_Ƕ4vŏz1=4qNZh,_J~sXYr˓gx( ?ηTm0ʶS#Xcfxv'u%3eZ_kh}?쇛1KbKxSV ^nXq+$gB'a٤D#--L?|^ڋmX S÷!`Ez=:P)ؓx8Zx~L{{`wo4fb0k\sf0x-8HekAgzfoV_gQx\3D+x+(/yʱZG Ż:g`Kϯ瑩cT5ܺͰaeN #kllT4ļ4Mh1:vވHjaӶ-c0b Y-Qqjd#W`q#:l_G?`O#5-o׀oBgmLZ g~Yg'lѴh؎/u_cy[``Ob^q~?uwܬDۇֳ# Z/7l LMS4}e~2(lҞ~%:c+hKc X )eu~+aQ.*/q/} _؟xvZ֫Zq>U="s XW[/yvڷ¦Tu08&9 `0`ŏkwxG]'+,!{czHPN+Xb/Fguo__ ȥTd`r|=bZǑ 5Mo;i;Tt`C/}]Z6zkJkeLG>m%Nj>r\|mmЅKȷ[KpKt^75B_t;8&W[_ta7nx5}G^P)v'|^Ck gGEǏ5m yf& }N跽5-_,"d#-_LSiρs$QA{*h`GM|ePیԲg>!{uqz%u=9?E`T%G?J}_7oң6s~cڏ?:RB ~l*A `؏+7`{m/ppUP=?vϝǰ~\G(lbkb*8p;6:y| yΘL%KL M!W568>$X|c2qa(7/%0zk_ӣ_650jC%!/_JS${+Q rR5;Qe(Ae!馉=8`! yպyZ4:&T-N:FƵޫsC # !vÏwG# `e#@ K\х2>N~>FsP;RWZ2=WҺ5|7ɑ&y^J:d߉߫PSuXd0dxL:Ԧ侒K*KIr5T55\ӥ\$JgXޖCR]*l\+oו+6>;rs} u 7kV9WJ}=kX>K?o쓯 rl?*R A? LE\Unšܕ#Z|Qzz̺(u5#ONKgJYH1 K~іFA AlCc١[N[g:6xzs2M; ֠<;֜g/MBΎRtrawAۮ7t|Aqʞl6_$c|D~严\2JYkJ\=]|/L1x'#m( ǝ{o:2W̲~,1ldž8z碻'OKɏA KdLT.ǎ)MY*=:+y<7>H|w۾O W\L0Iag._U[i1ڪq]1H  r|EWڿX6#$'|➏?A ~Z]('A `0 A'I `0 A@gA `0 OÏ &A `0 gÏr2Z A `0< ?~28T A `0  ?~6hi0 A d0lR1 A `x60ӊ&?-LA #CdqbV7b0鴌k=h[9?xmO,MA %ɣ¤jwDSsMG ?~:`R5 2D`F%s5䳜A煀O<$^`vS &UA ,# $Ïw,[ܦ1 S_Iytv"P?,=?}u}a:Wzǻ<9o¤j0 .31"/W.Q\r+55/!?95lCyw?~\ ٍGFkxB9ؐ#cN T ~\#IMw3_R揫oVߪYI[n>^U^#3mW8U$e(x^{uPڛU I6\[su|A[rXԗ$OǍryQ {I^Uw嚄>Jϒk{+kou AQ}-2o`&jǏ Y|͟aA cf|^,ȉb؏ݲfrU6*WYTyJl=?G]_uFǛ˸|XƯXcQ|({z]9-U,Pu*<S %3 K,W^]tG-UnV! .U*^<-o%:mb_SiC”:U7kGe1z!azW`LG̬ǁi0X'xJ;0^YQޞ6ء>*}'9cu!Tr,YQx.,+e{{#SexP\2$Ӣ&Ju!s 1_Jy-MFX8dzL6+|_ &˂OK ), 41yX&?NZѳ%~zѥuO{ s,vq%Ll:Чe7zҧv:me*|+V#ztߑj}GW:}3ͱRKfS~~os[«ǖx>9}G:"JV+lpo: '0F>~7~1]]rj:mGYy6>:$k&VNZd=a ӫg]ӑˇ?Wwd蕎Hxr9]Ɠ3@_he3KCʤfߑuM}٣t#^y3:.ѹl9@mWul1J"}+/Lzi{@ꄸtU3=Jv?~{>z|Q3_hN2F J߂WmbPg˅;#Gs ˧9ie&ǧF{B?]im\]':DS ز/ՏA{kcPM~<1,_1oºslq4thx6.&@pw*ji"D@mza*DYs7+ \Mm801 NNG ): 9?tRܙ|fyF׾#֬f-0_,Jǫz[OƢ˗*߼θap:2̦#?F֝lYw.<ꟲ3̍.]Ly8BìYmAym\7sɦ#,^yYZ#({Yu:}Pt:PӑW柱 zn"UIl:vYCL(G Eú'w!o_fz. 8%g3(Bʦ>,I3Xt45x=vw6?ODDj"ί҉DD zdXguD_Z7D_X bX K>F2mQ*K*EO3X TBFe.^!d ̕s5HԚKjhV}A`W2 P2('jߜjHO{k_f~%-'[7ϱlqgn#K񕬣 jNW)?>۷e//̘ޞ/W'fe_qz+9v,ve 6Ybydu*q`鷥#ME`iJaz`޴ rɗ,6xTkzujHbS,b5'^7=^BO ='tkS^ږLfԛfd yO}CڰXsxQkq㺵g+^Wiت~5iY<2]=5R28[aPzb0l}RckȪk N:~NtC_~9<ʐ&$<{]a|>zӂ/R"L?zFLe18SUgq0ֹaFQw䭒VaHAVC~9Baݑ}C4lVWpR;ڟuH;t'Yخ #2UnW%)SwY>,iӬc57*4fJH/>QE+8"=*]6ʸ^[z+LXhK駙zf٭S>>5ymivʗt.s.2&r.yzZH:ƫ ȏ' +֔bKXtl*Y^VRmė֬ yx~ߑ@01Cg#,+,΃cdSk=slC8VdShRǪ~OZG|c :=[KSӕ|&+>QI`@1Nʦ|%K_ͱk FOq)gw,\8D+oڥ@M_ΦKqR3k,WC(kLT=k"_>\+~̰okܚ̌2A+&Ǔ矠L65ST>Hx4WSvזm]K4^OƓRdwrsx,J?KwٺǰoJ6{XTq|Y7]a-MǓK)k;(œ@(_ ,xR6VoDVԍ`BՎMj%NǰSJxPQjJDz; O<Ϫ^a(ԝ5+1(_;ahدU\T_Mɳ9ۥ9~ҥ5u3Z!:n'TyyDYueY؎+dਅb'EVhl`DD-D _W6]ZnUrزQZ݂) cE?ڙ z,1hc1*)5Mu1Qc IYdfhav:Ǩ ìо==t$بGJs>c{8JM؏rVt.Jrgm~0O=8S3}Fq|.m?|J՝ᷦ_a͹"M?W-8c?awaLla~rcܟIFc.xz̡GL y'41jʿғu&f`i*].ESyܢx*vz|SKqtm;1}FkmNJQnVk<;g%uަD6NٓU*M3CwLxDW?mw2T>Mj&z\$چCɻ]_aQU3X<2[ɟza1u'jKˆ3~ ?|2?ZAya?3W}dzimaq)۩j9nS,.` (t4Y;%<[pQRpݤn8=uX+YajGn))S+;y۹]~ܥuěpUxLzl V`6}+ߛ!'! e>o؄}ȕ*C y`?&F<ڏͥ]#?, 'ÖˈH~3?oX)S6n[x7/ K%-V:٣b?:\7'>otyMǞ^ر4RXڜ)cqrhkҪ{+˲_ uxC !usNVq+jr>EA\a=Ꭓ13}w~O5SV|&oف,=<~igSrQlqyVh},wz=lfUlTco9>p ?ǍLT*aȺ2egBb6QYX;7TgӚe؈i2e<2b؏iS;²0-]Ǒ S}x1J5v eSҺ㹘@edߒz|8۫kLݶ&\XC?6k"gYѯD~u:WGE!ݽlj먕.!"pH3ڊešWUB~uDyf1$Ug}7N{ DV=dpRTt[icP5<{+ >[DO?,m:nX23-a&ZxZɖeUτrYF(}|PEaͮ;> /L<=Et['lVܮnB޲SWa}mrQq~aZ8/ +yja[y=ώs)3xZ|׫f{|ZnghŅ&ZSi~QIjJV`?fk~Ç"YCA.RbDZba &;\0!}Yp,'G⑌8lzӚffvԑeckʿeF(GkufL3]e'8$p]x0ObKsY%el"W-㟜agMs! ut[1}j*eV9SEf= >W~Lc7ѱo WX儽K^W[C`BfÊ= }ggGƔ[ u'w8?H,~l&:+ %&]ugVu\]:{qZN%=BM;R tH@bW(8;acHwN tQ pŠHM灣f3 7WS;+S-Ib?zߢp%F'D_yCX9~sT)b.Fv̏;<1L%W9٠eTzJCm$5|eL.` vrKw*[sX=>`,N+;,yu 2cqaUшӅ(nPgZ;GkXݱ3-O"Wp[x Fִp$+3c?>ʚ:au #ǔ_2}X g,ZiiL/0忑>=f+YB.ΖC#RQ@s5y`_ws1ѣUXz?X^1ͼؓM bzc&# \uYa?\1yv))Mj\MS:eal /ȬD cRwٟKzR$ts(yکW2-؊}o+ϪKy~D3[cY=-fF\Yv'ٖs=}=6fs*׊'TnvqeQ+{M59aqWBȅPXQ!פ5RȍP)@ aA~k y"#.K$cD؈y"#eΩU]UӨBn{wo:չ7Uˤg6ǔK:@!A'ޯ0ʷ ˺ 'tÀO'7>n0d\Go"};d/}bojcؒ/=S{mh] o-c0kTְf3<%K⮏_aFdD^ojq+ۻ`喋"߉=,rfi9m'[bbH rŸc3=Ӆa]Kx{i}Lj |RVwQnW0l(f& V&DzR1L2|_Q,F2V١SFyj8ϑk_A[Չxw TguY&Z#Ao|kP:TjF,ۈ:6]ѶyqSYkIfHRJX6`V}ѿ1er?pk>o%2={>zoNT[ٓAsʹ_+'3zGfVG.V)0'|K`;5[][GFo}`aZ& wXc_+ľv)Uj\n]-G:?fˑ+zf`%²x{mb_"nhҒu>j6ݣ4qQ/dܰX╌F +0PZ#~m eR xWتGq86}n[^wu.{'TQ.9#sJ}+\K;PQ]e^OIqz$FGo2ݖ3"Kt擣/y OTgLV|}x:zWӛۅҒ4X|;svB`KImx/&GԿ;>%ma뷞^ viqXn]fz(kմĜ6):EQ' x)OEc)~EQލ: "?vrTđ,4[-kI~DxL={^`Js䏩ޟrK^=nW `P~ZO`j~3ܹuUYt͞Q6Qe|U'؎s|S[//c6TIgw'ʵb%{tϫxDew,]@7/nkL_8fL VYE^<U%僤-dላ8cf)]-d.~&[MMj;yNs%ƽmѫEMu-0Fظ̴wpm$cD`G.0&[58g赼^J[䳹(_)ѨVbĠUX+q'shJ k^vSD.ugg6J^7mC*Ͻ{ |l3=1_?̭Ư]R.oG.ɗyn1G8қē\S5]%|(= 4O|糟exw$-]^n+A^=_EqZfX:ci# ='3ޝ7Rm_q J;%h'Xi_T_ "Dk;CʵQWb DK}cW8c'?3/,~oX+?XCYv-ZokYD~ӬS}J{Xc{L99 cWj+bZq=J>n fR]<)źU^[K>돵Isg2rJ{?{ߜ|(:Y%O N^/Mic<٪Cg.VB^J&?K'JQ?f =e빘-G툼G8 x2#ʆ VlW}׺Fi)v~ț0 Idݳd7kafzzʢR1gs[˗?춰.50F/=?ụ̈́'27cdϮ Gzb1}e9Fk?i~nj{N7ɺe-֌ZXiW=*xR P^rƴg^O.%ROmG0j+\0N YnWtMIwM-,~K:C=`<$N]=Ego0_}uV}O:G.-C܎s>5S/tH97f7}j<97B藕=ߐyiQHGhH=Ɠ$.NbGGs#$ЂgSL. wagG(rs*gf##p :xuYLLgzXݤqc]lkK3ɧF4ᓁ,O{N $8T9X\ׇYbgq[]DXO2|oӮ>h5J2hhsh{m)3d1]"/һ{-y^@ ύx|iz&Xz#-O{ui_P3gxQa_Xe=̕q6Y%|r쟦3SAf Z8X~pLsRLV."8Go8ⱢyUls }`۳}2?_= ׵2z*mz{Yؽz<4pُ:3}[>N'}=w!|D^?6ZC׶4jaΥ19~dV0!)~8&n ~dK[C@fٵ#|:EY;,灱$GImiļqo0R?Y ~V٦&m.Ɩ]8s~uKmE6WK%P=wPyg8*X'Wm7v g|F|V-F>KKK{##LО;])\R%F.2%[> פ}uv^|~B"qר6ov[q\9ٲE-RpaU.kPGmzQ0L+tEK4w<د1.sCֈj oK_/ߝhIr\U>+l鎱aJY0@]h{ʹ FdҊI[I"3%gUi$KF?u޶y\|g=Yɕp[#Z?Kz^q?,0\cq>89>t1ү7=3)eFN>XZ o **B+K_H[^3[|].tP 1e`(=̀?BQpqg '˜yXG,g)*#0 6osǓ|i}m;YPuĎ< `%x[t~;qXyc1sȏOI d%b-uB˝xӪ8+̫+nvGb?{'۵f #}Lڿ.oT_C'e463<8ǃ [ |&Jo #HҘfƓq߸|i[v3z1)(21÷0cJ~c +(,=-?vW25^k%ֺ=~9rzZhwRloq ԽGO%~G[Aړ |v)6%e&7mKmˡo!~y؎̥I:=ܻIrԩ*j* &a'=(U+PVYS ۬1<ۻni; j<ۥ|pܵ#菷iIwf 6(ƼpaU,&G)¢eqE)/z;{srFޞu|?8qVy eqکAp+Z1g@C +ǿ0&MDz2n>|3cqtqb[,Z;]fQ.Oj)o71%HIՒT|)d3][C\2~3U82bw᭠(1v썹n>.:a.= ƹ7ÜC3-^g8VQGY댁ne3|pTR-8XضyΉ7wӘ6kvӆᏝ1X7h^.væcyr\n^AcyWl^ytE[3w ,0fzjAM$V_;< Vt Cc`-V?ފ~z8bie~[ENo6hoYFӋud' \2OV#]Yڮ=ح0 RWoT)ƶw7WoK_7'>}XlMUo&%G g|o5aqcOrVV?O@oǽOH_lW[YޛԵwmo{00QEX<*=aZ"~[BVC&LB1>TaZ1b/!n?1vHe`p H{:Tasqұq.s0OӘ*<VvA}Fb8A7v 8v;6-0pu'2,#dnׅV?go3ǙĝFfV#.Wf9,F=96;:Z-Gv/|Ճ:ivVc3~OA܉iΦ3іcT?nhQ9ׯ۱;c11<Ǽ'ٿ>`gJ#)=<{F[+l%%uy\rm 'Z%|R5t+9c)k{oj604>(5[91_ԵM,=\*a2 \s?1^CQ]͸ayhKle )⻱^|{9[KKo#[[G~71w{\z2V>SlX'>ؖk=^Lu#EXu [JKx(Ҝ}vTHt#ZD$ӯ~vF;wzϼrGp8*GQ,ǥn_Hɷv>I?QL8g29qq U?sHY-[GW\RQA)ڰƫ4>/X24>&oX^&iyx~qqGO;C?=gFbd\Y+8EeYȟz?9enh{:i&o#b?u&lg&aTȼg?;gRs|f] ׾|pbXw65,GXO::'x2N, Li  U;n>ɻ xwy#=?Z]~ϿLZL-Me],.ʥZ?l%p/WGd̃;&R*hDV-5o!Kwbz1Ɇ@= p/womQ{ㆵdkD~v5c?:p.-VZny+ q3t#*>׍lIJ2p,)̥{?ZGbfx K|mK\0AO}{ U,N7}/BKڵˬZC0 C0 !\\K?M|S*cUorb1WN۬uQy,Gx٧ _\9mڦWg¼䈵,W.,[nX7 s ?GL=#mƑGn=?te,vf]KSoҳW!`!`A 7qY2x|++VZ41[ "7n +u"Q +xUFDS˽׆1zq)|/5٧\I-deϘ/#2lafu-(_K:aG#"`*g[K(k99k^$ 2_Q00 C0  @*as%YmXkx3XAjXąy-XeM +-U=G}wM,nUH0`[ѥ ?NRjԼ\~1m_>~LM!`!`![W5Zo[pcxG[AΘm@^̫aYуuJW'r%Ծkx!gY2g'Uwyɵ cBeŬک:vo)@g-~Eo v0 C0 xBy ۍӘDjhQZ@83wv5 OHhue΀CFϫylWҦ74,"<1 ,|zQTGZ x-_>Ĉ3ljyC0 C~# +h:Jy1ﶘWC2lEzp ^Zz+" zhDLp#MX+ƙCvY~y\9!lضQ̄K碁"<]g%Gӿ4 d9s`Pך+6 C0 CzŸ9J5fKx;XRF[ OFqx5{ GMoo||罫(b}091$ rPdc^`TNq7ŵ䪎s9y]2<;P>XYFOIY^Q6GQ^6wnuE+c3y-YnRYZ^;}ʗ+vî1G0 C0 C`)sbO͟[r>naoe<[-7*Vn m 2eY5 ~FW^ޫ6.grys Q;^ƩK1|xCvref@>֓k-}❂1hruZ<ӫ;u衦&WH y]k!`# TNW WVoKo[k\J.,r\ƺ\L>onװ]OƒLYP"8O^\^L?L.zXfE?ec>S~z|Dz/%V=XٴeAT螜KEʡ h*(,:c قDa9`|iQ\Xu-r60?/-y|)-juq^HǕ%r⥕qd6S^ŭ;*㼻:! +ϼ=y-M+{,W6vUVCp`y^#ܷ'7c 7x@!`! ÁizD,KvQίÃ'18&(S~kikkef=`q^ zn ҹ-e,%ZKLI׫.:?}Ae^lR.S】һ:s[WzNʠ2y2/#OZ~KZ,A_lcC0 Cx֡}?ӺH*wPP>!թ~s& Owj7OŜpm\俤;_0OOH/i5mh165O_5|P6RLxSI<"\@W姲DA~< /}1x15!`!PHm[4w\ 3~\:Vc. UzU^.},W//.LoT?Ww|*zvbj>vH0 C0 ?n>eDe'u2x'5ن!`!`Vc!`!`N"`Nk C0 C0 L_C0 C0 DDd!`!`f[!`!`;;6 C0 C7>3} C0 C0vw]m!`!Po}\o5f!`!`$f$&0 C0 C0j5 C0 CI>ItM!`!`@!`q՘k!`!}lC0 C0 zCz10 C0 C`'ص}׮]o`}l]~~/℞] l3Xփq?\mw'm'^<~DCqω?ƱV+_#ֿ?^D_N ܏.C{eh/UeM?`ݰ.Չ/L'se؃u+7X5omv׮|5ZX4bu 7Xkx+Ez_4Bw?t[Wv/V~]γ}pu骷qryzZ=]fp +`Ph+@Ǯ`$\#V O!X,nKT5wI_Yl4PNG  IHDRh7( sRGBgAMA a pHYsodJIDATx^M-uA|gg/<pfO"` |H [ē2HW6 vtW"0"B`Ԫսu~ݿ ޽{˪_U] ^ ,N5R! @  @^:UB` @` Щ 3 @+@WN 1@Xt  @ S% @f @V *!@0c xT @@  +@J@ @^:UB` @` Щ 3 @+@WN 1@Xt  @ S% Pw׏G8NG:%ֹh|"@C Ӹ=%*]M pü)x*z?7WUM_uʯj}4NT$U>4֛1W1O^Ǟ njQiOS2rLsW? *k8GWEؠ* h/cbl#~Ʉ'] =>i#z2.nG7ŕs8;QD0|l#~{K'NWRNr`Wl]YZv^>?o8zSĮx~EtmpE_{s _˜حbL `TLkUB1dVba ^\.@^0YD]o4~&!Ŷ6tu{XGs{1l;+NBumcc8ʭuy)ܓxB_jRݓ8j.-ݎV#o=8W~JRgqrNjK p˪ssK}=|:$7:/0re:G sBmdFE9FXC<͵ /F6yT1Ou;)%-zWIeqj&X띞[{dǰw'+N]FQlD{P q'ȸm2"O­%4ն)/fsiȺm G~D6oѿ㳭Vv[7a{+r4 ~J>"`Eb{j<8h-pЅȓQHn| >eLiVSx8jk͕f_ŧ-sg;zMF=tAqgOaXuxĨi)kDx"fNݛ3?!!I;icb׋d삩1;f\G(%Xzյ":Z,yO诱aR!Uj'VGy_1Qn=*|8UϪV{8]Y lS xKAWUƂᡟ3'N,6 :[,c[gxF!L=b1nc}|\46>VlWwu@ΣirY>@lVC1Ci8 y?tH;M9N[zʛO=^m{]sZF+~'ڐC<$[=_~ް]Oqx^n@;JT4ҳd=]ɝctʪiCzɎnsCBc[q!l~C6U"<7a88oǪ6IO&@+p{qa =ؤ' hg*,YR( 0O̮X3B2A`=zVAB`B t !@7A@$_i l<@8&J @`wA1 WZ@'o0I>f*@8xy pL1VA  ̃ c@ٯ 6Nxa |~U q; @c+ @7A$Eh/[*I3{RB uyLsm&ԲQf "ʀE@CDͿu p.9Xo+GN6Do={&CL朽2#gL"  DSX.2!$@`|40 qV߉PeB6Ȓ4{N=kTBZoumq[=Y٬}ZǴaOާaߏ`kgkFcg.*66mJL;3]r㩵!#< ;0 8EDKĄ+oӈL4WgGQ9y/\4'2ȋnC {ۖuf`K۫9gw'c{.Sʴ"RfTO L?uKN3?G9;{m#sC$ A'\u4ǣP6eH&bB@`>*Kz%~Sܼ)[}z0~^o[ן~Į,K+O.']|\)>6h/GE0^,#|Y\xZans "*¶ |baм0Qq?ٔOEՉO>nqqR@`wLj4MS xEtE\ES]H؉o~ⳏ<˟{'3!O?JXȈP1%V3T'h]~ k8z*LS Mwz*MAȱ.9 `}qguqo2 $\]tu q˸wZeZOtwyr\Bx0{8~?4gTU$³FtS?^g zUъX*4,h[8`ÅE|zv]5w#sVeﺹ1x[{"*̣ؗ[7?\%\yӺ {'o^\ZuQap  ɦBtE?Cu $^[`w#5b-">tXX׉~mxMh.%C O@oũWoOW;3Z9n)o[|פs̜W:M)PrEv'wSY_ɪooAm.g[ΨCX\y&kO~B~?^mX4Uֹ,-3<\njQB`e n6sh| (x\~EL@`+ kl9Qf/;n3^i`!.@.$}yh<` $1B` @` Щ 3 @+@WN 1@Xt  @ S% %|EjBe_LWNݿ|hSxO6EMo~/>Ӟݍ|qxm]<{;|~x@<'U{v͢ @`K5:wMߍKD?6artfpM`W\@Em-"+T+ 4g>vv?uBU_ːs.PpƄjcSa[ kiYZ"4x2ljWhrېvCRv"xj {4Tnۡmko}f7Mʙ@ilD_]_ |vЖ'¡p"9SQIyM=R9'Tey_vkm"li-Qy"[ĬcM@%]9 "L 9Jw5z!^|G^S<_`yg)4xYıwy+>ͧ!"n[duo-b׍ŗ $Y3*R=l[hEH@<4_YqȥM.p7Vo<Z5+!z/<`|" 9`r6Dk `PJg=`o;ǛnΆʽe<`=H?4%šw]l-SgIG8\z]*c:?[A9^IW po:sQ:-13 ״]鼱^4Lݹx⅛ptg9\ 9z⍊gu ͧXSWa^@SoϹ@T4nqַ%f؈-KW.W\斨jų!UZ}!J\C ag\X~!hZ֊B:/NKb~^@v Mލv<)ȻcP+@W۪Y|ۮp@`;@@/i* l@ u6M#FCq@;&A #, @ة4 pCގoK<~vWYZH`?=OYn83b+~-ťN[kx_7~ y_wo-Wq*x(6RVC'[ nGV!ꕕ{^?~˓8Lm; o4{L6;6ECC`B;ϸ.NI^r{"2_b\XeyNr<6ʴlқv^,okwb[7M83+ONw/ݦߓN0M[~*c/-=έ ]]~r.b{^߄{v dP2nTOWΛ{3\/xyrFs,>¥Ջ3׿7ъCϦH.3(v692X|䢠NiOKʎL﫰s,1C:,n˷M0#.{VqzUn@ūe#y_,"8ry#f% s֟Urs-mKU{/3\o+o #0pF +2ylkSOiĶl9mvE Z*!8})w3osFxߍr|q}& ЫGH:z"-Dͯ赔#G?!07Uϱ@>L*Js=`FkJ\[ҷ piÀۉy{ vª'x׭p*Έc֜gۋa=UBkЇkϺB`/r]t*9Cu1^`{t;RH;XY0ZiWc¥#šũ.7sAeA8bsʯ^g|v\/msc}?#9di[9lJ`#c-eӍmhYPϕ1pц?b'݆Zhn  'עYzan _"K!%X,.Ї}ٮ\u^rp׼7X}D9%DC!tiD4E}8چ"* = ~j@9x O> !@`w C> 7N!pNQ|SJV7]j϶՚pde{M&ݔ淉 pxV#~ 7N%uZua>aeXߩ)`pX $M比 0'tr<~SwyůJH _LӄmX[܇5$ec&Wz'^(Tĺpz&^UΉo6LmH]^Cz g[Zw8PJ^-qJtCeD(\{_MV/z'Ppp)>s6Dz6EbL?cXXY!7NDܮ`y! {KB6l7L͕%|czGe^24_%.=v$G*3/(]k^Flƹ4nީD,QxOy\[ }p$Nt˰|(mh\]=қY@v `(TEXEм2x,K-S \b}i)K\y >\Xଢ଼X6a8 Q[/Ҋ͖4Kyens;<`2.ni'Oߝ AuF@3¤(@PPR |F@JJt 3@ @C CI^yG xQT >gMz7 U޸SH s&v^rnO,1h?a$?=(ٍhP[vCPaZf mB .%bb\7^vrX6V?wEӴ{b R!o8s5n k4xkB{oW, 䕾u::ٗ{RNmwhԔV|"p"&Sk=z730ੈOmg[[5m34\x«6_S\z2\[{ 5!aoݠ֓[/| #`<XWZ/Mwǫ~=xþE[88)B{ZS<!ho#4!gz>a]kMS I꼨OX /za`HsiW2t^-ʥryn_0εUkojidwbg'rᲑ{6J|u 򯜸ܯgcp9_[Fvzܰz;=\]|nA,^{y8hC짷]*az*~|*b.m+L}[ I kCǹvj9mZN96XVO=߀;_@3w{k ?e_VoO'c&vnՊ獼eLZhNw{]4hmk:`/) UTͣl"OXNމ,sV#6ε.K]GW&Y mV0ud[W}YgmۙۏB,vǂziyƇϲ詚ufFuh.;^-ӵ!:W|a Tg Ыr6!] +JLNh:]F7gmzUHxjUNrwGeʳbӯڥmYjRN&yzgE?{V>ˠU.zo~+:v2eܙQLmxjؖmLyp3]x?e\5(T2E\gcgJnKメ{x+{8nxK nٶK)n&!{'Nu% EnCp-Х`{1v֮[qo/{.)N_` vE ?)]5dcnCK(z ⪾3]Rƺ gGJXU]Hfkު-+xVD;ҧ]t{ȉk p#lE.JĸIoˏ;>r#G];X;7yb> p,55-v@A'DL )KH ]?gےI[|Vu2suBFԩ'w?r9Ѽ.t!-vփs;W+#t%-⡦je*pzǕ (Qy׉]w_"o۶7C4T\w}Z, W/޹!eYe/a]a[Bٿ8R_m@Oj ^:uN ն)@ݨ!B6 J5')":^zmYLc=Jy{Bwåz|5E@_Xr6Zxtޮz8imjOZo}׎5uܕ"/F %()R1ϵXcXT. Kz˖[fk_s/ {ZTڱPBנN)b:%ω?!{ PjnXD:^^u< 0PBpw5 Ӌ=[9b_( T=u[͎sW;8X7*}ifoboI+F&@iv3ыn5ͷ{֮o/xU;$ix(@`F/_jnl z.D}a/<`Ҿq@s!8~C߫xX xAT@,ʒXv/m܊*@8|a00@"pq,U/^`xC?Vq8[.{PTe ܐa7l~s+{xI~F3Ǻ#SOh'x;ǩ,|.v"9Q󥊈9?0_09.uy%mjyCmh B*y":+ yoG[w#bu K>Z{yYlkER"ZlIcT5?;<, ׍|QC1"p F[ ~F:D؇[er|^nmD֔{~OxC?1eV ? ebhw2-B,gi!섷nSIhyn ޱxuEucG+KH}>b~'vYߕGjXMNU9nD4J+璻4q->E(ؤ[e޴.#hIYMM:]yaRrsa6kRK>nߦ-۽bRKz7W<P3$Iw[eF k CKE+\,r8W^y (hmA`6-3: s!zN`w,+e<3) c6H;n-Tca>Gf\@t`'<fٜ!ڜt[+A/`fmؕ׏6,a"S{G)e >h9Hlnhqfn6<qh6I|o=ūڌb֖M"J!1g1t)cM(##k9mݘm iU~޴o}|cso 1i 0inP ~aL;&/MHp߼[O&К:8 oHl[PfiHA=`?%۴yY_}Y7 ؏g L=`ٜ?ȣнwVP"b6- `9C2ac6q .M:_ -\=9?/?aI!A`G,s6tsxx3iBOOv | l5XgVϽ6H7^;7psC7qpIr(L 0Xq{MUq~gaKzvSq@.`{68lvHWoVl.yIxQ؉ p1;8f =9*K99^V,KێUfnaKǺ#varq/F`.~^HxN$ pٖim%IyΖ+E< q{AR<\RN1P,A`>.ŶDDK{>_xs&k1vʜ9e|>E\y=+ g`+ΆP*葐7w߫TOG>)Hݗok6x*ʒ^DZ떴R QWW}{;)#wLm%|.Fx0/#/6K ?I"N_"^_WZψ 9nCRfD6Vl"U=Ap6lvbA X5#/1HS-iSZJzSOʆP""q͇ÿ|\?ū帬FGH:< EK$yVm6퐲[\E[*ġnC~`VBOKHzPm"Y54m )=jC~Y^{p }oY; `BمKR]< d>5-G@؍{ pf>uPz[|v_ETŎ!OaDS,oZ;k-a3Zs jHz89z97j*9{1o ǫ9znmf!ϕ^g@SHq0:ҚǍvDPƫdu qˉL+C>".|nF!kМ V"j#D[DYgEuW+1ʄǻDu&B/pՊY `)S_F?>Oi!| =N^ f7`gˑxU#Fp0%>f 3@lAr͍՝#ޱm꽈o.x8HAA˝ vXNVX7aяx"C؇b!1DŽ_- Q >UiY< 3Vk[`d>,Azvյ,tP#@Ћ܆pxeճx"-E$ǣb'iҵV۝hqڌW+/tk pjV>fuRr﯈ۗlZ) ߶a*~Um׶BZĶ>/vr"~I9KuU> O,G^55@*EB@L%s@"K SYR8 0#xF=?x~C+.D^4@g').I^6uA$&e-N^9Bg" $ŬC^;B@OgH +@WOIym=@TTrx݀hdx;}%88^xc9``T$"xMJ,/_fYa -kFX[x<I%_nk pF@`I𒴩#@@`!Bf<\)p! @*EB } 0x @#{@ R$ @G!@3@gJ >p! @*EB } 0x @#{@ R$ @G!@3@gJ >p! @*EB } 0x @#{@ R$ @G!@3@gJ >p! @*EB } 0x @#{@ R$ @G!@3@gJ >p! @*EB } 0x @#{@ R$ @G!@3@gJ >p! @*EB } 0x @#{@ R$ @G!@3@gJ >!( fIENDB`DyK gastrointestinalsDyK  antacidsDyK antispasmodicssDyK  motilitymDyK ulcergDyK h2oDyK protonDyK antidiarrhoeals{DyK  chronicboweluDyK  laxativesyDyK  bulkforminguDyK  stimulantoDyK faecalqDyK osmoticDyK bowelcleansingDyK laxativepolicyDyK managementimpactedyDyK  haemorrhoidwDyK  intestinalDyK _CARDIOVASCULAR_SYSTEMDyK positiveinotropeswDyK  dieureticsuDyK  thiazidesDyK loopdieureticsDyK potassiumsparingDyK combinationdieureticsDyK osmoticdieureticsDyK antiarrhythmics{DyK  betablockersDyK drugsaffectingreninyDyK  vasodilatorDyK centrallyacting}DyK alphablockersyDyK  angiotensin}DyK antiotensinIIsDyK  nitratesDyK calciumchannelblockerswDyK  IvabradineDyK potassiumchannelDyK sympathomimeticsDyK anticoagulantsDyK antiplateletdrugsDyK clopidogrelprescribingDyK FibrinolyticdrugsDyK Antifibrinolyticdrugs}DyK lipidlowering}DyK AnionexchangesDyK  FibratesqDyK StatinsDyK GuidelinesforstatinssDyK  fishoilsyDyK  otheragentsDyK respiratorysystemDyK bronchodilatorsDyK selectivebeta2DyK antimuscarinics2{DyK  TheophyllineDyK combinationbronchodilatorsDyK inhalerdevicesDyK inhaledcorticosteroidsDyK LeukotriencereceptorDyK managementacuteasthma2DyK managementofcopdDyK solutionsnebulisationDyK antihistamines2DyK respiratorystimulantsoDyK oxygenwDyK  mucolyticsDyK aromaticinhalationsDyK coughpreparationsDyK centralnervoussystemuDyK  hypnoticsDyK drugspsychosesDyK antidepressants}DyK nauseavertigoDyK algorithmnauseaDyK algorithmnauseawDyK  analgesicswDyK  PainladdersDyK  nonopoidmDyK opoidDyK prophylaxismigraineDyK antiepileptics{DyK  parkinsonism}DyK dopaminergicsDyK antimuscarinics{DyK  reliefhiccupDyK drugssubstancedependenceDyK managenentalcoholwDyK  infections DyK yK http://ctcnt20/policy/81/Antimicrobial Current February 2010.pdfyX;H,]ą'cuDyK  endocrine}DyK drugsdiabetessDyK  insulinsDyK oralantibiotic}DyK hypoglycaemiaqDyK thyroidDyK corticosteroids2DyK pituitaryhormonesuDyK  drugsbone{DyK  urinarytractDyK vaginalantiinfective}DyK genitourinaryDyK "malignantdiseaseimmunosuppressionuDyK  cytotoxicDyK immunosuppressantsyDyK  sexhormonesDyK nutritionbloodsDyK  anaemiasDyK fluidselectrolyesDyK intravenousnutritionDyK enteralnutritionsDyK  mineralssDyK  vitaminsDyK musculoskeletalDyK drugsrheumaticoDyK nsaidsDyK corticosteroidinjectionsuDyK  drugsgoutDyK neuromusculardisordersDyK drugsenhanceneuromuscularDyK skeletelmusclerelaxantsDyK nocturnallegcrampsDyK topicalantirheumaticsDyK drugsactingeye}DyK antiinfectiveDyK corticosteroids3wDyK  mydriaticssDyK  glaucomakDyK miscDyK teardeficiencyqDyK earnosesDyK  drugsearwDyK  antiinflamwDyK  removalwaxuDyK  drugsnose{DyK  nasalallerguyDyK  nasalstaphyDyK drigsoropharynxwDyK  ulcerationDyK fungalinfectionsyDyK  oralhygienesDyK  drymouthkDyK skinuDyK  emollientDyK topicalantipruriticsDyK topicalcorticosteroidswDyK  sunscreensmDyK scalpDyK antiinfectiveskinDyK antibacterials{DyK  antifungals2yDyK  antivirals2yDyK  scableslice}DyK disinfectantsDyK woundmanagementDyK %_14._IMMUNOLOGICAL_PRODUCTS_AND VACCDyK _15._ANAESTHESIADyK intravenousanaesthesiaDyK inhalationalanaesthesiaDyK antimuscarinics2sDyK  sedativeyDyK  anxiolyticsDyK nonopoidanalgesicsDyK opoidanalgesicsDyK musclerelaxantsDyK anticholinesterasesyDyK  antanonistsDyK malignanthyperthermiaDyK localanaestheticsDyK yK 2http://nww.staffintranet.lhch.nhs.uk/library/departments/support_services/pharmacy/woundcareformulary/wound dressing formulary july 2011.xlsyX;H,]ą'cDyK yK 8http://www.mhra.gov.uk/PrintPreview/DSUArticlePage/CON300404?DynamicListQuery=dDocType%20%3cmatches%3e%20%60Publication%60%20%20%3cAND%3e%20%20xSecondLevel%20%3cmatches%3e%20%60Safety%20Guidance%60%20%20%3cAND%3e%20%20xThirdLevel%20%3cmatches%3e%20%60Medicines%60%20%20%3cAND%3e%20%20xFourthLevel%20%3cmatches%3e%20%60Drug%20Safety%20Update%60%20%3cand%3e%20%20xNHSNetOnly%20%3cmatches%3e%20%60No%60yX;H,]ą'c;DyK yK https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=101896yX;H,]ą'c$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytU$$If!vh#v#v#v :V l t0555 aytUDyK yK http://www.nice.org.uk/nicemedia/live/13284/52078/52078.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13115/50469/50469.pdfyX;H,]ą'c$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v:V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,$$If!vh#v #v #v :V l t065pyt6,}DyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Heart Failure Guideline Current March 2009.pdfyX;H,]ą'c$$If!vh#vS#v #v:V l t065S5apyt6,$$If!vh#vS#v #v:V l t065S5apyt6,$$If!vh#vS#v #v:V l t065S5apyt6,$$If!vh#vS#v #v:V l t065S5apyt6,DyK yK http://www.nice.org.uk/nicemedia/live/13970/61620/61620.pdfyX;H,]ą'cDyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Anticoagulation Policy Version 5 0 Mar 2013.pdfyX;H,]ą'cuDyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/EP Anticoagulation Guidelines Mar 2013.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13677/58470/58470.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13746/59295/59295.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13805/60040/60040.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/14086/62874/62874.pdfyX;H,]ą'cDyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Anticoagulation Policy Version 5 0 Mar 2013.pdfyX;H,]ą'cuDyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/EP Anticoagulation Guidelines Mar 2013.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13513/55411/55411.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/12324/45849/45849.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13588/56819/56819.pdfyX;H,]ą'c$$If!vh#vB#v: #v#v`#v:V l  t20J!5B5: 55`5p2ytj$$If!vh#vB#v: #v#v`#v:V l t0J!5B5: 55`5p2ytj$$If!vh#vB#v: #v#v`#v:V l t0J!5B5: 55`5p2ytj'$$If!vh#v #vp#v#vT#v:V l  t20x!65 5p55T5p2ytj$$If!vh#v #vp#v#vT#v:V l t0x!65 5p55T5p2ytj$$If!vh#v #vp#v#vT#v:V l t0x!65 5p55T5p2ytj$$If!vh#v #vp#v#vT#v:V l t0x!65 5p55T5p2ytj"$$If!vh#v #vp#v#vT#v:V l  t20x!65 5p55T5p2yttQ$$If!vh#v #vp#v#vT#v:V l t0x!65 5p55T5p2yttQ"$$If!vh#v#v'#v#v#v:V l  t20x!65 5p55T5p2ytj$$If!vh#v#v'#v#v#v:V l t0x!65 5p55T5p2ytj$$If!vh#v#v'#v#v#v:V l t0x!65 5p55T5p2ytj$$If!vh#v#v'#v#v#v:V l t0x!65 5p55T5p2ytj$$If!vh#v#v'#v#v#v:V l t0x!65 5p55T5p2ytj$$If!vh#v#v#v#v:V l  t20x!5555p2ytj$$If!vh#v#v#v#v:V l t0x!5555p2ytj$$If!vh#v #vp#v#vT#v:V l  t20x!5 5p55T5p2yt# $$If!vh#v #vp#v#vT#v:V l t0x!5 5p55T5p2yt# $$If!vh#vt#v#v#v:V l  t20x!5t555p2ytj$$If!vh#vt#v#v#v:V l t0x!5t555p2ytj$$If!vh#vt#v#v#v:V l t0x!5t555p2ytj$$If!vh#vt#v#v#v:V l t0x!5t555p2ytj"$$If!vh#vt#v#v#vT#v:V l  t20x!65t555T5p2ytj$$If!vh#vt#v#v#vT#v:V l t0x!65t555T5p2ytj$$If!vh#v:V l  t065pyttQs$$If!vh#v:V l t065yttQs$$If!vh#v:V l t065yttQs$$If!vh#v:V l t065yttQ0$$If!vh#vt#v#v#vT#v:V l  t20x!65t555T5/ p2ytj$$If!vh#vt#v#v#vT#v:V l t0x!65t555T5p2ytjDyK www.brit-thoracic.org.ukyK Zhttp://www.brit-thoracic.org.uk/yX;H,]ą'c$$If!vh#v #v:V l_  6Ps 0!5 54p yt\F$$If!vh#v #v:V l  6Ps 0!5 54p yt\F$$If!vh#v #v:V lU  6Ps 0!5 54p yt\F$$If!vh#v #v:V l4I  6Ps 0!5 54f4p yt\F$$If!vh#v #v:V l40  6Ps 0!5 54f4p yt\FDyK yK http://www.nice.org.uk/nicemedia/live/11945/40099/40099.pdfyX;H,]ą'cDyK www.nice.org.ukyK 0http://www.nice.org.uk/DyK yK http://www.nice.org.uk/nicemedia/live/11809/35940/35940.pdfyX;H,]ą'c)Dd ;ZK0  # AbB? jOݲR2*nyB? jOݲRPNG  IHDRH-sRGBIDATx^ \Lk3MQ&Z"-dʾ׾k.ٯ,d*d HDQ%ef93Sڛj4W,s9y)l @(AQE@ @@~@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y?_xkEμdy Twʇ @*@EGcwٕP5@ RR[J6Y:_B HZѿE%^}^}9HA @6f\2t @"_VZ  @@YX|~&'o}A/J@_uqL92Zbz@eRKCz5*DU+{?>vF\JȗيkWslZg@SUߞd͟W N ˄#~|JL);ԫWǼ;LI _O~=)d:g-:*\),\MI6{[\blZfMDI<CVPu:TS̄O_} Ru9hXY.ܲkMҗr4Oߴ7Φiic|N-8ˮC#at=7}^jE=m;Ju)q˶1:gŚwX(PHLzq< @{?01;Sx_R="'¼ϯ {;zoBG~^rRq+e_˶Oѡ??~ly՟osDv7.ǁT)Y|/čW,Ne\oO}ičx1$'N4>D{W6Ox|)}O[C뫱w~T1>NXL[Wv 2;}8U݄}6oSSٻB&@`x>ٷ:GZ/Gr0.g(>S,fg*zlJWYen磥^7WkWBb%1nj[}8עqRD0˧bWSDZ3'N&NjXÏ@NԊJ Hv[Vհb~ᵯScQ퍄u!4i˞eEҟ_:G.L'ZtG3Ͼu儸W#>-ZMIɲp\_VH@KRDos"Qo_d|J__D2|/BZckU`O΃?߳hTE] @ `xOb?u1nNk(R:̪bo h 07}F*tj3ҋ0N◍鿫רstzORm(IVsB_~;#,[^Ӥ@cMG9аax:մDT4!%?9uNkaI: ~.8szGl)@&M۟ WVvz (Ȩ^/zl<9]: WA܉O}S}J+[Zk7 *mJ~OOjUt?.'2LKΎ@ R0=oXcFu#7櫮X;MUo& 1W +4n>Nc[3%!Xii)ʌ߸fRRч(֘iT=^#5+Si9 IFt܍L <ȵjhSGV+B5 r5.3_SY"~e ѢRS~DShUk.{i? TC/N!@SGl*Ujc ]4ٙr%"v鍗.D CR?ܘ$XQE?/RTگOd:-ry:Juk *ᮦjeY rO.C͜Blw‡9&kgEٿs3c>mz̕z^ .zʓgc)S4zΔUS]a?̞=GqZ !9@  YUĜ*CPAS؝ csk{VM@fԩ\pϚRMM%n~>_k_ϘW9Č\LxQ j Fz㯬~X]5k{CWz @N@_A4PI6KHJ ,5k CQkR5L ֐DU[n&XdžOQ]=XjjU[ K+5Ԋ9iA7)VWQI$SP|SKI $ܔh,|htT1_ǡ @ \E?oG=NoW|:=}p*K2k(Nl$h )Q'dTDs_QQ*Ԯ9BV RRsO=81-kO%]d]$q ܟ|_NCR]IP^V"xA]fr?K33 @(\EWz*O|<;z 5QWw#5$p2Go'hz;hmSkhe˴_'*\RMUhSΊw#> x9}鸝eWKmK~VWKe8Խu#uRb*W@w/(U M4kd [j^,2> T/nˊ."১s,u5ʌƽoqT]A&bdl9vfk{G @SȢZ|*KYJCƇnNR5jj5{C_jH@ @Q>xEo~9CEqQm[͂!@+iJI~r^ye߸TM++rB ce*]qYT\ٽj ^#J̨ @ [ i @.r'F @`4@ r@_ @ @ϐ@1 @ P˝@ @!( @]#@ 0D?Cŀ @@ /wbd@  gHC @(wDN @ D i @.܉ @"! b@ @;12 @C3!P @ r'F @`4@ r@_ @ @ϐ@1 @ P˝@ @!( @]#@ 0D?Cŀ @@ /wbd@  gHC @(wDN @ D i @.?17̫ӱs<ʹ>s˽q*a`;0UE @`@EG6C;|=&t:O-t'xK"1@ k ޻s^|? W uq.+cYE @@)״Z~2;M2JQ!qƟguȴOA\r܏x?2Am1$ @\!ѿr-dkk>nLs5EOƑ??Q޾iv  0$/ jҿN t65vE/ n_:Y}oǦgf%O 9kKoiA=/-6UtKϘK^n\c{{ʹK!ۜ~sG[ĆvZ?Îgݝkqg,׉k\B&BE4mKsbNz8]}*Cv],!i5tu{/FQlQyqBr'Y xA~~kU%!& w<*-6:3wXK}; }#|Oo9{w`,^ސ @ŝroGq+/S2%K SQmzx:G} \T~w?y|~&%M "8oS8T8,&h{嫨S|n dpB= Ӭϓ9!1z0MtizmnӞK.Ig {<>7bWWR*V|$3=%>lWw:*'+ mU_|}}}P3s> v-iv ka8tAڼ)?H.EdZP/Toe [y\]HZ^q.*pZo\:ׇ5%'{懋,t^i<;7ܥ Iywkxk^i9z:6~ZP-;@  UUD9n^Eiڼe!R_%Eu=ʾ2Ku?;}b}ΦZji䊍mzۑ' 1b,3mc,E֎N&$^H0\9 ]GΪjCn佅+Bf?UgR|Ej=bYժ K+4f;+RJ&w!nL^J.$2b=M%G((ȵLsޏ6dҤ@"lѻE}46jS{Rst`ExOk||p=$o1iZ#uCm#i}7'{}ȳ3PTkb9zhcr䫓BӀ-c9֌>kXjyR?!@0$Wu囘/-6|~hr-kAW" /Gknj]-_=yOŇ_/x@y'㬕gʪ$.lˈzNͲ@ai͗L#YˆwNNǬ`Z<[ޭ&y!r֖߬#V\Ewժ+e+98wæx}fk0j4gM |'k3;m ߳TT#s;_ꦭtEfi&w"Olo/jq:sLi\78͋} @ 0$jMLLGS#/EiidUud~*dpciw]KjdF/ 3[d+ϨZ)U*|JEeEk=[i]?|ܠEw>yn#l4dN?FYyG\򗺰곔t^>gܡMټY>y8fMq~Y֯G*` @OaB%}K+ #!_^vٝg0Cv۫>DRwLAص+x W[UMtAؾ+OI&sZy}&&(Q0xah2yd]OU$RKҞջ':ԗKi)խ#yƋ0{S?'{c&IC|zُOn}#77h z v @)Px2ӓ?6ޠs2hes|kqG&vhH^P쓀D2)$.<g;'iсaQ)|43Y7 6}dہ8z Յȷ2تTeQ?>D$yjMժS1ynvTj* 7#(~FB='?S}u[YXq^Ó87)-~9t?|e/7/A`&l @%`H֖u boxY֓|zMnGh٩Y*Mɱ뜻svЬ}?Zmғ㯯ul#"k|$,uI ٱv=mTO&ғC77mn2nKgf<ɼrf ]-kQQ7 7E~Ѩ頗ҴZ}qﱟgitYrhQ-:_ߴUjC{#>+geL= zF5rZwSAM]M zeJ3'S!Qֲlxǩ&kRk vߵ9s6U(*uR7ȆNؔfi^Y+{i~ 7r}ɗ[z?i2k: yqKJF[G@ J,"VU5njbbrڢA:;A @@^)&@W~ݺu555UT eQ~yxo!*BcO~1a цCT ;rFX!Ç6%Rr*jC(g߾uݛ$vG;v.眑<E"QH\-CgY?%!!ן&Gyk?8dKѿlJ+90tX;A!yR.1c*ճZYJ)返p8 HJ1ξmF_t E/&@.ѿpS>VM25(Ȅh&RNHmא I1k@/Ն*N gOJtُ<PhtA%`ܷ}체kjxY*6Z١?o[ąyB, >9Wg&|:lDh4_FϐD9NGOdn:nО~&[ʼʳ(^)k~ XOFIO.-@`פ#gFr0iJ2pBT@_:?=!:WTtG$[boĉdyǷ@Ȅ ֐!2p#ݜJ,?B#V 3QbvHMP@icNsԭOKP@JPW,IшQt@ @?5Dn+PгR)40ϩ~G Lz;lKciDYW){*E'Y~0_ZȐ Ieќ٘#M$Qn z/uegu޺#cC|3M:̸'D nK~c1Jh|;#!^9zl.=k[4t\ꋳ:zTGOe{<*Lz~7d\[Wbҳڢ|mEY;z~uY/?"_]nj7sVVq9I/ɛ / )H 9{$Zx_X| B*hfz\K4#f=ݗn?'l)aqo2L_^&ͬQK Xʿ6_^yXܳW5 dȆ뾐Q7~PJ(P?CП] TZ G[󓬣ؤ9JMHڐoTfkH{dz?}O s|gxX@ٳcg,a4:\m?}/ϰqwt˷&ɛN{ǣ52 SO&-6xQN̗J֝ɟZ&u{f]ڨE]/m[C4͡3?=pE])f2 nͫ3̪ s,ӨvxNg%ȷmpD?չ~s3\ᰵoJYݻ 3 ;t9L[DE;L[}ᛏ~tԗ+3~럻oFWo))@J,!b?m F; 25b-yn[Kj2]87t_-oR_LR[oW</|gQ[HB_.݅xIWgc&|Me-nAdkA@\kXtAzүERRP][-_?|CYժ)WV1QͻR7 /㾗$ᆶLPa)6ݓV|4VB^)g5RTkb9zhc䫓BȍD4@I~fj$"II-]Kl {~:=Ȍn?y=2.ė<̹co Ǝo z)vR[ZS4dLKlʣOCCxӴ ]՗$#SsV]NjN=r 4lIv]f  ThϋLLAhi~^KXJzϞفLHN"cm'ﯯ$ 3b3|,kMai-/9w60i?ت(zn=4}X[:Xsu*}?_BzMUs7%Mpg<fwT HN_ۛgobOߟ|1ǥŸamѝj"(?yTg$P_mYq?)sHziw? S!n|h0 > ObKJR>6zT-}z=İӞ)M&-2_2D>(@FkZu&sh*qV'_eUr駣RC[5RTzP%=Oۿ~M6sϪcN|K77!xVy%5pYctT(@q~pAD?VJV4U>KWÒ `>f iY٪f9/ãT͝܉>>Qjz4hPӉ>{wbtF-ۋ|HU*0IW͠AӒמ$f]GZ r'K*7A,Ər#8Xyzfn %Jܖ~W0szuIV.'._ 6I^z0j G5FKY=ɓ9ܢ S Nd6o  !ϴ†H"ڶ< YӉ_`٫ׯmI5lo`j7w]qoݭK*+fdnG|DVNndTKGs}Ü[i>.6u^{fpS\?~P;]2nnk8E>'(ϙ ɬKc3z޳[GUg QD!0,`@IAVYu)Ϋ};|-&\ϓW-̡X5u'}v-n.7G]B-0S~󼵗cRəMb' ԏ1Iy&WZJԪ?}3Ap !G'>w2s3uoב{*w||"H*k$ fI²5};uO <R][uw' ZyȉŃ'ȟ1KVRaӚT\RPʳYނIl}I8omܝ~wuw70x9Wi@!&g /L:n\|+˾|K`  3[zq_v>mx&v}zA1gyPJvumְ2ϑ\s9l<~ Wjz7Cvlꡝ,{rsӢu~o2%NR_O[KR{ڛ t`6rym1q YUTJkfOB ^ȪT3TZ=Ǹf=Z!/7bRػS,Xk<:f+Xf[| 3kfeO)#PUE}yl[_kˡK_ϵPOڋ 3NWW`itpE=Z@ù9KgBJBQa]؅&U~ʵY+KQUt;9"Fx!a=F):ul^%_JW}*c;wwn= x1/uTnvbt-VBp>a䍏}80г:<>5qz[}>xYe g^fHr~B(?+E>7ꉛ#z/w{GI%!gr3SbOc>}:шzq-e8c8z,y(y}o*7q}w~͞q$^H#zSQ-zݔLyinkCVɳ)kٍuHTV 5kKowE ; 3<}0Gk]s|粁mt zkW6)H0lޖc=ǵV4roXdP,V#7>b8ޑ9LRg{őKҰ>tӛL[\8w=6Z7yKʮ[Ϭ{ȉNUVM>=yQIdݭ\K0ߣ*[M̂h~J EKQz]̚SMtQ(MԄ' m aD[ƫ>js [}.%4yL4}*Ȼ5{1e’a +wlKVS& 1Mf~is:FjĴ^Z7UQ(vur!y@a|lP )YJwTE,}XF1S??Gђ4n6CGH.Nv8ꔇa}pNM6tP7͆l{wRk}\P;)S lKӵ1dɔ}ЮgiH"BWio類֤C~d2 J2T_PΧH,秽>6}/ :^OPL !)`+@x[GR4sQz؄L3T\vq0u}n-~]SY%VYe?6:G.r'{ KIwal,܇{IA@R=ϰ{RZuEdbWtG&Q#IICzjT֨%l8y@/:B 6h,XGAYI|ZE~'WJON+}R*[y{UM>Ɲu[zIyȣ,_?ɩ}Zj]C[)\ DV}=Qx_rUs4 t?4:kWy4 G o-ؤ9y܂ͪzs>>>.?:D/ԡnAVf̵C7oOXsu7?ХȿZZO_ݾA%=s$%ݒxe%Tabߏ=|ǡT{yէ2SKteO!>Sc#~^SXj*klE>ǮŠɢgÓ87)-~qMPGŋa\-BB^]NME}$ Ie R960N?[fꑺ~bǐ jCt#K 4<14:udUim˿Z r2YmIWD [wKj- ћ{y/.P}͈}ҹ\dwis;O jS󕡐NUs,Mi:339l1Yby6 lBs- "uq౴OcLn2\\L˴C&%*K)~7+OjLڍ$v2$远`,J,ЬA=F !%>I~ꈞ 5g˱3+>*̿mߎ$+huhIf>}hϲ%%uʯmlhFrl)er1;}5 ~G7%ZĘxF AASZL^svƳTSfŦH:O\7FŇNۺyPcg†#gN0=EbPk@ M6fn>{1M@8Ť% @À"0r_wmHfG>i3(LzscgT6b7ʵ>|=/#G*`cfB~t@*~I%|(@+¨L ;v&/cJ P~ט f gfT+2a 4RS~ Ps@2+@f+8խV_Փ9杻eRT*e 0_d]yUm$ʯ7v-?+oۢf)^p_٬J @@NnyB92RmD2P(< qV܎DYɾ-TPW@PHW:9w J@ 0Q{Rr QZ?\NX> r<]q@:( %Կ:o7@! \&ʌBʳyn}ԝ2^2DnգAZ:i9v߳&0( Gs*&+ݺ܂dR ͐ap\4@eO+~^&3t؈̄|Nl-P_@Wd$+]|CrWnzƌ~C Dz /!RT=KwmεcOuuuA'fWW[N}SW"l-ȉ ˧OW/_''G5!HY@KUǎtu[lM]@vz"5Ș712Vh@ip+<X%j@ @ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @? @Eѿ4 @ D @DҨ' @@ @@^KK @@>@ y@//-zB @+JF @``+)C @Y(  @O"e@ 0K"3K\ i|#UG!yIO[u-@ ȋyii @ @ /奥QO@  G @ F=!@ } @"_^Z @@ ȋyii @ @ /奥QO@  G @ F=!@ } @"_^ZC_aQe@@npғۦGK$D\2#&w)K c!HGQp QF@|Do#000sa q9sOi1+PvAn]Ynȱ7m:&mD%y6:$a_T_7\H#+@&N8wRПKn!ȍD3O&t30J0O3axD"#@ + :7_OBr@Rʢ(@EG+OOsO+3_7$9|8+(! G7Y;{X ?<0$id;?+-٩{7~V.lƐrXwÇ U*7_s`H\KA~-eVeD;(40F%jVTE~~Nпq)?J@Gc]]1˱_?=TOO[Ì qqrN7$пdžصf@;]vN;~{[/zb˔3n2y/qN>cwYnR_]7N+,5G):r]smcA7Kfņܽc@zf=]{gM t4' #yHW vv=H}z/~.,.-;!W v33}}0w)Ns=<ĤzEK'P A- K F } '31ˑQ ”b8(Qg6m kCQu.iA?%?8=g(}{vۼ`TϐDQD}%ӻ{1M9?50oKu%''9?6sl\33<|Ɂ<*-ީn$k^viuoܡ㶅$$T`\2wplU_g3{/t5#|O0wvr`/g7M! Apy7wEOKlhjg3x]HYE>tHen*7J@dDuiӦ8ȦbSMuL;WѦx~anSSQD{N& +{[̽7k s:WJ"~~zm T%_Mxe=luwR&SO-xMzSϒ9OlB} *7A29//mjqSڑCL7fU2+YO{ٙ~tRwv3FXT¦ο`fl_HWٮtQfz#(gj  M4G۽.ZIaPu@ r'۷ouF PSJz.KtR7f "6EB)ַl(?WllۮxCypr"3~-rrj,f:7 6tfF%\}\s֭?}ְղw~5YꭇLsmE{pA`h'&5f)6S>^{+ZC{EBtp9ԜNJQ虣IN !ٛLwGuEJIݤ[?35J"ܧ>Nrg)W&&dhEZMg͘AFpk`_, Q牓'1˱2:VC׏U*9"EM)Y&e9VKo\^{zM^Jt&ʹ?,s,SǬW筽JsS_I̬eͅ$}dہt:756"oggbGu'7aFՕ|IA՚U:X.vzyѳ`bJΙ9þ˗rQ9[H$KʠinI)?" {:r_;ܗ-^"<%@yaHڍ5i7Bdb2BqqS,dDžC)e?>9r3k_NgFYʣWϴѧ868{,p쟄di>1Qpc3MȊvF??nE3<8:EW3ЌYvOR4O!5/^?7^E/ S󨁗3}7dou-gCc*E2al٧vNnMދvobILL0FRY.Odzl\I54L2wp?毬G  quhieYn]Z){yO,9Ɗ~Bܼ3;WR%`eN{m3{^kM&-0IQίs5Ѩ頗ҴZ}ﱟUyjB,C8rƈ^ԳgT^#u7Vf8ek&;ub(C |L5NOR3yjaک^eT!#)H4<|6l(H:?zkW6)؍]aؼ-{ C6e-ζ7{j`;`&!E{|YП\867GW2CY(})B^:GW/2܍< (<~}H94c?鋶Id{%;ͤ}A:#n/MGFN=Prr$~MLZZ֋RrY-'9MZh3kd";mY]BAo_o*O%|o<(!$vmX$3cMoNuE Q'3MX Ozy/%Y1mܷl h@/ÍHC @2?_E9p\K$);g_**8OeO*MOq$C'sM:{ LΓً*ʎdr씃K G3Xܵ3 T_ %5~ZcpG$ɝ!ZCI[aRWAɭWѿw>dGRUgbp#@ -"3C gLQ>&.$7ﮜ!3=媷 斯ʒsы]%_5GmK+@J& PdΏpQrg˂@fcm=# E%#_2H\Fp\웁#(75ӧt>cGJ߉CB( @ 6oL8*1U;q;u'dwnT;Bf0O3m=g⹥OG9s9qw*JjtW#9gLIGg7:GON;?ׇ$(%ٗ.uHDRcЫ^^ Ig$]L۬!q9>*|3s-xV2^$a %@Zɽ+%TpKy㧅lHL;.zzׅY#5SpCEL>-*5WYeG0,s 6^Z%OO͓p >W_I:a SɝB$5['pGODon"jhoתXoBu\;91'=ǭwEJzv΋Df }(5ptu8Ym; ڡ6$lc"1ivd#͍ʦ_C6E%ݽ笗hr1g\y7w{E~//ss{$2=Hx[ZKvF/g#bgYt2mj`UJAF[5o5_K1BݲG%c >#;ux@dBcoOQc&l^EQɃɓ ˷b2>Ǿz-Yvu/C*NM'TgNLݕ~]RѽwX6  tpjݝID%?QY<9nG$ }%(㐑7m(*i3} yXq:8V0!Lk;,l^??-.wz0=nٰ@G8d鷩Q֏kc]'M~uuۼ6zl<9Tg/Mvlv^Y}>X8wxA͵u y%~ėo?}wl:kmc'Mz9I[s„#2³cwٯ@Qe2?#4' #ydb!8穠pT+u!L /kVu~>FQݪ~,&g7忠] ߊ)郀2𒟇%<۰U_T{υlSFO.TWp.\a ihBN;p <~Mw]-]s3wg~Ϫ ?6rlڠ~Cnc /"fDPjeVt'=)}P?(X=;o7Yjy׼um1۹> Np<]{I!I|nܵ#f?x-U?OZ8jLNY30;@6 EOKlhjg3xhWOM9cz P]K'sXKC+:ӂV.ZS!qc~j`nǝۗ>ˬт3:qȳ @*o:={eb٪ Q%S 7l"T+$.OaAu+1.;[Mvv΋'p8=lYOυ'd$~xOw= !Ip^UӨu]S)F ~quWxw koTDˤܺv㕰o_|& ={OҞC郗U\ݰ_*{ ?Qo~:t:U!e 2R{ 26:=;OwY;Pt{ޞH0{{u{9xPiYX#y$J|~9 [kϺtU"=wmfc&<#Be$1ڒ{<jfY^b<"Ne_>Yק'%|A ?q]'rLIz_n>6% 0 8"PO%Iz-)R51}6DtOH{9krwK*۠} )%uSXywo~Pɏ/:eDTvxk:x޽1돉. kW~'QKZӵxdĄ{J+^R^+xTA#3 Q W.挫4f; kdҭ o([R$hP)5'.07r >u1) ?m荀s~ױ7mT$הoݽإ='bϊCsܙiـzm>zΚ/xzO__&DŽ9ITL{o#A@&*g|5Vcz}yF , u;|K1䑙GCN7N0|[}:j(ߪ4l-<;jN߇?[\Cv{̈́Uh,Qeo)T7m_ß^At:3ٯuEDuZIQb?gGnj5aa Փ7~QоYVyzn=(`jY-Fz]G }fk0jklبtq,k]a!d^c7_~2no$"jE=`BbBܻGpUPeȽO?Z[ E} "|c`db[AGDH~sLφǗv%y7z {ʍ[;q:}g$6S8MzgEum۞N}7ygUOwj\'ϙ9y\n.k'waeX8@;e?} }=, }3QIxu'Z+A3&741iDN| u8{U7T =˧MKzO6{ЛDB,_<'G웵& inݥ3"GJijZ5~GeMsaN g1KXJ:[/۳aPl,Ru(uC1Ͻ2ōH[ژj(*66LVg̀ }V5lߙ>=t[j޸V8'=ss1J8fkz9:9PkҒӭQ0Emw+tKT}*4N?D B !G6 6ut3%ސd=bT$$E;Y$_T=2fO'aR$wCR˵U$GltLrz(JpSâR_Zf\KGԝHq";ZUuzrGQ?3>,KۧSj/w69H3J=x8z7#e~~c0~F6S/Nz1>>.6V\'ktiҀE)ZX(?ľ3IIo?JG_{^n};2|' )EYsKM[Y_<9(I (7oJef+Ghe=3w}q}rKRW )mdcr<>x]k;y7dSƂVlVkq{VBWO_v wͳ!_TwF7. ;LIbiXO^ja6Gˢengo}O{cFzEb |kd<ڵm[c:X Nffb.Xbjkߗ~+Z:N;"XVֻu=mTO&喠v'U} u-#Ywv#z0-xE K<ٔ 6 h[7W'!x6oZα[0_zE.r[};Z[XuxZ+nBgc1횷h7p/T>Kf;4ׁIwvhpBiguךw).]ڐ j՘R  k Y^L{'=]~y<(1Nz몠L_RM[=rqF;vD=;Iñ٪j0⪾f-!_bB|yO!2R^\83' XNss;õuR +_:[esSLd.nj}ZPA"(>fonZCe-ζ7{j`;`&ο"KErF½z\:k}F%ֻ:բKw^fՆG|V˘zjkܵ75<|6,>i4!fZf7}z+Еd9.rYїeb{uQoNS] ӆ|N^B.uhlj5C ?zq3ᦪ?⏃+7~KvLF- X .`dHW‡7^  'ImVnG1v&&f(׭V)Wb^nE?aо#VE[ĩ;mqvc>Aj ECӿ}ƩV }qX=w7: !5뾐ӱ8(ԓiƜ<)> SZ?gºL TؿL㕮juԑtORTӀ UX$}+B"f1JZ鱔kϽQ)!Wwv-dE*Sd唵“mq+Ec!ePbqzw/C@ ? ,!ՌGVcHQɴY,ϐ6)b /__^Q4)^:UW_UT/#GA@Fu$U Eeb}R #PA g޿l ,{t"qfV8VbV9wgJ!PZOz_ViWZc;ؓ#S^4 \B XPR `Tl8HG_Kede3f r|\+%PGVq0Id{_D~(}Db9B~"s@U[?n1x(Cָ cZP@_~H/JV|iPf 0NT ? +F`ʅ䱧ґx}h`"^+ "fM?SWI-D_d2tla36,f,U@ ᜟUn#@ e[=eYS&}?H?!kcYo͒CdCH9(OBŃ^\7fIWjǞ)}TۺtC7nZ*L%??=1:@4O[/^jd` P^rYGN_2WYH`G;S02tFCvpܒ'#d^@nny]L$/ +}@UݷaŊepϥs[]H;2~0w(>鋨,y&G/Bnmq8b0`bFHx $~ r*wɤ?+|^*w}Q"H/-IG<Dneck;xafI t&oM:~]va܄g/LO۬hc3ڒrbךyntu9:'LS殾s? #;z a~335sE=H?ĽW;=:# ޥgOys9Cbںy#jO}}lk48J I5_^&`[(E]7{06>Ko|ȼk`p8 %YNjd?iz4oM#r ĄJ,bcN>.C?U_Ev'Oyԉ4>]$ҵ%j4a߅cL9׼."ANk7J}3['\[6sD*nhe.(,Ǯϣ[uX$?=l-QǨnG~Z Yu,ܫT t`E~CvmH+*pw7kHQqvFص ۩}ǣ4ng3{J|HI?Wqϵic\" jv0P\{=EYlw-0C#/.A2s㊨>ʼn91WWv\yf*o=s|uw٭[7m&MԮ][4*}}?|ɓ۷o_OKBWېC_[{ǎ=ﮜhKv&&M6TQQT%~;HfڑD7h\taHOQ#7@-% %xl5|(>Q5"epoFnYԽ2wuЩotF>#޸TѦ"^]1~H%]7tUD{Y&$&In?w7`Ml ꨑ/'.`0{:ʬ놻N:>i]GK4"%gժ)"wKQo/߿}4Ej m ǯӵQcVDeEjcWHlYYh}bm4SkKnUaOa6.JSMv#AIEDFFFVV.ؾ}jjjdS__6. |obbccߗp_N5k400W~@[ ̐_+ <6ӄE s}P ('\p)08^ XM gqi*$=6GD~Zof}ZǎlƦ~!Qմ<}@fjAhrQN3n}$ V16kkSQcƍ`SUxRjȢu^b/͑#co@Z?Vu~4p?:Ӗﺖiɺ^f8)TQbٝC=S U2˺z R彻~`A.őw>yn#l4i=flz(e=((U=n潽qΫ/qT c7@ `Hq?kVz?` 7)=$vs9A^vٝg0Cv۫>[/89kY#iЂ.Hw)ߤ tU:OY}ZϤ% F(jڹL^?$w(dq'I뒴:t:_/=]L(v @`C^/F%q)NR;'u8kqGQo;z/.Mp> K$zRȫdrɃzmАsGժсaQ)|Bo3v-n.l*ȶ!qFIA&J|.CJUCd oT%S1ynvTj*)⋅= @.EͤA*;LY*_/fi{,Zvv=P6%7뜻svЬ}?ZmaSk[8H+E[ԭ&w3dɲ(7Q=-ZK>9tcv.ƸtMXP3d^CJiobl3.]8b |+Tb`k׶mq`1|;n=żN2- @`3{TKk:p[>ذˢg1chTDеʨϨ"Q?KhԎstKNikϾ僌ɸOIWY]Z`Tn_ߴUjC{#>+geL= zF5rZwSAM]M zeJ3'3)kٍuHTV 5X?=hYvHCy˾[ʖimp @*xFhpS3^B! i,y!iQȌN2T(h 0cYTjuA_!@ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F gD3 @) # @ 0B?# @KY@ @ ( @ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F gD3 @) # @ 0B?# @KY@ @ ( @ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F gD3 @) # @ 0B?# @KY@ @ ( @ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F gD3 @) # @ 0B?# @KY@ @ ( @ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F gD3 @) # @ 0B?# @KY@ @ ( @ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F gD3 @) # @ 0B?# @KY@ @ ( @ _  @@ψf@! @ DR@F @`F4 @ ) 2 @#3P@ HAѿ @!̀B@ @@ , @ Dh @R@/dd@ F|># BT^=m[9L&^r(HX Yy[ Kʄ9 !l807 @ &:t 3*C@z5r 0U?S[ @KZA @2( @$-_ҢH @L@ԖA @ iDEz @` @ I (҃ @S3eP.@ HZѿE @*蟩-rA @@%- @ TDLm  @@/iQ@  gjˠ\ @I"=@ 0U?S[ @KZA @2( @$-_ҢH @L@ԖA @ iDEz @` @ I (҃ @S3eP.@ HZѿE @*蟩-rA @@%- @ TDLm  @@/iQ@  gjˠ\ @I"=@ 0U?S[ @KZA @2( @$-_ҢH @L@ԖA @ iDEz @` @ I (҃ @S3eP.@ HZѿE @*蟩-rA @@%- @ TDLm  @@/iQ@  gjˠ\ @I"=@ 0U?S[ @KZA @2( @$-_ҢH @L@ԖA @ iDEz @` @ I (҃ @S3eP.@ HZѿE @*蟩-rA @@%- @ TDLm  @@/iQ@  gjH6),YHoD Fϟ;w2/pС>|5*uW-:xpae W5r("XMpw/˅t3O*) QQQ[7wΜXׯ{9|8LnQDLn(_7vwYr=#We`V[xaRR_xut93gCBkE۴isg$'hKw8@j׮]0mճ'9DeÝaK***yru)iD>c]]U\%Y,%7.tH!0ޖs'=L*i)!Lh-^\c?J'P0!_B)]pT%76ii7-ь iOOΜ&6(C@R;$)[萒j #)&2D7dgrȄɓ 9QK0H )jdyR; ^+sN> =a5,CfB$Ú KVu8 m۾oH5|KS[^9~ 0EtHɤBYJ VV@0yHEx"RMA7W;{̯]v|-)-:$ %,V {MOxX1Pi$+V>bDI>sG/v'cƦjȬI2>޾}#5| ԫ_nݺ2d˗g.(;\rE#F$_*;/VSSkڴl$ ** '/ ʫTt:: ~_+7SܻrO! /6یT_J!nW۷0*훵lݬA=Y`RʏOÃo$6 9Ykkѵ8Ka~@N;ٷiۦEիI'bsA_,Qw 쿎9shp 6\2 J.d@bbO߿a_a锛1ccg"=sW#d#bcf ,0T 2@Ix]}1OX:p)*#AxC/-ECOs"94ŽKG^;o"G|U[lNDwdCdj?p‡7Unۼ*OXÑ+sr:vE/p?{~γ&y5tٺ'd:4WvWT td;Ш7`+dѿ$MGRL_F/IbYH+g/,ҭd؉ٸBf"*F&.TD/ }Je-}"Wbț$<=kᧀ|NMά'O 4'ӁזDeR|:y&@vƘ^gd?(Lms{ KbPk4H_b ! CyBHПߘ'rIs} XsWݦ C s^62 3F^|0=+s u)3.A:F1?&t aOQ߈dL+W*d0:l4o6*W*{mH$+at>.ZndR(kZZYWbr}KnkN 3j ]n8MNJ)R(!KM@f'L &*K&! O&-^)9m]G^/#+.U: 9gDai1S=wdԟ}$C(F %:3p"B7d샌HS ѿ]W'!yG *$Y 7=ʻ$۰l 5ycp{J 6f΂ ypiZܣV(J=L TD 'Q$0 HB ًxe2̃O6:?Oԣwk;efDD?m]wzL ?&LҖkH:W: oJegi3n&t'q;_D͊$YН͸y:dfYPO{xn큟ztv K-31 ˝zy$Ȝ;NU)' Ɵ.8A9K\t`̉iF%O|>mٌ \d*᧿ahzdK`lgsr jWEA½Rɑ$CHe-v \?J}yO/|gbkWIS4zTv]gK"*)/[.o z彻{{8%~1?s][KT[Gr 9'ɦr~AǮ**"= ?(Y)>q>#)iTt/Ks$ͮ^^5JDb?KL\rȕQȿ;I'R|ȝ:Nt^v`Á t9bC'J<2cO^ˋsG{\89ߕ)/D$\êg+٧ir]?=M+BE'uQN#$+<- bNiMtlKߖ'nЗ.k}f<՘MQV[jw^ܳ6}9'Ubڑ<.dSYCxᑝ1[FNjhKQa9G(U]C=2,>qcP){ cnzMҧSJ ;9ϛ DލҔdydܔ &zB%=cމ)xq^_)v-Ks'+n]S6-+.ꦓ |V['+04Phds׊a559?iw.88I$5$"槀5WxB?Ƈ7l^)M?C,G@M>[i#V":}fc`ȍ./ xF"\nQJ:Հ(^AF557g9mEOf+AR:SۀT&0,\Up>}|7Nn5mkKr(U܆\{>}'> F.T/.J\hɝ JC\ZD}М͗^^{2΄[Gq>)uK~K#\Go@/w/y21+Zܾ'扮nVs8WyHhjw_~gh6 yOW}v{ӫOaIHȪgVVB>NW_?_-<6#|ׯ=I} =2j}ՂT??~n݆ IM;<׀Y_`$S4Oߘ]`DKOi?_Oha{SRO';ҩڠVY*}V葙MtHOl)*Miv'13dݟ\Z o[RTd./20&7yάkƺ.J$pwNɓ.NY](*,oF|9 :6{=uQ5ɶoy)܊|Uݹw> >Jդ]ݬP ^T7S@rd [;M3H77|*ȇgZEɯv/ӌ6gVdžصf@;]2ou׉8!#IK/UjщD2fdnGf|a#<ᖎdN']8Y}]%}Nr5 s'yh/\7KlyAkشfG+Q M(|?#뒭Fi5|TdNXzڠ(;VEDIݔfu6Vt;:"j7U]s[Hs!hM4PJ:U۵իY}wYp?RW"Ekhu4PYC&Klj=+96~cRGQ{x_F"=]̉nVɀ݀T}7gA轭l[X?iS/$^{nМ#Jp4@]RR7ό|KW_:~k_ƈ0E+VjC6>7!zѼfƃEKfI)ȂXPLT[kȦn~92\ޮwp]{bPCeaϵۧ5ͽ$.-F]5G^ⵥL_!/{588y ȅk410i5v:{fb ()ߝ$4[+AgAa-w/>'/+`=[ZwudOXf5[Uk}ɮb/TQSfj~TWl:{K fVk:iZнx۽o,ev\@GBDQ,,Ucm\O[ZR3%6zyn sqiR^U9uy͸_1B3|*Uk.-VN o_xDRwLAʡ-sSR qdJ)¼*yutӺO(qgs݂nJd' /}ӓ*x2o AŚEW&>ȿ{V"q1Oc z/Vu_+qRZyv+UX-9SNR\{bCgRMj;e:23P -^1D԰U=M̳|?|U}1I27MǮE?:D:nAlHt$ ru2 (nDE.{b Pľ=zu1)]hJvƑn/ !c2+Bk\݇Ue[b/Ğe]B|ݘ}EWdCMRRn5'JOd8=y^Nuq97ԉWqT$[U}s\/ y':%\;%۷Ե%d{䳯ӹ?l7nPW/-8H` h5GE߾7"P:.,&4nϴ?%QU"W,- [/N֋޲CÛ'!Gr_{Md۷cN-Yυ/ֲp*]/mR24d7b+D 2tF6(YٴZawN)O)t/'(XjF :tƈ%(UMSc-;*짎N[]Qs;y~/F8}H蔦[>Ș|OI-NTqxivWock%x Q[ '6Lc2$]+.ߨ!ܑ39];mqv>.88Urtȕ!79}LЇ뾐ӱkqn)&&f$լo#F_KQK˯-*}R]@1aѷńɘrEc/^mXcu1'Sw+}8R^XIܼCyD!@(`ռOVgaeJ˟}c_Qc@*RWEW{J dL+W*١=cOj[9p{PY G@%@/69{H|Y&^'JIV޲T8_Ň2]NK(_rϢJ#/CW`ri Хs_FT<+w&::\2CǏ!O@ȵ+2(*{O -䛠ag2#5~ٰ|!h(CtzNX,IzvA*7y~:r]smcA7K =))3,Ue?{VzؐsHk:Dh7;)Yt#ЊT3??-.^HܖJƥgJ,+4.&`BϬ_T.[%9vb>Nz^>.6t G:/+`ٚdgcE6ymjԹ[  P_ǯ`^^@ȹS tw쩮nhhQJqcc߿z~=av=gOB {:q@BNǮbN[=L 4z#fkKd71b_JQ|nܵn3GfFu?>98gytXQX$4hsj.fσn| UfN; `#K:֦NR3K O]y5;xX;w:ID$lw-0G14Fx_\UC.ğm=[ƠFrԽ(ߝsLCXpd2i@]Jٛܚ# ف.~ݗ8HUf ;9vkП]6r @T"ڿmgv߭;x4HǓV;;ZQ7B,VeGhMuC+wAaY&M=ߣ(碸-f2M T]4L!!W+Dg+eroߺ[)l(޼^5ې7@JT#q~b^xHd/Z:Kn?w7^s͏:=l_0ĴrN[j;LaOQuӮzʭMcwMIޙo^U 'á^nQ-ɱeӗ}K 6ID?Em@-%tACyؐDTѦ"^]1~H%]7tU'fpc3McF2o0 wW xݢ!(=f_tf9;T%Y>R7vm[5ĊIDϊI@?Mӻ33*--EBhGE(/يKY*)KvEiAP(*yE,ST3rO{={ɾb|X{k!#1fM6Iu6?HcT/\mW^̓%?$7 <Z`$Iy:D &̚267VCi;wޏCj񈱗BBYп  룺kb?Cz /\9_IOBzN+iv .rA D4Mȓſg6$`r2_Dc*gu!NZQ+/%m,@KDė$!` 짏$G/ S юؗt%NzM4[қT=R^@L[‚laMR9M>]Tk&+E,,d'*4~ތQ]&M|*E!#l:3B0하)zVrͰ_П="?Ȃ\ d @mhאhaF#6БFCѿVŽPأ&קiKixUѺ=d5 He/ ΋(8rc}y2T6<;ϯ>VM0rT~=j _>}(u׻pckd #yNPeoSHeL:AdHSW\,#7VW=@G@jN̾A(z$כSI#ǔ4Zwb  ~4c؟߬䡏N/flv 󻦑UDBM)G[ XI,Nسt'bdAD6nȿǙ6ٰOXZL. o_o6Zw̯YxD<0j"t08+ TG_mCIsv߬1?fצgc\;~Gzo}5D:{S"WY7lIkT{d&iqɅҬIOJlQUI.E;S>R9|E.]BC+KU3&-$7'5\H$3\cRj&$(z9M9jl:wwLRP5( c.Ox_Sv}s %)nfb޽Aؘ}:OGDbdݬ t<taOYc`_#!?9yV4MHkq%]Dkݗo#ESXd4l[ʨ.2w$TVȢkmۛI#BţԹ?d* 3 T>X0ם8~bNGW6h˧}N6*Bw/^6d*_HBJ%.՜3#64Dٿi~{1$fi;̼}9KRWY./,9TUC.%=^Voݿ;|&/"cʙ'# ;nU7ߔkK_ < 9^oE*J) jkI( (ɘ&_(>sTjXXNE&T島H62'+Ob >v ^Eƭocd%\dB u?qso4«`; ^_rs>pz#u my8]mwlaoϟUY𫬨_wO-˸{|fwsJ05_рX΅J#ZM_h }=Y+yԁz):Vlƾ#-Υ%< ^l)?L^^}ܬā `&;LITg-n;>;bHaJZv^BLdԋ{+Mtf,Z8tagW36*=V?i[& bgWBF{ 0|}B]w st&dV3Οal<&iDn{;0e9OurwZmcW>yI067(:tghxǙpIV}/x; ͨʌ 2iY Yb^xaFq4Q^Ŝo8eZ*{ooԉOa5-J^1t6?Lת~vj*}x{\?y=&W\'-B$̏vf&檅5.BJ@tⴙ)ne7_$~I !4gX_JGQV&f5ol5OxkDea7>X.fC|ϿhQ_]ڔ-1|WcU4ޙCJh,Ge5 "mE#{{ ?''Re]y{9+XQS}gf}܆N5jDx8 B)W{L|6Zar+E!*A#uV4|s;k)lď}en{qQcW {Gyh[fˣYE+ccOg3a{{3._mSȿ,[c:iAga"[۩~w1@0ɄfR^&諪gėm큜@+9ԋ?{o*5, A +ppy7bctjVNM꯷/Y_ 7yxIeI0FxzqҲB7jfyʯe竑nN`"D~7p?ŒK\&88`kk/KuĚ{⤦(wrݣ](R_/Uʺu035 NRvFsNb43Q:H}M&`5TcbtH'. !go9L%@,HLmePͻ0 ;/2?UGb8 b#Ԩqu%;pY _I&3nD;3jDEnXkn?ʣL5HM.  %@,b9Ya˸!ŏ3?QJr!LZDQ)0XI> з~úTT1id0ro@@@Wha9 U, }VReی>@J?}ixfiQn@ ʾ<5GzhZM9[i[_eA,I*a;nDoZњ(g=bhecWb, &зچapz9>( ؅@)X֧VK$T`CzWJ(-ޟqDE)'GbKviH rʹctm^{|/Q53̟ f֣hi*$-ַ6Z[@߭ap eu\@GW)*(! />6wsv"tlhB.Q#7c_59mUX=k>%,={; ȅ&2 qF?/UUQ!1@%^ |I۔zF&EȤ{0u@;pnγt->Ahń[+6zr#F𿐪ŴOȫ3ĒȻ[yމ y@p8wy˲ĂcL&(j E<ScV΅6@2FS3o(\&C~MY{^TlXH ӫ>@B@Z$&N,HWɗ@:k, nv $GqfBoeV%_nV;roSem?N-XG'ahj^ж ɧyR/b>;oZKTd@t4f *zCd1.=sr c_.G]~Ԑh\b~|N3ƌl&wTPI@tnZʌskr*:jfqvQ[Ǚ߃G).OC5 W#4lj caNs\%@ k۽uBW_?M8x޶n8E7ⓗx߻+8ZBe}gqڶ?>g7\2 dB2.\O5W"6o<;7HZe樅&(_=^InY}S# p"Z.[s%/MJvgsIӷm*w`?6ܽw5]v*/ohH?&a頎 4+@*"Ա{{{s8뗫1u/aHs@Gfŕwf,Dj+_p6#%F+NXӐ'ʏ^{Iˌ_[}4%BuIr6[I8LS^~kde7!W} -g&J?*=([)$,"%VSX{:>b!i%%'yvjyv8mϭe竑nܗX䀃ϻSrRmR}ɖ'rs19yڛBs5_:nίoˑ|) Kvr$f ǭBڒHOw Og-Lj5nD`V{؜h?+,|&|8oA~d5i PycǢ1"Ҳ"y:nQԟ/){-N<#oǽiY/^7_wPh'~iy VМܜ6іW=g.f YiQ{f":5IsͰ3 : @Ol'-$ l:n:_]j>ZE?Rh\E_LbƥC\W7{=*+69G*LX[m7{ YGF'~"DK\{גAb8!Im#kC*6 balr"$>;Wݷns= [(/.$NjzXyp6QUٰ~! XUvjWYE57Tj_٠igJ ᄆ.߱gTt}rs֗Af* ۊ]X@Tkmt>T4Cn3{6n*vt'Dp9vh!@{~ێ3K'ig 4%muF&i~)E}&{Y|wSF_t gg.?)mxW8GY˻Bd4q~o>}kC޽LhW暳4?ebC5 ha4܆4T5=.=n$-GR*( `9yB?YWiv7>N竄-ui4+vn}Bj[:j7GƾcMF3V!D5'[ #2i_qiB暢]t7ȘEnٌV+ v3 )j*I$h0S?뜍Xz+.^w#PLi(V*>P||]e4Fi CY$WBJ>AwF&WtyxɣhP1ZC :$>WR>V֔dƞqzh" >y뽂c_%T< ~%͔irxl XAh iL7es ^B\&ʩ,EbTDg%5ŕDduyEbkI|?kLN@goM^R6[kM5 q/yL)gs7FbFA%AV/)Oo_I|wdWL~{x45__V\v5C?(&^p/3reX#>^n{Zb* KDp Naowֱ^ ]jkRvYIRgT~z Jk!&lQRP0c݅*?-.7-(nժoO.1UU7[/A*9>o'1սՑXy]+h.0tlb:0x 80_&'xi3;8seɏq??=gm&cٻX.*㗲5ѹԬvSoc_ ,# 3|r'md[m16 5n_ϭQ>z_xQO18AuM5AcfJd{ G}}6]!{o<,3 #[OHd0@?$lzc/Y.\oF砟 elH3tB%(  G~d 4<,4qyύ a>򟙷/gIJ*4>7-^ I.iHB<Ȓ)u9~9y>*ȄO?Ǽ}j@00.lָ͇v/2=Re8xU_&Y?K!B+ZiߘqRƪ0,=;ϫhYLv@9eqn]iخhHO_bU+\=䲯<+kGH@Ft|A'Sbճ;*Ǝ1Rzԃ6A59-xjވR2bb+*hh?JoώL''1,l2 ()+;J/$k-:y^V r_IjZGn-!(8_GDqtjtU7MeMYFx+NXͳY<)N"nwAZ0~Z'8N Fˊ~t*&6yW-3IPl _s!y}-v{9r4e2Ŷko MJv|9:Pa攡+.?xpqAC-sQܜN-d埇>.;_\7pLM׮3~t-_hf R"a0c7GTӯ-pc?6K!$F<=@cə}pXT_-t&L'Ui*5zdXHY* {wAғL5aIcH.n=%M2kDoc,ߛFOě^YBO881:5+'&ۗl%e~^Tf/ߢ;w!j*>|ƻL& ܰ|Vƿ o81#]eGx_B]i$l>7K$9Һwov?;8@!7G;EfBU_PT|&'OyDy'-қUcjK Yf?iTs}_-F ]=lív&6ngRTeݺh0/)ğ΄<Һ,*,K]Eɺw.Qvd"GqRSM9NZtN܏Y/Juq%^9F[O_SS ɾu.IP77a1vS+·=ix1EV[cfZǻ rsR}Hojs1~~1%sv-'%$3zo@KL4֒‘n\!Y511G{9/԰O*lZD'E`z$?27`4'ᨰ?jS-nMA1Li7X\qXR^g:G= @} )#7RbARdJo+]ja} _d~ySdi0I6`o"߅V=tKqþMd з~úGR nþ {>  e!lͷ"_'a g(/khL7@BEf=~I:9ǐZMz\0ņ׶~z@gur! /4sܿ@^FSuzt"T<wϡ!SYbik۪о-_S--3p*ܜcFԵ ݽu'n'v Mnm #3Gv\ON![r̕"-!(B*, wtXЏ I[-ݵ9v _[f-ot Kw/'$Ĺ6:Lc*څ{*|J~%~{u)fИA8w jzɻFVV7ѥIN;a6R:*OHe=3~E^Cj}R6 yXyWav;j[-@@p0Ҍ|IJbym2.,oҒ▟ ;oo} vP}_-@yA>q?cskFƾQU(,N.BնsĆ__;>y=HVV8"f#4%OήFگw0kKW9vHYڅeg޸PD6O_=e,OLVk,ZHr?lDܼʿ|lysAo =msW'݃ <'IW~(j37z+TﺽUMs/AE "'5Xֲ>?|U*TWpoI?`~y񲥉 x䚚;pL\K]#j8sئH3[;V 7|u>4lC^u#P"s؎i.Wv1gG'X[ER2vw>1?>'cHG+5k hR\ XaLc0wx[Xw3[8A1VnĿ]Ϫ'7PR {M*>m0wIB!_AO;,Ȭ,a#P^Q@ՠ]W$ 7vb`Wʟm7?ԝ2M|L႐lB̪'n1b~̮M4<Nw@'$u+8gu#Dg=,/R 7gӟ+ANX` Ao4A îH|}i3m rwd>_Vw~b9W_Xr*s"ST{ɦBBCEYSG;]3 IC*Bc @*A,4*1f_/%Y8 0}kŨ0Ē{N+/EEz#ѥgd캈"Xt6kCkh@{3{):V[^lS=Y闥F}sv{B aH d"s#ͣ"aME)8‚gt\IV0 =NAYkce2yqA}2:'ޣc;)ܡq:SƭJ̔GII[/u!9W[Aa„K UI*io {]RP5X7m9EYb0O{RR>5WlGsg7Xq+.?@Άr |4÷1WPMF'5N@b~W ˬl',3{:Dg7|ڎ-*sNM5}ꤑ}+<7Sv X[Z|zwҝ9rŠܺufeHhQ6P>u[S dƯ-Oڕ9{Lq?-GO/7&9δ2"u[Uts: +u%\ ~`4 (۞@G&c+3r'l%1gUϙ >iYYiQ{f":]ͩ[yU^ ,ܴڴ@+Lduh:`[-u+&d?Y.~eK׾'yvjΑ_ȿ=G~mF,^Q0}kYc+ӛZu6>>IO9ʼn]gܙ[.⿴U uN]vQF2) V<9nԬk_o_%2,$Ǣ3"͈ ['޻q{y\IJYqZ߿v{MO5_:nίEg15nD`V{n9~VXsk㷇>.;_\7pL"?@NaMN%i~QُE-Y-%-v{9r4efAڛ9yMEe -d!ǔC2__ph?7Q- cn,e ; cR&pv~W.pۙԢ֭/lP3upB 3rjG |WX,ٸtu*"g~-9h '$mdm(׶d OٽTE_PTf#?=*SģN\zZam2/ w_n|Sda"}ϵԗ't-{ TP6qڹA.3AIz{Dʤ9XՑ5كn1P@HZoIcG[b(W6{AzՆf?,=m))E'*㡙lT#w@N^n@o!@^LF$[O|i'>ppgM֯_k-Z#!WU"5EF)~ '9';˃ ɚ ZIDAT9$v|)&wџ$Fs&d# )2n44T=Ε3 ֿS>|A'bSLWE`~Iֳi_ߺQmkz)T&h;C*Wm*NVBak%m6$ =L)/ Wbk[u?_n!^9e}%4zlDPme9u S?Z}+Q6ŷ}bV\U2g(/m=[Z& 4Ƀ nh)B›|WZFvHiJ[-@mᛄ$LzB|etXfC=[4ж|(2JSD3@3k2 5$uBZm~ '2Jb́y}[O[y&M;FzS fǺSڷ'>wi?^T$WI7kڥ=64q4_؇@۾'6ݏ>>ξnW}&M &0, RT+oRJiFҒDO\V/?%lXAQ5{;*M°]L'c;kHF$C._} l/".߯ͧoT{Ji'&5{rV W-6BiF.JKp찖_Cl1>~8+9o% #/8NUde|SV4`HRJDjr;}14"4{,NOt>2m@236^`(t@Ii,廪 ؜2[Tج7>".WpGjE(RJ_RwO'6n)nq̶$*'-6ג *: :_"ފ 4+vnf?4 _g gg.?)sSf;fj7n5ӎ-DjNj!ʌL278d1s(ƟhAKi|6}Qcȑ9_3ޭ,c31o~y{'f0w{_k rxSRauq~ጕ&^p/Ѝ!8I;y:6XYeٌ*nptbzA%kOFИ8N6n㗲>U;k^q)OJqHxAн/rߴxvW ٺu/'/4}wWp믵ʂqϼD p"c+xR qT?ˡ/G.T꿆gBg^Lg i䲧ߑڒ[5[jMWjbfK= ݾ{z}gֈ 7Da_k)z]3{0OJU{샔%IlW 973=ysAŪwLOQ@t@o^!&JGIIzgS~]p;.oTI&}:cWƓ+Td_8FYm֡ok̽ 6*ɪڹ'vSzh1}{|F}9N ]ن[aJep>nL{m_|IZaC+FLؿ,ݏ/8NVfi%f#} 7zk{)3*f=Z^^s gJ#7Z{jշ'PpEϝR}!`Byk6aƺ yɵӳPʞ$}Guܢ1V9";i1 >~k,eB@| [n%}:eO̚X2XUHv?NT4-ujA5_%*YWK*Np D҉dCv2u[TC*D! O|&j0@+C{[C^h;`3EmpZ3 Z23,ExM,_lPRhw׾럊-v{9r4ea_!o܆9/-Z*_{ͳܜcLyexFN$֖p⯷nީ=~^&u_{Lh4~e^ذd[>&rϓ򺶭qu&b}T|u':Cd_LWC+3]vBwqL4֒ᄤ8+=yy9xɕ[7SOJH@Hh6 FɚhJJ8QI[ϿRx;jjϸ=lvy7US]ɉ?:$x؀}V}l:*ٻ-l+տ!kK;l( rq/"bfBR)'u2eRlaFB|8!iY2nVM% Jvپy. 3\cϔ#J~S/k =i!?[/~(⭜bOpuD``oѨBLQ:Dw8IVC[Sp1Ki ge,P?X~X9l6X_>Z:I$H) j^)"$X7 %G+I6*(ޟ&qOͷ"_'a<~ҟeU?ѿƂKңnq"bcK[ݦœaSeuS^])I5'RRsE 2tdBA$@,M pvq5OɨEoٌmqSQR2뮾j&v=+O tlI@OMh_A_Z; HzJS/ulJ{oZ5ӔQ4dۼmD]!}}n7^Q~  ]{.譡m.(#jd_,ӗuz*ޥ(L,xpx6.S5H?*mjHJ^;cxCl 'RO*nO,J(E+ol~qqbߓ(ۊꂬ|ʊRlJ3Q*:.{Gm>bNalo[|7޽LC 6lKQK)K䰩ThByw-[V(o܃>a 2#Hg}aو1>CԅT_ NP`k2$oG'dDd׭&H} G_]9 WW~xzd%Fur򘢚-qCu̸4!ssMZ&cn vnf_oF,MtD'Rj7Gƾx^Bi޲X#t[  g}q[Xt8+c#fh: ދ{7,ֵ2 rGE~Ф}ZN! "LJĕqҳh͋+ __=; 7ll>#fo(;;4%2Q7k lr/Pi%$?UVab)ܡyajM:}ؼ)Nt:wlDSo,⑷=?!.3/&0@ݲzTCxN+鹆 pSSKYY煀1-0Ri+]kM,V 4eE}Ε by(hZ|-8~)+K^?DjV;G ragfɥ,))vr\a~'wֻNM?L7I 8q y3h"`r&>>#;Zzpn!Iq̹;&:\Pf<܆Xo:kR\G"ŏO8e3&۸3 l6l{u쯃׈ە^."h:=_ .]]W=L 6*_̍==Cw銽lyH7税Ӂ@L&-||q?&=2XOC=OF5Tұ&QGl ^@=}Djr:y*wRt>fXKor<6fub>d˟prpE|qT𠍏(ylHVO骉2T\x\QNu2#=m'1l}K'Oq2uzaP܆8 @ЯyhW|IuU4-m@^OΙ|ذ') POGmےHO1!46S3VAOCK DZM )n3p لy]>ʀu,~:'G,C&%mV_ZjGJ, 9_\$Ͽ<D.:vZ]-!|bouOOk9gk:תhJyMqEƱߌ zWb[Bn}zN g_gٻwov*߾}K| C7/uAu|&ɉ~-[(:|G ;;;5%e(YY/Dz,v\AR!])((p/'=u⊓6@*v 2DQsR(Pt!.>/!CvT*c_B}铔TZ*7J/DPKZfX}} $$.A6#PXXTPE^hu¬=o}їÑw@qlY>}TP1UUUy6cDvpEQh *ʈ{qbǼdB!0JOh%5]ǰ/H}33/j#F`gѪˌǏc4uF76vXvsE;3pq=` IJJreN*xw8?}֌arzöɊs!æëjCs<]g[llRE۽: # @O6P t@{Q菲P w7蟻@ ? @rK-B`/M@ @OTOJJf4tVaq`\s@Ђ@p<l3f ?]gD]$ @m%vv@=@ UT/wUa @J9|D,DCAZ @NΟGU>l xD6`/@ "#"mLMIf#N+@ ؉/֯Y;bia/] gm@ 1ZWQz[tL,@ ->ݷvrdw<;z Qrr9J_P @/3gnߌ9w"E/2^m?<`Ua ]`>>6nDU>yXN 2\ahB@ZZzeNNKvAN`S3@:l7wwH4 '@ ~8U{л;@yiL[!9`@E &J|>NLR\Lwh0H @!RGw杹i)* ?<kxAk t%B:hA& @ '@vP' c@ @Grݻ @_h@@! {ql崀R@ hA/uY4|鲥tD@ R(P/oo qk> @K lXcއ'OB?0̂Ea @tZG}TPP @ P]G@A]$ "h)kp AB[ @ QAз1H"@yedyxA2!%ٟx5Q'5Dq?:WBBr; @#lПcuc@q&qf!BsǎaT%?;`@IF>i7bb?WFuX.0.@I0* `-`s.@ 9h>g-:CЃ@ P1`/Hg2 @$%%ٰq#E/h8g=@ `/oăH @"Н~qa/a@ hL8My@`ylA2@ `/|6@ @y g[ @ ؋@w І9p$ApЍ W0* @M;J;J rr9PkP%|!ƌ?N3?MשM)]FLKss\@5 g g O4@ Pi? V#XIVű Y@=``8]Og;=brx_;3 @@?֭ ]OYAoߌa4tXt ( @0|4|LMM7lxE5)m[(G[P?v\ !hЂ@0o`#2mS.[ЦZ Hh옻wPN)@po߾md2[[Q6sیޞvZM ]zaD BeVu0(@ 7 =gf)D "@= -#5Ѳef!emt>ПRFL   @xXH\@ @ߍmv"#"(^X{@Mzz۽Iۧhm ^f,Gj Jq3 0DL˛i>BՁwUt  P!J|Mj6$?N ǫE ѿsm`@FlXcQQQF:A[ D8"D P)P#a_`#p/"dPucA' ?9(oPs.BO76h\3/H@C9 B "k(DÇ?*+ +(Õ^P+Js(G+@ ^֊/^x1/x_l/蟭f 6l5#LKl]gKP_;wͯ{YlE(cD񯮞3iv.[i4&$`oin|2I>]BMfn퉖Q\Ucbq7a?2V@h_Ü73i  lK"?&jD[oß9Sђ?`G@5HU # @t!>rDBB e( 1_k_c(^|A S ԪhWoG@ @M MhEANпݙlK5;z/}UP̶zb@ %^:m 0{EO)V: PZjoTvML  @w n`TΙ&F?JG=h~AhȦj 泿ġYl"&IJji E({6_M> d5SY!/@<@tȈ.!@(vс4_*LQ[`/VXm'βf @t/֯Y;ֶ@`vEEI4_v)X,#+/8Y"~Y=*$/p1OvT!Oq >s++R"m,4;!y:$= f x]IiC*Hl%//#c>u˱jtH,j2Bug (6[ז4ɃxaF t`t=la`0R95KaĂER/ǽiҷT19薅=r 耨X[p)s6;8?Lg7G֯2&;'Ŀ)%Ͼg&8gvz&it  @ߙ;}M8[DOs)OV=IJKaXz̃}' #hs":^N"`6ma/.ļmX^K\No5zBA Br~|$M{TCVZ'l$ic-LWSlmml'(di)`o)@tt(]a`?)5YG 䈿3㯦h_|SD1Bg4iN^P?(Bŕ.V^$_k'|z.Ԅp4z&7=>.Ť}:VƼ-o]ZUAJI/ I 7ho3Vƺɲa@?$QiiJ]'Aw zl労1ߑQNyh?QS)`%KZko^XKj?ğɱŌ%^=$7f[yH*AEc3yhI:/y>i_QV9Ŗ-ӓ>| 30!6>l vpg2+%SM}?s,S!*rDTxK2XOe&|XATӯ4k SRk"Pvɀ"T*xohM3GܲՂQϢ gn Qm>+0wDOJZGIaO{56ḃUXXyG2_#,=Mc{M_A9 \8?`V`3)' s;Ɵԛ I|dQS\_^@yJ茨I$i9Oe_y㆒3K߾psy ifp~L@D{Pq'[mp⣧<_pJ QT3}@{ UF'?bt]Ew|J)"]Y#[IcG( 9'Ń-z_wsr9:$dw;}?Mz@gPp PGRscNmNz7:R@}Kv:êKoq'F8%cᜋ(>eq)@4@{ep:v)}Rb(e GL=fbt.XJ[xpDJ,A\ajɱ|Ez*99IdYNǞ53$a˼ƕ쇊Yi)@>}D9kUL '.?-e n߯i} 7UUZV۞@/YcXװ,O]fP>"$=zSs"~{\&~fF"] @K(Ν`/p!!TǦϯ%UͽѺ7wSoruif j3,cVꅓf7Z/ݶpׅB^?(Cg.|{|J~~|D>b4R]s:: =}3fp= GcT;rb(_x8&Pq=&:bZ2xꢽQ 21.cV;{2iS[\Ǔ7p\'b7ngIg mm< 7Izh>}i96ˀw0D  ٰq1cX=6FA[.-``?yCz1\ I]A~u.Ā {gv+kIl>i-NFҽў^&Ι_.cmFİEpJ@ PG`eK&8"n&ΪziJMvOt5kW4' GS=^fżf?n!^-aP `s4@ Bah D=0>,$ , CN%}LN5m  `/ n%?, (C Z#}( ?P @œ  a:z;@;  y6x^׬ kH&?O>@ DFD۽`/'?S`]": 4Z|Nez78*~YspƠ%;K&~e(#:K؀ &۷%I زc|  gYrz3n. @p-[>}8wB޽.FC&ڷT)Z3ay U&3Fin!"[_ud `PyA2(g`m+[[+C[ĒQ Sl- n@ { p ތKңz.ԒQ5H%:Œeh/"uyZ71nTIm3+ oPEpҿ4u?? nw6U0{o^h}}AdMu,N W~ʕnfdt,6^yZTK}^f_fy PS ͈͚U)'O3PD(̝7"kK^DJQ_( *DVY`(g/3@zxG@ `_] `bߔŸXq~jߋ.}}:;5g3"oIֹ cͿݻ/OߗT;>wt|#|L8a]_ӎwIքU˽c a )5WN|!7EJǸǚSOGrAq-aصKwˌڷ/MW "6DLJӯuj'}f`2Bm| FX[xu k2G٭ ˭iB,xnh:@$ZNMj^&s?QLƧp|V^nvV +vrBza v֠g ^RgosrR,0װcgzj/3o_7iosiԮϫcr+4$/÷"5aE=Ji{_{d؝̓iߑUOػXnA'9(5cL"z$}$Tr3UOڗPo7ϓP7}>؜bNjlq«4&K ~U-=ȃg{|t>ǛB6a6AS P=<< ;}9t@=ΕVٰwp~K[+_;.]'-ďsZH=?osXl7BDgf؟ſ6^qsu2kɲHfYg[ˡAzL[BRCD–S7c]&MFO5/^ҽkY@ hOBBF 0yd>Zdk3S7pՖK/>z,}_ܼaNz!F ,aoĤ7`}v.h_@_ 8h/mUPP8Aa y}a9bX^WCF*0tP_Uq>4dj 7E_~>VW]cX uCL,K'G JbFW헌`_j޿eyCƎR@U'pTm_B#>}E4nq'F8}Є)M2S&FS24y Zd:` &CC%˾ʁf@0` x-owk-=z NI!'Y:}eS Vw 1@gsc % L]u4tf?TNtJ8ɟdOʾh5h zu@rGjjj`.h koYMd>(HL'-S ."w?z򜴟*(U>~Qļ{1/u*loИ.I5.kDpLBU9@DTEZu:Z M@Њ7B\e_^{tAC.$k?_3P w;M?GX̒G">ǔ3O| #wf^~Y h/ןϤ>Zvmqʙfѿ_(%ǧsT|SeԤ6!bmuIJHP8͋j׋!Ud<d2U MQ@ }3ܥp{Lhmx-p"c"8W'P61"n&!1{ǩɢ7p ``JTfZe9\^^hU; o9@Sf.?x݁3L&W3=V?ys:ofJUu4>ѴejNlMΪv3as,GE0u$%y:q6$gƍcƌ(8E"9FkO];~z _`lㄵzT?X¯]%܁8k_oF!>Ѷ^wprz?~\?ҳ RX5#> ' ~WNb]RpFSew^9mڈVQ 1QwζR^X[8hw1  :klINNݢ ؊Hl$K4ſ\jgU zdHW3zD@ʯ~ J-D<:u/ṭ4 *cT]yr_B~f켄9v|uXnOS4g Xli;cׯY;ŋl)`/ QlCy*ۘإKy;m{GF"}.0>W1o%_h }=YYˎCH\F[8sϛ'oݤ]Bև#;wDZfc 9rAi *^pWw1D Gb;gC ΐ]Ԙ%1,lF~m P;Vݳo1(Tg;1cƌ961& @DT>a;N"?#U4\YbmwCN[iɓ3u܂r+)2x7 ˑS췆~L :Mn;S@b i?Ά:A)MV։ea&:DgW W,].nrcJ(E,J &yvDe%i15:̔Dnf]s^WJ. oky ib_àK[Ѭ2+%JdDߺ|"&”`X]CRf1 Q?E8wft5 ܐ=~D+͜6gñ/8aB|b8E p#&f =U2w'L%nӗA8)m^㾉7 %G+I6%2S _ Ik'2JSDz(/.$3TCO,[qVʰNUF2C:X9yUcnS3"V]jYѕh3,GTm@5.JCU}/8Wy&!ysj&~&yza ga7ye=z b"CsrQC㿴lUnۓ38w#Fyi̿TUE?NHRCrU$;?KUX/]{޺ܞ9  B5.V,_cf@ XJ ??CӇ`@{ @Dulg Tz/8N{rVTꂬ|ʊR_Ltϕwi*I)dɂefd巖8D~MY{^"p/$pl+r  ^I摿fPlӏ5F’h35 :;Cn!Nnr%Vظ+TZkj ͖t nlTۻxKQN ɍ9{w j bィ+JSݠVo,}oK̏}0agS>Zǯ0a i_?.oR]ft#Gf.o02/.'?CHqRVjcm+8".)mOqH0?-2{wWp믵_3{z}g֨~+nkrbo$fTw+gtwoG=|$VQۏ'nn=[e~&V?{v>jm+4޹8f4޼T4sڨ]w|k6M'Vŀ&K-OL8;f;wtBr׉ǻetp1\>!C->b?}&*nc/U?k;zha^dM!*Y [ټ~;hjLfK )0ryD<0<rh3; Ж,B|B(]Ѕ@GfudQ9pgsjfjj6l:~( x|3g+e@=S{, ?9WIkUyU͛E, U'9,.E[P>R9yncvmz=uZXk5 Ɖyg\,uH ̧Na웁K O ]B )ƔkZڋ# "'sPUPaI${`8`OIN;}s@+#?I_R"ߴ;\BBhwyr_B~s2NX` ,OŻOl*/$$>TT]+//Nt8}gA:R"B/O?dʪ}}΄Q?;O8hXvk84hLm@UAfA͝br @@$8')qⲌ Wow)q97b_VDX[gC9{PJp9-NQo6\cC`57 ym&rcpZ[^W6kcv잯k.[0V_mX odj@ P !K7{x@?/8V o}:%ga=OS}NזuizJd,wA8}c- }t_zF? ?iltme'Za"Csrs ns:ٝbI(;hƋvW K ]q1yn2+<)ExzqҲB7jfyE~p(N<#oǽiY/^7_wPKDU|WIٚbB)l_9e}%Pv ~rrؽ3GpN)mM?!R˼Г ./{w'7tw QA~QUI #Dp9vh2,$edn(r_DcM5TY_Lv&'萤OHjO.ƌj ǡ<^lOeĨ1\IGW#Ԩ)n㰤*]qY _񨈒O3nBˍߙW&*t kmGy-3q²fkN88+OeVJrɈuX S!5:YrHc!ŏ3?/z3t0X@@W}a9 U, ksvd*KN޼W)PUP8ttAɓ'1Dڂ@@ʜV9azBvǾiQњ(Ѡ=bhkecb, &[aW8!Es7yw}Ol!%X }jQlGmjZ?)ѷҊhi0!i4]5֟vd$ot@UAfTTYEmmoUAycJ R(c  ЈD4݁-1|܌ǒv>[.S|qojoO.5EnAarLBlݩ[HKUUgu{Js=}Rkό_䐓p=”Wg*Mlk,^DBڍPUGŨ*( UA; @HZ)1mHc5@2FS3oT)HDe_5NfyjSa! d(ϰ3}q%$qdW~طҊ[+aYJUSPe5ShmbT5=.=G,nk,=&{fTm|᢮Ht"l=/@W@gϟ?J  @O*zCd1䓱]z涓h\ XDi\f!ia=U 󉌛?{]Fbb>4#fh: ދ"?nX flhXNbQunkdƒ=(ROY; .blj~;hjLfKz ay&s]%YuC;Eȏ;|nRV:J jf,<СֳCp'RHȱ_~L @qevz{3 L8"|&Ϊz?2 ɐf6@$ xʿh'4ٶ! C@HC+`I{m' ;[P}(,2CO@C FPt'&rhg礤$6T@"?(G+Ӵ.N^t؍P߹l@ /^@kh@w@$ p?6Uljh3`3:X#k]]G^V@u gk p%Nذq^vvE?; t @+OO PUP= Nf@2_Ɔlџ&JlH?En6 cB߿{v/@ 5h A ]NN"%TƝt##* kMu?WIM!o]q27 [Fj/%ё%f$!: ,kX'V[O-+IW,eƯ-%@-YkceGv3a; H*NX<:k/MuD+YW VZdmU V" Dcfʣ[N{U*ؠǟɉ!Tm@+/farrHtd0 =ޮ;p;# DkrݦĤfFYakfnϭ|5rm3ƎEyc6EeeExH3jN &fN#SaYy9A YnNr12<#'VQ*X䀃ϻI^ۤz-uYDiWmz.0o0TܜN-d"ڴ@+LduhNnNm |{qS|<|LŻvf/@iBB|meh3"ÇchzA<B}'= `wb˭o,/l:*ٻ- Eftkkk/jzXyp6QUٰ~! bɃd7ToӰǖt4.)VE?Rh\dŒK\G(xl/bƮRB8>!)Yf?)M6\3dmpWjjj6lظP*? ix 4\B`'O5E^pW`wb.>uRPN NeLR4UhjƊЙreɽm bBʦko=!%tKm`bARdJo+]z[")ħ:=aE_J)1^m UzJurz"v^f˖3ATt&>e9y]id}9sm `~q޲nmDҠ&=nh)B›|Ҽy4PDg?dDԕR)I|Sر&H( ʮ0UطRjʲ(W%=CʖVWcR{6,,>Ф  ,2DPUvs$%|!-Ps:m,ZV`V(F{GT4\-DCwpM$] XBI@PVb"Y^,g;;6C2cRa9QwNXVNJZL\ÙT2]A߼ڿ *l_qBccys^41K@24`^Q?zk+}laL2I1-}n4~rTUe{{ |\dsz AǛճ)n4zܛOώejR59:;EdNP0w' =B ҩ$! Zԋ]A9fΘbXl㄄WZ=p@?+VBi4ըPn-iS}}|H]_gUZZZ.$ :O`H @KhifDrnQi'6m?O'۱DkW2lioVпٴè?کq;Է0(8<%U o|*K z_á {|wl}/p}Ym)j7ngQYߏvYLTջ 4j̕ gPtr_(35=Ԧ]?e,|.O%\@h1˗Pz! N @@Sv FFQ^8BB2 H6W/]U*QP_6๹(CF !1@AH%P [$!i:~hB-dIbNG9i5JPtskN25Agr2aeLWFo  {PmI'^b҈Aoa6MB&pѣg ]w~߄>Fhm~Κ}`v'F%F'oA=TOoc2ov?'cV٥եHF2ٚM-@hCg~ EynܰRK 7$ ֫vh7m,|Δ[aSŒlNtJ̃W,K7. i h}eHRP?V $Y4hYoo8cmY4ͣЫZېjAF~^ݐ-,h#<|#F[o<@@Zby%[6Jk>H@LY[h1nDDSbo߾ ;KR4Pъyh펀^ۡmȻg]Zvm@UU:rG AqR# wQ܉;-D_|Av9<,L`ƒJ(;{W!,^ZtZpW#-AUDHU=L Tj o}ASE>-cbEvP#xaGXnga=bn!ZgSО0ٖ=GY-)Ղ(61Yv}H}~P e YEay a^Zeھm:  : U4AQ9MbiTl: m>ꗘ gEWK'F޽~Y'wp061AcĉAh)0:Б#(Z@&@q .F|v:(C#vhNY-=soΚxTzT J^^`54@+z~vb?}Z)7!% "G'|uغzZ[n E6(ߗ/_i }ќcssqECFt&:@=*&PZ4A9tD).Po ?h8PJlBxN|>Dz0pCE@D}^:k'&;;( jL[nh-hϟʜ3UNxkd@Ȕ0?Undv堭\Yaѿ]?ؗ4ёݭ\V"qѯ_u|o+G[sNEWoG$Olے zw׮'p2Gsr ݫ˂ @n>Ocg[?sVfh=ZcpN;uxHR+GsN&@/oltoSa0o$7B Z0Gh-*z-{́эf@+zOާ2E w迱l4o6U8={M'<EE|\W~;G U 9#iddo{?@MrMGFH/7l +&ї"47@<ё^h_oX+wߚE9:bA vȽx"{O$z pr ZuQMREGg$.w}$70lRɾG([Xܵ6 |C@0h&}*dHDG/y $DLJy{ǃtriNPV{ ُ2"<ݻç: N]0=9?dd,.!l^ nr+9sTH9ϡէ/!MD|s\(m\~G? ,hw`ݙF `iCT%#߇a1JʯGBCBxGY_^30%YImf$7C^ fޱ >$̪Qub} ݷjA^|xv{rW"ʸo Ln蒿>Uxzv|Eƾwo5 3 @;l d0h :K-5+:lF7}G=8\,?P cDͫg} ~FgXE\Nsޖ.B3or+HL.j՛dpZKeɍ*OҬQ'V+ߢ>Zq;t3KWNu S#^b*e8waŰr@{|ECAe G ~0A0/pʄcP?d䈩՗Ao)jar3c yL0!P\μ͌Ed.@҄K[,r)sWQ$JhPVK+-^y)!]5~&Gi2 \tZhLji[ҕf ! @m !9ݯEJo{x/ Iih7ԅ4NXRdi&Fs_09 *sY|1Jp @3`G<-c򤑎?ٕW7#cGɥ4# bFX'quJ_S}m& ϼ^M$  %EeY5L7FeBD偳1ߺ/nKFa=Ƕ@)fwS@UUmg .>/nsUjv|/JgxfH 7ml{w^%VP_|=HWg{Usдu+G^UcFlz4CV )h%k*w {s1^FsF~#7ס10yɤ%㘉#1 Ւӣ܇b`_.z#F >b„?F/zQi' w$@@dmfr,yPF;B@goɯ_H "Z?0ͳwrt=VВ-X_SHKS>Ik쌥'`?zޭOo ZOH4E NDd3xrcAwуcuS|d]+VQϷ7cFdY9~9Ff=e!Ќ~ ~Q? #hZI/ҭG^?iNߞEقOry0S28qa@`VB`p ( VKD|?ҬvϢGܱތa6uӁK/˫h&Yc)wY 2s{b=@Csմ%̸OydP AdA6oQr7.~Kq2*h]DE~SO0&6"}o$G#'&P#7pODp6J`լH3Q@- ֬YDhZ[ϪgYo7" ss{ ^zyNkoxgT\Th&G˒zc­_{X/+ fonr^ԭȜƣ/}{33{=L?`K<ⴘhȝСcGY1T|lo30C4*R|{i_ǵtTe19USu/~퀀J??'ځƠ"h_N*m6JD|h83P&`p|J͋=ch>=ѵ-}Uf]N\Kɶ٩ s1nn@s1u1y ~*qqwkq$kG3?\+WBG;@n H[Y_m4T w>EZ@ _oԌ7/۳|I 1z"+O u>#Gv>yρsKCqav |]gP'2>Ao.,!,2<*lw=譠 }utqqOUK0{ v3c#aBXЌ( 'Y$e@@4 Vc] ~&6>W#rKك,:5;6((m2Kr jYβ_fIvJza~NJ:hNGd UY^Ab6vKq><('&ۯR%2K.c*+irEu`4EXaLO`Psr@c@[xu؍QB$ yf!кڈ[)~wPs-3aȩd#dմ z0e.&ubRޜcdd3mivCf{n-B0 xaR9tE11eٍt)vj4ֶ+1L#i9hSC!@u@O߼=ͲQC.PjPYԟQ heZwo3zg\3s.i6pҼgvMf6 վo4Ui޳A^=ܗaj%dk%>dp/pYɷbWBoM|w3a,ӝ0wŦ4^jv|/9O5PHZ: %;Aqlo0P(b J6jݽ[ @$@``މ8Щ_VtUYL߿+t,|Qq@G&s{A`Yzzzh\LCSSIIGd?*8_~Ef~':r]Ki*r fCn@_xef˗/?x€@0%8y>@  TmcPZZڦTeK@[[@@03@ @{!W3@ @@  @ *@*B @f 3@"@ @ ѿ4fG5$k, Ȗ6H @ Z[Qf_gz@ h oS>Ic@P$@ @%>q3Vx_Ī*\'Gu i~@@ h/ le2q6D @ &Vbڱhm/Kك,zVZS2Yl~.g;}3|Vyvu?6/fC$;m>z=2o|Md_(̸ȏ{j dM/,N_KM hJ_\=f EӫKoٳi4l~u}/5݁1rCPGih{4Yus{3wr9d{ 0-dfVx\\EF$iK6 udVinT v[άJxHM{f[r@vEE=t$XQ/(!mxߨ?,%M[-sl1BS͛ۍ2 #z~ȱ g^uZ[5(|OɘPc[\VF53*AwV//,mJ^]1{4^ʬ`Og9sEγJ#nuW"GٻdLzr6\^Q9xݰDTݨa=qEj] j]4fBХ]&n_3_un8N-ΑU峣rZꍍ zD|mjcݿ,ZO4  JEtj)k.Sg==ds;\@ @"g5ㄵy8١׫K |g*0g;oSbv SmX`ɢdx3ZeAAf IB fOR'Y )VjJ__H$uS7JشϮ\{B﮺]CwcwUOu7(d1?ݎge2OlQ)f{CxNGL?'m5#~T.[4&{*k~B}zs+2ͤ}zZ>lS*Y -G"i؂sS_(t|w̒xAFQqoqs/;U|O^<)YFr@վG#yIAey/5A펼)S" ;p&/+^.T+ (S 0)1KF|.0*B':jb8qwЧj0F<1MC-{H 7[Cd hX}oo?)O k`9zId1{Ήy #0,u?z=A\t2}l_Y=~.jM'4>a.&]*k唡q[z^d>^VʧNduw^nS:dU |=Ѥ_'Yol!51Oa' Xv%rk],n GW_ǵtTe19US̔1,EܧⴘŨtB9j_oLAqOة5,3w9Ҵ\<}?   GҘvcW(]gt;@`N_AF)2vxѶd~R6ANkxZXf-u\uˢ<95hƩjҳ>unUs ";9^[.YnG8oա. eQӨηAݫDl*z=-'x3{?p֩d)c\L)GT[^-^Pqxf 2ʕQFX"vhA?F ,eքy1<H,HRI$@ Z'kiֺVk ܥ~rY.grGGwbD6F>Ś`Á*!Y17=L]B3>}UA8s*Yщ_6{NZ>~pް#䉐{P29=?؂zV5巃h}+zI4:G_R|ɛw}c՗XznEݙ4~A ({\@ @!H_1tOu& 6StX'V/kf:ěOMO}DUq͜{{.h]מ{_5H yـnYiѕɺ7Vꭼ` ΀oʻw!r{xXtAog-7Ǘ"})iơS?ܡ]`%t]|}jG{ c~w$t7g_tY>_%I!fۚuo Z4'6qI3^|}8a|هk<4M hM0*>>=GopZ7)l,ە;'EoЫWGO_EQh)Q>je}|rBCisw6$ *Es5Ž!EN/qVU(Y5=+4|0 U1)rxLK h ?GNFu3,3;OŸ>HM9~ͦ êmVo_aoab]BMm D~g ]-.;Ą$m  AY{o(Nfά Kl4e;$0?{PdZ%;L 7ިzG#MeѢ?l¸-퟿χpwۤg?b片{~LOڵ};1=do6y2dSRRƉuպt2T(hRLA]@+0? Ej$PMaOɻVٶ ͥ4xKB6Ǿ0Kz riB3g;uq>FZy{n~˷XvF3X$yznkG$P'g 4]ߴ]. @,#$]8q.:?de>V$rF Ӫj;Z|+K;- ڧ| 8x_XV̊hc#t\|+\2w73ԃ^{ƒ7>k;ZK7^'̉ ܭWw>\@ hY1;|ͦ2__Y9طyOY2cSN?< mɢfG @]e:$YEE߅\R$߹{Wж j3㗫D3½z=ˠ2XԇseO=6&D-[Ӡt @ e}f <d/IG aӤ-u5mv=۴. bˁ{=\:@[cg]o^ĹTlwnI7N?eڐ,XFan? F8 @4t騂/FǨi[^e/`/qK  @ ^嵕CMN @ ^]uY8 Ft  @ `}jk:fjxqy?@R @ 0-<n]X}QG0&K񽂯%pӡ@ ""R  @R8gM h@ @h?CX,v']zz['[^\!#%`/ɭJ8s~ef)Ȍqr_yCnVӣK6x= bOY=V/ <7io};Ӷ1VlJNŞCF'$7m7npjw.u0+ +rL]}B^Z%y={T_FXn[۾?UUzc­_{X/V;Vūܖqi7 pȪ9h779/qVdNwCJ[h[qk -eĕw/_NYAMբ-򈩺 }$}*ƌљD';p&/+^.T~ fGR׶ %b>=nMR;[!gWH1 ܆2/-*\#*Hw#0ZSwK,1i#<¬ɗ+\6qi?PU)p-loh1E0Xu;# Bo{V|fNSDa=7.Z(IE_k> 7RJQhz@&?s8q-Z oTW uQ?e :%::$S!0*b׷;wO3S.Bg[P|j,ni쐓mhf3~xnAaޫ9k-='NLaѹ;~TH5sjػGRXHHo^WHt;tO^.fIF.ۯQ,f5daU2+=ƒ7>ȫC `W"!kp,b%ͦZ*i$p|DF f$UZ7 (Yߘ/뮺Ǖmu'?ܢ|.侮/f>Ij[p~u,nWSѿ]x-_UĈ́Rp0tUĨ_>̭(Tj5@@ @GZv-B̲KKM|zڗhSXk\Aa)wg+nv&%+}>bS,7})Iݘ7`yͣlvÎP$O>|ω/|`s.<7^ c?a=%V{ݥ>pLf{&j5`հaªbYJI'YJf\}r]&y<4H,HJ(p|b͋=cKR4t~ F_f|'i1}pkh qXҗ0-GΝF젤,D\]ZUc4v%_g|c5;tEǝ0y}gPKD}1:C}u s\) U~nDwݼ]$(TRF hCr:h+7񗣷[aLd{ =?!oEՕ DeQH#ʨ_3 ]=xP\vO}KXeNd =}񯛜dQl~=ԓhz { C CMmp! 9gDbP'$teQ]]t{DZ}J5pfB h:޵SY=aU7nQU)썔Dh_M5W#FCy>},~٫vz=-rܾQk]E[ݢ7v3Y4{X%F;l}!#;y9V}١0gu$.a4O<}pDǗv.t(&A@ @=$ `\56( k2#gdYEVO3 𐸻ŬE{=:#'uHÞUC볣7Vpk<41@} ڌƘTuQ[_$E*׷F:Ut-LSs2meX/ng gC:ZI:{;D.DS&%>>aQ/3|YzĊO|Q[.\9e$M[..HAo.,!l2<*]ũ vGy0o޲oI@l]3ҢKin: gW!fvx$;%VgG\ @ ~4SF nrԥRɷb|wI)Ǻb ?=Z3q/~*g,)̯PENgԌtσ&"&f 1 =Ϲ׉H0QeVO‡JJd03$3E5 I[Iό_3DWC|Πo hb]_aCj#VlqYC&Yd΄!#.ԊڶMQ!f: Y5Ζod|r}5OǕYÖXG;sЉ-g?hĔe7>q #O5`3}l]O`_-;`&Ja!\L:I"7'Lxݐٞ+5T$A @%b:gewTtU~zZn,0V{Do?uDtP>zC{'D*EK {='/Sʚ}{sF΢{Yh{Veާ2:$FDY?A/ki?&W]wVvSUsGozkfN=Nl.('t8] sȔ}t<8KUFP7]Jc m7]ݽf΄AX|гxLw܍s.+d=ٳWԡgkMձvZl+:}Z~Dpd y/-HhX#@ G@Qs3 ^ދl4?&V J(bGNmW-&k7(4}yשIς2)Ts07CiG* XלxMFcB{ɽgB@Qs$!Q?%1-*-*bLvIQ|K"_Bpi_N͖qpEIpwOEm9#?8ۂ~p9uYw;)&H@%,NvqWo.ruiH ٧*1n_}y9ffQ}U`ob`.Mw,$~1)C؛;vg'[~g]3rۉhcЪw:NMkOз?^$@ sFz;"#cԴ-/WXTk-LA @^n?W@ 6 嫫Nw2kCB߶ @ hi]uWlZ>BEF[| @ \`쿹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ @@ @s迹HC9@ @ s %-m(uX=S-S u[<ٷ|n@@->3 "khGx2Z^z(j)\%5jUi(&YlӾ<^m?=/=&Vd7^& @EƥdGvQb{iR}I^yzAJ.?prV:c#D+i.x)2oon5'\nX/O-6uٹQw9*eX(4Fʵ6EH3-q1o a *&3R.7HW$*[5erBRzM?k09JmM)Mx3:zbËiͅ /M8-L,sہ{迼?.wˏ}}?$mX7K~;hՠus>m;ql`W4%Gfs$ *b+Æ!,ʧw4>GQs8q̡w[Ij/)wp7ٔ ^FulRZGs!Ki߿|d;*6֓GG9oWg凞>k<Uɜ8eENӷE}[ ˢ=X7ɘN@6ISj.5=sfV{>I$z`LTA17 f;WynX/-xi8$ɀU1o/nf]YẠKEˏ}+ݾ5X_#_]]s М*QXܐS<',=Ez^̍nVMt.3/^f~,T Kq&gC:IwX-dXi c1m|>fm-+Ӣ.Εd3o>8,z 4S7{1JܕU (n84F=DTKYAA~z(yg,>P}!kozO8څ'{oz7,5תnGsx(KG:y0ᵆSs5ub ' prVםȋ\+ fU˥&nY$_p׉Zy'dni2ܚvO 6g獄",}"IP(+aOR-($ÂzXM;^pZTi Ecqvd԰\̧@>Y oIV=5쵛 XRyÛh c Xq2zxU/'|,G4[0hVK^O?.OLc0P/[s1n:%RmSg8?ɜd7(:&nGFF }wzL[<νK 5T@Xp) Cy4^_'Y'f~~'a {tn$1d #4\ ZU$٫.S8_ e'^;oS$OX}&$Ɉ +P"ؓȣX9o=\]߫4Ew׭84:Zn>I%xQ EFyy+}'0g#7B޼ zqtsa <فl0PbMbd>{L*_ uߗj'#"6kn@GӐY Ic:ɋu.A2S%71j N.:GsKbGTӣ= wV"k르؝vm9#BX_QXP.^YwQKnۘ7B1:_z&}r. F CҨC5ӋI,7?Ϋ[$Y^q3iT=7itI+QC$eMdKcO@ L f)Z`&F9s|dc@f/U~FWi8#ݍ !ώ͗Uwyא:KdQS ٶ\9wᰨq^tKҪ},nu\ƅ&: umzvGTǬ[=Rю3EnSeTfICIbѿOdbH'ZíոTQP=0/ȡh,9Hۆqs܄)Њ 5-?9pxwlև22)ˢgKP9 8.3mmW" >YvO5*h!cy~iݮO>2p.f_0ߴ`UO@*4hk.$Pƒ:^Z;Gj4%OԢ3*|o@k(S$~L)ar0Ncw*D^" x'Tg˄xOP<;\~4cM3*Ƴ q?UHKΨ= U>|tYkUOȓUq$ V#RWS Ddgd;wȣ'AU\)=&YڇX? P(,ԸW֬]T?-$rnm{ٯcNu4ZS6ͰLM[xđZ=U[Wl>"|L`Z0mFEFdOVE=+i<3Elb[AQI++,Dw>%( Pk3v(˪M,E'd4'h w<s*Q5Wtj>]NaQc&d`Jaˋ3ұ΃+VnyCtTԜ4v>A6%ޡU |[ڹ4-5'oq= [O vX9qnjeb:K MdŕEIXߡz{Xh)b LVb:/T/0HHd*r|5EbPnez 닥,(jPyEchs6W4_Ɔ&  j<ήgnXv^Ğv5;i'x2U~+UI_]$S/y8ԩ5$)/9"Eʠ'\ hT3㜲lo]yGqSrnjb}[1QQ1ӻ'ذ2)0URzHHU$E`a}KHL, {xum{2K; TR_gI b/" [XEu#f( @K1B*Xx}WƩ$< )aϢSv@`y9'{W)9% 7;M0rGڻe#?jԗ"FT8#OvP]4@Px_-*!BT_>{eZYZPRS!r]-Dd NNQEdɴ\D9ysa)uBˤc]žˎ_B灮G?8w]5I-;Yt䆥̊FЩ11^4%'5EMحS 2h҂R&#/=F-$koūVc(.Z,qcr#4TF ;,)&U2*,G<7@"IxU{jc4JiEX%ӳ+QkO4M-)=2*+`=;ˋWVBՈQSDO[qeL:TR$CPT:RSMM`A° rVi//-|, i HOySˑֈѕUHZUΒ8lN}ހNjhOI2].,+U{Ȁ$XBD7$4-u{]U3rޱw=Og*UbO+Sm=avw".$(&!7"gUfG1vQ kwl(i1qU7($aٯr,\>>Off«"Ē q^"|L`-ǏsZVNNWM٩_ ]QEwţZң?~&Mva/)IQ=1pĻϱ3'rHRΩWzUVQEy߽> ߹wxoma߃?˗Q(_>}x=gm?my[FCz.ENcAFP|T*B>>c;r%LjaU)VFJS+{vU,ֳ_?($t)7jj_?ز奒h[A uKעϻzE ^7/:v͖9 l Z:&I,BB~q?P-,: j x.L2ug;?ɠD_`ZeSi}v*AҲrY<8J$^Q#ęX%Ae%]]# ?{\uf$%;(՚`:#p (uY/& ^eŹ^ԫOW@kqTsIx5cyXyʅךjD 1uZ\i_u|m-D[_ՖN{PlSs ;lZsduYL,ِ: <e%#h'uE ԱͧgFZ|݅?Ofj{OsU'~MQ D&=᥂Gq^:X-$SuȭU~I@R`}6ew{mx^zУ܇8=sh?,~k[چ'ޮڵv@~D(wc_3i]GO0 TgQ*='L?[n->Y 6RRx7HzN=) ah l`k=|5`?xZa3ekTd@s1GpfNT`"|V d?qqp/{toˆUVu~0o)#_^<~ 7k. ʜwD C*_VN̳ &p[{~X h9n]4isVN?[AZ} (g4O8ٚw+ m|駒N9k Z;!xK:7]z`{H@ 7g( @<[ @ h7g( @<[ @ h7g( @<[ @ h7g( @<[H@g4wtZzQcM3JFrw )Iӣ4FQ% h oq1HEs %R@G!6e\[`c)klLy%D9ybc]締(DX@n! MI!tYNI˗p8)ZcEfuh|5 LE.'ñc[?l X @ ^ @^-z @?m- Otc2YCLb ^㲨iOM7b.ZlP,JϚJVX农لgB!tA @k!j[-򈩺8 Մp8;+deۙo"#Cb>bO BWrddd&} Í~Ȕ|NDvɑ[!aA~fj9GWδ~"Wm>)ߡ6Z9K/GZER_KdC<0w[OQG6NrI*X+1!Nea>k4lJWK%]ua R f~~'aȯ;ޞaz$@j}ɤ} O2=FoB;Wm>ebd8q\3Pcq!0K='kx]e6k}O9p~zD->ё?w6VYv <%=@ط0H$Qyr=UE$'G*j+G]AN}J}PPY<H@ ?W*r$7gk5٪+Ds x+ :DflW{ |3jа*1kx-dG;KyV3Ey~ehaO/]As<Tu͕c2KET 9P1Y,bT#jgO#I!<32cֺVKbOܹZU?ug7i\LloA_q^ѣ>G^8wb*EwÚekm$G3վpaj5Mjx \"?>V"z4Q"AK_労䌚y2"m,ҹ#ϺvBW=AXZb;1 :w6lR+za,[EUzje/m\Qdڲ Ģ,@)| hdbPy^2RsРE!Gk,LsÒrO$%b=UJSj|M*MbOE%^V)8.,jvۨ TYcz̑Ny~*\AB(ΈK:5ZB6=/)& iسrU(& Y[*& ~_~ج 9Xߒ"0 ^ruJˊsIOnu*Ɔ|_ohҴڇZCK}oOTe4'h w<kŠfGEK.JFu}Yw2K; b)Y#+^<)/1,31/ t$~јmeޙ}9 4d߱[w YyiAQ)Q%SQRK3 "/;^\43TRv4dd29yYPYZP:@S:)pJQ( geǨo-終7)D{n!*#i!!ku `|ˎ)T:8A,+AjvT!~.,oi4FT8*>f7r;I㚥d\\{%E()a2d {d:u6ʎA򒩂lG젤0B灮G˱cȟcmfq'XURI@4?6|+dQe軒jg%jOmF)gUPhNϮ'**1IRR3?Q^}rWns6\(Xs擰!T}U[X:R4z̀.;oB&T Kk^"`#rwLuѐ:VHOvDս$8o1 vR !Oaq)h)ƹ!Y5)<nXvamoN~d-WMbjFJIRxRJYZ\(ִ"D}ضn奨ݫ*}kz/+gUmB H @5hnD\_LMx P!$.{U{ȀނU裭ŤUOi Uf]3nnI\HT4L`Uf_쳍1jIo GIJ [wpo,;}͕ "b>'0 ^6kc~V}Xhq w7NX)}33Ug 8 P* ,k0rޱw=OtB+;߉[pnd_* _&d_1O 4OE#nd~WKp~h͠o|mC% @4@ii>ןW?.FYL"{% ,}/EԄ~#M㝢3(bhҙGhb;:͑^uREsF8s#oҨ,R5 F\R ߍ|]5uQ* U՝ -d~[畁 >Ijq ^zlP:c*ު\7ۙb͡l0a9Љbe%B~/k~sV,rо"Ug˨ 9AR 0 >0T(Lg|N.KߡS,ѷ^'ZT& zĞ>0KF NUAq~qu *H8d)t@ qΝZ` _=$*̢Kv&jۉVP:&}N+O=*~M^ܻvT_k"%13*Գ[_]'+EKVR1'ދ&~9IS$v\ .у)b%y[4NWYSoF+,+olLUƘԚznu&uMSG#O!T5>>7vl{'C.Zb>cHhծ*O]U4qٯZGd0bw].Ox\.ReP~}Ea}P_q?u* d&Ew&P"(_G sdIgYܟ$}Nd+R1  2o?~%XIAF?ԃUl!;[JQ4ObC*w' zqߙ* J~;?u6e7,W~{I_sC~"2!giwl+M|C@ <Z~F wXbZh?u;ɜ{\;mҐLzG}$)Kz ;G4g[ܰ f[_@>dp?PS/We@:MϥrIN|Òp$XU\xXBF!%%:nϐZ'0)q׷\_mQ_s}nNWkq;:Oȟ7A?έKxyͫ:B98e ?CGˉpp8,?%v79DD$JՍ\~2~S~ ogdBֲ:F#=æKe0)纄ғe♈< 4}v:$'w=,cFל|V0(k~=ARO#Q24ޓ"| @e PhRQC̹քgȲyʆR@ @&[}@: @ x o<@ h o@ @hk @ ok}@ 0o @Bbi @@>@  ۋAO @ ?@ h/ o/=@ D@ @追X@  @Bbi @@>@  ۋAO @ ?@ h/ o/=@ D@ @追X@ 4=K4Ld7}IPB](w{Cr7p8EXۋLȋ>K|$@Ky &yG,Cby!onm--4h2`_0I [{4U1&SWT&P o[ɒ@HPegl8x*%C@#AJVn,JҶ"57ϯKFn=O0F~ QUzK7 Vof~oixѐCh=mg2R[}aa }vNjߍ)"#0 ۘT7/FEVSDYEybT'56`]Q^H'XL(Dm0SVd+/Jʉ I5i7KX֔·ZArFּ7i*\珷0dj$m=fȲJ]0J"//-˝cg(mX.?zOw)[%GfV]&O$5ciz7tJNJvsXp8)ZSg{۟H:&i"Զ~cQ+TqNϧJ()(IS7KXll<rF֋gL|u^ujdY̮mHJ\s˯xZsVFyqK/za'9#B@ @@"-ӊ~M.yU'V^ CϮJU(ODIO5s]]xgA.^+WW9fghk*cQA;AMqj'M]bEZwJB,ᤓ>gg]c5>a6ihq3e..dDzhs+N/+>_>͂di_n hD~7+Jeӹ8kuyDWL2HozhZ7OML${my/Q>ͼ]#؂/ mȇxWyuYTEF|&lϭ8د>^p)c$'!j]g/Ruz Zz^c nceIP6MQ<`XW\N ZUԘBW>Zc~o$1\T+!qpcGM[FB _| x4 ^_Z=3V=ȗYVCFA ͭnTŶUOѸlӟ\Ym~Q_yUV~k1Ҙe!""Q *ºoZ6fPVP~5<ygq9!%ZD~ˌ>9N߸p36\gҪ+bC0=1אqm[Z`P[#FAY;+O M*0cǟB@~m0uύέxjB8ni#x1^Dw7LzM;|&q+cUAHsɲ̉Yxe/sg\`buI&L;UJ7$&%-ͷJSZvЊ=k{8'*{³#7^Yn9ר|=V`b`jq<͑D$+BWׯ|=4SцfXķ:nkg!i<}ҤgJ& )tQ@ſP>/oWN }o(A+EZ 9"Ě[Zf$2{UZM_.< Kpw;;YqamYqѦ3kq8 D"HL+!u7ow|!~q 'QnX(kC:"Gowe([_)\v$eUI*?Z_$7k2f~twrI*Et7&'OxqƋoe%=ݡKC^Ƒ ]et՝<)BD򬀅$ui'vY$yHzhZsґ'Yle6l[ ^Sw`'{?cmzvGTfEXumB .S̶4sB][bN`IBk{ĂDxT9IWLSm[u1`9iW|u*9JՊ4hdiwv[یHdq!LIDAT^1LҚykķ-j爀fDdSKۊLe:ZˮeӇk l<>\"-(xx]CwuI+Ag1TY,̊%]9B+.|tYkU9hr)1Ri?&Ub͑~E0ՒOaݯzZciߥzoSKϮc=)L|q;EsNlf8onQWS Dp7ACO_QAK1x˝#RwߣB{2Pnx;Q7!zX|RF1D:' VB2`*cyz4QzI QA{y%ug9ZU7Ca;'Aoegrd(\ѲQQ5[VsGz惄bKdITNբѿluRUiLLz%먤f'%c&z^؍]NL'YRZ VWP樁h4d@X(%ռj d4&lawĹ}y4`xBIR9>K! !âfǾzMe08D^oIiaAjenbL.g׍S Gxb^UJ,H-)*P*KT=h0;()c Z%CNPdTz~ĞhHyvUE@ &7siZjnѠkc$i~E=G /U#ChX88ϋuCrãsҤ]3+EϐܙtCf|WTdQd0K}RMu :qj:|CT^zu:4{*^@_$&\DM 5y?;p*+,k1QQbW6Q(?peTE ]n gV~j'LSo'"(Kb*JjG~W naɩ= v`_4UPB灮G˱cȟcmfq'@eeǨo-wqV&| 䵹mѷWiLrrqZ~hS- Q\gvAMI/AEF$.ICyeJj^Wjթuof4PE^v&:؅:#*}эSq9w$JXB]DTa#Bi#K҄ Vq[ݼtR& s! ѰMZ Ҵ9ƴ}wY=ZM `ƾ|5i>zU_r_V$yk̯X=%ozQm[k}2: ,ݽ2pQ5;pFLpqrY~g6Q(R?p1*|G=ߝ7beYуQ$ICGY(/EakL$Q6FgՎ(4L'gMi^ j'^蝿JNV9AQ;:hHjFz폷cFUmΆ k|!5#䰝ȱ7^8/IkO$,[VY)Sٹ8ٖ/,P!@һRU%QIPy7exCG59=d ͺaOa+`Wp57&є#lNB@КAG\ "W q^w%Jo]TFE} ,UB. 9R\hŸؓǏg2N3ͺ>=OʍZ /1Ѥ%8`h<|YGT.G[W Id F;n޹bv7*qԼ$+ F:#H ;|^k 8ܠ5W_|rl,YI|{>&x5 |M {bObwk蒈$hh7s[H"6vz[W~'n:~vw4 3+_&^B1޽.a~$A_Iacs5FÅ]kZJ=gpF:Mr2`>:gx%eԙ#zJX2^ZU!s zs똕413j*: g=,~V >53Nh^b3"߈*iؓC'lKP2w3><}-GLi xY TXxU2 GbN|Yg1܃IWOh9wQŤ!raE~|=1.UC)BdO>vqh*|?}Ay}b ыk&<A^yp֕[NId"˨8}t.D*Ū X HHX#&UK7{9]UX^֭֜X夡} pK5b-sD 嵆8hݾ8O-8U/{8NVBKh@kȒ h봴 yr]kvg|NHbKd5JqBz]cآ{{>xeسq->4SzU?vXev/^GE>}v;s^xG[}:h{/"^޾lO;OӮz#-wOׯ\ yElW~Cbʣ;x#ՙڕ9*Fō~|i^qƹ֐!XMŎ+V ?į pH&ymV$;ܱ O‘_<8J|mKt_=mP|GW`v_u|[=.*K]WW8C [E9c fΣwԻ ځ +=उg$jĴ-umM^(Zea#{&sĻd*'Fp`SR_qcK"FhD#X^.DIf fo9Ζyf`/j"=~l>lk>aL^M=8rM^s ώu?woeJjɵHIk=S)|3˒N-po>ͅwfezw#! J.qTTUZ DgeUm,L1~Iϥ\]HN|ÒЦ8In؅]ulcg~2On_}6 #_I}@ӄ{hV~q&ZL Y% $Ɋ]uЫGfXO&SM$l ;lZiQ(o?N?To@4)f]#6Imw8i(&(]XI'fprfQҟxd37ِ:aey1nJ>f-HaIδPxҙ7 Su@YCƤ2ґ4^ F EGKu ͛ebTo1 ^g"[t?:dž**D1pfЩMx(@6JEmb|OֶY[xCI#?1#NqIdϽX]D^uc#/Ƌoe)_n=0VTfeZ#k$9>Ys,=ݡN8Y:~iU2W;yDs XhLR7_V%xX,ZU$U*b&F aE fDIIBKڒ.@ hj+akVw h{+/fRbƁٍND.Zա` @mE=tB iaԒ1DR ݳs7'* KRZ^;gFz3)}J(X*EibIB 1ckCYBD(G}U*Zm}T7zΧ?]ƍ:qK,Ni|1lVIJgpP @=ݳgO{dv7?}N\B'Y28;zh 4U>z1LFUɎ{#O1'm!+I:r[/ӉyƳ:ݛ 3*+pf8[Fe;5?g'= 7룢7D=?_ũ*e9 OqV8/ =dH7^#6~R}\pm2R.ZgQo5T*{߿'?jуz7W d 748Yq2 3d҉*2N`zcԫ7T~x}{k{Q>\r5K~JשϚ4H&7?e )4@i4/w?fPƩSxeslϵ?'|cy6 md( F w=h׌=A&e2lp6. x} *uM!7GzY4.ਹ( A1iEɀӣ ^y‘?>ދ%I!4O: @%}WZQ/@ h`bF{@ Zd-E@ dB @ h)Ih @ww |@ @@R$ @ @- @"Kv@ @{'{@ Zd-E@ dB @ h)Ih @ww |@ @@R$ @ @- @"Kv@ @{'{@ Zd-E@ dB @ h)Ih @ww |@ @@R$v(>k'יq.&Ē:k1WR\by@a+hE4IbqVЗVԽ%q'u-=Zu >*gX=4hL"}-TTs3(- r6T*25;tH}åKJ$e Uv;Q;\zAb[NY'B^ڹK&]ou]{1(HVJTr d+3`1atJ\\OiLh|:4vq!K}8l*G}y\kc7ߜ5Z-F:fB`w9Yy .7IEnqk8{vVYr>ns|I~2}ۄa6FrBQ~h+?clIWh%*+ZR|ddd[ McuHjeEIZ]NVjVgJ&?dN\x#vwOQr]0R*tNjxkeJ4't|3?W+iF}uȷz}\limE__[xAD^мŇskENѿٿopDXwhKo/푪J rJE"59ZI`fe&uQ5SsɧOMAV(IZki6&`/3џL֒&`o_JJ ߝ3TJ=m$xo/x[DsB:CH"ˡg.&(LزH='͏)P}Dɭo8[6}YHm erl!MsZ@c ߻rSgR#@)HC.>iҳBk,쿩j[z;n%cEa*uu{gs>k>nGlǯ zS{Z's}zW /bۣN|2NoS`Br:` ̎Ug1&AH<[TiHE!pbm򱎉T⴫>*0עU >+j?97b˹X6%?Ȟ`땨bQ+k"iM3~<(sY1EzG"20lwT1Χc\YfXRaNdo8B!$__1j9xNB׊B,sC09nǖ.IJ[tfKZL5"/9/qPrZ{.c9rTV s/{35jy,K+KLԷ?-8۝?^9a1 s/r8󔕗cis5:睸2C3MD!bhZ-k@ÓYqOD!S9s^ t3Vf&\fG4Us8 tPW1$T[TNT8E`ȍJEx^SZ,L^Avt' ]2'1Rž vbm 5grbcq)>Ǝ(}_W3x#yL7?U{96ڹN1nوIӒK-עؗl^׾KI7o ſ4k)8`"#CAٹ@E޾\bjىw"#RAn;ܽ{ywk6LkBz!6|QCSOҩ/4}sv)?Fri/{/SvJo׎/&>v`|%u FV]lIo['WmdeOv ڻAUDe迯 `m|7:kk[lY>ھdٖ뾾7N-R``!Sm!}g{F }7HÎS=k&>Y o9˼WE&EWVt; [_pٝhdzb>9u`\Q\.XsjĶkw|Q:0Ϭ<ߪW,rG]UaD[IR*y,Y/PLj'5l՘ɏ9g},O5ZY۵1⦅'og.܃XqǪ7^aqJ]ՕWm_M* R3oс % +*BBhpl%(4M7*םCʐ$vd;@Yw6Z?n?5bxU٦UH%LS1za$}`cf -xo_|ƦNBo展ިx3^ʙՁ¥%歽K4c?l;P;R"ţ '4Ix?XcߺoAz?VM>^m[Y̶}jx&T]I ϒKꍿF[d>`o>r-'iJc* agI),OנF/}dABO_z3ĮI6ɘob=\wT)Lg&1'85?Xc^~KkMN5א|i"Ff,VzI svMGO{춠ϬwG v#d<+M'T}bu1mcK Vۤ,1Ӷ[ q??X[7p8QDI:g?Dz\W /;69hXyWPE@|p܆$!y:m7=xaQjHŠé&Bˮ gCZW҂ϫhGNN;SU0j0z"PNB,ONx N,kچ895cqsrqtoLؕ'^߬_Gcf4I[E-ԟ=':2g3j>̤9h˪Z\9Eh&Xl U;Ď46Cr>TbFɸb[>wiFo٪!X^}Ydm 0i9'!@2lՕm8L]\wI/"Aɋ}uPM\wϯD)9i8UVNzZ.6kkN1ɩ=AUd"sg~M?Ì홸3fF7Ԝj!/:4c5ùdiFi!rnٸ8'$7IC腵pFvƌH,R뷼k1ӰS3͊".;uY 2hLzh F*LUT F /!G3D+(v.ƾcJt, =fFˋ?JVv^/ϴ\Q3Fga3QRٿ\?K(ʩ6 :ܜ̄G^']dֺ2 "%U|ZǑYtjK/D(LKH-FHM$zIoISDH-u*R26g7>@k O,q"IYiIJbjm&2"RQ(Nf6v"tA 2(œwsRGQRFZaca=DsNIY!rY;3yJLٹ&S~w ~x_d%2G*cJmF`c&O@@˜8屎6uAl]NHiIňQ7#idE2}\]2)ڇkr9ҭYU9r E~o.2 ,D2EivϴzB:c6Ĩg8AL<˛QYX)) 1e\qN)1!zfE*F X<XWoyע#2INEl( vÃw!q͉`Q@eQD, #ca} Ѭ/V+0!p-(ᚵ'hZmVf1F v,-;!й6-#u(C$M:Ť)i@ESQ Jb!G7w朥k+y9]1oͨ"ЙĵC7uM \VIE!7bwH.~[Jr)Z;jn8n4쿋B7hVy  &99&S{4u,VD]`.E;D#ԖTK!`"{ᒕ0 =3Kt/_{!QP?"o:Nȳ ΪKz|wu&1dX&.Z5{7?ܺ~҉]VڗjIՉ @t53BN!+Qt.:őo#33sÎ;/_ %[V҄=:( 5&d@==GUq:G;s6~\2#55YT|m=b͝zv`9a\;Ak(j G&GT#<"f}[I{(#&Jrmu%>?&Q c2G l=@2RWGT z1}k5 42}s5dNj=uxQ\њ>yÅ!:zm i+E3<U"*Ńl^sS_*;L,eaVlxZo)LU;\Ktg ܭXlx7Xnds"K06.+ZhNLֱYsvۿOV*y/ȈrOu!Xd/\p:k#Yb=}UtDIѭS竃t2LrEtRwr)  w\wHsMz::5N82&3?Ex T4GOQ)NhЭo\hyw)#-5g\ q={%D~^R):װ0o*60TF>&eay/MmTJ{$TC~jR5g[ER̊H!pY3Jzs+y/hz4غ_zdTW2؍]XnZITTGs=9ְm}AaEd9,uYX@RSr!S]C֮^BS# :͈>*"UI\;6f&c=mG[{tUϛHUAzMfm7@w׎B/!֜.\^s 3IM̬]G3Ӈڼ(־N-%Zºln8\zDH `L∺`h@ӿ0čR!C‹`fػfZ0T6?R!%+##秾bL셋lw^HtkL͸µ2ziݴ٣X|Z#-Sg}7SpF@6֏+JI*;>b~p m{=zK[~aF˗C 콨%$:qPA1<3u\lDx6'>q{R*oyG-b$fJ@;Kz]FY+3t&V >!F0m[̜\L.܊ĞjD)t/@`(Lhe\`)-2W - n# 7"ny%2?~0evS6wt3%^dzS>mfN1ak̘ftkKؠv7$=R)oƛͨ"PN1M&.!Xv^Eeaí6uu"qщ%5 šOo0XJbh=ג$J,60\I&겂^C›dXaK~G3M `()&k%/xVD-dYᴥbcw`p a0Np% SCYlW5SitRVv6ycvs^t:{Ə xs}rԾvlWowvG|_Fk:Bٶd!e FBzwwp$u Ǘ~{~ވiڙ']G0W~`:In?9]IԄo]fvI$l,]hWo_q_164tI|Sۡqo$iXud~ܥGBbCxn_v9IyCń+y=F=禋vKuX샻Ob}b0onC~Dshq% 䛛03ݗ>v6Ng$_WzE2DQe.t:bn[3ASupƣO eMJ.KE_mStf+Oi.?؍z6@3l^ԡ{lUuk^dIU69^[WWd9 &{;JQ>8kςDFwƏܥoތ*Hl;sos ]3u~'p6Qx3E;߶<͇f?#Ν &:ӃOӂesd}$hfn0S,Ma)%B: K0E^V0'_OM-&ŖG "XH}}*s%/)-~֫Ԍ(ߑM.Xt/\Rj.gIݖ[ZxnI} 9V3l[ʩ}{cߠv{PڐnSqE3J5wӑ-o<; 7k+ P~`):?`oS"~2Hfέ@?D@mPoNO讷 } { 6Xbi3ήjNkzϠLa : Ōa7ԑکx~1Ft]~݉`5ӨSN]ވ߿GdZUc衠E;0ji\Y"ƁBM.`[42۹n<R 9SwN$̛ #.B <Ͽނ5UpQ ۞^U:F}68?sA#Pj%`%E/G=G-#5o&~ qo}"bnm  ~&LBFH.xiR(A~ 3C%߱hDP$dؠ*L8s>iSEщ|qcl"dw4w󁙒1cp1KIxwE?l}|X?Ɂhg՟#NfY/t)pۃ l~㶝c#jE?p`ie5w]Ww<`@t@ : xQ, z @@ @G!G4 @  @ dҠ'@ | @tctIrB6&~{G--|Bi@Ik- R!dq:Oڋĸ準\#.f[ bCC":birNg wTmu!^7{=f1O>J*k.FM_A ъKrh÷^)_:KZ~Z~?TCTm{t u8 X`tVw*(*)2Oʸnz =lK"ί9cՉC9|wkz5" >PrW6;sNϤ3f'/q֎C?y|3Yz]GwsiyRbH~[ uC[G5NVA^VV^AײuVѢ@Brfmn5%m"mlA@L3( M-1|oC\;;οyԲ!ʬ>}Z~1}[A71-2mGǧ<ܵ|D>ж4֚oO<>iW^c)v[E-.SEy_T#D|QFaw#Z:żl1 |-K.\!;Pm%-H5TVɽZIh'#vPy!F_]SZ&6F-@u8hͥC+mzɉRępe6ZeUOw?J7:-(2irIhL289-g[׉}G @ 3='3;\}|}Q)eO _3<1ct%zń:{keguNٕigW.jj8,dV.`N"lQJaT@KM׉ {Wɵ³v.B~Yp lrQ_΃ןy<5Ӑ&};u[{Z bYglȖR{Z's}"υx꘸JE*NgY+Ŵ %Q7gZԷNi(+5>d\OÍ>-Cj BG\1~ Cqe"xf2bk?Hǣ>n%c3ܶnaf\2둷eBV)})gq@[^"{H6%=:v:sE d*ا,֞ \B, ?!qe53#4}[:mUŠ(4ˢK+>5Oiʋw1|Qwac>gز&Nj(ek)+/ _L,=gËY2cs?bql(~'3 7M_nfTԳ_f4)DGvKODqgh;# SJ(,"\wqowl\Ļ &cR~čv_A۹{/SvJEۮ޿ov?Du>?k[lĵI\۞*3]pȩƜ%4(cQBHQXVEJy@Y.Z7j" L庫N,ݻسb5\ܴz]h#7Q 6܍sqzɕ柯.s|=s w Fx>cok@GSkFk H"Yy4޹rQў?oOQO{WzSײvkR,1[y)PmGX<Le:zkX-4>l&ǺkW4\rUdIr}as[КǞp^Pl6 C ¿R(Mϒ)Lps72 =jHjoGK _q+R]CmD:7rSe%im52x#Qg7lH4Xo챨jfҠ6iԭ!w+dέ9_K#1~%U2v$/& rum#ixvdP??XA 5UWX@P%A[l_JFm|كZ0Bs7zoz>kү z2b=\wTC+O]agURb}1;n3)^NDz]B>d<+L!&z3N䆏u>@䦼{+ &M9ݲ:峄+@hO;6K=pI:g?X ΢įAh^JYGj@E5\Y *e5:򘃶d.q~(@9zӳFux^.}$phHb YѡLipOi)ogR M}Qj\~l54h(ν"ڃŲJ2vt*^0 >~$&/r$w\0\B4x؞) =v[g~wdi?R =DV ՚G Xaž QO^!i4d~gej?6cN<9:y≶*;/#zk)q#idn|6׆ rgPS"KdeʚFb=zsai_uGM5<{Sv^qDꅆ ( +1v$(*b'֙Cu++圤\C\优dS-UYFZh /\~f6H ̧nWLr"Xe@k Uh2 =Im( EJbONU3Ǔ6\W#HVZ7T{~ yѡ$3T=oxZ$j5u)9q 8?޼y#op]-g0!%<>ˑ0NtXB?e3i5N>udV="2Kr9F̕S_~l jKR wƴ.@&-_G6! T5zVeD'w\%1hIzlFdQU3֤y!"qi;aE?JXeїLbC~7)"$dRJc>PI6%4 )!,Q@TW8%eUތ=9U &3YŖȈjuUIlڴ~տA|ɈFg4  : oe')82SS^zPZH O:B"MRU4p^\.{-Sd;V?HKy_a_L{SA>D%nj?=T1n V2g)vVX3C5M )qq jhuK?%e!ƣL{9Q>*R26>u#?'qx& kӞ~iIňQ7nwQii6pp%^|NGtMp2D.fy6+B`GϪ)]Foe :i!G5kr܏9~3Z EN}ښe4S(zplFCCL=OZgH賤5Ίle9m7U|LJ[L[qCklu c4~8' |whNk4 ֯Q#c2ܽ&kSU49Z?E8YwRs4f/Xszy|/Wn=Շ1+t^эY^=̙a}86RN|fqɶݦDK>ᇸ6eTF ߥs]iRGE8Ñ ^Dž<BCN<3򹎫}_I^|'N) p1pǥw947D/!pH/$%4AWz"?1V]05l`fCu7˞ťBw=HjtWOD}.u`^bdXB>K1[N"h52QH璡6 jvdG^J)/LEm- SCh7?UAzHURj>Vɍ)B=G85M%79?]A}9c4f{*#ТͅoAt=Mb +fcaYn2ЦwsJ-ԏSj>D P ͼg[7Sߚ;v7$56*%!oC~jR5Bq 3gy{ |?NacG})Ú~JۨKKg;c1;1KD蒽?w0L9|ǿ> ;q튡vlUy%|֜M%%/޾ɓwiZ&\'gEUOq# [ň%$:qPA1|Y)E1m"8mka7YGe]ɦBau> v0=RǁClx&Drhl 31?y[0NdRrؑ+{3W6  0"w y)FbǮb2e| L ٮP>mfN12ŋ3h:\ j,ˀ3|l⃀X7[^q24PSeO}:N w -,4ey{]Ɗy$7孧[CG8?|[ojPz^mޖ}Xh?=}!=)DȼzYMݕk!t!Q،5j~r@Lae/wfH+6)C".UDj)-)2#w]wú_i,:qDC72!gY*=dDmmh:tհ2Vt3F.-W2 QoK'TO~9բ\No|U+wW#We?9Nk{&gN/:M_+MԂCo7^]]s# _kf/ν j2E/^zr}?m^OI Ƌ"# +Qq(E.J(Ǟ|spق5z3>U r$ByqvokMkyrJByNK}=֏C[&8nZO߉V$Kƣ&~VPojG/ɨ*3`/oS Gp}&tSg5i:*_ѭ~McTPVZ+^ =F l712e+a`-ꘪ(#rsfEL>PAl rةg cmo?eݍRF9+Ʌ}w2ի]&xiAbiZ%??kg~uy՜B8ݴ~ڥ|Reѧ0C_.yf5X?pA8eQ(5ֱF<>_#> 'YLqJ4={;Ӊݧ !5MZzC3osW" _k`]!`YN;|7Á2ΝW-I _9;9IxYo%MjRTǞ<{)-GuBRͭb눍߾x=\?v߳9F0In)`ӳ.H*J Kv{=Wi* D_"AOeTﰐhF*{b{怩l)l4&|΀ػ_sF7fl҄wtCGy6 7]ܾb4}I|xnC'/9IjD|K;wM~bKyQ̎t۹n<4[tr>]7zgDtKt~Dݶ#,bI;`MG^0Яvn.;#?E;v/-`K\fDۤ!BWyQ?SÚ}(OK[ )o֗Q㑛>\p-3ם^LJ>4B+mV}at̠맚Sm=tzϠL<{zaܰ`/cd ot)s4ԿSxe3wE{O IH|_( F}X)M~.R<},f+ξɧZkQVxpn* ;ǴfUaf7QW"փ,?6"vG4vG/bGAG泽}ŇrZM#2fE2aAgo8*tP0 $Wgyg>aBi& ?bdbuK^F? fԈ8n<_ <\]} m -Bwjͅ-;,ZD6h{ @ @ mN6G @)yR @6'9t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @99t@ D)n@ @͑C@ @@J x @9BiN?Hk @Oƭ'4 Z@ @@ dҠ'@ | @twK@ @ @ Q@Q, z @@ @G!G4 @  @ dҠ'@ | @t!/ݹ; =L@P(uAd@ @ݳgO˴ԜVe$Uj5e&(Zj@& (|y}fbuFm7,k:@ >)ػ˷=G ]XBLg%u>,!6W^KᒢlKK/ (0۵PY{VO\|Ms?⤃r"vu@Uޣor{?'gd|x}cyDWkt{zzOI򴷮IzD|ib~p6ܤҩhJyovū:{wX뛙t}jaIT1ffUB(yR1gO_.H/ls}j-isqgH=bC#=iKPEH樱J]^C+·sL;EBE ls$ udf$ \vI1zb2s3^ZeSz7}VYiԦ\ATZNҳ.Z -pm:/jXrFNU*z6ݽBw_ V'#2>vŻOZ8b@@A#vݗ_ LA]rb՘!UJ'N2}[_pߜ{/;BrYWIOi|=/2rydްn7 QB*υQZ *ffA t $T!qGv#~Q ^fJ WZ5Hhr$!A0'N6+kV܎F1`DXL\lxv#aĂq*'8d<gDV~vs"Ҕr獅6odҠ8<@=#H'__cƹ߉\GlRletη-~k/YoC)+DC5yrXnU_Y;uޢAc>Κ/_u-4ї *}MكCcm& VvHD2M^iNj\yLݎ=n#UcM`%?ٝ{*Ư>{"N Mkдqpa&j/?VLCp*S'4&:_2Jcۇ&ZuM1^ÇlMLaU!ZCf[.s_2`aO ԬIJWO|ՅDqYߎ>Ƭ^*CDwB7ݷ1ټ\Xa—fjq*}$p`{܍vR[8KERF *Cfcul7r_Ԫ3+(REԵϭ60M_3 Ψ^w}tiu`~ߏLYB`qґ*8 .^b8 撸IK~jlKٗ7_Vf\$0 }OaY`@A3A3_|sd鿿N5VD=?b_hBۉcҟ+{V-9 +T]VJ e݇͟Nؽrf#7ERj VDҴ6:PVkamړuU9zPs:Yi0pJʪ-F:S쬊5 X(U[QUKFp-' x:S|1R_i27wZ1"ZeMW N~(Ӝ"F?bP:\ *jdHs*cG3VeErDRA#95SUZ[R)=8KO\IyMVT_d@bcl{F ¶1 n}PJ6iddǨWcm׳w1 gdz,Yis~^JfB&,B #g]Jӗ QB{E 8[Ȅ @DN[ރ~6E͝ǵsb䎸]f( AW%NGMJ96?Et[D^~uUWJ.+%]4?sB!e: GT9RSXuޔULIwl1}؆W?/j~h|TwceՌU%xn]j6S|^0kNŚ C؛N^QVN4Xsth [}͖kvZ~,R[b/rME>ޙ#LvRO6-$*E(H+UO jtIkɵ]SoVoK#lP7c4# `RJ"ibͼi7epx(ꌙ:à =gGcZ4(0@:"Q prīx=e7[r/a| I |*OsqAq5ɬ)x /;D<=w*DlΰAsk 4jb߽CUb rv1{ Zvq7KVGOȫ;uC{@5%ۿy&>Ƨe)UUYa+xv7iaB%hjF¨6~j"(D86>H)2D x5ټ=: b{S=)(p2(Ny>6%& :bog]/r/3.$~Zޣ}!D(H˫irοs֣S3Ź_a%}}3tt<<,[_{3]]Q:gJiJUΖ^Vw۵mv &Mmx̲co'-:"xu #wwi@2G\MشQ$sSN󒡦_è}u;t1cŀ@[+*@Cٛ7?sC(m众|_V3+In;㶞_b%i @ә+D)sC/y?[Wڱ ݴ-7](}6ͱ]gGv@ t ށ@ @gmz@ %ٿtC@ @@v' @ ]K?@ ڎdmz@ %ٿtC@ @@v' @ ]K?@ ڎdY>\:zy@! R-I&$?DhY!J}XBlVwkC},\:r~%Ux5F y OD@CI}z7<ɧp4&;dk7Ē*VqEV]6sG5B&Ʉ3ϳ[8oܲ5ORBB;iqՂ`4BG!sΨm_t{QIQAF ! ^W$Z!I"x emN@? {i|ⴃc23{z5'_Qx$Z̜̄k~9ϊyʈ2§wDJXF/t` V喭nēDy WDq 84w%Iy}<WҞIa4t]z=Avb}_y}ɹ8ېL+:qqP,@ H7yNނ]Gh*"rc8!P cddUZo!%ԡÎK}^fo+9ABM/8$%_7u\3@ ~XȄz# _w3zv]IJ]9l!Iu.)O+h) 35gIq=FB>7{=d$υ&)-i5_zLןy"q|v.bc=H5t>')YOCŠB ]NWVvG{Gg~:]Pċd=i3mK!0XR%.Ș|e>ב&7V>NzsD)|uтÕ5%խWc3ӴF%ZvP ,g-i   !+sݟuwyX꘸J<5Ӑ1sw#hb6є}KW#C!BRp_>KTaFB>vDvNw#j>P!_E7 /?,4r'Neipio6B!_sv<Y,T`ى&6;:hGTujx'L! >ԡ",jn6aW9x"vvɴSJ]ʭvVK+!Y(xΆDo:tj^ sG%I=`j|\baM^^~gYʩmpс{(]E0^as ʦ?hg-{P٫тBC A;QÇ? Ӆm 6 "%A LD|=w+=3WwR4f`J~M}e:?u~ٵԻoeSz7%㷠-bMO6uA˺]<&*#c'6ꚚBg9y'UHt"I sFk"uEY%FȥOO;ɴ,dCfXvpGR4/]hn *a{tjFҬ8 :Z: = O6p×L("W(hWHT^-*rd=|<Х"GK XaEE_E7TRP оH}揬}w=o'oeQ:Nѓ6g]_ƪߴȠTaA=shZj'wE,&XaJVJIi:cDx&qG111 Æ8QηzڒZR_i27h FJ'I٥n炊2PK6f4ƪ!%CK;Ղ"|]z\h'&L -Mk3Bi-tVjR].dǨWcm]♫I,YbK DK܉Ts͇{i=i8oG !(Jzy]/i~X8s: * :**%%VfFSRVELm0] Ykb2ZUtMUWc픗/{ψHغFpy1+8qvRA @& FG X7ДDܽ8ŚyQi7eBF:oٻ*Ob-IIYiڣ_o,u389E^NUYQP]_UWօ+^ZM;U.{{xLԕh]GӦخ ҽ*6{ #-qtUWe&h)%U9Z` ܃&sNJ ڡΰwmx\S|oØ?j <]ȵ]S:v g8E`9>3f72Po*y0@Xljm/僟-0Gzg()ϯK7^*Ёee_Gh< +bt+c!а ͉*V0!Eظ"#Bt!T䣡Cd;)]߸w @h? NxNJa cܐǯoY67X_[veZ ׵@/Ŵ%c\%|g+7iNj=UVo< !"aEE.tRʣNFcԽPs3O:J(k(J=Ykr]Ooѻ9+/6ފ*R_VTD u";fpȴG\t"[ Yo_0sGJ]Z̛Azj&w1dBB}:+׽!ROReW g>x&:kQ]dTیmzU-BЛ`-p*~uxt;>ԉϣ2\xP?y=2o,H~ɂ_Ҡݍ!m{Ϝ'9wغTV\TTʒ1wx16 K?aC)!Eĸ p]dz&INǯDCa @{! yӒg I($(;_Y;}2syyfLyĕcRqA{v`y":IK$u+J9S苔rt?ЀGZj#5wQ;^ i(K%ҵMx&c0QtӲJڪ*i]45b#b 42\?s5^vq7KI@Oȣ*їRSUŵ\Ap36?mڗ3a",T?srh6~W5N+ 3fщRT>f%0؂6fEu]FK׮Ĉw^C/ʠ e^S%y`a1&R^{5LWIyrA腓gf^B>OWlbV^b^sB}).uлGCxQO^gIuX@]w:tBG>ůI)&j^Q[@ׯbYJ7Ы 2rGZMwEa rvR8w:u8Ẩ.J8C)(ۿ6{'=%US  ~T+oeoo`l7RNOe7ko켉7Ss04ámokb?D1lIQhIV)__wNm]*NF?_!:ݬrv;E."7ySq~uen1㶼t:}<矙7*ɘ9u232/yob(]YgJ'}(=NffGO.rp?wҡotu ,;+S .,kG︾Qy3WNz=-2W]^ÐW.*O.TVK&]ΖDŽNcj%o`Rȡ T -*:ZxZ %ϑm/)sҽHR~g欹n 5F*wXp^j 9 AJ&{ΛW.=I@2w)e)\!UXOŰXc+..<9`kTtNyn:B:N0Q Ti_ߨE%=j&f7dT'n>2@O#]ZЂsZfs"y]M[/7^+@@ @G!Qgt@ @M @ Q@Q, z @@ @G!G4 @  @ dҠ'@ | @twK@ @ @ Q@Q, z @@ @G!G4 @  @ dҠ'@ | @twK@ @ @ Q@Q, z @@ @G!G4 @  @ dҠ'@ | @twK@ @ @ Q@Q, z @@ @G!G4 @  @ dҠ'@ ?1 uIENDB`DyK yK http://www.nice.org.uk/nicemedia/live/13649/57889/57889.pdfyX;H,]ą'c $$If!vh#v#v#v#v! :V l  t(0x!65555! / p(ytj$$If!vh#v#v#v#v! :V l t0x!65555! p(ytj $$If!vh#v#v#v|#v` :V l  t(0x!65555/ p(ytjDyK yK http://www.nice.org.uk/nicemedia/live/13969/61603/61603.pdfyX;H,]ą'c$$If!vh#v#v#v|#v` :V l t0x!65555p(ytj}DyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Lithium Therapy Protocol Current June 2011.pdfyX;H,]ą'cDyK yK 8http://www.mhra.gov.uk/PrintPreview/DSUArticlePage/CON300404?DynamicListQuery=dDocType%20%3cmatches%3e%20%60Publication%60%20%20%3cAND%3e%20%20xSecondLevel%20%3cmatches%3e%20%60Safety%20Guidance%60%20%20%3cAND%3e%20%20xThirdLevel%20%3cmatches%3e%20%60Medicines%60%20%20%3cAND%3e%20%20xFourthLevel%20%3cmatches%3e%20%60Drug%20Safety%20Update%60%20%3cand%3e%20%20xNHSNetOnly%20%3cmatches%3e%20%60No%60yX;H,]ą'cDyK yK http://ctcnt20/policy/81/Acute Pain Current June 2011.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/11809/35940/35940.pdfyX;H,]ą'c$$If !vh#vU#v:V l0,5U5/ 4a $$If !vh#vU#v:V l40+,5U5/ / 4a f4$$If !vh#vU#v#v#v#v:V l40+,5U5555/ / / 4a f4$$If !vh#vU#v#v#v#v:V lX0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l-0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l-0,5U5555/ / 4a $$If !vh#vU#v#v#v#v:V l0,5U5555/ / / / 4a oDyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Antimicrobial Policy 3.1 April 2012.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/12060/42040/42040.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/pdf/TA168fullguidance.pdfyX;H,]ą'c$$If!vh#vS#vR#vS:V l  t(&&&&065Tp(&&&&ytcDyK yK http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Insulin policy v 4 3 Nov 2012.pdfyX;H,]ą'c$$If!vh#vS#vR#vS:V l4 t06+5Tyt$$If!vh#vS#vR#vS:V l4 t06+5TytDyK yK http://www.nice.org.uk/nicemedia/live/11482/32518/32518.pdfyX;H,]ą'c$$If!vh#vS#vR#vS:V ln t065Tyt$$If!vh#vS#vR#vS:V l t065Tyt$$If!vh#v#v:V l  t&&065p&&yt}$$If!vh#v#v:V l2 t065yt$$If!vh#v#v:V l4 t06+5yt$$If!vh#v#v:V l4 t06+5yt$$If!vh#v#v:V l4 t06+5yt}$$If!vh#v#v:V l2 t065ytDyK yK http://www.nice.org.uk/nicemedia/live/13670/58205/58205.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdfyX;H,]ą'cDyK yK http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdfyX;H,]ą'ccDyK yK http://nww.staffintranet.lhch.nhs.uk/library/departments/support_services/pharmacy/wound_dressing_formulary_march_09.docQDd #0  # A"Q?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOP[$dghijklmnopqrstuvwxyz{|}~Root Entry FL] Data WordDocument3ObjectPool`HqL_1424784704dO)`HqqOle EPRINTf8{CompObj  !"#$& dO)*Microsoft PowerPoint 97-2003 PresentationMSPresentationPowerPoint.Show.89q #_) Coburn JaneCoburn JaneOh+'0 `      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#e&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abc( hijklmnopqrstuvwxyz{|}~l 1H% EMF8{ {a#F, EMF+@XXFEMF+@ @ 0@?!@ "@ *@$??+@ @ !@ @ *@$??!@ @ !K@0 @@@@ " FEMF++@ @ !@ @ *@$??!@ +@ @ !@ 2@;E E@ *@$??!@ +@ @ !@ @ *@$??!@ *@$99+@ *@$99 @$ K JJ!b $$>>'% % V0 LF]LF]% % $$AAFdXEMF++@ *@$99jkB {C @$JH( $$=='% % V0:ZZZ% % $$AAFEMF+@@4FA?@<0JJHH@( $$==_888% '%  [`7\ ZZ}Z}ZZZ % % $$AA( " F EMF++@ *@$UU@UU@+@ *@$??kB8C+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??kB8C@ !!K@0   $$??kB8C  Rp"Arial?u+t   aE!t8o>EXBq+t/wg v,w8B#tx`+tx>+tF^wcwGDIC&3w`HTHwT0ww !,DF^wdv%    TYTH14LPatient Extubated IV morphine infusion discontinued!!  !,% ( " " FEMF++@ *@$UU@UU@+@ *@$99jkBD @$fRJH( !b $$=='f% % V0:^!+J+J^!^!% % $$AAFEMF+@@4FA?@<0RJRJHH@( $$==_888% '%  [`7 E!JE!J++E!++J+kJ+kJ^!Jw!w!^!+ % % $$AA( " FEMF++@ *@$UU@UU@+@ *@$??kBW; D+@ *@$??kBW;D+@ *@$??kBW;D+@ *@$??kBW;D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??kBW; D@ !!K@0   $$??kBW; D  Rp"Arial?u+t   aE!tq o>E[Bq+t/wg v,w C#tx`+tx>+tF^wcwGDIC&3wHTHwT0ww !,DF^wdv%    TY/Qi1LtParacetamol 1g QDS !, '$!% ( " " FL@EMF++@ *@$??kBW;D@ !!K@0   $$??kBW;D  Rp"Arial?u+t   aE!tlw !10U/wg v1D#tx`+tx>+tF^wcwGDIC&3wHTHw@T0\xxXDF^wdv%    TYk;1LPLUS Dihydrocodeine 30mgs 3!$!$, % ( " " FL@EMF++@ *@$??kBW;D@ !!K@0   $$??kBW;D  Rp"Arial?u+t   aE!tlw !1@Λ/wg v1E#tx`+tx>+tF^wcwGDIC&3w@HTHw@T0\xxXDF^wdv%    TT<kL1LP-% ( " " FL@EMF++@ *@$??kBW;D@ !!K@0   $$??kBW;D  Rp"Arial?u+t   aE!tlw !1/wg v1F#tx`+tx>+tF^wcwGDIC&3wLHTHw@T0\xxXDF^wdv%    TpMk1LX4 hrly % ( " " FEMF++@ *@$UU@UU@+@ *@$99 EZC @$fId"I( !b $$>>'f% % V0~ c~FB ~F[[B ~FB % % $$AAFEMF+@@4FA?@<0IId"Id"I@( $$>>_888% '%  [` f rF6 [6 [ rF rF6 F~F[[[B [O ~FO FB F % % $$AA( " Fl`EMF++@ *@$UU@UU@+@ *@$??EXiC+@ *@$??EXiC+@ *@$??E4D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??EXiC@ !!K@0   $$??EXiC  Rp"Arial?u+t   aE!t@(o>E^Bq+t/wg v,w@(G#tx`+tx>+tF^wcwGDIC&3wITHw`T0ww !,DF^wdv%    T 9 L`Continue *  % ( " " FL@EMF++@ *@$??EXiC@ !!K@0   $$??EXiC  Rp"Arial?u+t   aE!tlw !9R (:/wg v9H#tx`+tx>+tF^wcwGDIC&3wDITHw@T0\xxXDF^wdv%    TR 9LxRegular Paracetamol + * '    1 "% ( " " FL@EMF++@ *@$??E4D@ !!K@0   $$??E4D  Rp"Arial?u+t   aE!tlw !9p%ܷ/wg v9I#tx`+tx>+tF^wcwGDIC&3w ITHw@T0\xxXDF^wdv%    T| ^9LhDihydrocodeine*    % ( " " FEMF++@ *@$UU@UU@+@ *@$99WGDU D @$xcI`ƃI( !b $$>>'% % V0Q2,27~F7~F,2,% % $$AAFEMF+@@4FA?@<0xcIxcI`ƃI`ƃI@( $$>>_888% '%  [`O 2,F,F7272,2727~F7rF7rF,~F,2,2,27 % % $$AA( " F\PEMF++@ *@$UU@UU@+@ *@$??WDD+@ *@$??WD,D+@ *@$??WDD+@ *@$??WDD+@ *@$??WDD+@ *@$??WD,D+@ *@$??WDD+@ *@$??WD,D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??WDD@ !!K@0   $$??WDD  Rp"Arial?u+t   aE!ts.o>Enq+t/wg v,w.J#tx`+tx>+tF^wcwGDIC&3wITHwPT0ww !,DF^wdv%    Tp1LhASSESS Patient#!!!!!!% ( " " FL@EMF++@ *@$??WD,D@ !!K@0   $$??WD,D  Rp"Tahoma?u+t   aE!tlw !1@6K/wg v1K#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    TpE 2LxSedation score 0 or 1 % ( " " FL@EMF++@ *@$??WDD@ !!K@0   $$??WDD  Rp"Tahoma?u+t   aE!tlw !2, ѷ/wg v2L#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    Tp H2LpRespiratory rate  % ( " " FL@EMF++@ *@$??WDD@ !!K@0   $$??WDD  Rp"Tahoma?u+t   aE!tlw !2(?0U/wg v2M#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    TT Ho2LP>$% ( " " FL@EMF++@ *@$??WDD@ !!K@0   $$??WDD  Rp"Tahoma?u+t   aE!tlw !o2/wg vo2N#tx`+tx>+tF^wcwGDIC&3w ITHw@T0\xxXDF^wdv%    Tx H2L\10 /min* % ( " " FL@EMF++@ *@$??WD,D@ !!K@0   $$??WD,D  Rp"Tahoma?u+t   aE!tlw !ۣ2  </wg v2O#tx`+tx>+tF^wcwGDIC&3w90mmHg $**"% ( " " FL@EMF++@ *@$??WDD@ !!K@0   $$??WDD  Rp"Tahoma?u+t   aE!tlw !2(U/wg v2P#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    Tpo2L|No other strong opioid !  % ( " " FL@EMF++@ *@$??WD,D@ !!K@0   $$??WD,D  Rp"Tahoma?u+t   aE!tlw !2/wg v2Q#tx`+tx>+tF^wcwGDIC&3wEAq+t/wg v,w R#tx`+tx>+tF^wcwGDIC&3w4ITHw`T0ww !,DF^wdv%    T))LxGive Oxycontin 12 hrly      % ( " " FL@EMF++@ *@$??XvD5D@ !!K@0   $$??XvD5D  Rp"Tahoma?u+t   aE!tlw !)p/wg v)S#tx`+tx>+tF^wcwGDIC&3wܕITHw@T0\xxXDF^wdv%    T)[ ) Lhas prescribed  % ( " " FL@EMF++@ *@$??XvDuD@ !!K@0   $$??XvDuD  Rp"Tahoma?u+t   aE!tlw ! ) K/wg v )T#tx`+tx>+tF^wcwGDIC&3w0ITHw@T0\xxXDF^wdv%    T[)L|Reassess pain in 1 hour     % ( " " F EMF++@ *@$UU@UU@+@ *@$99fDD@ (H#J5^4J4^BJdH4^BJNH4^BJ|I5^4JN+I#JN+I(HN+I_HN+I|INHdH_H/(H.@ f( !b $$>>'f%  ;WB;6|X;X4b[;]=]?]Ab[B|XB6WBBX4p?B=A=?==p?;WB;=<>p W % $$AAF`TEMF+@ @4FA?@  ( ! $$>>_888% '%  [m ZSWBu;|Xu;Yz;Y;Z;Z;[;q[<[J<:\<\<\=$]\=^]=v]=]>]1>]^>]>]>]>]?]K?]{?]?]?]@]2@v]]@^]@$]@\'A\oA:\A[Aq["B[QBZwBZBYBYB|XBWBBABFAB@BH@wB?QBb?"B>A>AA>oA='A=@u=@]=]@H=2@5=@&=?=?={? =K? =? =>=>=>&=^>5=1>H=>]==u===\===A><><>J<><>!=> ==l==k=====s==s==^=>_=>M=:>M=9>>=e>>=e>2=>2=>*=>*=>$=>$=>#=?#=?$=J?$=I?*=w?*=w?2=?2=?>=?>=?M=?M=?_=(@^='@s=R@s=Q@={@=z@=@=@>A>AR>\AQ>[A>A>A?A?Am? Bl? B?9B?9BO@`BO@_B@~B@~BJABIABABABWBBWBB|XB|XBYBYBYBYB Z~BZ~BZ_BZ`BZ9BZ9Bg[ Bf[ B[A[A,\A+\A\[A\\A\A\A]@]@I]z@H]{@`]Q@`]R@u]'@t](@]?]?]?]?]?]?]w?]w?]I?]J?]?]?]>]>]>]>]>]>]e>]e>]9>]:>t]>u]>`]=`]=H]=I]=]k=]l=\ =\!=\<\<+\<,\<[_<[`E/wg v,wU#tx`+tx>+tF^wcwGDIC&3wITHw`T0ww !,DF^wdv%    T{9 :LlSEEK ADVICE FROM%$$((,''$"*-4% ( " " FL@EMF++@ *@$??]NDWD@ !!K@0   $$??]NDWD  Rp"Tahoma?u+t   aE!tlw !:@b/wg v:V#tx`+tx>+tF^wcwGDIC&3wtITHw@T0\xxXDF^wdv%    Tp :"LAcute Pain Nurse Specialist (APNS)#  '    # ' % ( " " FL@EMF++@ *@$??]NDlE@ !!K@0   $$??]NDlE  Rp"Tahoma?u+t   aE!tlw !:U" x/wg v:W#tx`+tx>+tF^wcwGDIC&3wDITHw@T0\xxXDF^wdv%    T= L:L|Or On call Anaesthetist))  #   % ( " " FEMF++@ *@$UU@UU@+@ *@$99EUUD@ PD`mHIJD"J`mHJ`HI`H@ ̙( !b $$>>'%  % V4M mB*G'FX']*FX,G,%  % $$AAF`TEMF+@ @4FA?@  ( ! $$>>_888% '%  [xH  OB*G'IX']*IX,G,OB*G,G,FX,AX,]*]*AX'FX'G'G'rB*rB*G, % % $$AA" ( " F<0EMF++@ *@$UU@UU@+@ *@$??֮EӠD+@ *@$??֮ED+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??֮EӠD@ !!K@0   $$??֮EӠD  Rp"Arial?u+t   aE!t1dk/wg v,wX#tx`+tx>+tF^wcwGDIC&3wITHw0T0ww !,DF^wdv%    T;  M 9 LdMorphine PCA1#### '*)% ( " " FL@EMF++@ *@$??֮ED@ !!K@0   $$??֮ED  Rp"Tahoma?u+t   aE!tlw ! 9 0 /wg v 9Y#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    TL2 ~)L|ENSURE NO OTHER OPIOIDS      % ( " " FEMF++@ *@$UU@UU@+@ *@$99XcDUUD@PD`mH/H/IJ`mH/I`H/H`H@( !b $$=='%  % V48"T%C#O)b#Ol"T)b!Y%C!Y%  % $$AAF`TEMF+@@4FA?@( $$==_888% '%  [x 8"TC O/b Ol"T/b:YC:Y8"T0C Y%CY)bYb Yul Tul9Tb:O)b+tF^wcwGDIC&3wITHw0T0ww !,DF^wdv%    Tn M9 L`OXYCODONE-'&*-*-*'% ( " " FL@EMF++@ *@$??UDD@ !!K@0   $$??UDD  Rp"Tahoma?u+t   aE!tlw !9Ȏ /wg v9[#tx`+tx>+tF^wcwGDIC&3wHITHw@T0\xxXDF^wdv%    TLZ~)L|ENSURE NO OTHER OPIOIDS      % ( " " FEMF++@ *@$UU@UU@+@ *@$99U_ED @$̙LI84I( !b $$>>'% % V0E  ,J.,J6A\6A\.,J.% % $$AAFEMF+@@4FA?@<0LILI84I84I@( $$>>_888% '%  [`B   J.N\.N\6 J6 J.9J6,Jz6A\z65\65\.A\/,J/9J.9J6 % % $$AA( " FEMF++@ *@$UU@UU@+@ *@$??U?ED+@ *@$??U?ED+@ *@$??U?ED+@ *@$??U?ED+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??U?ED@ !!K@0   $$??U?ED  Rp"Tahoma?u+t   aE!t@Zo>Eeq+t/wg v,w@Z\#tx`+tx>+tF^wcwGDIC&3wLITHwT0ww !,DF^wdv%    Td 4 2LxEstablish use of PCAI % ( " " FL@EMF++@ *@$??U?ED@ !!K@0   $$??U?ED  Rp"Tahoma?u+t   aE!tlw !2P*/wg v2]#tx`+tx>+tF^wcwGDIC&3w ITHw@T0\xxXDF^wdv%    Td  W2LlEncourage demand*% ( " " FL@EMF++@ *@$??U?ED@ !!K@0   $$??U?ED  Rp"Tahoma?u+t   aE!tlw !2`ht/wg v2^#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    Td X 2LtGive IV ParacetamolK! * % ( " " FL@EMF++@ *@$??U?ED@ !!K@0   $$??U?ED  Rp"Tahoma?u+t   aE!tlw !2(Pо/wg v2_#tx`+tx>+tF^wcwGDIC&3wITHw@T0\xxXDF^wdv%    Tt ; 2 L`1 G 6hrly! % ( " " FL@EMF++@ *@$UU@UU@+@ *@$99WDWD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$99"E+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$99END+@ *@$UU@UU@+@ *@$??E.D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??E.D@ !!K@0   $$??E.D  Rp"Tahoma?u+t   aE!tlw !2 /wg v2`#tx`+tx>+tF^wcwGDIC&3w8ITHw@T0\xxXDF^wdv%    T|  N: LhPain Score >2&#%%$"/%% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99̦DXqD+@ *@$UU@UU@+@ *@$??DX1D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??DX1D@ !!K@0   $$??DX1D  Rp"Arial?u+t   aE!tlw !:k 8K/wg v:a#tx`+tx>+tF^wcwGDIC&3wITHw`T0\xxXDF^wdv%    T`SXALTYes(%%% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99z`CUD+@ *@$UU@UU@+@ *@$??z~CUD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??z~CUD@ !!K@0   $$??z~CUD  Rp"Tahoma?u+t   aE!tlw !AӲ/wg vAb#tx`+tx>+tF^wcwGDIC&3wITHw`T0\xxXDF^wdv%    TEB LhPain Score >2,(+*#)(7+% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99XD C+@ *@$UU@UU@+@ *@$??W7D C+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??W7D C@ !!K@0   $$??W7D C  Rp"Tahoma?u+t   aE!tlw !B n K/wg vBc#tx`+tx>+tF^wcwGDIC&3w8ITHw`T0\xxXDF^wdv%    T\ ;K-LGUIDELINES for Analgesia Post Cardiac Surgery87$9.+$:.0.!30-/-'-1.'2-!/-(00!/-!+% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99wCZC+@ *@$UU@UU@+@ *@$??UCC+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??UCC@ !!K@0   $$??UCC  Rp"Tahoma?u+t   aE!tlw !;K@-/wg v;Kd#tx`+tx>+tF^wcwGDIC&3wlITHw`T0\xxXDF^wdv%    T: LhPain Score >2&#%%$"/%% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99D[}C+@ *@$UU@UU@+@ *@$??D[C+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??D[C@ !!K@0   $$??D[C  Rp"Tahoma?u+t   aE!tlw !: XK/wg v:e#tx`+tx>+tF^wcwGDIC&3wITHw`T0\xxXDF^wdv%    T&EB LhPain Score >2,(+*#)(7+% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99VE+@ *@$UU@UU@+@ *@$??RVE+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??RVE@ !!K@0   $$??RVE  Rp"Arial?u+t   aE!tlw !B K/wg vBf#tx`+tx>+tF^wcwGDIC&3wTITHw`T0\xxXDF^wdv%    T1ELALL PATIENTS REQUIRING REGULAR OPIOIDS SHOULD BE PRESCRIBED LAXATIVES# !$ !$!'$ $ $'$!'$#$'! ' $!!$'$$$!!$!!$$ $!$#! !!!% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99U uDtD+@ *@$UU@UU@+@ *@$??U|DTD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??U|DTD@ !!K@0   $$??U|DTD  Rp"Tahoma?u+t   aE!tlw !1E%/wg v1g#tx`+tx>+tF^wcwGDIC&3wITHw`T0\xxXDF^wdv%    T: LhPain Score >2&#%%$"/%% ( " " FEMF++@ *@$UU@UU@+@ *@$994iDW;D @$IH( !b $$=='% % V0)E:rE:|9\|9\rE:r% % $$AAFEMF+@@4FA?@<0IIHH@( $$==_888% '%  [`& ,:}rR\}rR\},:},:}r^:|E:|9\| \| \r9\rE:r^:r^:| % % $$AA( " Fl`EMF++@ *@$UU@UU@+@ *@$??pDD+@ *@$??pD D+@ *@$??pDMD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??pDD@ !!K@0   $$??pDD  Rp"Tahoma?u+t   aE!ty`o>EBq+t/wg v,w`h#tx`+tx>+tF^wcwGDIC&3wJTHw`T0ww !,DF^wdv%    T5^g)LpGive Oxynorm 5mg   ( ( % ( " " FL@EMF++@ *@$??pD D@ !!K@0   $$??pD D  Rp"Tahoma?u+t   aE!tlw !)(U/wg v)i#tx`+tx>+tF^wcwGDIC&3w JTHw@T0\xxXDF^wdv%    Tg) Lhas prescribed  % ( " " FL@EMF++@ *@$??pDMD@ !!K@0   $$??pDMD  Rp"Tahoma?u+t   aE!tlw !) K/wg v)j#tx`+tx>+tF^wcwGDIC&3w JTHw@T0\xxXDF^wdv%    T)L|Reassess pain in 1 hour     % ( " " F\PEMF++@ *@$UU@UU@+@ *@$99UDX{D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$99D[}C+@ *@$UU@UU@+@ *@$??`D[C+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??`D[C@ !!K@0   $$??`D[C  Rp"Tahoma?u+t   aE!tlw !)/wg v)k#tx`+tx>+tF^wcwGDIC&3wpJTHwPT0\xxXDF^wdv%    TXEBLPNo4)% ( " " FL@EMF++@ *@$UU@UU@+@ *@$99CC@pFF?X@ A?`@, ? H@!b $$==_888% %  [LW 66 % % $$AA( FEMF++@ *@$99CUC@pFF?X@ A?`@, ?RH@$$==_888% %  [L   ^! % % $$AA( FEMF++@ *@$99Dt D@pFF?X@ A?`@, H?@$$==_888% %  [L; J"#O"#O"J"J"N "pP"N#N " % % $$AA( FEMF++@ *@$99UDt D@pFF?X@ A?`@, .H?@$$==_888% %  [L ; p"v"v"p"p"v "Hx"v#v " % % $$AA( FEMF++@ *@$993Et D@pFF?X@ A?`@, ` I?@$$>>_888% %  [L; @ZEZE|@|@ZE~FkEE % % $$AA( F(EMF++@ *@$99nDXqD@>F?d @ A?( ?@@@, ?.H@$$==_888% %  [LD z_U$z_9*^9*^U$z_U$`)/_+N^)`) % % $$AA( FEMF++@ *@$99:(DUmLD@ @4>F?@!, J?@! $$>>_888% %  V,+ 8eMeM % % $$AA( FdXEMF++@ *@$99:D/D @$hJTH( $$=='% % V0y*G+G2y2y+G+% % $$AA" F EMF++@ *@$UU@UU@+@ *@$??D2D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??D2D@ !!K@0   $$??D2D  Rp"Tahoma?u+t   aE!tXxp$t X/wg vw$tl#tx`+tx>+tF^wcwGDIC&3w@&JTHwT0ww !,DF^wdv%    TPBLlCONSIDER OPTIONS-44* 3)14,) 44*% ( " " F(EMF++@ *@$UU@UU@+@ *@$99:DFXD@"@/HSGSG@/Hm J6~JhJSGhJ@/HhJ[IhJGsI6~J`ƃIm J`ƃI@/H`ƃISG`ƃIGsI[I@"( !b $$=='%  ;G9X(G7=I 6FK 66v 6X(!x 6y7y96y|HX(yJ!x-Lv-L6FK-LX(=I-LGJG|H=<>y` % $$AAF`TEMF+@#@4FA?@"#( $$==_888% '%  [`v^E}G9GX9G8G8GB8G7#H7[HR7H7H6(I6yIf6I=6&J6J6J5FK5v5{v5v68w6w=6wf65x6x6x7yR7`v % $$AAF`TEMF+@%@4FA?@$%( $$==_888% '%  [`~^xE9X98&8FB8o77R7 7[ 6 6 f6K =6 6 6a 5 535 45j4646!5=6u5f65666U676S76767$7B8E78]78k7X9p79p7}Hk7H]7?IE7I$7I6JJ6J6JU6*K6iK5Ku5K!5K4Lj43L 4AL3FL FLa AL 3L LK K K K[ iK *KJJoJJFI&I?IH}H9,|H,{H1H1H?7I?4IVIUIuItI4J2JJ}JJJ; K9 K| CK{ AK xK wK K K_ K] K K K L Lg Le L L L3L3L4L4Lb4L_4L4K4K5K 5K_5K]5K5wK5xK5AK5CK36K16Kn6Jl6J6~J6J62J64J6I6I7I7I,74I,77I:7H97H>7{H>7|H>79>7997\9:7^9,79,7978786T86V868686767l6q7n6s71607362756565656]56_56 5k65l64L64M6_466b4664(64(63#63#6 #6 #6e (6g (6 66 66 M6 L6] l6_ k6 6 6 6 6{ 6| 69 27; 07s7r77788tV8uT8U8V8?9?91^91\9,9,9,|H % % $$AA( " F, EMF++@ *@$UU@UU@+@ *@$??0C(Y`D+@ *@$??0C(qD+@ *@$??0ClD+@ *@$??0CD+@ *@$??0CD+@ *@$??0CD+@ *@$??0ClD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??0C(Y`D@ !!K@0   $$??0C(Y`D  Rp"Tahoma?u+t   aE!tM(o>ED/wg v,w(q#tx`+tx>+tF^wcwGDIC&3wl9JTHw T0ww !,DF^wdv%    TpnT:LXNSAIDS-%(,%% ( " " FL@EMF++@ *@$??0C(qD@ !!K@0   $$??0C(qD  Rp"Tahoma?u+t   aE!tlw !۽:gH/wg v:r#tx`+tx>+tF^wcwGDIC&3wt>JTHw@T0\xxXDF^wdv%    T2LtContraindicated in:!   % ( " " FL@EMF++@ *@$??0ClD@ !!K@0   $$??0ClD  Rp"Tahoma?u+t   aE!tlw !2PW`ľ/wg v2s#tx`+tx>+tF^wcwGDIC&3wAJTHw@T0\xxXDF^wdv%    T M>2 LRenal failure, peptic ulceration     % ( " " FL@EMF++@ *@$??0CD@ !!K@0   $$??0CD  Rp"Tahoma?u+t   aE!tlw !2 9Q/wg v2t#tx`+tx>+tF^wcwGDIC&3wEJTHw@T0\xxXDF^wdv%    T?wz2 L`or gastro% ( " " FL@EMF++@ *@$??0CD@ !!K@0   $$??0CD  Rp"Tahoma?u+t   aE!tlw !2 W/wg v2u#tx`+tx>+tF^wcwGDIC&3wHJTHw@T0\xxXDF^wdv%    TTx?z2LP-% ( " " FL@EMF++@ *@$??0CD@ !!K@0   $$??0CD  Rp"Tahoma?u+t   aE!tlw !20t/wg v2v#tx`+tx>+tF^wcwGDIC&3wKJTHw@T0\xxXDF^wdv%    T?*z2Ltintestinal bleeding     % ( " " FL@EMF++@ *@$??0ClD@ !!K@0   $$??0ClD  Rp"Tahoma?u+t   aE!tlw !2X5/wg v2w#tx`+tx>+tF^wcwGDIC&3wtOJTHw@T0\xxXDF^wdv%    T{S2Lpand severe asthma*% ( " " F(EMF++@ *@$UU@UU@+@ *@$99VE"^D@&@ H{G{G@ HI >II{GI@ HI0/IIpCI >IRIIRI@ HRI{GRIpCI0/I@&̙( !b $$>>'%  ;B;X(BjvCFD6UX(VxWjxW;6xW"#X(xW#V$U$6FD$X(vC$B#B"#=<>Yx  % $$AAF`TEMF+@'@4FA?@&'( $$>>_888% '%  [Vu =yB;BBBBBC`3C'lCCCCCDFDU'VMVsVVVVW'BW`VWgWsW}WWW;W"#WJ#}Wp#sW#fW#VW#BW#W6$Ve$Vy$V$sV$MV$'V$U$FD$D$C$C$C$Cy$lCe$3C6$C#B#B#B#Bp#BJ#B"#B;B"#B!#BH#BG#Bl#Bk#B#B#B#B#C#C#C#C#EC%$CC#${CQ$zCP$Cc$Cc$Cs$Cr$C$C~$C$C$"D$!D$GD$FD$U$U$%V$$V$IV$HV$lV~$kV$Vr$Vs$Vc$Vc$VP$VQ$W#$W%$.W#-W#@W#@W#PW#OW#\W#[W#eWk#eWl#jWG#jWH#lW!#lW"#lW;lW<jWjWeWeW[W\WOWPW@W@W-Wn.WoW7W9V V VVVVkVlVHVIV$V%VUUFDGD!D"DCCCCCCCCzC {C CC9EC7CoCnCCBBBBBBBBB<B;B"# % % $$AA( " Fl`EMF++@ *@$UU@UU@+@ *@$??_EUMlD+@ *@$??_EU}D+@ *@$??_E&D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??_EUMlD@ !!K@0   $$??_EUMlD  Rp"Tahoma?u+t   aE!tMЗo>EF/wg v,wЗx#tx`+tx>+tF^wcwGDIC&3w,ZJTHw`T0ww !,DF^wdv%    T 6: LdMORPHINE PCA4-*&,-$&'(% ( " " FL@EMF++@ *@$??_EU}D@ !!K@0   $$??_EU}D  Rp"Tahoma?u+t   aE!tlw !6: 0Ϸ/wg v6:y#tx`+tx>+tF^wcwGDIC&3w^JTHw@T0\xxXDF^wdv%    TR (q)LlPrescribe if NBM   &% ( " " FL@EMF++@ *@$??_E&D@ !!K@0   $$??_E&D  Rp"Tahoma?u+t   aE!tlw !q)@/wg vq)z#tx`+tx>+tF^wcwGDIC&3waJTHw@T0\xxXDF^wdv%    T( Z)Lor absence of bowel sounds   % % ( " " FEMF++@ *@$UU@UU@+@ *@$99jkBTD @$I@MH( !b $$=='% % V0: riPV'V'PP% % $$AAFEMF+@(@4FA?@)<0II@MH@MH@)(( $$==_888% '%  [`7uk P2'P2'VVPVnV'nV'V'P'PPPV % % $$AA( " F EMF++@ *@$UU@UU@+@ *@$??kBD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??kBD@ !!K@0   $$??kBD  Rp"Arial?u+t   aE!t}o>EIq+t/wg v,w{#tx`+tx>+tF^wcwGDIC&3wiJTHwT0ww !,DF^wdv%    TY!SY1LxNSAID contraindicated$!!$  % ( " " FEMF++@ *@$UU@UU@+@ *@$99+tF^wcwGDIC&3wTmJTHwT0\xxXDF^wdv%    T@p: L`OXYCODONE-(''-,--$% ( " " FL@EMF++@ *@$??DmD@ !!K@0   $$??DmD  Rp"Tahoma?u+t   aE!tlw !:' ^/wg v:}#tx`+tx>+tF^wcwGDIC&3w`sJTHw@T0\xxXDF^wdv%    T:)LxPrescribe Oxycodone 10   % ( " " FL@EMF++@ *@$??DmD@ !!K@0   $$??DmD  Rp"Tahoma?u+t   aE!tlw !)Yַ/wg v)~#tx`+tx>+tF^wcwGDIC&3wvJTHw@T0\xxXDF^wdv%    TT;I)LP-% ( " " FL@EMF++@ *@$??DmD@ !!K@0   $$??DmD  Rp"Tahoma?u+t   aE!tlw !ۻ)d/wg v)#tx`+tx>+tF^wcwGDIC&3wyJTHw@T0\xxXDF^wdv%    TJ0) Ld20mg 12hrly#  % ( " " FL@EMF++@ *@$??DzD@ !!K@0   $$??DzD  Rp"Tahoma?u+t   aE!tlw !)) [/wg v)#tx`+tx>+tF^wcwGDIC&3w<}JTHw@T0\xxXDF^wdv%    TT),L(If frail / elderly prescribe oxycontin10mg          # % ( " " FL@EMF++@ *@$??DWCD@ !!K@0   $$??DWCD  Rp"Tahoma?u+t   aE!tlw !)۷,/wg v)#tx`+tx>+tF^wcwGDIC&3wHJTHw@T0\xxXDF^wdv%    T|K)L\12 hrly)  % ( " " FL@EMF++@ *@$??DWD@ !!K@0   $$??DWD  Rp"Tahoma?u+t   aE!tlw !) m@/wg v)#tx`+tx>+tF^wcwGDIC&3w|JTHw@T0\xxXDF^wdv%    TK})LpPlus oxynorm 5mg 3  # # % ( " " FL@EMF++@ *@$??DWD@ !!K@0   $$??DWD  Rp"Tahoma?u+t   aE!tlw !)@4/wg v)#tx`+tx>+tF^wcwGDIC&3wJTHw@T0\xxXDF^wdv%    TTK}y)LP-% ( " " FL@EMF++@ *@$??DWD@ !!K@0   $$??DWD  Rp"Tahoma?u+t   aE!tlw !y)`/wg vy)#tx`+tx>+tF^wcwGDIC&3wJTHw@T0\xxXDF^wdv%    TK}) L`4hrly PRN  % ( " " FL@EMF++@ *@$??DWÏD@ !!K@0   $$??DWÏD  Rp"Tahoma?u+t   aE!tlw !ۈ)) P@/wg v)#tx`+tx>+tF^wcwGDIC&3w4JTHw@T0\xxXDF^wdv%    T}*H)LFor a maximum of three days  ( ((   % ( " " FEMF++@ *@$UU@UU@+@ *@$99UBҾD @$JI( !b $$=='̙% % V0Qv^a_uW7uW7a_a_% % $$AAFEMF+@*@4FA?@+<0JJII@+*( $$==_888% '%  [`Oxa H_p7H_p7uuH_6uuW7u>7u>7a_W7z_z_6a_6u % % $$AA( " FEMF++@ *@$UU@UU@+@ *@$??UBVpD+@ *@$??UBVD+@ *@$??UBVpD+@ *@$??UBVD+@ *@$??UBVpD+@ *@$??UBVD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??UBVpD@ !!K@0   $$??UBVpD  Rp"Tahoma?u+t   aE!tqo>EFq+t/wg v,w#tx`+tx>+tF^wcwGDIC&3wPJTHwT0ww !,DF^wdv%    Tp472LpSuggest Prescribe ! % ( " " FL@EMF++@ *@$??UBVD@ !!K@0   $$??UBVD  Rp"Tahoma?u+t   aE!tlw !2PBP/wg v2#tx`+tx>+tF^wcwGDIC&3wlJTHw@T0\xxXDF^wdv%    Tp8s2 LdSingle dose  % ( " " FL@EMF++@ *@$??UBVpD@ !!K@0   $$??UBVpD  Rp"Tahoma?u+t   aE!tlw !2- ø/wg v2#tx`+tx>+tF^wcwGDIC&3wJTHw@T0\xxXDF^wdv%    Tpt2LtDiclofenac 100mg PR&  0!$% ( " " FL@EMF++@ *@$??UBVD@ !!K@0   $$??UBVD  Rp"Tahoma?u+t   aE!tlw !2PC/wg v2#tx`+tx>+tF^wcwGDIC&3w0JTHw@T0\xxXDF^wdv%    Tp{2LOr single Ibuprofen 400mg PO '    0!'% ( " " FL@EMF++@ *@$??UBVpD@ !!K@0   $$??UBVpD  Rp"Tahoma?u+t   aE!tlw !2I/wg v2#tx`+tx>+tF^wcwGDIC&3wJTHw@T0\xxXDF^wdv%    Tp)LConsider ibuprofen 400mg TDS   (  % ( " " FL@EMF++@ *@$??UBVD@ !!K@0   $$??UBVD  Rp"Tahoma?u+t   aE!tlw !)pKPћ/wg v)#tx`+tx>+tF^wcwGDIC&3wJTHw@T0\xxXDF^wdv%    Tp&[X2L|Reassess pain in 1 hour     % ( " " FXLEMF++@ *@$UU@UU@+@ *@$99:(DUmLD@,>F?d @ A?( ?@@@-, ? H@-,!b $$==_888% %  [L0b R*3R*4)4)3R*3*H4* 6&)H4*H4 % % $$AA( F(EMF++@ *@$99LEUmLD@.>F?d @ A?( ?@@@/, ? H@/.$$>>_888% %  [L 0 b HMHMJLJLHMM$"ML$M$ % % $$AA( FEMF++@ *@$994DBD@0@4F?@1,  |I?@10$$>>_888% %  V,s% 4)C)C) 4) % % $$AA( FEMF++@ *@$99DBD@2pFF?X@ A?`@3, ?@H@32$$==_888% %  [Lw  jxRjx0X'x0X'xRjxRyWHx}YwWyW % % $$AA( " F<0EMF++@ *@$998.DTD+@ *@$UU@UU@+@ *@$??5D4D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??5D4D@ !!K@0   $$??5D4D  Rp"Tahoma?u+t   aE!t0UK$to>ERq+t/wg v,w#tx`+tx>+tF^wcwGDIC&3wJTHw0T0ww !,DF^wdv%    T`F_:LTYES'$%% ( " " FEMF++@ *@$UU@UU@+@ *@$9U?DBD@4@4>F?@5, HRH@54!b $$==_888% %  V,'0^Rc:M(:gM/Q % % $$AA( F(EMF++@ *@$94iDWgD@6>F?d @ A?( ?@@@7, ?RI@76$$==_888% %  [L0 :M:4949M:M&;4E:3d94&;4 % % $$AA( FEMF++@ *@$99D0D@8pFF?X@ A?`@9, @MH?@98$$==_888% %  [Lp+G 'oS+oS+S'S'oSm+R,Sm+XTm+R % % $$AA( " F<0EMF++@ *@$99`HC D+@ *@$UU@UU@+@ *@$??`fCD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??`fCD@ !!K@0   $$??`fCD  Rp"Tahoma?u+t   aE!tK$to>E[q+t/wg v,w#tx`+tx>+tF^wcwGDIC&3wJTHw0T0ww !,DF^wdv%    TX@:LPNO--% ( " " FL@EMF++@ *@$UU@UU@+@ *@$99CD@:pFF?X@ A?`@;, ?H@;:!b $$==_888% %  [Lwg sVs^0^0VsV]Ra_]] % % $$AA( FEMF++@ *@$99CU)D@<pFF?X@ A?`@=, ? H@=<$$>>_888% %  [Lw? : :: > > :: : l>) 4? l> l> % % $$AA( FEMF++@ *@$99X:DE@>pFF?X@ A?`@?, <`J?@?>$$>>_888% %  [L; ?ZA=>_888% %  V,K ~Fn-KRn-KR-~F- % % $$AA( " F<0EMF++@ *@$99DD+@ *@$UU@UU@+@ *@$??@DD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??@DD@ !!K@0   $$??@DD  Rp"Tahoma?u+t   aE!tK$t@Co>Eu?q+t/wg v,w@C#tx`+tx>+tF^wcwGDIC&3wJTHw0T0ww !,DF^wdv%    TY2 LhPain Score >2!  ) % ( " " FXLEMF++@ *@$UU@UU@+@ *@$99nDUmLD@>F?d @ A?( ?@@@ , ? H@ !b $$==_888% %  [L0b z_3z_4^4^3z_3`H4/_ 6N^H4`H4 % % $$AA( FEMF++@ *@$99ChD@ pFF?X@ A?`@ , ?cTH@  $$==_888% %  [Lw  s-LsUO0UO0-Ls-LORPOO % % $$AA( FEMF++@ *@$99LED@ pFF?X@ A?`@ , ? MH@  $$>>_888% %  [L   3M$3M&M&M$3M$M&"M'L&M& % % $$AA( FEMF++@ *@$99$EWD@pFF?X@ A?`@, ? H@$$>>_888% %  [L; W  \Rz-\RO.;RO.;Rz-\Rz-R-.KR.Q-.R-. % % $$AA( FEMF++@ *@$99$EbD@pFF?X@ A?`@, ?RH@$$>>_888% %  [L; W  \RU6\R7;R7;RU6\RU6R7KR8Q7R7 % % $$AA( FEMF++@ *@$99$EU)D@pFF?X@ A?`@, ? H@$$>>_888% %  [L; ?W r \R:\R:;R:;R:\R:R:KR;Q:R: % % $$AA( FEMF++@ *@$99UD`D@pFF?X@ A?`@, p I?@$$==_888% %  [LS KYncncJnKYJnKYncame)ncncam % % $$AA( FEMF++@ *@$994DND@@4F?@, ?RH@$$==_888% %  V,~B+ho+h tg tgo % % $$AA( FEMF++@ *@$94DU)D@pFF?X@ A?`@, ` I?@$$==_888% %  [L3O hs]s].th.ths]EsA\ t]t]Es % % $$AA( FEMF++@ *@$99WDD@pFF?X@ A?`@, ? H@$$==_888% %  [L MiM\kYM\kYMiMiBNkzMlLkBNk % % $$AA( " F<0EMF++@ *@$99X1oD"^D+@ *@$UU@UU@+@ *@$??XvDaD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??XvDaD@ !!K@0   $$??XvDaD  Rp"Tahoma?u+t   aE!tPK$to>EBq+t/wg v,w#tx`+tx>+tF^wcwGDIC&3wJTHw0T0ww !,DF^wdv%    TX@BLPOR41% ( " " Fl`EMF++@ *@$UU@UU@+@ *@$99D"^D+@ *@$UU@UU@+@ *@$??LDaD+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??LDaD@ !!K@0   $$??LDaD  Rp"Tahoma?u+t   aE!tlw !BhH/wg vB#tx`+tx>+tF^wcwGDIC&3wJTHw`T0\xxXDF^wdv%    TX7BLPOR41% ( " " FEMF++@ *@$UU@UU@+@ *@$994DX)D+@ *@$UU@UU@+@ *@$??DX D+@ *@$??DXi-D+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??DX D@ !!K@0   $$??DX D  Rp"Tahoma?u+t   aE!tlw !BH/wg vB#tx`+tx>+tF^wcwGDIC&3w,JTHwT0\xxXDF^wdv%    T )=LFor patients prescribed long term opioids please seek advice       (         % ( " " FL@EMF++@ *@$??DXi-D@ !!K@0   $$??DXi-D  Rp"Tahoma?u+t   aE!tlw !)4Q=]/wg v)#tx`+tx>+tF^wcwGDIC&3wJTHw@T0\xxXDF^wdv%    T ,)!Lfrom APNS or on call Anaesthetist(       % ( " " FL@EMF++@ *@$UU@UU@+@ *@$99DD@pFF?X@ A?`@,  H?@!b $$==_888% %  [L A\y]y]zA\zA\y]2y/_y]z]2y % % $$AA( FEMF++@ *@$99DD@pFF?X@ A?`@, RH?@$$==_888% %  [Ll vyyyyzvzvyy2y?{yyzy2y % % $$AA( " F, EMF++@ *@$99VE`E+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$99UEE+@ *@$UU@UU@+@ *@$??5EE+@ *@$UU@UU@+@ *@$UU@UU@+@ *@$??5EE@ !!K@0   $$??5EE  Rp"Tahoma?u+t   aE!t`K$txo>E>q+t/wg v,wx#tx`+tx>+tF^wcwGDIC&3wKTHw T0ww !,DF^wdv%    T  %LJC / KM/ SA review date 10/14        % ( " " F,~ ~EMF++@ *@$UU@UU@+@ *@$99UD+@ @ !@ @ *@$99UD!@ +@ *@$G?:?UD$@ @ ||JFIFC      C  w" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@~rV?cJAKE凟'̧8/7__=}3śoq_w_ * q哳icτQ?>Gg_Q_fG@2ϻ<&Kqm;ht va8-哷88\WC8@? 2߲}l"׼y(ծ tm㱕:S9l e;&!,fua9V۾G<P"+w;^tMAPHm<=c8=+7V>'-sK}7,#OC>x#c!Cӄ$̵{?!`jbp9Z+뭬|%?>GgG?G|e4/o3"2I*Ht~j~)ў^=%w6 cFO_,7Zxh(v*q%Z ]G&3ݟmxo ]xER ڮt (U*pA{qf?? S=O7@aXe gq|`|cUbЬHPOrpl,gNYI췻N$x/6VfbҼC[?Zfmi:AcFҽwM?3o\9mĚ6]K2JnFq"eٶO@+W M[泸 .]b8AyuPpn'/1QUWvW`V%fg9;F.vOt>>τQ_B񎗠pGX1R;\ Oa_Ts -^䴸߈MS.m{ŸVǚ,zEtITA y/yDP"+i)ο-5m ـ\fINF}+G1(i8GT!:XɤUCYxH4 T1^եQ*$ qX?uTd[[?Be:>A<0S HJW?Z?o|/KY CQeFÐH,Ake7$*Wwzulc֦]bQms9YYiw#^/@>$U,I'r}װ}ʟ2+x<1] nw}L`~j~-~Gț#EX󸏠Ԛ^6 MIpHǝ!S+܏u%UOZsjäkn=T}09Weh>Mlێs,#>5VoVtOw?_,xůbڅųHSB&wmB{ٵ]$19 :rk?YUuo[x0I y{z!^/?wӿE|xtZ KKQEW'y;v#$2%ԅH Ͱ|/ Kk_-~4x[G_5ԃ_}%^8 a?{叔f@k e$͆ jȍ$6K$oVq"Y/O'%/ j6 Z;9dCtqU<09Ƞ?|?Qa_ |HCNeiu#U2.v =_m+_[U% ]6݌n$rW8B"[>z7+ "2*0dOO 5V?l4SMΓFX=?Uŏ'#'A?J}CM~Siw{% ݹkG20u !r j_Ə8/sxOƯ 4EݜW > S"ns_c& E8!񵷎10?nZn--1l 2/E>%_UfϽDB7`RPʤ^gI<5ƞ}/PZލrҮvHa80S+*/KOiֳ^ |;i(5;M|w|B?f۟ ԯO>I iͻ'OmĒ$O LHN2S"Qg?Xh:g컽7g ?GkO7>,q:|fV8%Rjy~Q_#*?x[i3ƏxvQ$#p'@.S7)oFA<7 ŝsTƭ⿰]Ikh Xct9)j/k;c\$բ( +)h.Ww嗑*L|Iks]Ph/x7_|-mhSK ɦFl! 2sO⿉WzOk s)Wžk"7_'% uo-73şK>_x_R}Bh^&pFy_?MߍkK7^/KZKt6kq)QրuN~ڷO7~'kZFͬyaA ~rzҕ&3aOGRO)7?O_BCmh֌Ϋ>sPKZ<߷G||$N(U6i,6{Xy嘯85;G5=n&W?f} M#<,\m#=7ߴ>&ε@2:4E\Ogm\CS6+?փoŷ"b|da3[Ԧņs$FtWF:,^8<-<|3?{eU&bw6h}=wOxgA{O ]uVH:0wuG?? ~_CwiŸ4.0 1,8+S y 'Qƒ^dkg$i"&I)tx N?Ƌk[iEFRako ߍjoNIeȼ?,:E}֢XDH*s}޴ꂊgHm75?|u:gkYխXȖ홣sG9XQEhQ/о 3O%Σ4Et ƀk%Ρp[_eᵊ e?gE~~G+.?|Ujןcm.x Ys̪mѿ#/N~7~!H,Ȱt2@ ǟ-  f>zlGꭢxÚ?ڴ)ʹlkd1e#Ho_grWm<7\vVp^4 O"k **K1h>DYop4%lW|r qH '4<|!Oо$Zu =ZzƌKF?xHm~e#-At ^Ѯ& ݊ށ4vf|E~?Q.?t Ef D[޸5(\LOt:mj.yoT1@O?vC ͮq4N%cb>Wҿ? |⯊ޱ}ke{ihBYV q؃_Z~?Lzi/[; S+ G`s_F/+GNJns%?Z t?( ªkt[KSӴkV(`E.P:j?u'!jG|1cm}?dHG&&%CV!$H*Ӿ7o`v pwz%5DUDQ`(h?eJĹ/ L|lt?f߇vڭKk82 Kn/ );c/F]6?J؟~^d6` nIfPH!R1@O+#OoO{"/7l2-"y ehFOi#Bivs7܂%$e8OYzk h]>6^t/ |7tW0Gvd,+Ύ ;5tKۻSܖW+mmhp+|+~F/oYů򘬵9,"5_/8XHk )_g E6sc}&@-#F28ea`ʠ=?Ӿ.MrJ :mfW*c1G* +۞zK4?mK!AiaT"@< @{Wa| '@,fY\nO`rO_S)ܞ=wž)]/Ǻ#񆸎tYʱr,DPlOO8 W `|A\|?Wlgg>-y&ϕۑ_E%-޸MT~Κ.M{q?N[ /,[j='o$42ȥIZQf|F妝g7<{B&=u0dς@x<RFG zcQ_?^O-ZOyOXKkøHH'qlz4Oۧ O~:O49N仁$8`/SΊe ~,xZ_Eխ]Դ8⹸'"M:3r-`H*P&_7ړ퍬Ay oxC29.chf[_5ľ^w_ 4(+V-ׂfkQ :HKRHe#A-,mh~Q_?P߇:5ί/殛id.H؞bMO@j.h>=𝾡{^Y%pdh" u9 x~iE"DtLOlCWe0iv]\HHK1W Oϋ5_0/Rx#=Cj`T:W?c(:emCIdO #\B"buI:¿kڇ |5}gS .p1g2JV2#'$gkB {|)e}{qrNyjPXnï(pXzgBtO%jk]J/ ZFK.FAz l~QG8Ο >'=#G¯> P-(XGڇ>\)f\9(%#[4WF|f&ܟC+VۏFXCFᏉU {jn,jʗe"U8=T?d'/~7ob|\'l/bpW (t?o__px/&N >~2ZDx=B7~_^CYq<0!GcU$b(?/MY"W}0\}KC;H~H;n;HIW>+g fSo[4.˔{ĿP7k+?$ h[uLF.3 y|wi*EcxsY%*sVzX>3^_­LR[]n;h'* #9ݯoAנc2j.‚zw5 |8I?i|L|g/W67ic%ڪmCl) 0 [qq];~j&Sk pb1+i:M=%&t5|N!xC뱝'MIAVqM#}N9=+ Mߴ4@õx<6FK܏/EnO8e9-Zv%v|]s:ͫjF^c<߿g>ٯ3E-exhZ" 2J1_/Q_F~?Tߋ߲~mhZׇ-:fWC=W^ ^+9T`攠z'~ϣ'{eV6 ƣOjջ> |#k4{△}:n&B2k8c߆qq qƥi O_B|}x*E52xq_aN(jNҳqJjvV?kqqքwJM?ɣO¹*zf:eϗ?kBV{V;Er1 ;tXPەUE?Ś=ƝZ}涺fU=U{rs:RKN5[.W_٧yMh9`jʜ]GėfH=+_+kM%Y&z+`=|_9,~2j3WWo2v6 NPvvɅi_cW?B0?+jL/? +珨 ( ( (?3Ew?5׮_S'5qx–k6K DM`= z?Zfh#\%6r[qvɆqAIXz'˿:EMa]A?57<l6p(sb6W_>צe]ˋl-[h\Ɓn xLN*8=q_< >jT>'ėW1%Ε M@]\ځG5~I{9hkǤ3x0,nI ;mW=i*߬>)W׈,-M^s Uс&'f~[.^g\D|qgNH.`P.IݛD 6#-_;e{ऺ_ r T-–X@v}x~Po0xM䷴:Dh2F8~σ$d{OΩrzi1O m-]cM K--4:EhUG/+~R6,P}S^W*swk4&?xp9+د?`?߷>(xB1w0΄:d\=Q!7~ .}yth{]udmKH28QDo'8V+k_=Ugx)"d$-n}'I7-51si@_/|N%Im[]XI+`9_|(gGS,hGF+뱱L(෶E(vj@o~GwA-x+˯cW3V38k;'Wz9/8^W1_?'8y@!S>>hڎe_p5}!cI+:*ux0p'_M!7 U_䵕_֢b{Y]U7c'5>=ϳas+2 EIځ;\;_ɭ tM";y)12Sʬzhxgj]Yc7vʗsT HU |O|ioϖ ]>fT/3as1_xoI="a5 @ܴ?:voh>"^ kk^ ڳtW$@?xHHo/_W𶣥xzr#e'7&>A$wW׀/O^&.l5 u=FC yWoO5lj>?n72@tuojO߶u&9Vg~?wÏOx'e4ZA$VDw&golP%c5vmO=<+\jWmn'@#R~\r;{񗍼gyCXUt.Z32<g׏_/7vxkblӭ"Uy$O'5>*nNQӯhnmbYa6ee`C;[i[t?it'$k+,rA +Xrkcb?bc?g~'_>ySdg;lFj4 ǿ g_ ;HP-&d_M+ } >?mX\Ⱦn+ʶFNdf'OA_ͯGh)ayogeuF%afIぐB 놋x+Ǿ3_F>mQf/HZdO?> %[Xɚ2iX%|wv'J;lv/KTI_Rq$;U]WLf(14E$g̟ 'Qxw⍗7?#OHf},@hQE|?&>$m?z_ucz~˾!ak~Hv8qb1ցO-ŏKƖ>)[(<,o^E1,29bσI~/cƫo%ßK׌Z׋n5,mmyl)_xev$+Z'ş?3^W_ k~ց; iG+XA8'*ÿT^fZtԷӢI_y.A"1؏D߆7g%}EM+; hK%K%4O>8PDlWӿ_K4˛ul9(N^9&7w;\5Hv7=>? /ex?M)|񍖣%xOD~mȟ0dR$Sӧ8''y?sկW%|xvyæ]`e\evhA~.dk+vnfװ@(w37|xo/?;:%Ger rF+%Eh| <15}D\^b"񪝂3 =W ~/[[:7\k}Ay,a`4qFb$l22OK_^ }*W{$ 7 #E_pWe[DE5ׄ.V´O!A9⿡ψO|-M6WkP #u䡗'8*zWT¼md_k.M #]2=;AbN1^Y/ ZakhŴWw1!E* =??T )`i <5sO?e -$ KI&yvH3~U7g\O'odLz$c? AA_9_x&Em_99e$v5 ?Xm6X\E!_A!X4|Cx+ <5ok⯎U|1%)h^c@8yȁFE{?׏(Sk-_Ɵ|kx E@$H9O|/OG48C$ķ3T HKցsh a翑$8hiTP&ϛo!O(_nO='Rߍc_\\PJ@ 72ov<[~>JCGE3=EE=_S?C s/'⯉-|-<]v|-n#HDhШ1c^u7_ŭ~EN\Ssul,c)~g_K9lw]M?=Rj1Xm$$|91&2w|/}5}k^9kkFb`FͽfE&_' :G`25^|[~?o>YjS#b!*A K7o3&~-дhywZ~l󯺰##"RyV9?XMohDKf]Ύ>#|h-%Bݛ!5k 8o L g1bx~P24af cf1ڼIB:Si_Lq:eӽ`~Zß)|+tn^T 6诡 (beߌ)b xz5 <hV@ ֿ=f5[akV]<u(;KnObfKm- 0ā#p8^. 1x]FP*][ũr;㗄h߆ZWi!mui(uqz8 A mkVqj>XX_ZɝK9+ǭ~jm~xX}Yiwfk 94fE%R~b=;i!4  ? .k]> wq MBWr{2z???~"x|Sݵzf-܁;+g_BoRX߷W-OA[P~x4= G(`0Dmkzagm3,i̪X5a_v>&m $2CJVb kSt^Y8&phGߵۿtXIԌIRXAOCG*sA?Կ|>jԯ-d0J$ #_S + =Vp$_J z~vuzm-'vQE~/m}~Wg>'~v:zxv4{UӒBAsȯ0NyT喭۷shT8R掉6ெ>*|AѼ7D:vp"Ig`3nG>i s:db;M+QeQ-z7 V˧xGJW4: nW ;'k{UF}֯_y.UK8:PW֤U|/p*ZݢCs?>xX(Oѭ$ I88KJG_ݡ8DT`+ڟ?jZoBb}?Z1:Wǿǟ?|GjOY <5kATӋW}_rxĕs:PWk9_!>0|7? Mz:\ҷϨXSiƿ0?>.,ߏ'._: ^| = }7~sMk̴~f|fyEG5ݺЮ(U 0~cP__{UF}֯_Yz2GG_Xk@խ:ߌ= Up|Dkl3M5=L"! \ۇ_GR'iPhVomea@B/!ތw0 : =M\&K赽Zqq ib4,-;[ܕZ-}^v*GU@\O^#~ꖺ Xc1́=ukW(?k?kN||>rLIq#ny+|ceN3zu깗X*}NNWʽҽHGMVgԵodn9cůF<D?WncϋK>#5{N?N *$ʵ¬Rtfmv[K_١iö65}H+AT?>^k(|M7~xXך?:Q֤eF@RNOҾ?nMjdqJhޤÌ+ȲO js~I^}Npxw3bE #Ov濞 {_K;kw-Ԟ_.5-Y$z7Q~+ |Qiq-پԃܕjn9'gÏo^%oF +V긒?Jx&VR?Od欒_n)ӧWݨJN4W?I?go!5M^7څc0` /L;Nr9v<JF r/}TðSR&I/+y?+ ^1qomեkJ .TԷWύΧ_: VO^#3*;9=MpUǟ|Gj ysg&~߆e)FQJKDg++JjSۋտ- /wҾƯ>~:g][AԗUsiIk8RW Ql\W953|L C#FjB:?@+>((((((((((((+/(gO➍724=)t{u/ⷄ&`X׆ElImHLD0Mքݤ^-LvUBu"MߢݞE?qQg񦀾/iMQ8梕 /ݵvMw~Eҥok5++@|sៅouR49<ۛ =e"~ռ-/ĺma,q\#z0P麪/i{;_.ku{w:(>~_T=_3[ ,2Wg\E**Ż+&컾+biRݕW}gU5~Tڕ孅{V(_Vf /◅X4t_;*oF8 ji%{kφF=i/>[kY4q  $ "FnhѦͰ8{JRt_z ))bp5?QVW2C7O,,Q߮UmPo3ck}ba}WTW)o* ׮Ozo3Z=j%ե +C+ OIק(ߺkB8LKqՌߖILТ+ (QEQE(*u<3WEŵq.іڊXw8vDJ)["߲_J]a<&Ol1J+a8ncJjp{4QEuVPK1Vv 4?S w":6gk^Ԟ/WFm/\; /hnnUEf)sE~}h_mі~"7D'HUH|:n8zQEI oX|wa}C3=|) «W_ $ /-k[?i=iZ/#{R\y HRy9WL߰m7Ÿfmc@LA ω-HQn( ǾXz09_)c7Ρ&kՕvõyho(ĝOFk}Pvbղ:4Oqtp5)F&9'^e.hu]K0Zt븤JU`K.Wo>Y&v_ ?|tnv~$eݼ:lzvgq %w(8澅~cM_:a_ uu(t; y@R2U#眐OeNJ8b0uDnK/2V~;sPTJǙ7+7ȯ_M~:(xKOI xX4GchIh1 0ϻR(%M~i!c?kk/~q͒\+05;sr#.L9^\:n{Gi $553Qq~QiM3(1LJg#ּ7 Z&'I'm)xAp9(qExtqY~'F3rEck`s<&L,R/5wEM G?< s+F*J Z>$_ׅ.SwҐ_cesT2I8_KǿCὗï|ּwhE ]Cs)FI;f?ߴ ~|q[9'uKB6N\~| Syw>"!bQ#Wۥ~~jEƏi\*Ѱpp;W>?U5qiʖҩqv'?K'luINWž%1٬3(sK1'O?ſ ,|cB/Ɲkpú!nNH,1sqz-88?d카ٻumq2+*iPW|qW[)So-<4/ h%U+ns)R}p>5' qxeRU* 4~wm?l'K c̠[l _NWQs (m}ie;m [dED w&gώBFc捨Yw[\]NuXw Q\ۃ0N?pV^ޡK;V{v %Cq+še/zi&,m}ƒ! 8[ȨUN)6i-^bFZiGDҵlϏ?i,?~:Mcr T_fx炿g>&j3bc7E"+"nPE|sG|0E5xMf;] 8 won  xZ]ǐu=u&v` .@]~_~Oj1ifo ʁ`,F W!|*Ծ#+P7VY|.1 e\)ujIi>jyCŞmdY|1X#VdFN1ҽvMZlaWvwzF*<} l|I8#_KKAӗ{co&j~+ vd'?},Bnv9 ۻ8OLq~Cn_v[~0ǓY[䌜kaןI٩5dG)BQɧk9?y2^lO|v}:{?>۩칈IHh''8S[ۑD.gu1\bJæw&mR[KGG$~\OM#Nl`3H#?}+jswo hvW_f›[Y>Y;Hd1Qe2Ƭ,8뮐u^C8„*3mOJOzU?S; v?e7ǚË ɯ[p6˳sI!RF98 ~з_e&) {-wt!bw`^\|3/?>#oOSȹK58Z1dLWpq)#C@׭QjvRy q 2ȊFAd~ i>Ck ^IxF S"jzQQ3\<:Q՛Jy5:ԯ&'s$ɢ;$M~P Q- D-4I94lKWW0ci s_ֿ3?igޗVZޏs>xS^ ]OhC-6R%¦$d,/l{ d:τuM?w59y2 1lJÆja'GS0Q/6/-S#h)Rp|kϩc_|A? u 3GnRtM別s$ٝT7|WRO ??xi+_vK=xgn8=޵(MjxwÝeMeu>'HKR61тK:V|;[N8*T䣢yϒ~lӊhc9}9eө's\kͯ$~%A=H~'H|*nM;Ki%V ,a% >J?$6_őH݋kkៅr|+>o<6jַ:|=Qw1) q]\?ѥf|*rNqoI7lq?b+,42h۩v4zVT)& 9xo6z8AjbOZ mڄ~rF၎ψ?GZk]%m>y-%럵ě g?ubg61[]}@p1_ӟ5ƽsGw'wj ڬx#jʧqSHّaX:SR%m/{?xgEֲ,+O17 `n6蚅? ZN!E99?Fq%Q$k|~9aI6~Š(c(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((? ( 1(EPF=QEQEQEsj(b(Q@=4~(E ( AEPQӦ( ~4t( z(袀:QEcQEQEQEQE~Q@Q@PPF3PޏQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@@!$@ @4(!DBw!b   QX,Z ZwP(x+ (w{{{{{{{{{{{{{{{{{{{{w{{{w{www{w{{{{{{{www{www{{{wwwww{{{{{{{{{w{{w{{wwsww{{{{{w{w{sws{{{{{wwwww{{{w{{{w{swwww{{{{{w{{{{{{{{{{w{w{w{w{{{{{{{w{wwww{{{w{www{{wK]Wcsww[[OKO[[wwwo_v:v::>O_k{w{{o_KB66v::B;ScoocK;KK~_wgOK>N~_kwkOSs{\_K:v6:v6>F]Wco{\_OK;O|c{w:w6:v66>]Scs{{{k~[B:v6:v6>Jo{g6*>o{oC KwoB kwB6"~_{{}_  X&Cgwwv2V.g{{wc>6"76Ws{o^OW&6">?2 :swKo{JV2s{sKW& "6G V*c{s[x. &7 >owK !k{{wv2 V2w{ws~S26W"Gg{{w6FskW.J{k6&o{cw.BwoF"x*K* Bw{O!x.[sw X[w{c*x*2>C^K>C:x& "]Ww{sw.  W&g{{{g> 7?S___SCW" 6o{sG y&C___WCw*  :kwC  s{wB w.s{{kw. y&:S_c[^Kw*  W"[{{w_ 6S___S: :o{wO  7?G__[G[cc[S66 5Go{wx. >w{{g7" Bw{{k.  o{{_x* Cwk: *^K[_[S:6   :ww\Wv2>^O[_cW_Gy" C[__ 8[w{sss{{{w{wwk  Ss{{{{{wo>  >o{: x"cs{{wv.  w.s{w[ W&_s{{wkC Bs{w2  Bw{cy& Fw{k2  4&o{cx* >s{w]O >o{{{wk=G  >s{{{{{{{{woc6 2owF [ww{{{gX"  6o{{o2 Y*Gw{{o: k{s> 8~W{{k6 Fw{sv. W&c{o>  Sw{{sO7 6ss\O 6~Ow{{sO  6kwC o{s> w*o{{G >o{{s[7 xWwsB^Kos{{{{wsg7  :o{sw.  W&osw.  2soW"  7"_w{o?  \Swwy. >swcX" >s{k.  "s{{_y* Csw2  6gw{g: :sw{{wo_:  :k{B owgX" 6k{wg. x"SK8 Bwo>  g{w> 7[{wk.Gwsw*  x&c{cV&  y&ow{s2  6_{wC X&c{{o6" 6swos.  w&s{wv. w.s{{_ ]Kow_& 6ws. >sgx& Bsk2 &s{cy* Bws6 W*o{{Wx  >swwgS:& V.~_s>  s{{g7 6o{wcW* w&[o^O Bw{o> cs{{{w{w{{{{wo: X"~Ww{{{wwkW. 7"~[{{sx*  Xcw{{{{{{w{{[6" 6o{s> 7\W{sC y*csx.  6o{wG gww?  W*s{wx. X_wsK X"_{kw{{k.  "o{_x* >ww2  &swwkx&:w{oOk{w?  swcX" :o{_W& w.csw^O Gwo> _COOOOO_OO^OS^OO_KK& 7~[w{woc~S6X 5&]S{{sx2 Z??O^OS~OS_OO~O~O]So{gw. 6o{wkx* 7"g{wB y&c{wX.  6osow2 w.s{{wW. .s{{_ Co{{{W8 2sw. W&g{_X" Bw{k2  "s{cx*  W&s{s6 V&o{gy*  >w{gw. w.F_kw{wC s{{g7  2o{w_V" x2k{s^S F{{o>   7~[{{{o]S:" "Ko{{{sW.  N{sos{{{{wo> >ssF y&_{ox.  6kwG 7cww{{w_y& v2sw=K :kw{{s^KX&~_{{wwssssoog_X >s{{{o. V&o{{sw.  .osx. ~Oo{{{wc2  [{s*  >kw{{o^O ;O{{{k.  "o{_x*Gsw{{w2  5&o{{ky*  >wwF .[oww{{{w?  kw{{cX"  :k{sW6 6sw^S7 K{o?   6"5&&V*4&5.4*U.5*U*5*U.5*V" 7_{{gB 6"w.Gcwwsx.  WV&5&5*4*U.4*U*4*U.3.\[{oB .[oww{wwo[6 :k{wC  x&c{{sw*  6owG  x&Wgs{wwsg6 \Sw{o: :[os{w{sg> Y"_{s\[_oowwwsooc; 6\Sw{{w{sk*  x*osww{{sw. x.s{{gV* :csw{w{skOy& s{B 8Ggswwwwww{{{w{s?  gswww{{g7 2gk~W 6o{w^S F{o:  cosossssssssog: 7}[{cV*  y&>Wgww{{sw* y"[goossssssww{o]OW" 5.>OOO:W. "Ko{sG x*c{ow2 :kwG  YV*:Fowk> 5v.B;O;SBw2" 8y"[{{k32!&v2BOOo{{{J>>:66 2::>>R{sV. V.o{{k: V.FO;SF:6&x*~Ws{wx.  8"w2BO;SB. Wwk.  o{{_x* {w2:BBu>{{s2 4*o{{kX. >wwg7& 6F;OKF:36R{w:WB>>:W" 26::BFs{cW 2_K >o{{]S7Gwo;  gw{{{{{s:8~[{o>  x&_s{{{{ox.  x&cw{wo}W6""6]Oo{wKU2gwU2>s{wOc]SU26[s{w_>4&w2O>?  X"_{s:Wu6!":}[s{w52  U:{wv6u:w{wc[>&W&:g{k.  5&o{{gV2[=O5.!%{{w>42sov6Bs{{oFx.FswB!  46k{c7 .?7 Co{w]SBwo:  k{s>8~W{{{s6  So{{{{{{{sw*  W"cs{{{{{{{sogW]O=KK=K^OWcoo{{{occck{{ocgck{{sgggcwsskc~S=K=G>K_O_ks{wsgW^K>K 7[{w=O  *_owwww{ssowsw. z"_swwswwwsww{{{ww{{{{{{{{{{{{{{{{{{{{{{{{ww{{{w{{w=O X"_{{{w{w{{{{wox* V&sw{{{{ws{{{{{{{{{{{{{{{{{{{{{w{{{wwssswws_*  W"gsswwwwww{w{{{{{{{{{{{{{{{{{{{{{{{w{sC gw{{{{g6"    ks> 7~W{k> w2>GKKB:V2*B{{sv. x*w2v6v66v6w6v2v6v6v:T>wwO W"[{sBU2sscU2v2v26v2v6w2w*  .v2v6v2w2v2w6v:v>[_{{O5&!w{g5* ~Sw{]W" OwsBo{B 5&}[{s~W6"T2osu2 %k{{;O  W&_wwog|_[_{k5.V.k{{\W !R{{ok\_[{{{\[]S^KO^K~S_w{{o~SO^O]Wk{{c^S^O~S\W{{g^OS^O~Wo{wk[>K>62.26>G~Wgw{w_]S^OO^KO^K~S^OO_KO_KO^O]W;Ww{w:O V._{{gU.W.gkBNs{{okkoo{{{{{w{{{{{{{{{{{{w{{{{w{{{{{{=)%J)J)J))%1FsZJ)J)J)))J)k-{o)%1ssRdZk)%c 5ssRcZk{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{)%1wRZo{kkggggcgckgggggkgggggkgkgcckggggcgggggggcgcgcgggggggcggggggggggggggggggggkggcgcgggggcggggggggggggkcgcgggcgcggkggggggggggcgggggggggcgggcggggkggggcggggkggcgcgcgggcgcgggggggggcgcccgcggggggggggkggcgcgcggggggggkggcgcggggw*)dc 1|ssRcd:k{c%               J)%5sRdcZowc                                                                 J{))dd1{osRdZkw[                             FwsN=========9========A===A==FRJA=A==RNsB======sNsZktRF5J-!!)%5BR^{{o1F====B^)%5sw^1F5J)!))51J^{{{oVB1J)!*)5BZ{os^1F9J)!!J-=sN9g{{VRJRJRJRJRJbssN====9R{VA==9=BZkwcsN91 %!K-51FVZkw{ZkRBk- %!k-=sNZk[o=A===sN{RJ====AsN{osN9K-!k-5cZkZB1)%J)9R9g=====1F{Z=====SN{9k9====BsZ=1!)%1=Z{o{cRJRJ1JRJRNg{Zk^RJ=l1J) *)k-=1JZ{o^RJRJRJRJRJsN9gRJRJRNRJRJRwsb1J=l1)%)%K-91FZZk{{9gtR=k1J) J)5RJc{oV9k-!!J)9RJZkB=====tR{{V===A=B9gsZ1J5J)!)%5=V9kwcRJ9l1)% K-=RZkRd{o9gsN=1 !1=Z[o9gB====1F9g{oV9J)!!)%5sN{wc1F9J)!)%11F^{V=====g[oRNRJRJRJRJRJ{_ Yx*w.2x..x.2w2x2w.2x.w.w**78*w..w..x..w.2x..w.2x.2w.x.*&   8*w**x.2x.y2x22w.2w...x.x*X&  X.x..w*2w2x2x..x..w.w2w2.*y 6&2>GO~W[ccggokkggc_[=SKB6W* Csk-dcd!J)c J)w{9ccB{|sV1c dc c dc )%^cRJ*)dc5[og1dd5Zw^9!cdc cdc c =^{ZkRJ)%c ccc 1RssJ)d9{:k*)k-sw9c c R{oRJ))dc dc sN{s1F!c!1JsZc5s)%c 1V*)c ddc1FsRN %c dc c A9gc J){oBJ){VddsRJ)c dc  RJ[ow=cc Bw^AJ)dc cc cJ-[ow9c{1Jc Zk9gB)%c ddddc csNdc =9ggJ)c Zd1sw5Z{9gA!c cc c c5Vww9c cdc={osNc9kZoFcdcc)%sRwRdVbk-dc k-{o^1c d c 1Z{5^Vddc {{[6gsswssswswssssk^G _GkssssssssssssssssocW""_oosssswssswssss[y* 6goosswwwssswwwsk_G8 7*?Sgoss{w{{{w{{{{{{{{wwsoc[=G67" Bw{k-dcJ)))RZwRJ %))k-k-k-)%!^1F)%%J)!J-k-k-)%dd19g{{SN)%!k-k-k-J))%c *)V{{c1!)%k-k-J-!dBs{oJ)dAw:kJ-d1s{9V{o9%J)K-k-J))%RJ{^!!J)k-k-J)!1B{w)%k-Bd)%J)1J)!1F9g)%d J-k-k-J))%=9w1FJ){Zcc RJ)d K-K-k-J) dd9k-1F{9g=dJ){{92J{oZk1J)J)k-k-J)!dZV %J-J)k-J)!2JVc!k-k-J-)%Z1ww9V^k-d%J-k-k-J)J)ctRs1F)%k-k-k-)) c VVd5!J)k-J-J) c!tRVR{VJ-k-J)!J)s{9I%J)-j))%dJ-%c cZ{c  x"gw{w[X"  :k{{{s  X"gs{{{{wg.  86_osw{{{{{wwk]W:W" Gsk-cc 51FB1FF1FB1FF1FB1F1F1FFF1F1FBsNJ)cJ){:kcc cJ)Zkc))c)%1F^s{w|s9gR9J)^dRJ))d=^{o{s9gF cV{c)%d!Fcs{ws^Bc k-9g{o=5VZkw{w:kRNJ)c VsJ)c9{ZkJ)ck-sw9dRtRc1sN:kw{{wZkcRJ5 RJZkJ)sN{o{{{{o^= c dc =wJ)c c 1bc9{o{{s{ow!RJZkw{wscFdc 5wBd)%Vc w=c cc J)sNZk{w{oRk-c FZ1dc J)=RJZgZkZkZoZk:k^ZRJB1!1w9c {RJdZkwRJc1VZow{{sZkZRN1^Zk)%BVZks{w{oRJ)%c c1Fsdc 9cw{{o9gZcc1sw9ddVZo1d5^{o{{{wgRJ!c ))VRk-1FZ{os{s9gAc RsRcck-R{ow{ZkRJ)c 9{RVZk!dd5c{{{oZk{=c c 9cs{{w9gsNK-dc^Zc w[ Bwk-!9gJ)J)^c V{sZk1FBbRJ)%dBwAcAw!c9kZdJ)w{=dB{oJ)c ZsJ)=w9kJ-1sw9dVs9cV=A{A{)%k1=d)%{oVk1{ 5wF*){Z{%^|sJ)d1FVc RN{{9RJ{os)% c{9g1)%Zk1FsZ1ww9Vw9csN:k %c9gwZ*)J-wVc!{oVJ){oVVsN{ow9gBcVw_ :sw Bwk- 9gJ)J){=)%cw5dRJ9g)%1FRJRJRJRNRJsN1JRJRJRJRJRJRJRJRJsN2JRNRJRJRJRJRJ9gbRJ)%l1w))cZk1ZVc =ccd1g))k1Zk{sJ-=w:kJ)d1w{9V^J)RJRNRJRJRJRJRJRJRJRJRJRJRJsNRJRJ2JRJRJRJRJSNRJR{oZkl1d1BRZcZk{oZo{oZk{sZk=w)%k-=d)){os9ddk-AsNZcZkZo{oZk[oZks5wFJ){Zc1FdRJc 1JJ):k{91J{oRd1RN2JRN2JRJRJRJRJRJRJRJRJsNRJsNRJRJRJRJRJSN1FRJR{{9gSNk-c !VRJcw^d1ww9VR=:kdck-{{c1FJ-ck-9gV9gRNd1FVVsN{oRd!=1FV^ZkZk{o[oZoZo{o1JccVw_   x.og.  6gw_7" Gsw]O 5cwwwocS=G2x*6W777x&2]Ocs{{o> Gwk-d!cJ)dddJ){sNsNc)%c ccg!ccccdddddc c 1F^ d1F*)dd1{s{))d9gJ)^Vd5^B[o))cJ-Zks*)={ZkJ)k-sw9ccR^ccddc dc dc c  b{Zk1dc dd=w)%!9d!Zk{c9cc9sBc {Vdd1FcVcc1FZc Vw9d{RJdZksNcccdcc dcc d)%{oc91Z{RJd{oZd1w{9cV{RJdBZkc ))s^1c cc 9csRcZoR c c BRddV{sRddZks1F!cc^Zd{w[ w*g{{{[6 _{wC 6Ww{s6 x*g{{o6" W&_oo]WGW*   6cw{k2 Bwk-!9gJ)J)9g)%5wRc )%s9g! !    dtR^1{)%k-Zk))cZk=V{RJc 1FZk)%^!d1{s|sJ)=w9kJ-1|s{9V^c)%9gwZFk-!d={{)%s=)%{owcRJ5!c 5wFZksN1F1FZ1J=J-s{9g1F{oRdd  ! d)%{ZkJ)l1RJcRJsZ1sw9VZd5^9{^%!9sN{oRZRJcBVVsNdZkZoR9)%!dccVw_  ^Oww: Cww[W"  >o{[ ^Oww=K  X*  _w{w_6 Gwk1dd!cJ)cJ){s9c dc!9gw99{{o5dcc%b{{{{{w{{{{{{{{{wBcc%c^ ccc!^))dZ:kdcVdk1{oZk!cc{ cw=d1FsJ)=wZk*)1555515555555555515551R9g cJ-w{{w{{{w{w{w{w{{Zk1dk-{{wZk9g^^VRRRR^^^d=wJ)d1F9%{ow{ocb^ZsRRRVZ^^d9sBA=dcdc )%w=BJ)d1F{w9d=wFc Zk^c5{{w{w{w{w{w{{{w{c)%d5ZkcJ-RN9kRJddd{oZdd1155551555555515151515dV9g)%cd!^J-cVRd1R:ksRcc 1{s1VRdV{sNdc cZkws9gc^ZRRsNRV^^=cZdd{{[ 6kw_ w*gwo6  W"_wsW*  2o{g >w{{sC Bwk- 9g*)J){tRsNc)%dRRB{s11b5w)%*)Zk5=k-B{{59Rc!|sR)%9g{sK-=w:kJ)VwBV^!RJssN{)%dd b=c)%{o 9{Bd9g{!{)%VZ1Fk-RJ{9!cs)%dcs19kZV=d)%cRJds^VFd1[o1JK-{os119gVdRRJ)sVRsNZo=d!ZkV{_  _woX*  }Ww{[cww]S7=Os{]S c{w>  "~_{wW Fwk-d!cJ-dc J)wgcJ)RJJ)cw5RJ{{=b^!c c 9{sJ)cc c)%9k{Bdc!ss9{{sk-c!s{=cd %c{RJccRsJ)d=wZkJ)c c ddddccdR9gJ)d)%Z{oJ-)%sBc ^s)%c %^9d!{osNR{Bd 9gRJd9^dZVddFJ)cd1F{w9d %c1Fcc9c c))Zk:kck-9cd^RJdc{oZcc dddddc cdcVs1K-9gwB^[ok-c%^sNcRZ!dRRVsNc9k{o)%d5|sZd{{[ >sw^O  >k{gBkoX*  W*k{{o      Bww_  X&Cgww[y*Bwk-!9gJ))%{)%|s{1d9ws55c^J)sN^ sNs)%1Fs^K-c g{o %cRJw{oRJJ)wwBc 9g{R!Z|sJ-Aw9kJ- %1FsNsNsNRNsNSNsNRNsNSNsNRNsNSNsNRNsNSNsNsNRJ)%Vc)%BwRZk=1VswBdc5{{)%9:k{=c)%{oR1R{o{1Fdk-{o1Fd9Zk{RJZksN9Zk{g5d1J9J)w{9c=Zk{F{s^!cRJw{sNdwRd5w1JcsZ%1FRNsNsNsNRNsNSNsNRNsNSNsNRNsNSNsNRNsNSNsN1F*)Vw5AZkwR!*)cBRJw{Vc1c{o5dFVcRR[oZk91F9g{^))cVV{_  g{k  x*_{wJ%[w>O W{wGSgow{{wW Bwk- 9gJ)cJ)Zk-sV9g{oAccd5[ob %c1Fc c ^)%R^k-*)sN{[o1F!d)%1J{swVk-9^{sK-=w:kJ)1s{9Vb1d1Fww9c c 1Fsw)%^V!5sRc w{RJ9{oFcJ)ZkAd19g{oAc=RN 1FJ)9g{9s=c19gZk-dc c )%SN{{1F c cRc9g^1ww9dVwsN)%cd =ZowBd{oR9g=c ={oVc RccdcZc!ddJ)VV{_  W&s{c 2k{{Wx*owF cw{{{{{{{{{{{{{gx*  V*F}[ks{www{{oC Gwk-d!cJ)dc J){{o!c d^1c c )%wwZ=))cc1sNZk^c !{oZkF)%c c ^J)c dcRZkRJJ-c c %9cw{^1Fk-dcdc1B9g{ZksN5!dc c )%=ZwsJ)d=wZkJ)ddk-sw9cRZoR5!d!9Vsw9gR5!dc c 1R{ow)%ddcwRk-d1sRc ddccdw{ZksN9)%c K-1FZk{Bd)%{sR5c c c %Bc{sR5c c k-RJ{o9g dF[ocZkw9d{oR1cc *)Bg{:kRN5c cJ)=^wsR5c c c Rcdcdcc cc 9gZd1sw5cV{9gsN1 c c J)=^w{oRJJ)c dbsNdsR9!dd5RsRcV9gc c dZsZBk-dcd)%5gwZd{{[W{{{o2  [ww> g{{{g  >ssG  X"C_s{{k~O Bwk-!9g{{{w{{{{{w{{w{{{{{{ZocRsN1FBSNRZcs{{{{{ww^RRJRJRJVZ{{{{{{{scVsNRJ1FsNR^9k{wwcZRsN1FRJRJVZ9gs{wZk^VsNRJ1FRJRZ^{o{|sJ-Aw9kJ-k-s{9V{w9gZRSN1F1JRJVZ9gs{{{ocVRRJ1J1FsRRZ9gs{{{{{w{w9gZRJ1F1FRZ9gw{w{w{w=c))c{{{{{{{ww{ocZRsN1FRJRJVV9gs{{{w{scVR1F1JSNVZ9gww9gZtRRJ1J1FRVc{og!1F^R{9{s^VsN2J1FsNR^9g{sgZVRJ1F1FsNV^Zk{{sgVRRN1FsNsNR^Zkw{{w{{{{{F{ow{{{{{w{Zdl1ww9dV{w:k^VsN1FRJRJRVg|s{{{obVsNRJ1FRJRZ^{oww{{ww{{wZkVVRJRJRJRVgs{w{{{{{{w{{sRJ9g{{{{w{{{{w9g^VsN1J1F2JRVbZkw{V{_  6owW  :s_x& G Gwk1dd!csJ)d=wZk*)dk-sw9dR5d!{oc B9g%dd)%Vww9ddRJc c {oZd1sw5ddVsN9gZdd{{[ [{{cx* 7c{{sG  6&o{wW ]Ks{o:  Ckww{so]OW* Bw1!g{sJ)d=w:kk-c1sw9V9)%{oc!c1Fs=%=^sscc{91JsZ1sw9VsNZkVc{_ :w{sC  ?swcW&  _{{kV*  x*sw~S7  GX" Gwk-!c|s{os{os{os{s*)d=wZkJ)dk-sw9cV9c !{ogdBc5c c )%92JV^g9gZk9g9g^Z1F9)%9w9RJ{oZ1sw5Vw{s{os{os{ow{Rc :kV{{[x&cw[8  g{{oC :ww]S 7]S{{{{{{{{{{k2  :k{{{{wwso~[FW* Bwk-9g9gsK-c c ={:kJ)cc l1w{9Vw^RJ9k-)%{oc!c 1F{s1F!cl1w9cwcsR=J)!wZ1ww9dcVw==wwgRN=k1{oVdc{_ s{\W"  ]S{s> W[{wo^S67 Gw99999=9{os))dd=w9gdc F{{w{w{w9c{R=9===9R{Vc{[ :koB*c{wkW"  6~Sw{k:  y&c{{wgw.  6o{w[6" Ws{c& Bw{9k^c^b^{ow9g^^^ccsZk^bc^cgwbcc^c^{_  W"_{{:[So{w: 2s{w]S ]Ow{wG 7_w{s6>s{B Gw{[ Gs{ss{w]SX&[{wg.  6k{{g6 Gsw~W  _{{w_   Bww_  x*g{_W& GssC ~W{s:  x&_{oW&  W&k{{kB6" W.:]Occ: Fw{w[_Sw{o6  w*c{{_W& >k{{[ Osw^O  .gw{wk_^K?2.X&W&W"y*.26C>KW_oswwwwk:Bww_  .o{s=K =Ow{w: cw{sx.  .o{{k  y*_w{{{w{wwwwwwwww{{{{{o: Gw{[[ww_7"  2kw~[ Kww~[  WssB  7Go{{s6Bw{{_  >o{k2  Wws.  w*ks"  6k{c *Wo{{o. Gww[ g{sG :o{{=O }S{{{G cw{o2  w*]Skw{wwkx& Bww_ >Kw{{w[  W"_{{oV&  .s{g"  CwwW  7:Skw{wg* K{w[ 7"ksw{w{{{{{{{{{{{{{wwg7"  ^Ko{w{{{{www{wwk=C  _w{{{{{{{{{{{wwg: 6gww{w{{{{w{w{{w[&  66K_oswww{{{{{{{wwwswgO7 F{w_  _CS[W[[_[[[[[[[_[[[[[[W6  XSW_[_[_[[W[[[WWK  2W_[[[_[[[[[[[[WS_?>?W[[[[_[[[[[[[[WS.   7x&:>GW_kosswsww{w{wwwwssosg_O=C2W& Fw{_                          5"w*266>>B>>66.x*V&6" Bwwc                          Gw{_             Bw{wc!                                 Jws;SK=G=G>K=G=G=G=G=G=G=G=G=G=G=G=G=G=G=G=G=G=G=G>G>G>G>G=G=G=K=G=G=G=KK>KK=K=G=K=G=G=G>G>C>G=G>K=K>K>G>G=G=G=G=G=G=K=G=K=G=G=C^G=G=K=G=K=K=K>K=GC=G=G=G=G>G>G>G=G=K=G>K=G=G=G=GG=G=GC=G=K=OG=K=G>K=G>K=G>KG^K>G>GGG=G>G=G=GG=G>G=G=GGG_KG>K=G>G=G>KK>K=G=KG^G=G>G=G>GGG>G>G>G>G>G=G>KG=K=K>K=G>K=G>G=G>K=G>K>G>G>G>G=G>G=G>G=G=K=G=KG>K=G=K=G>G=G=K=G=K>G>G>G>G=G=KτQ?>Gg_Q_fG@2ϻ<&Kqm;ht va8-哷88\WC8@? 2߲}l"׼y(ծ tm㱕:S9l e;&!,fua9V۾G<P"+w;^tMAPHm<=c8=+7V>'-sK}7,#OC>x#c!Cӄ$̵{?!`jbp9Z+뭬|%?>GgG?G|e4/o3"2I*Ht~j~)ў^=%w6 cFO_,7Zxh(v*q%Z ]G&3ݟmxo ]xER ڮt (U*pA{qf?? S=O7@aXe gq|`|cUbЬHPOrpl,gNYI췻N$x/6VfbҼC[?Zfmi:AcFҽwM?3o\9mĚ6]K2JnFq"eٶO@+W M[泸 .]b8AyuPpn'/1QUWvW`V%fg9;F.vOt>>τQ_B񎗠pGX1R;\ Oa_Ts -^䴸߈MS.m{ŸVǚ,zEtITA y/yDP"+i)ο-5m ـ\fINF}+G1(i8GT!:XɤUCYxH4 T1^եQ*$ qX?uTd[[?Be:>A<0S HJW?Z?o|/KY CQeFÐH,Ake7$*Wwzulc֦]bQms9YYiw#^/@>$U,I'r}װ}ʟ2+x<1] nw}L`~j~-~Gț#EX󸏠Ԛ^6 MIpHǝ!S+܏u%UOZsjäkn=T}09Weh>Mlێs,#>5VoVtOw?_,xůbڅųHSB&wmB{ٵ]$19 :rk?YUuo[x0I y{z!^/?wӿE|xtZ KKQEW'y;v#$2%ԅH Ͱ|/ Kk_-~4x[G_5ԃ_}%^8 a?{叔f@k e$͆ jȍ$6K$oVq"Y/O'%/ j6 Z;9dCtqU<09Ƞ?|?Qa_ |HCNeiu#U2.v =_m+_[U% ]6݌n$rW8B"[>z7+ "2*0dOO 5V?l4SMΓFX=?Uŏ'#'A?J}CM~Siw{% ݹkG20u !r j_Ə8/sxOƯ 4EݜW > S"ns_c& E8!񵷎10?nZn--1l 2/E>%_UfϽDB7`RPʤ^gI<5ƞ}/PZލrҮvHa80S+*/KOiֳ^ |;i(5;M|w|B?f۟ ԯO>I iͻ'OmĒ$O LHN2S"Qg?Xh:g컽7g ?GkO7>,q:|fV8%Rjy~Q_#*?x[i3ƏxvQ$#p'@.S7)oFA<7 ŝsTƭ⿰]Ikh Xct9)j/k;c\$բ( +)h.Ww嗑*L|Iks]Ph/x7_|-mhSK ɦFl! 2sO⿉WzOk s)Wžk"7_'% uo-73şK>_x_R}Bh^&pFy_?MߍkK7^/KZKt6kq)QրuN~ڷO7~'kZFͬyaA ~rzҕ&3aOGRO)7?O_BCmh֌Ϋ>sPKZ<߷G||$N(U6i,6{Xy嘯85;G5=n&W?f} M#<,\m#=7ߴ>&ε@2:4E\Ogm\CS6+?փoŷ"b|da3[Ԧņs$FtWF:,^8<-<|3?{eU&bw6h}=wOxgA{O ]uVH:0wuG?? ~_CwiŸ4.0 1,8+S y 'Qƒ^dkg$i"&I)tx N?Ƌk[iEFRako ߍjoNIeȼ?,:E}֢XDH*s}޴ꂊgHm75?|u:gkYխXȖ홣sG9XQEhQ/о 3O%Σ4Et ƀk%Ρp[_eᵊ e?gE~~G+.?|Ujןcm.x Ys̪mѿ#/N~7~!H,Ȱt2@ ǟ-  f>zlGꭢxÚ?ڴ)ʹlkd1e#Ho_grWm<7\vVp^4 O"k **K1h>DYop4%lW|r qH '4<|!Oо$Zu =ZzƌKF?xHm~e#-At ^Ѯ& ݊ށ4vf|E~?Q.?t Ef D[޸5(\LOt:mj.yoT1@O?vC ͮq4N%cb>Wҿ? |⯊ޱ}ke{ihBYV q؃_Z~?Lzi/[; S+ G`s_F/+GNJns%?Z t?( ªkt[KSӴkV(`E.P:j?u'!jG|1cm}?dHG&&%CV!$H*Ӿ7o`v pwz%5DUDQ`(h?eJĹ/ L|lt?f߇vڭKk82 Kn/ );c/F]6?J؟~^d6` nIfPH!R1@O+#OoO{"/7l2-"y ehFOi#Bivs7܂%$e8OYzk h]>6^t/ |7tW0Gvd,+Ύ ;5tKۻSܖW+mmhp+|+~F/oYů򘬵9,"5_/8XHk )_g E6sc}&@-#F28ea`ʠ=?Ӿ.MrJ :mfW*c1G* +۞zK4?mK!AiaT"@< @{Wa| '@,fY\nO`rO_S)ܞ=wž)]/Ǻ#񆸎tYʱr,DPlOO8 W `|A\|?Wlgg>-y&ϕۑ_E%-޸MT~Κ.M{q?N[ /,[j='o$42ȥIZQf|F妝g7<{B&=u0dς@x<RFG zcQ_?^O-ZOyOXKkøHH'qlz4Oۧ O~:O49N仁$8`/SΊe ~,xZ_Eխ]Դ8⹸'"M:3r-`H*P&_7ړ퍬Ay oxC29.chf[_5ľ^w_ 4(+V-ׂfkQ :HKRHe#A-,mh~Q_?P߇:5ί/殛id.H؞bMO@j.h>=𝾡{^Y%pdh" u9 x~iE"DtLOlCWe0iv]\HHK1W Oϋ5_0/Rx#=Cj`T:W?c(:emCIdO #\B"buI:¿kڇ |5}gS .p1g2JV2#'$gkB {|)e}{qrNyjPXnï(pXzgBtO%jk]J/ ZFK.FAz l~QG8Ο >'=#G¯> P-(XGڇ>\)f\9(%#[4WF|f&ܟC+VۏFXCFᏉU {jn,jʗe"U8=T?d'/~7ob|\'l/bpW (t?o__px/&N >~2ZDx=B7~_^CYq<0!GcU$b(?/MY"W}0\}KC;H~H;n;HIW>+g fSo[4.˔{ĿP7k+?$ h[uLF.3 y|wi*EcxsY%*sVzX>3^_­LR[]n;h'* #9ݯoAנc2j.‚zw5 |8I?i|L|g/W67ic%ڪmCl) 0 [qq];~j&Sk pb1+i:M=%&t5|N!xC뱝'MIAVqM#}N9=+ Mߴ4@õx<6FK܏/EnO8e9-Zv%v|]s:ͫjF^c<߿g>ٯ3E-exhZ" 2J1_/Q_F~?Tߋ߲~mhZׇ-:fWC=W^ ^+9T`攠z'~ϣ'{eV6 ƣOjջ> |#k4{△}:n&B2k8c߆qq qƥi O_B|}x*E52xq_aN(jNҳqJjvV?kqqքwJM?ɣO¹*zf:eϗ?kBV{V;Er1 ;tXPەUE?Ś=ƝZ}涺fU=U{rs:RKN5[.W_٧yMh9`jʜ]GėfH=+_+kM%Y&z+`=|_9,~2j3WWo2v6 NPvvɅi_cW?B0?+jL/? +珨 ( ( (?3Ew?5׮_S'5qx–k6K DM`= z?Zfh#\%6r[qvɆqAIXz'˿:EMa]A?57<l6p(sb6W_>צe]ˋl-[h\Ɓn xLN*8=q_< >jT>'ėW1%Ε M@]\ځG5~I{9hkǤ3x0,nI ;mW=i*߬>)W׈,-M^s Uс&'f~[.^g\D|qgNH.`P.IݛD 6#-_;e{ऺ_ r T-–X@v}x~Po0xM䷴:Dh2F8~σ$d{OΩrzi1O m-]cM K--4:EhUG/+~R6,P}S^W*swk4&?xp9+د?`?߷>(xB1w0΄:d\=Q!7~ .}yth{]udmKH28QDo'8V+k_=Ugx)"d$-n}'I7-51si@_/|N%Im[]XI+`9_|(gGS,hGF+뱱L(෶E(vj@o~GwA-x+˯cW3V38k;'Wz9/8^W1_?'8y@!S>>hڎe_p5}!cI+:*ux0p'_M!7 U_䵕_֢b{Y]U7c'5>=ϳas+2 EIځ;\;_ɭ tM";y)12Sʬzhxgj]Yc7vʗsT HU |O|ioϖ ]>fT/3as1_xoI="a5 @ܴ?:voh>"^ kk^ ڳtW$@?xHHo/_W𶣥xzr#e'7&>A$wW׀/O^&.l5 u=FC yWoO5lj>?n72@tuojO߶u&9Vg~?wÏOx'e4ZA$VDw&golP%c5vmO=<+\jWmn'@#R~\r;{񗍼gyCXUt.Z32<g׏_/7vxkblӭ"Uy$O'5>*nNQӯhnmbYa6ee`C;[i[t?it'$k+,rA +Xrkcb?bc?g~'_>ySdg;lFj4 ǿ g_ ;HP-&d_M+ } >?mX\Ⱦn+ʶFNdf'OA_ͯGh)ayogeuF%afIぐB 놋x+Ǿ3_F>mQf/HZdO?> %[Xɚ2iX%|wv'J;lv/KTI_Rq$;U]WLf(14E$g̟ 'Qxw⍗7?#OHf},@hQE|?&>$m?z_ucz~˾!ak~Hv8qb1ցO-ŏKƖ>)[(<,o^E1,29bσI~/cƫo%ßK׌Z׋n5,mmyl)_xev$+Z'ş?3^W_ k~ց; iG+XA8'*ÿT^fZtԷӢI_y.A"1؏D߆7g%}EM+; hK%K%4O>8PDlWӿ_K4˛ul9(N^9&7w;\5Hv7=>? /ex?M)|񍖣%xOD~mȟ0dR$Sӧ8''y?sկW%|xvyæ]`e\evhA~.dk+vnfװ@(w37|xo/?;:%Ger rF+%Eh| <15}D\^b"񪝂3 =W ~/[[:7\k}Ay,a`4qFb$l22OK_^ }*W{$ 7 #E_pWe[DE5ׄ.V´O!A9⿡ψO|-M6WkP #u䡗'8*zWT¼md_k.M #]2=;AbN1^Y/ ZakhŴWw1!E* =??T )`i <5sO?e -$ KI&yvH3~U7g\O'odLz$c? AA_9_x&Em_99e$v5 ?Xm6X\E!_A!X4|Cx+ <5ok⯎U|1%)h^c@8yȁFE{?׏(Sk-_Ɵ|kx E@$H9O|/OG48C$ķ3T HKցsh a翑$8hiTP&ϛo!O(_nO='Rߍc_\\PJ@ 72ov<[~>JCGE3=EE=_S?C s/'⯉-|-<]v|-n#HDhШ1c^u7_ŭ~EN\Ssul,c)~g_K9lw]M?=Rj1Xm$$|91&2w|/}5}k^9kkFb`FͽfE&_' :G`25^|[~?o>YjS#b!*A K7o3&~-дhywZ~l󯺰##"RyV9?XMohDKf]Ύ>#|h-%Bݛ!5k 8o L g1bx~P24af cf1ڼIB:Si_Lq:eӽ`~Zß)|+tn^T 6诡 (beߌ)b xz5 <hV@ ֿ=f5[akV]<u(;KnObfKm- 0ā#p8^. 1x]FP*][ũr;㗄h߆ZWi!mui(uqz8 A mkVqj>XX_ZɝK9+ǭ~jm~xX}Yiwfk 94fE%R~b=;i!4  ? .k]> wq MBWr{2z???~"x|Sݵzf-܁;+g_BoRX߷W-OA[P~x4= G(`0Dmkzagm3,i̪X5a_v>&m $2CJVb kSt^Y8&phGߵۿtXIԌIRXAOCG*sA?Կ|>jԯ-d0J$ #_S + =Vp$_J z~vuzm-'vQE~/m}~Wg>'~v:zxv4{UӒBAsȯ0NyT喭۷shT8R掉6ெ>*|AѼ7D:vp"Ig`3nG>i s:db;M+QeQ-z7 V˧xGJW4: nW ;'k{UF}֯_y.UK8:PW֤U|/p*ZݢCs?>xX(Oѭ$ I88KJG_ݡ8DT`+ڟ?jZoBb}?Z1:Wǿǟ?|GjOY <5kATӋW}_rxĕs:PWk9_!>0|7? Mz:\ҷϨXSiƿ0?>.,ߏ'._: ^| = }7~sMk̴~f|fyEG5ݺЮ(U 0~cP__{UF}֯_Yz2GG_Xk@խ:ߌ= Up|Dkl3M5=L"! \ۇ_GR'iPhVomea@B/!ތw0 : =M\&K赽Zqq ib4,-;[ܕZ-}^v*GU@\O^#~ꖺ Xc1́=ukW(?k?kN||>rLIq#ny+|ceN3zu깗X*}NNWʽҽHGMVgԵodn9cůF<D?WncϋK>#5{N?N *$ʵ¬Rtfmv[K_١iö65}H+AT?>^k(|M7~xXך?:Q֤eF@RNOҾ?nMjdqJhޤÌ+ȲO js~I^}Npxw3bE #Ov濞 {_K;kw-Ԟ_.5-Y$z7Q~+ |Qiq-پԃܕjn9'gÏo^%oF +V긒?Jx&VR?Od欒_n)ӧWݨJN4W?I?go!5M^7څc0` /L;Nr9v<JF r/}TðSR&I/+y?+ ^1qomեkJ .TԷWύΧ_: VO^#3*;9=MpUǟ|Gj ysg&~߆e)FQJKDg++JjSۋտ- /wҾƯ>~:g][AԗUsiIk8RW Ql\W953|L C#FjB:?@+>((((((((((((+/(gO➍724=)t{u/ⷄ&`X׆ElImHLD0Mքݤ^-LvUBu"MߢݞE?qQg񦀾/iMQ8梕 /ݵvMw~Eҥok5++@|sៅouR49<ۛ =e"~ռ-/ĺma,q\#z0P麪/i{;_.ku{w:(>~_T=_3[ ,2Wg\E**Ż+&컾+biRݕW}gU5~Tڕ孅{V(_Vf /◅X4t_;*oF8 ji%{kφF=i/>[kY4q  $ "FnhѦͰ8{JRt_z ))bp5?QVW2C7O,,Q߮UmPo3ck}ba}WTW)o* ׮Ozo3Z=j%ե +C+ OIק(ߺkB8LKqՌߖILТ+ (QEQE(*u<3WEŵq.іڊXw8vDJ)["߲_J]a<&Ol1J+a8ncJjp{4QEuVPK1Vv 4?S w":6gk^Ԟ/WFm/\; /hnnUEf)sE~}h_mі~"7D'HUH|:n8zQEI oX|wa}C3=|) «W_ $ /-k[?i=iZ/#{R\y HRy9WL߰m7Ÿfmc@LA ω-HQn( ǾXz09_)c7Ρ&kՕvõyho(ĝOFk}Pvbղ:4Oqtp5)F&9'^e.hu]K0Zt븤JU`K.Wo>Y&v_ ?|tnv~$eݼ:lzvgq %w(8澅~cM_:a_ uu(t; y@R2U#眐OeNJ8b0uDnK/2V~;sPTJǙ7+7ȯ_M~:(xKOI xX4GchIh1 0ϻR(%M~i!c?kk/~q͒\+05;sr#.L9^\:n{Gi $553Qq~QiM3(1LJg#ּ7 Z&'I'm)xAp9(qExtqY~'F3rEck`s<&L,R/5wEM G?< s+F*J Z>$_ׅ.SwҐ_cesT2I8_KǿCὗï|ּwhE ]Cs)FI;f?ߴ ~|q[9'uKB6N\~| Syw>"!bQ#Wۥ~~jEƏi\*Ѱpp;W>?U5qiʖҩqv'?K'luINWž%1٬3(sK1'O?ſ ,|cB/Ɲkpú!nNH,1sqz-88?d카ٻumq2+*iPW|qW[)So-<4/ h%U+ns)R}p>5' qxeRU* 4~wm?l'K c̠[l _NWQs (m}ie;m [dED w&gώBFc捨Yw[\]NuXw Q\ۃ0N?pV^ޡK;V{v %Cq+še/zi&,m}ƒ! 8[ȨUN)6i-^bFZiGDҵlϏ?i,?~:Mcr T_fx炿g>&j3bc7E"+"nPE|sG|0E5xMf;] 8 won  xZ]ǐu=u&v` .@]~_~Oj1ifo ʁ`,F W!|*Ծ#+P7VY|.1 e\)ujIi>jyCŞmdY|1X#VdFN1ҽvMZlaWvwzF*<} l|I8#_KKAӗ{co&j~+ vd'?},Bnv9 ۻ8OLq~Cn_v[~0ǓY[䌜kaןI٩5dG)BQɧk9?y2^lO|v}:{?>۩칈IHh''8S[ۑD.gu1\bJæw&mR[KGG$~\OM#Nl`3H#?}+jswo hvW_f›[Y>Y;Hd1Qe2Ƭ,8뮐u^C8„*3mOJOzU?S; v?e7ǚË ɯ[p6˳sI!RF98 ~з_e&) {-wt!bw`^\|3/?>#oOSȹK58Z1dLWpq)#C@׭QjvRy q 2ȊFAd~ i>Ck ^IxF S"jzQQ3\<:Q՛Jy5:ԯ&'s$ɢ;$M~P Q- D-4I94lKWW0ci s_ֿ3?igޗVZޏs>xS^ ]OhC-6R%¦$d,/l{ d:τuM?w59y2 1lJÆja'GS0Q/6/-S#h)Rp|kϩc_|A? u 3GnRtM別s$ٝT7|WRO ??xi+_vK=xgn8=޵(MjxwÝeMeu>'HKR61тK:V|;[N8*T䣢yϒ~lӊhc9}9eө's\kͯ$~%A=H~'H|*nM;Ki%V ,a% >J?$6_őH݋kkៅr|+>o<6jַ:|=Qw1) q]\?ѥf|*rNqoI7lq?b+,42h۩v4zVT)& 9xo6z8AjbOZ mڄ~rF၎ψ?GZk]%m>y-%럵ě g?ubg61[]}@p1_ӟ5ƽsGw'wj ڬx#jʧqSHّaX:SR%m/{?xgEֲ,+O17 `n6蚅? ZN!E99?Fq%Q$k|~9aI6~Š(c(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((? ( 1(EPF=QEQEQEsj(b(Q@=4~(E ( AEPQӦ( ~4t( z(袀:QEcQEQEQEQE~Q@Q@PPF3PޏQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@hx  Slide 1jchau Coburn Jane25Microsoft Office PowerPoint@P68@ @@_0@<{Y ՜.+,0    dOn-screen Show (4:3)RLBUHTGPowerPoint Document( g)DocumentSummaryInformation8 1Table 'SummaryInformation('  x(L `/ 0DTahoma"DArial@ .  @n?" dd@  @@`` "  <dI     ,R$n)QQL^$| 0e0e    3 @ 5% 8c8c     ?1 d0u0@Ty2 NP'p<'pA)BCD|E||s " 0e@        @ABC DEFGHIJK5%LMNOPQRSTUWYZ[ \]^_ `abN 5%  N 5%  N    5%    !"?N@ABC DEFGHIJK5%LMNOPQRSTUWYZ[ \]^_ `abp3ff̙@Hʚ;ʚ;<4dddd cTcg4ededB,ppp@ i)___PPT12 %0___PPT10 pp?  O  /(PK!V[Content_Types].xml (|N0H+8 (8ĪVEBpֻ3iVwbl VLly Ё9!u{yL IuF^k2#z cẽN`0[mb` \!#s,Hё9}~TU 6Ul¼;{-dۡx/ ftΓCR}o v|i@T;\/E_PK! K& _rels/.rels ( 0nS=H^DtiUۛc a)hěBUrdk)Dd gIDr*dS("QlT3Q4b̜'օ9I]e3\0ťQ.D=vtr5aƓI+D#V0;f[e!/PK!tableStyles.xml I0@Ὁwh}-CQ$ +w*!@he/?JXd45ݤ{c@qqi` yߥ>\`Y{ff` R>&- {p_/̴>?" dd@,|?" dd@   " @ ` n?" dd@   @@``@n?" dd@  @@``PR    @ ` ` p>>#PK![Content_Types].xml|N0H+r@%r(0r&7yܪ}{&i*T8f;L6VT-{V~n^{)@ŀ< uw}l IvVNLTL3pG|ﴉ`(UoȮy=J2:88Z )9kR /Ju"(\fhnX soiɶGgϤqsJ8 `ֳ'*e$ ީ3/zPK!*8 _rels/.rels 0DnzЃXmlo0of5OIw AN{cݠv=m 838yG 6U} ShLq`L)d=Ҍ\@.;3, ;$e͂): vq}j:zɥ'k茜(f,ƁXA6\m>PK! 9d~A!!drs/slideMasters/slideMaster1.xmlMn@z4`le%j` qWCoktף$?`U;ax)[O$#!pB$ʖ YqHg`8~5'o0b |b,Z,GDM!ҕ:Ŷ&,͢'C.Iζmf)bb5|cp6|N-WS)(! :P]!`!Y?r*G(6W[OPMdϦAEϴ.QN} =2,p>N^^"&G1ě~a.{  ꆈ4ḒWɰK[/h15 |$gp#2 N||$gxS#>#'Fˡ/!P{$y]‘ d@$$q3hH ȸ@$pD$a4e7'l0KX Y AoH!/k"I.(W O_r ӥʅEsT_Kgb_&$$~H ww+u袚x[Pvݠ-vG Cq508epL0k"SFߏC0З/#WoX;t۴V_j^A0jKt O2Ft"bRl=wVwRD.nEmu{6,*p먝ѬBViux@TV܏˨|So 0:˧A|.P:J5:uRزTf_ljP)I7xh+;iR>~PK-![Content_Types].xmlPK-!*8 ,_rels/.relsPK-! 9d~A!!drs/slideMasters/slideMaster1.xmlPK )"!"!(    f@??Rectangle 2 ` c 0   `??Rectangle 3< ` c 0 X   `??Rectangle 4"  PK![Content_Types].xmlJ0*miG]`Hm6 Xwt?. g#Wi3E).+7 >ON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!  drs/shapexml.xmlVn6}/ Zh-,|Mp#N4Ej(R(I )ǎhCL9s9Ï$;a\FBJ:cBXJ*TʤV"Ϣn~c9JjT&tkm9j*>R(˴)G*Alð*X Ru2w!y X6X  1m5f 0?U _D[L"8SOp[ _ù-URRn}.ej!V/ɌCBg?11)|j!ltLq-q9vmN,~ b-KS[EQB deee1#8FqZ7'@T.vY$.im5 |q7p6 ƋiQ;̦Y7f!G86NeyytYjH@@S+R^agD_^??/`hݭ6/ QY3#(La =8;US -cׄ4˩'h].պh\PT_)}@N: .V> DVvma^k'#q6JEv#5u$\P.*P޿"Bl\x~%3KXܻ~s U.E6k "-c`K51O.ϙVvc*,$l'xKʪVtK=J֫j**b"KtO)3fwS?\mr4^(:-}`S+fS]p9Bb"ޤNCVj' nEɓ0xu bQ_#]6{+ukx7_EŢ^&V5f2P^]liSt}9:ꟓěPK!A.drs/downrev.xmlDMK1@!El UMK=Zhf7%IA̛-תx6p7@6\}nAńlLa1an}:mSD1GuJ]u,jrG#V0*m"wgD;lX.SM ,_fݿB?Va9hHG?)_՛l, DI@PK-![Content_Types].xmlPK-!1_a ._rels/.relsPK-!  )drs/shapexml.xmlPK-!A.drs/downrev.xmlPK^ `R c:2___PPT9  X E     ``??Rectangle 5"%  PK![Content_Types].xmlJ0*miG]`Hm6 Xwt?. g#Wi3E).+7 >ON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!W+ drs/shapexml.xmlVn6}/ Zh-E* _n)%*VC*EN{gHwwy(sr?KA\ׅ >pO q ) J~ը|,QЍ1ըө /YAU\^t ,SҼ0~SB0%^m5)2cJ$+Oj n,U\KqHuIgNcnYVk8c;*SRׄ0m8,ln'5&ݯ*YcD.vT* aϷ.;ORks^4P HvY l2OSOo4;o=U@O[/ZD=/CI8-ޢZ~Tdиc}EС?06Bvʆg@ z]/}o2\L4t2) CB5nv$+8" 2px O0bR$IlV黠8)lIhtYZhHW8UDe/{{Ѐ p7JR G)HqE@. >YȦ*h)XM9S+hUV,JQ >?3]jѵ 4tm\Јʼ2$V8NǷpHAi*Rz´u[X9@J6 gK96鹒fldj!n'x)k}#S8^`! JS(682 Ƅ痺QߟvǹsgzN[Z7ף\[Ì83= MY`XrN*bK8&[.&ZYgNk>)fV$NEK mR9蝛Zvo52f)H58.[e.37Jb#.~؇}Ig5:%ЛPK!ːdrs/downrev.xmlDOk1G~0^fkA(RjB=N7cvf$~8xYgkq$* 銍7"1)8Qjv-o踍F$ 16(b軆8c:c䶖,Jz.ZW?ܭΛ~QJt'xynGX]lv` PK-![Content_Types].xmlPK-!1_a ._rels/.relsPK-!W+ )drs/shapexml.xmlPK-!ː drs/downrev.xmlPK^R  c:2___PPT9  {JC / KM Review date 09/07  E     `.n??Rectangle 6"k e PK![Content_Types].xmlJ0*miG]`Hm6 Xwt?. g#Wi3E).+7 >ON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!2drs/shapexml.xmlVKo6t-dI~`-[n`)LKT"U,wI76qsIq8oOY[*R>Ey&w3F&8G؟~c=nj .f\Fz5نV j" WKP*]7UUnKi9N*xf`=Vd:1s =4-ؒK̰ă7EDJP7irm7zʆ7mz["6@v6W@ p*!}!KQaM=۝Cr(܈Э6K,~8KR ^{2^B})f!Hq*SʍNv0 |neZ"D kz4Oɶv@ im:  V7A8a#O'%#<D9ZT5Q 3D,Hw/D*~#w 5W 5j^k TS7pkPƀ5f3ˏ:+-O]-6nzCiBY k"9^xלWWV']H43t^7ɻ{=> zFPK!#drs/downrev.xmlDJ@@Ba؍nK-Z1;MBawmҿwǙ7MfkԑB=f ok. l?WwbBx&'0&[񚎛T*p@Rkơo}pd ;Fd٭vX|NJ?yt޶\~>Θ~~*QuxUVZ_N_kH@PK-![Content_Types].xmlPK-!1_a ._rels/.relsPK-!2)drs/shapexml.xmlPK-!#Udrs/downrev.xmlPKZ^ `R c:2___PPT9  p*  E  <  c $ ? 33i)___PPT12 $0___PPT10.`aPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V.`mp"-{\<{;IZ~4׋O۷onٝ (!]B/A''#ҹtKS8p =">mրgl|Q"^Y}Q(whBOD"/? ÃHVU nvĢtٲ߫:B|S6/5XoO,ˋ}Xv:UO*O3:*/KkMU&{CnCn]3VWoy߰cr݈׍$mڸ)ȵ 4R-t {MBndnf^ɹzVlLblG9Zwdh0IL_cM)5)+%ʝ;;Z/fÖ{#$m6:rQvpWvMNj5ZJjs Ǣ샳(sݳ'l7W`֛݁rkXC OۚI0z3 9?8vuFpӠ % K[7pa`  GUjm_ٽ+\io~-}T<˼i:y|Su6}:gȔp7V6L[D2''Sxw=lON{Q:Jߌ`}]AC5zF^jxbK@dXĿNC~P}ߪA-ـUCC'8InLnQj2X_$:H9~LN%-$Ț=+j1Daj% R =j;(Zthvp{_kPD@amENqUoj}bc0iB2_IMSV'*d o #-;4:N oz~N@"kob(lLj_.I$-rI\/fK,eJ ' ѡ:Qu:m̦{3ԊM?4gaFS0w|ʘFv頷ӺjUCZmot-mm#KDfOtM39h,9cIrG8gɃƒqdQ A29 7 ?ƃ9e; ~$hӿwl(t:a&?Q͔8tకvS瞈f%u>lඥ&jؠ#yKhTfMWSR Q zΐzD|8 .˳B1 IFu#[t -RQ4x%mW"{ZD枺]1>SG>w< 'rPC3P^9D>(fMhƙ8`?@Y ӰA†~j PsZ(O42f̓/"Mp6QMn<3\]b_lgdiP]7?s~Fq3S 7I]p:^v k 7m]7(X(x=_1lo&1vF.67pEq+ d~noA+ϵN+nqE/{ô<͞XDx+҉xㆳ`&S3p&v2QK_>3_7!&Pq?o\Ӷ'j5o0iܸ!cI=BlҿPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!81 Dtheme/theme/theme1.xmlPK-! ѐ'theme/theme/_rels/themeManager.xml.relsPK]: PK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!E9!drs/slideLayouts/slideLayout1.xmlUn!}@'vV&m;},΢lS'n՗̙sf`zj\1IU ?O&YGdIlOS]XQޒzu0- W",XMLZ85YiOEQV.qoSUךIA A&4Mf&xb܊;r(؛vzxХ($5,|SN@ch6.Y2y Ah- ڍ,J0sB"fm0Op"$h\oz8`Ko2uc9T;Rz[E_, <:}P}>Py=0RrQ+ TwFaiꏇd~~6Q>q Hօ\ro7 3⋏º H%vWV;7 +Cw:fP h!,Đߑo.!2 %xf࣎PV)QB*} +I=qM]_B!ш(;lCG :*8k>~Uq}G3_ոsc :GXx3sGC**,iccv PK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!E9!drs/slideLayouts/slideLayout1.xmlPKPK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!Uzq!drs/slideLayouts/slideLayout1.xmlUn0?'ʣ( vM.y#"Ij}4 Ejw83KM.֝fAY3'I#lӔ?.>q"5r72wWƾD j6FWWU([' (?UtuvrH>}jlK'M, ^jZˆAs^췔A-5g9X93H 0C*j``%H\KL}ξ瞩& (> a oO#f [O9IW$Q LE*ڇ#7+s6)nUPBρ I~',iNe1;ĕُ1>lV\_f=/RC\čЦ~Må9z\ûx%aJ+̢eQQҳL ܉()M3'O_E̼ =2cFF)6$dku*g 8ZO&8^aJs%f!c(n(ӽHMU.q,XHa1ZR+rU~~]۽8^v9x@l͝>+w0'PK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!Uzq!drs/slideLayouts/slideLayout1.xmlPKPK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!NL!drs/slideLayouts/slideLayout1.xmlXMs6wk'ok"gbI;8H!X @_߷(Q_dX<`o-l/K5*)\ͣoo3Ry(LU3#,wCG[kYg(y[VBa.+u-^]/؅/.ƽ* ),k Brm^:ƭ>Vʓ!bL1GW?4 {8qSy=;ڝun`+oʱtQ&~޽v__m%`']eϢ2NC 2h< n xjfeH!/nd[Zgؕ}gdnd3[2} \8[*]rPGO} k]>i<R8DP,Ed`tkœGqܟLF`D \#jE)S4;Ẹx8}[2MxM{F튛RP3Fl7|#EB 6v} 5<ݖ-3hm[L /qz6UIdB[!n!^)<8$ <S(}G oŃILR* %ZSԠ %@4J'CwsgL(p']r'/[K!6]emK9:@5߬Pki_k}Vf\pCe]jh|;IR.ۦJe{N%iղs[Ҕh,>d]ܖ]n^\:ovGr|9f_LjYn%,"/ʿrZ2N=砃DeG eMߣR=E^h'v, aROwJQ9nn2smtSʏ!݈)eҠb^~Ҷ2:* QLxv

ЧgU|eT`P'(xR~w!p<(xvlD]&OP!Br,jVaAcwd-v0ły)S¢T [n2a1uBZm?jY=h~YUK ?Zdcn-yHܞ>bgX,&ϫI 69`Pj<ѝsg)rl+5S%$##X~CT-kSg!a4Amp&0:I0N?Eǣab{W{HWIVPMemf/f˭a$QBWfJ&ܰ6B37-,#vcϰB\s2 1q2|cA<2#bE^YyuE?A4( Dh>J*ѕuC }ZT)?t@PvxڭigagTm_:KXvz \6s= f͞"M-UN|#m^K*eRlAo{ U!`_>iLƇT盳sTBf+JuWl@^.e0  (ȸx@l"P#ɱK[$dt >G-o +W\#~ǥfiNL$,:䭥r3ߑhdwt*w':%:hJR#=nF){ ߉f;IhzGdr;q4yY>na{ݽ"`(mIꏼ-W(vKs@!D^PK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!a !drs/slideLayouts/slideLayout1.xmlPKHpuPK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!aBp!drs/slideLayouts/slideLayout1.xmlRN0#-&x^VjqvClk=x\uFVahb6LYs{,D%hgU{X,zw"Z3略ʡH[܋ዼ0X>F'Fx4A!Rn|9nU R=`?9K4l X˭.C]b `;Tjl~7oYSQx0 O *42z&+ S]d_T\Y?`RXTS_[9*O3_1PK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!aBp!drs/slideLayouts/slideLayout1.xmlPK`PK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!lі!drs/slideLayouts/slideLayout1.xmlSn0?'s( Rm.Ill%" rJ%%%iC.|,g;z1R/WRծn_,r(ϟ6^ESI0 JyUQ7At-\xE7swZV#tj5~sCKI@Ǧqaa#KѳZjΚQ =ײb`ja1D1lCNxAu"e1̰ EOya5BWm@b(%?٘FN =kT7wX. ^.M&E˹ZL>_TMP;u&,n\=&xAP&ҁF.H}} pQ5~-{A._vqfJ||{7sKLi^&-`=]÷ns_z$UPK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!lі!drs/slideLayouts/slideLayout1.xmlPK2PPK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!mv!drs/slideLayouts/slideLayout1.xmlX]F}xOl>l0Z;R&/UY/4akˌ^;bIV_l g|D9ce,|_ןޅU+V&,%{^rSEuܲxVpuvTFuEKx` ~ʧQ" pe>f7?T 9S`fUmت>l5cԾoՋX/O"m^*Opc)ɬ%=1VՃwie H?0Y .F'˟ vY,nXѰvsOX"SV܌ۻqzA K!Ukw\:S9W [R~^|5d3WCT8b sG1MaQ^[掶"?unicP9廯+hB-sΠubg7K 'Zqi) oɊ 'J^&L20eQo?"r>C>rT X"%IܠbXd象fO'*/D@Zc=7;A.T&4uۋtMz-ɂ>N4߲:^P%qKN: CiKN[Z PZҴA6=RȥiÖ9LlK:IC)C.RnOK9Eop(8$pAY|bKQ*#!#.d)7Z„+Nrvr? &ߑ1o6q9GHzSPvpiĤdFk5}bUXXӡXvXKئAXt j#0MKƒEX9LS_~f?{+',Ux,;?u:][NgdpQkf:CI;QiqS2v\/jNwuVy:m8Mh4.ktrVʮƜ$fvLxN뼆GhͿ5p'tL/ 0L-VGm!aPK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!mv!drs/slideLayouts/slideLayout1.xmlPK@OPK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!o !drs/slideLayouts/slideLayout1.xmlWMS0wA;$x0CZ@4[.䑄I$[@Bh)Ė>>ٲbJRq&~/цr)(X1~]GC!tLGAfLN2VP},K&0>L}wvÂ"h>rM&&QSuڳi8u̪DI é #`ГOOL0qS+,HTS,~TSE24AL40*Ca~h\b<1 Q [_ј- Ie4n`tϋb:}8pFZQP +ڞ]?kR_h/5-o*!%qJ| /?PK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!o !drs/slideLayouts/slideLayout1.xmlPKp0gPK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!I84 !drs/slideLayouts/slideLayout1.xml[o0';XyoI%4*TjuiuL82ا8I09s?jU)ƖDy1E]m<8G: j-'Zje[Uu|-k^ϊ=l^;4o`WWRGA_祐jQIZ;oec;Zs 1]rZ)~J^D %hLL 3)8#AiS<)IN/oM3kWzX>V Q/<bOo竹LdiO>Ay)u '6,# ]>!TnGzIq!0'ue?ؠ9!ҋx9d!qvȎiזy!*n#{&X mC,)V 3!G. . ʱ. 7~qid (81q(8t O%`6_-heHىE!Dxf y/+~Wٽe8\84q}+jAѭ1_PK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!I84 !drs/slideLayouts/slideLayout1.xmlPK PK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!WfV!drs/slideLayouts/slideLayout1.xmlo '@Ni$}hI+ĬP/w`[&^/w;QE3>>qZJ?Ͼp 8{rԖ^U7/%x-‹Ƣq mQ9Iڍ*&yN7ՈuD*Y͞fzIC {Kٚ%#t男Xihha-BFt@J۵Cqve.ݷKduz^Yj27mVrq| %`HNP.0-UQ?#E>"8J]F3t8Ƈ:S [#=ӆw6ŜYG>D]xd{OL2>&Dϴa  J+qE݄BBÎaXt,CINN%8V* %LACwdMl@`mTEAL*u_6)2@ Tplؿ#LS!P Cߨ u-ԯ͋ */7GO2Sw>zԱ݁}hSе@_"-YE4}5bPK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!WfV!drs/slideLayouts/slideLayout1.xmlPK!PK!M[Content_Types].xml|N0 EHC-jaj; +,Kq:=ig ,?ϵYD&oDzCwO-gkcg$./XQ{jsԈHt䒦AFP0skfx(壓8?.C(ũ{R(Mb˳7{-IF#{_R'dK0FFjr'"&@_'PK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!!drs/slideLayouts/slideLayout1.xmln0/RdC<#Ѷ"Hڵ߾3\,M@ŖP][NvL(=O"DՍXϣ_gEDl.߿dy}K`]y1Fq k>$lթUV7[gI2[ڈwUS]m0֯7ԁ&?CiK2 ՚pv0F Z3F%ojfi Qr)͸=*HQ0{+ .ׁDJ-AG!loH~<|[m~~ `Ij*,HUP ]N,ߕW kFzePJR5(ƴS$KG8%lN:ΓEVв4>o]%fiYAZ;%tLk9QMFLGXrGa{4"g{$#U|se% r¥.K3C` ;]󆥣cPK-!M[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!!drs/slideLayouts/slideLayout1.xmlPKB Default DesignQIZ C6;6 5(   ^   `??Rectangle 2" PK![Content_Types].xmlJ0*miG]`Hm6 Xwt?. g#Wi3E).+7 >ON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!mQ drs/shapexml.xmlVn6}/Z(l"ci70LKT"U%v7)9gfCɜu!x7PONO  Ϸ?וüW+U;:iIQQLȒ(LS\JS0wj-(߭SuI[hunfOsBǗT=qNI;,mt"甤{;ƿj_Q/S ^cHEe{3hwi d|dy- mGds]Eq2$؍Ac)ZAϸio;+Y;*цbW"t٭jI<_bY0v-lk͜2n2ך?F2~!,bȏ(`|M,aޛf ER~Izh"IDAB e c+RmNdΘtv!5ok[OLV Eߡ ?Fr0z2{y~MF|ժrP~o[+ȸ,P+ϖVOM(R0;`B{u&&˾? {#o8h9&`0.]|&gOq2LH'MC]L$eh:=$ (R|%UslCN-{/hj9 t[Sh ]ps!_]g/ zEEDABXay\M9(PGxÙLk(+V|S%zƢEȪW°k6YpeiFX6JJ d<ohKƚ3a$')*D^j+|h88u.\``/84xզ>\gd&3t6(gLp51ղ%%]Sem0X]%DY NJ_#w8^dF~/m^kW `4ll^O%`&x*2EYp5DsS 0.Ծ.ɱ[DMebcFL~ɚLtu 8oRV_TΠZ Im:nh df[8we<\T/%(%-$u;mo5>꣑PK!%fdrs/downrev.xmlDAO@&͘x1BЈA6tgB˿wA7LW   ekˤBSm[y !STPФR$~`3 nj9J;iPbC%(Xvݾ\^cux O;_ԛV0 *A)zQ6PK-![Content_Types].xmlPK-!1_a ._rels/.relsPK-!mQ )drs/shapexml.xmlPK-!%fdrs/downrev.xmlPK@7R  c:2___PPT9  Z  G   b   `??Rectangle 3"  PK![Content_Types].xmlJ0*miG]`Hm6 Xwt?. g#Wi3E).+7 >ON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!% drs/shapexml.xmlVn6}/ Z(l"ci70LKTF"U%v71) gCWU&ň7>%\2ӈTR}|OaUlհѭժ-/Xu#K.JU0zjW\hqPھk,n]"Y2Q;(<m5fn ,b{|y$ri|o9K*,#TK%DS ?vUI6e ZƏLS;0 ps/#lXjGa/q1¨lD[,U︼1FT,G[V|9NEגsq3 46vi @MWVو|0^ͽПͼbzE:tcn!,I zh,VeBZe1o5e cd%ƝdOsEv,G1j[$6+XП#opvON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!|K$v"drs/shapexml.xmlX]o6} uP-'cw 3%*"E'NKʱÐ 8 es޾ۖw't+Mf|m, àg#5^n]%":Qض.;ORk^W{呡iܧ-jC㤚EZ` Z3{_D!xZK\70e¥ntp6 "?jf~4{=Ot a4Zi*!a<ѪVyjB *̑KVĴ/I!p:Z:fyU؎I{{ͣ??a/8E.^wI궻6m-YM9U2՘pj^B.R,$ۏ\W~,v3uk-V2RfiPb_ M]kb`mX +;(p% c@욯wڸՂ/D噒flsqk)4%r?MF&ּA]%qB>VΎX  ܡ]+ n]3@=f4# thPM\]j ar4Kj*ūO\EcamIA o[vļ[}[bArV$5E(~{]k.RץÔWj]7bp@굅e lR&m29*Ys] vk~)/~6M us}}6c '6НѶo&+CcJAsN6'J}ֱ}?QʑgWZ>Ju-ǝ@WG ;G1}:'?}c > T"BgˤEMvı+3bt7LNl8>SM(XͶھ?WQa"9_z i:Q;􁜂e(PK-![Content_Types].xmlPK-!1_a ._rels/.relsPK-!|K$v")drs/shapexml.xmlPK-!򀄬ydrs/downrev.xmlPK z c RClick to edit Master text styles Second level Third level Fourth level Fifth level!     Sl   f@??Rectangle 6"  PK![Content_Types].xmlJ0*miG]`Hm6 Xwt?. g#Wi3E).+7 >ON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK! drs/shapexml.xmlVn6}/Z(d"ci70LKT"U%vw6993s>J쨬 7]TdJ?ujExF4q_h~Oը|Q[QS[ZFT,$ [ԩ$)WDᢒuBwJRpn]^t,q0 ]>1<1Nkf c)纍|O,${|ŝwѱb$ϸc;:B 5qjT";$n~j㌶jg]d4J 2:䲼#H qױ=('QGȇA &AkcЖWhG+H억Ҕq(n@79@ k3\Fw|yQ؟{?y4`Лug,Gg!F"($=BeJQ\ݤ젬v&B'эvC2r@L:;Pi Ʋ6S(w0'a-Á-$QoQ- NI8*g=S߂_FFe)pXQ&l j]" &t_gb;^׋sߛ So< |2wnj'äz#[o8f ,^' TˣK-ъ[R8)lEpڙ)( jM"7 յ3pB^LZ>u(*zyyON ޑ1ˋz "+R RhB.} /<^ITխ%rHK4uK~I0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!V " <drs/shapexml.xmlVMo6 t-KlI* i7{%*VC*E%N;CI qs){3f>}՜3VR9\MnnVSQP.KG:S3ivҤVf2մ= WJUS v(2j>zxPJ8`Jܯ+JHd8 "h ^|DΠ?fJwm }/D H|Sζp*%-{ƿwY莗~4l(d[jr%[Y\H*g}o_PWC.WrH<)%'&+ E_򇡗 w9#7\#7$K^sTJ}ގ<@#?w߁F'u@xUN-A(LhZq>a>ȋ vha,^E6/09{˷aB/|[oRTX(u,^B-t\.*TzRNϒ&a/B㖇'4ЎL@@Q+VV.#z_^7yܭTOyPZH9? AXyGtGtLBuT`5u6LjWbxP4/d֞5\YoZ?B}'%=و+Ckxч!?&09dTU7[Z1)`/5Hɮ{`kV&B6 Vxu`g7t6L`Zh{ѕԝɂR =5e-&T`Dm2p 6URNOd|yv|ܝFOmw7Έ٦[?KqxQ׻ ԧY8,U:)ya&?0spDnLn'X ؾL-LWTQџi U&>m 7`ƉPK!R!drs/downrev.xmlDN0DHuQ 6ԭP,X_GۑmXr43:ը:6un' 0ҥofG-3rZ^^,0s _.C}ƹ+R&'X>F[siiLVLJ{Z7To%Ϊzq܏a; [!`F?ܡ'"@T|yp/~36Ĕ^hvvo L*IuŘtO]Q߫T7U:WkCֽmM ؁O(c5c4MMh z9S HVg20pf \}@U:Hq |,I'\A ikpPDGrHv܃朌*1G֊QK8+ֻǬi:ljM#)jsͱL>W քAOV^S>QͺI#wGM*Vjh=l0j&$U{/U'3ӑnrvJb\t 6+R7%:)V†l fR ɸf)ՁBH2a`d_^^jt6)Zk `Gߵd2!rhDz"bшMP}T«SDf/ea 0+R\[U&[ չ t n;*&/H7g^C1LD\C*Ro hLhAP]v@ڜ445IG$(G*BY2w fwY!QbaC]WBT  %qͫdd:lsǮ7˫UDO,ڬUV3g+hiE8Vk+VMJ8b]c7DLBT~AmEBd Adm0iRִewVmF-\0{Zƞ7g>;//إ=[۱M =0421C{`ʔ4DC& -GtPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!PF-qtheme/theme/theme1.xmlPK-! ѐ'{ theme/theme/_rels/themeManager.xml.relsPK]v : 'SPK![Content_Types].xml|N0H+r@%r(0r&7yܪ}{&i*T8f;L6VT-{V~n^{)@ŀ< uw}l IvVNLTL3pG|ﴉ`(UoȮy=J2:88Z )9kR /Ju"(\fhnX soiɶGgϤqsJ8 `ֳ'*e$ ީ3/zPK!*8 _rels/.rels 0DnzЃXmlo0of5OIw AN{cݠv=m 838yG 6U} ShLq`L)d=Ҍ\@.;3, ;$e͂): vq}j:zɥ'k茜(f,ƁXA6\m>PK!^Z2" !drs/slideMasters/slideMaster1.xmlKn0z""XYe4e Hd\ MÒ P[+3G?562ckrX$E9{{}IYdV"g;ayIa# l9k8 [ RN:. Ѝ4nV,7Y˲Pn ˷UC3Z#,{%-I;isF&@dq2gԃyR++E5# d[ 0z. c6>XԷ(bm7'Rfѻ04ZJ?ߥgv䐷EUv()Xk^7B&Q7(dܞ iNT6`r6|WMё]2ө>/mBh,^q*!;q{z=x zAm:3Ig"7G%+g(P9R0 FTYl 10 /min Systolic BP>90mmHg No other strong opioid within last 60minutesN C ' "  . "  06 .  c  l??AutoShape 9"@F -@  ? Give Oxycontin 12 hrly as prescribed Reassess pain in 1 hour 8@ G > C  @ XB  n $nf??AutoShape 10"@I LSEEK ADVICE FROM Acute Pain Nurse Specialist (APNS) Or On call AnaesthetistM = M 6R  nM??AutoShape 11"@   $Morphine PCA ENSURE NO OTHER OPIOIDS$%  A  % 3R   n??AutoShape 12"@   !OXYCODONE ENSURE NO OTHER OPIOIDS$"  A  " K   n??AutoShape 13"@F %  EEstablish use of PCA Encourage demand Give IV Paracetamol 1 G 6hrlyF F  F    `??Text Box 19"@ o  ^ ( 2E     `@??Text Box 20"@V f "( 2G      `??Text Box 25f  & e Pain Score >2 2    `??Text Box 28] m 1 aYes 2C    ``??Text Box 31, g Pain Score >2 2    `??Text Box 38W9 -GUIDELINES for Analgesia Post Cardiac Surgery.( 2. .   ` ??Text Box 41 e Pain Score >2 2    `??Text Box 43 { g Pain Score >2 2  ;  b??Text Box 1033a EALL PATIENTS REQUIRING REGULAR OPIOIDS SHOULD BE PRESCRIBED LAXATIVES"F( 2FG  F    j@3??Rectangle 104"@ Z  c Pain Score >2   c  p??AutoShape 105"@   9 Give Oxynorm 5mg as prescribed Reassess pain in 1 hour :: G 8 C  :   b3??Text Box 117"@ gM T 2    b`3??Text Box 141"@p{ \No 2  B  f??Line 144B  f??Line 145zB  f??Line 146/ /B  f??Line 148/ p/B  f??Line 149//B  lo??Line 155]m m ?B  fo??Line 157" "   b??Text Box 158"@@ jCONSIDER OPTIONS 2     p`??AutoShape 159"@}%  T    ! j̙??AutoShape 160"@}%  x NSAIDS Contraindicated in: Renal failure, peptic ulceration or gastro-intestinal bleeding and severe asthma 4y  R   y I " p ??AutoShape 161"@  9MORPHINE PCA Prescribe if NBM or absence of bowel sounds :  -  : : # p??AutoShape 162"@ qc   NSAID contraindicated& c    $ d3??Rectangle 164"@}j  & OXYCODONE Prescribe Oxycodone 10-20mg 12hrly (If frail / elderly prescribe oxycontin10mg 12 hrly) Plus oxynorm 5mg 3-4hrly PRN For a maximum of three days4  u "    % p@̙??AutoShape 165"@s & Suggest Prescribe Single dose Diclofenac 100mg PR Or single Ibuprofen 400mg PO Consider ibuprofen 400mg TDS Reassess pain in 1 hour * Q 4    B & lo??Line 166"  }B ' lo??Line 168"}B ( `??Line 170 ~ 6 B ) f??Line 171 pp  * b3??Text Box 172"@ :n  [YES 2  B + fo??Line 176S  B , lo??Line 178"S B - f??Line 179 g  . b3??Text Box 180"@ P  ZNO 2  B / f??Line 181c s B 0 f??Line 182 ,B 1 f??Line 183B 2 f??Line 184%   B 3@ `??Line 190 M # B 4 f??Line 191 M M F B 5 `??Line 195   6 b`3??Text Box 200"@I@ S ~Pain Score >2 .  2    B 7 lo??Line 203"m m }B 8 f??Line 204%  B 9 f??Line 205 B : f??Line 206 F B ; f??Line 207  B < f??Line 208 IB = f??Line 2099 # 9 B > `??Line 210f ~ ~ B ?@ f??Line 211  ~ B @ f??Line 212 M M  A b3??Text Box 213"@-j~ \OR 2   B b 3??Text Box 214"@~ \OR 2  Y C b3??Text Box 215"@~  _For patients prescribed long term opioids please seek advice from APNS or on call Anaesthetist` 2`  ` B D f??Line 216 m B E f??Line 217C F b3??Text Box 218"@  T 2   G b@3??Text Box 219"@P)5 yJC / KM/ SA review date 10/14 2    H A&??&LHCH Trust FT logoPicture 220LHCH Trust FT logo 7 3380___PPT10. c" KC+(    f ??Rectangle 7y K  r*" G      r0e0e ?Rectangle 2Jp   c   ~0e0e ?Rectangle 3 z  c R    3380___PPT10.@CrP %)? TahomaArialDefault DesignPowerPoint Presentation  Fonts UsedTheme Slide TitlesOh+'0l   ( 4 @LT\dGASTRO-INTESTINAL SYSTEMjcrawNormal                          ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | }  fKT18{ (E@m4Px} xTlvCD !D0"ݳ,@yIhWK)UÊZP+Uh" Rז^նj`>fYHvufyfΜyy9llB@ddޱBT\ lj61$[d03gmQpChh@.4{C$j @aZH0\B-AKBl-)\9t&Hd|zAk"?Lkz;Ӧ~6a [ p"bo a8r@0CcaO_g=#ebkJٌmg}6ޙcJ} M䜤(w;UfU628OʕBlu!T }&XfB E]ț.Eeb5Xuo.W).ÿKRHY\kQ+R5R ۽l%R*ÔZ&t 8 ?e]Y3f=4ے̓Nfud}Ye>,y؀4mf`Н#BܓXGS|W-6j/¾ 3h佌MOo +K.CpCc ߘ}g*lYkکucFB~&\_7Q +ےKl18Τ9nrt@~ 2z T r\/}@dlX=e ʬ7^@jF;Qnk k uU U(k r̕ m\ʱ1i.4 NC|'ou-:όUU~:4CNl YtO?.!o,;iێMjSLM"J3&E6M}X|?ˀRV X;]gR1 1_9GcT.@Lv1̓i]ڱl֩.ҴcՀDc]9w-/VW@N99vʢ}Ի<ıл{>oww pCvbY;^5 (bWe(9%:dNG]JKJ|{e=AbxK˅K\zJ'ԫarʏqKZ1YN#b[O1\SwJO =N_Og^ȧڀj@ LG׀TߺA@8WtApey1њ%p͢.Tou:ԅ..ԢHR-M}]9לڢ3ѓͨ۩.ڃE ye+Y Olܹ(2} $MzK x-lwy.ĶXA$6ƾB,DC໱ߌf<֌Y9rM>PV'_xaG)1=܊{#l@=lW,I)NP. RǘGH>gWQom}SG6J&ܯΝZ?kC;~ZʷUi6 4Й}THzr|ض~x:w'bA无AǽPpCXN~@E` )}#-Cuˁ-&دJ@g_M_帢i!Ǘ4د&ȁc).o, /J}%P }\ ]b߄X^ F4iE'&J^#=܌h2zn.Bإڼ"p]6 {ygJ]eŻB @_Vr~]=vS%bol@$^v|ջ鏃nJ3i3Ҵ``E]+r|Is|ov9qR}/ѣ"E IƝy؞2{-t=< YQN2BE~3h;ěB/!!sw>e}o!Wko r̕ m嬎e8 ?R[>;mywA|ݒ_*me3T_f59l?A'Yf</.& ]}w^9) ! xͷ1/VFTwB0P`ig ш^ ΰdx kPlN|r8N~7|}?.f@*@^Ҝ_f{m]my9f>=i@4ߠC=q"ǐ $+qX  ~d8#=D !F>24?jQtuB_^5\;R,͹Lp^0i3m] '!+8+)[q\fypҗvaOg|_keCCbd󙖺|T:G; p蔜Rb_cd$P,t51:uʵ FĪNQԩNES:e-77E?ntoQ':Cfc2~>0Y8U|U@s_@~祶&k}[Q^?bs`<|Ȉ*Ɨ/ `sv=^;W13e 1f=lhw 9~Ef׃}[ -\΋l h!SWG"cg6ݠy q32Ǜ鵵FgFʷ`{<{C}{Mkkwdlsf߮@g?3ԗiA_{gcc W w~er g}4Ei}\ѽ>גr!F"@`@1;szrp^A嘒H mŘ/~lfs+kkW{խqo?!w?t~PUœc =# '=tx $8l6缿 U̫_^ ^{6'#ڭqu6?A<k忣aRNQ:oU߼~U'ڪaߌ@/'ޝ~wQ}=M<3{g=zVz>.NL&zwoyHϧ'Wb yVy7y89-j=垙 V-5K׵=itÛm=|{/ ,M jF`A5@@%pÐ:>Y?H{8Qzϻ1 h s +7_p?azM i k3V\U3(mE0W[<[<+xx#mU: V Vvx2m? |{W:'z'yWyW{xz*y*{<5bρ`C禆77Wp_1x7/81N{x{nw{u?t8t'kko17p;|6A u67q5i5v9gwi_έl-rϭ9%E8*]Z).8 cc19 }@8eL{gwlభad`]|{+ێﻳ7nͱFWAW8 0i473Eb"1aNZ-}ŠMMf T\_r/AmSu#}$ q0 2c,fR^ ~4ҴAՀD۳tcq1{s2tE6Q=1y jbwb ,c1'-lcc]=l:c$/f߽;1_Y5HۄL?VI9 +͈-!sQs:ނhg(]eQ/Iy.L-֑uImr|^K} ]¥{lE?>+s;XtXs+9 :kσgkQVVPX"SB}5~QG=6р QU9SON4멺z&xm_V>r3c9sę`}:U lbO,8P4*ƥ?ȩ236ps- elHg M@ &y4u- ?ýw٦s\+t򋀩H ҝo_, aG~Ԟ`j^y|G]4wh%h9Z69X޳[K gr`6 csm5?ÍA`{MΨz} !u ~y GaWü^8A7͑YYpXnSP"]݇s'`g>|3wo`L8؅}i_A\V"|O~i@4ѡ.AKCq2Dӥ~M}ƅQ;z}-tY](g p,tڑvWtdG87FnWq.Efg,dMf2䑞s]~7eF:SɇnYO흉>B}@4}T?Iv2H\.,5~QcQq%#s闳/;9vl hg?[Q3ҬG{ ;M9V?n35FԄݔ]wA `bw 6C+>Ѷ62Y럠.?8ԱqJ'cwf=) N r̘/njj`Ɵ %}j4y4nxɤ:\F7% k[rq앋'4 +dRͻ&~wB/Ⱦ IUR$oIu3>[Js-O?At2X 䍵Ͻ3TkiA|:u'hO(E ]9 0i/G}u -G >zՀЈ!U/~@ 2} 3j2iCTO^Cˑ~h@5 !N}lE,}l)o_.<u;4Н 뎆kGNW}lwguxk1}yO``Jw֢\9&9>nF|-l_̪_V>}3k9Oqy\N E].αJ /ʠ,.{̼9RT}qQAw_\$&Q8h a(v&h3񅓵Ԩ߅r\tx|Is4-5G; pP.#M 1 a"hO09d?dlO r\/}XdЭ[˰2CpU}tѴ*⣋&BUk 5/ ˙2WƏ24eRtM@wvْX9wݗƟd]hl_+*uM?~6 8LOAp'b3t|XF/NY?oY;LMC|G f>Gup`V/<φ"EL٪k\ 2¿ͯ.ǯ,4mCp@=" Hz|yJbcXc8p@3K:MVX?bt8t,tl^+u5:vї ׹lJqRBV ^[ lѿzŶ^uL3N$`^N@;m3_`J>극gN0YghHҪ=}}ꉴ9{=d:9 9t,mN#uV"ˈEL٪L͙:ؘsi3U̚ƒ96Ϭd/U[ҝ?[e7WAnhk'R?h7* ;4<:?Ll/cczޯQ^>Ъ}O} h Yw-JI'VbqM[k]}/ࣼ>; 8_iOfhKA\9ۜ}9JtVk⏴9s/@}*1y&6z"mޥ4 T"^mNi "lep| f,G?FzOQJ]Y…'_5^?OZO{]xߋ5KgO;;6E#E/./4b`cLzf>m3-c!hBKsfnxUyͦE9_R־j'U:_Ѫ?rLW]{yCYX̆o3^1P;!6Ft`e3B7gJǷn :.v>RZnk_3*Y#O#UL'4ꉴ934שΝ)MAX؜C?7l΅bN9؜ԗ }ŽaG_^0t/KR͑͑}͉|ߩϱ' 46up=);6 3ߛxxleX s̏jCs_w3?M;_s7Y i>wcy)Jfˬ5 ;I߆o.KoKĻ3Imm8e @OSg/t>[ܺ i++@2Po87i LEЬG[kfM}Fo6LGC ӃI?XV6k'6LKH` )}Fivg`|9 A]7~-O/.#Xfsn{gSq^ &?cwM^GʊUWdA7?.~!F̶#FAl l7L"nX6r,tr<y ω OAOz+2,g\lu,sf:p 3|]ͥ7hwާ]wK~uViu[Qi+:/ǜ򧼝4Yuh5 [ܬ6` gF !du#[ &;|2&M}g_@;s ~> ˕9F#NLufЭߦZ ໔+!؇!2i 27 04Js~s4mu ">xoN@xZ}6cSASYYVC^eOv[{]p}鬮m/u:vɽFUǒ*dur;^WJ]߿NqURbSv_^Sԥ'~nSgSkQvc8T| M?|*q>UU⏼_x>nzl'rt>3my6?/{n2A݊Ӹ}S{l2? zLy[(Dbp} I%?Q J؊~nym`h./^ c?8V]5˶j ݫEYXK~xd_2T bMvՒ @i2w4}@>o!H,1;Gr5gΝvexƴO'-E<yVgcР6"'O||$ޙiΧqi-MTi=mA½T&B)TKNriڔ6 HPEХ@}?X*..+j/*'ʺ-WXYW҄&3gfΜ}{dMܣs}g(tRIzݣ2+c?ʎI?zoMC[(rI;2ؒ^;sQۅ؞DȹAl9rqߜoASM3}^;!}ȅ[%~ownw>oܞeĉ9mZނ\ޛ|'(fr ;[}}ze1LBvbVwހwZ.Dk-ed=x;8F\ %ނgaن1:mVZ[=^z(-QUQ#;rREBrNS=t1ѧZݕQ VxK{Q]"0/;!-@@{<Ģ}Ǵhڄ{ uϵ9wLĚLW~܂M%T{뺺zo K8Xm#1XGVcO>߰ w/ :i[ep)3L ~Q~kJ磌я~]i;=b-?]o{u8yt{?vҒlmY7w5t3].+rXVJ[VrV>rnv;2]'^\CmW;9g>vm:v8X}xz]eVVvln^a^}xRR~zVd?Q}8V許:v;nxv>gKtY*Uvjove\cC>kNԹZ|и:lA8A yY?ee@^Ϝ74漮yso7:3[i---7-·Z[^qn]mu{ 1*Gۼz{ɾ?m[+|zgl*YKn>nͻ|wymxDoiwpb-MZ Li)4շ|#n9.(e5-oGytCsk$ tY YUNd:rOUIZ5pIG ҇=]%}TeQv\:eFzVhzV`dmiaη%'VO5S|qK%/Uǔl̄_<CpTOBݺW)vD>B;ԭ1V_5U5>F{_I}xKXJɸI8r!ox[ ~t'<өh{+9T9To3="[-:slV"yLLS{l[=[ۊ]֗S[Mw T[oD{ȱq b-ؿ8jVO𡻾 b+˛&![2 b'z茭-@WdFp%穿5W3W+̋_6כQך&g|@ژ|t"Jə2^z$%KMMf(~9NJ,N5(Ƙ 1fI㥥WJ/i4<ӽӟ_%}a2*M̗5/0M/i6V.7' IǟJ;IyNt⇜Kpft1f1RNJ\/VfbS\d)''pnL~9#j<;:*qp(b;Q2~:Z6F}xV6F[>MھT}C/F:ucձGqJd$9y]չ"rrsWr_Fgߔ:R9/Oy͹=3):ƺRR5y\S\g\$c?WQcu?u?s+~ٷxˋ7:77;+nhy,c$sAzt!T8t}i}i}쥦wm%ö u KJL3KJMJFbCLǥ|@7.%LKϚJM1RH*4+FXҦ]wKuH}H6KzX#%i`̕EzQT+]JR_ɔi{K\;W8fhdPqVyGY|nBΕ}m5seq~V{Z+m|ÚQR2J=X.W76p!0/;!-@+D w.Q \3ĞM4ɽgN-0܁oj.蛚 =(ęNK$#9؈s]c8nHV硔Kd뙎e#3Sq4e| iB]Ty:-y@(Y 4,/S¶*vnA$!OhHdĂcwIߔc{h4`_g{pHo wB ~*dR!4 $xV<_7"w KϹ*Ge0`=:ggJ_rڼc`U9w/}c]5; yw)"Dwg Հ{N2x [Yo%7Ctҩ$HqZf,EiSLp=9Dz\G]lC``X6\/$3(1:QU_?TKN. # G7\ensJ<Q(?*IG~cϿlg&nʙgbMN 3+e`C*݄/(8y2,CY_)3v pDb9Jnw[5Xs9Ss 93@'&DG>3g,d)l|Σ}d`_~}hYweVUʔ۝RNc9I'B{WfmglخŃs۵xp3 T֡1Boua_W}98>s_ӀK{@yo|Ƕmby 끩F잏.Ւ )fN :49%y> o)hX/3ӭVB~v'uOY16T|=XUgYGh'2WỸݙ>9iSӶgp?Y~.ɽ;~3q-D@m^jFyU&[wxr7yF}gJϳz簾~G2r3<wahr5Ը7F73TU>fVOAZUV:Pd q8kųk{*pwx Ud߫*O*?l'Z'XӬ_Z?O^`ZK ˭ X0xdh.6kpz{Նlr u_c` 6}a݋ M'W6rO6u_b * ==_-ɞImgxy k<ՀMrY qYxCyiyNlNNkVk= ziU6SNGmݟdX~?ʴ o샏ˬ+dY8d}?]I3/'3~GšZK&P"mu6Zh]=^;`~__j߫^`u೯#8UIKrz_g_>;BݷSW,b7!_T8!yFKm[VMo Z^Yg2J=X.󍷴O6NX kNH P$:搡)W#Htk܈򸑾tXFQ36BH'Oף: Dl! 2By qp xIR pK1nfߞ#yp`4gX73:eeB5]r }A<614E@\Q.8D ť~]*DLGx:u-8YlC.q| .\؝3p%^a=֍r_7r>uYp c)lԃeOru ڀ~0YnYwpmȱz>q >^P݊o[plP$ǎwqȭ}p:q ԓ22Zw/q6ř~rɲ9MЗsVM?G{urqcYe-^a^lw;**ǜJ}y Owt* ʱȿ:!/pv糮JŀE>sV[%b%<qyXXo Mw=k͘"@@P15s1vNicXwsƔ9)}O):ǔpiƔQւ8҈>oBr{vBuB2IĔzdNK7%UoE| h~lbaBł`}iԹw:cwNԍܱ o|ElC\䁧sǂcG;x>Δ;X`xyLߗ8:+89WCQ/s\fu̧o#XDޏ\&xhhDіx8`L"~pAi?kջg_g6.Zޫv"؎~aF[mȣ+Q6<}ME#qlXr[池+c)`^Z>^"U 8'fk }`D_ĸ6Anj0)}@pB+Y&J #"p)ݾuy0O`LD]u8_ XL/:+S@rXH ґI~/JNjQ`5A~PYTm|g LΕ!W ά ™(3X7qr)"9a4>'݀.Cv#1_0߯"=r`-\d.PscE'b|VK<&+PUY ,Ķ(*tmUԭtb-(iQ!fb*Ѿ*Q#/P\s1lOJ&!0ݔI+?@=0 0?:!KO|D|4>IcV«K'`Oi9lfűX7Q;抶 jge[`?*cU]SkٴT_grc+߸? |_+oA+-SQkhe?;(R lOiK)/C4|>Z4Xe#1>!;?lon' יe#Ko|N}Z){8㖫&,^ tWRPg[s:D`aY*Hxlo؁TZtBZ(5"bF2\S^sJUNֶP4Gmȵk!#s͂cwZϑ飴ϙv/4D 6AҶv\LeЧ:o;x]WtX'BQ'g)Q.!GK¥#Xc~ 2ȥ#GK;qp6uK.qKK\LWG|@qSP 9s _76s# ꃊٌIy)6#u_SjATaء勝}Kʘ @uQuQ.Dч|~Գg{S~t~+?,V{j 95 O ~Gr^:g瀭@X~d|2QlkDs;*IHz(lcBVw]1`h֍:ZqmI ~C[=e;_e +݀ KcU2]Qv"u_(c 8I1տOASBL) F!эu!$㚖kZ A=VckYyikN3hA=p}8 \?2_Xw卲ݨG+O{b3V\2[7c7(`v@@7Q; u]vVU9bm-N1hx+Zpj1Fӯȁz>w=m3NRNG ;Jtr| 4}S G~G0O{ҟ T/c2"3 AC6!ζol?>'x;:ۈd8NT9x;[xo >Uտ`V_^UEo]2y޴5uh\S<gs:5)׎ z m? \S?k pD9ts͝aw,зY wG,uĢ)׎SwBNJ'|'mľqlǥجRظ+>vJ=X?G ;~]חY?RԿf.']ͤSMޗ9$}bFxҶ_}R¶K wZnv+  rLvlQ3s6'%Ѩ/abe+織(-x<}:y[gL{^M~@$PZ,7¦9VWT:i΋pk FbkyzoUB,\L.|ON_еq[@?@`.LÀ!3$._}H<s}qLsɁ8WvQg,%^`lb.TGꃊ46Eu)ųlFŶk{CWٌi9YZ6iSOWLϡ)[|sh}sh}Ga2UlUSZ)mڤ]&զ=iPơ!|eDO@{qп^:3zh>(zOًˠgb{9?o^^~~M>L3QXPҾL/fڗ3_K{g_&2o ԱӾ<Ks]0I`P83p#|Ûx|w}݈ێA*u/:r]AuC? RNP / O!/XP̩40=< 1LxXaa<0?,yL_N?Maټ`>),o>˃<#˚N |hs a`Potc+@Ms)0 0#<}fl_|,ٰ?i`w4p戁Nz|hk v:h_ _f@, 3e9L6wo . ,>O`?|Ph|/# (3PL+@a:x0: <_F`:0te6k?>L^]^ol7ktpj^ܔS1Vڲ]pA֡=4 P#жnou=b=5-g 4=S;^t9怟 :Jgy*OryR0Pv 4n"Ai< :: #+dGP4A(9'j2ifW7$^(_1ԽefO+f?YUA~=` P ]w S*<]eUٛpAxM_o}N蠭  p vfD軭 iׁ/("ZVȆ)j KEuMIݐp _VuA^aIpgB> N1hAէx(P`:xNj={3;,PYN:G8D8EMV>(s5U9eIKw 哐Q>Be W13\vVn{=< :~dD䩨s /\LL|=F[/(,zʪgM-;޾7o޽$|NLv!_eߵKkn.Y"J\6;Q9#최2^I5IȰiS-Za 5D! '}h)f+ ̞n)\Y~]nx+YDe$V=]O'ЧY B&V,eV0/U| 'zaƌUIs0T1dB:Y A2 ⎖0~Lb>¼ӹh(68KYT^Q!vůGNnE E Vryw&-(ҩb7I`eSn{45W/\ֻo/½!CA;n-R+捗b)5?KKƄ}aigi Q\cB*5.ETL F ,FfΕWiP"JXH$fOW0VH/QJ*$ZoP\EguT*\VK'6P~^hfiQ^鎽\ٚhy(XiAG% TЙ +nZ>KuJ/-*pJU ]N^*ͥ$4Dt+f/95'MbPX@&XgϺ1PyN|0Lʷea!AaRWz"RVhTJ7</7 fQoٝueƍqZn>t8u߃" #**n9Œd##fޯ([Y!hZ֬H ejQSX24'u- }d8?pDZ{ 6'r]Is! ~{gZk$VÒ%_nҡX?mDJAx'Xh5442{Mhq35'$A2,+z؅G:#.VJ_tN5jkШrYa"i,BZXH^Vud׀\Iǿ9vRYO D")' |o;JĄ#B J^Y6JVI68 >5\띡ܡ,ʐ-X۔>wq4e</)Kk?MtU# -}=V枡R]]JNزp`<W-;Yɔ#rgyќ6gBO!;m"^LdQ}T's!O~{'Lj5/nts^-tz4 煉YJ lyb"RJ~Xn2=#ܗ(lX28s#xlKr yyl k9XV_Q/y_CW&sQZWlz{wXAe /+/lAr#l8C>sK;T/nWSCլVɞk,쎽=_uzD>GrF4ŕٻ&+'+d-(JθFm/?EZ,~I: NwJC,UK=rPVsDvkK8S=>z4Y:Ǧa z?몂l꼀Do*KG; hs;zT9.\.}3XexȫE84GaG~[`xYIɧK:6LO D4=ҦB]XHVj(7n: 4%~# |VV؇6fՃVPkTZTI-:<j-'#Z-ϜP\->&@5?./ fq^*8Oxs{p&8A qV}>NĪ.,R)( J QƉđ֔"p3T'XaZCWۗGݺ`RYvFK^ԤGsQ$}'=[A[66VotP(I9tNgH$B~2 J0ehl&yz]eeI+%3"`)ק+styF~ϕ ()$xQcqR]X[o rm sęT-[cl'倲n*:b<x^ɢARj4FlԢS_WsKrhꧭb 3-u (=84{ާx2UWe/15f/;*_~v gT"ѵiFNX-Aؿ莺bvj|G-p =֔hF2}mo9/-Zoy/Ծ>PҡM:MkZDsjcCNotםv{}Io9])ACw]^wuh],2 %np╋)=1bX%P|IO󃺤fo"j_&d\?yA듮EIԢEH,d-m7.Ie0J1L>Hc5*naɌOkV'yOm퍘0ak/c`۪Ghmj~+;q)G%og>@dmx@]Cz@$ʣU(Fm ^9?{ي S y«+1(ܞN,=9Z OJ S=?[GyWRV[o)QV0C|"E+ṛy0nfu1.s*.s :obrQ"\Ð,JKNkR)9 ({E"6sEm* Q@ 6O>PU|F6gU E{q[cÔ׮*gB57$q}"ī~;+ r9<ι? dl`Ѕmt޷׈uOKeH; "1nѭ{qQG2oۺȋ_w%NԧW>0 wz}h:Cˮ.ңK.Ē%IWBw{Mυ2O<~sL45EBR{b1ˉtQ+ 7蔓t=7"H**:fC/DIl_oa tC)zM^[%̏7v s:ta KYkbRٚ@8p4M]d*=aҩ+OGӍWp"]¢ji;Xv=5}ԟ e+mryY=!7G6tH3ń3x`zO{9qI(x,hP:3+5N'PD,Rz7m;u5 ^SwC7M/˱#̔#lomZ V.xPFRiZ_g:nmVVZ?:wC 10,5:M$xөyRRω) jMw#Tf"g']B`DOE-8r=w{P 7+Dr s>{bB"^LA] yČjFNR9 } ncYz"6I/ؖd'W%Ew]`ݲ;nzrs2K,C_[ b!3t'}>mfj =wޮsRݮ C[,W( xj-8YP1MZv~lxkI?-ݢf!uhǫU L)RGѯ?.fCH-?aGl`y9ɻo$GߪrWTA"yvꂞk4?Ԅ{tB}di/b6ޱ^6 0,t'vz9f;\<;|)7R hc&!lLMtz(',zT4 IEЭz G:6$ʏ/>  &SFmJ}r/KU[1yu+6j2x9T yKF|`vUzo_lKcȼ"woc>{G msp+]Sc!ͺ:4^-d²8$m?0Jz2޺sB0> -r}⁼ Y-}&Bc&Q Э]=Qs%d|ahfX9 '"cffGOvC*܎ުZ^pЦQ`஡H뱑GO=3Z(6W E\cq*-E`zɂ}d.3Eհ(;}:7aoZj+_*= ̛3Om˴}\МA u:fҋ*87!ń*7Ҩ7J&[kzdt>yW|1KZ#j/:wxiF 2B5>,ϰI13 _  RE!7 >J >x4-Vp|d,RLtrɝyWzG$%Lͫ T-;68<ځ ƑhekKnB"0\WR.:ቘud?i2bi1a"0Ҩ={"3K7rZy%%Җ#k"Wa|5{S4'F0Bܦ)frg_{\`n[ry~d١m"WA0X}vh HLJ}:ҋƔ/FPwyKѬshT .XsTt7Sv^W[g}dNCGZũ^r&ȆAqe?-`~]K,wkq))ܼbg+[6UٝŶͯ(4JNok y0Z R1%4xhd%DU>8Q`L[FD_6v-NzGynD/&,Q=,_z׌wC ,V4Ɏh: \ ؈29LnfsbҡuyGLfOQb´磮 29 5.v^e<2$hx(.}x?|<9׹s }U)7vSo7:ʲn%`~ څ݈ª0uhA`Ob7U[e9M ;_ƬF6Uh5V "BK-in+UQ|=8z慠f<7hGoㆅHldŕsT\9QPţcoڢD 1rje+yD UsbZ>qMbּu`m/<͌dur!Vlr1eB;E$m\2SʹZ?q'.QSHhOJ#-A&Ecv*x#dz!5-dCgK+6K .<4RMIb=$)J N6+À3=0@70V]d쵍y0\utl"!4ICBKCSX s8f[:Or7UcCدxΆăO]̪1fbsa"Pp5Ņj^dKX8Nr roWmIqM(? TBЋy<TKr>q_}}|m-!'Oy5\7PjODp=#2hA0,ϰwЦorg0≟_)n(ssh LA4Lgެ|ɕbL.9W725 4MyavzO&6~\ }NKR߷;`$=]oeύ".*M2o yr(#_Ȅ]C¨p@mȻ]m[861s*m|zlj,YY)g4}#wx\f ʯ/*ݡX[>«q%3UU( =%~vil#S?Ֆ+N,mn~دVrLSR,'&$lI\eFFi7rPv` J M%|8GNa^6{-1QЀ`eS}J]$QƔWM՟Sy LJ5#bgjH6,UxW^pV~5ttsp]L/Vg2F.;UX:{K1}_p?> 7gy}ƸvA딬"s5zPN.=9“qB,QT[G}[ܢ43{|:@?v{~@ayZ@nsm&F?斣 &p.K|Ü^֏>ynԍbCLHG-?&++4xSTmt?;䯋ՑV1ͮ_Dv6 1D2+|%gMsOfFF=lk ɾ1Uc@JS,2ɐv_ *nc}F}:c\.hmJ?`na* Ro0Xcye ӫj-oƚ8';,_?(tdQzV+C=c3vQQhF-Kea#OuKem0,&Rj|7>YyOȒL'o&)pXb'H)Ce8#wf$MT4tR![}ڭ떗x`/݋7n#"殘f+ޏ#f>tF|SlGS?.=ߪ>%zb<=Tlpɕ4oϺr#o~)^Z6d {&3&vh 9_~7G+}l H0탡Z[)a3X1vAg>v{Se,*彏ANb}'gO`R5̺;G)clGX9Z ٬jQ}a^;DnTIbzr hʊ{E̦s6vFYFu=X O NVSҾzY/ͯENZ@#n6vkoiG2wqB!=!Cm{p_$- ~m }I2mQ\DeVG0L3uXLc6;)=OI};iN@N˥p%)x) (")AC(~{#$#~&35v-|,}F8az҆B䢋{"r~տrΣ=\S5l^&ʣWe&clz14 f@=NSr_UƽYfÉvֻ8è;_, דV7yƒgS@<*'x|k˻9_,:H`s ]vȎ{ uH3-憳%d$>@iv [K(^YN^㋺HW[⏜=nܞK!=|A!p Fՠ؂z$"sSqC+0Uշ^R mǰ6Ce{W.;ȔUѮ1`x{ܠeӋa9G^Fr2y*K0@|}&2^N|!G(Wb-^ kJkZCu{i6ϙuԣ^R<k%#{qDҐ=+ܪu"s5?vFğ1th헿Jү 2nR-pe([ptvqB^g;b` voee! \MJU`~T'@֟ϊa\l.`\:8 Wk4[2L_S^j}iU< i!W ;BOWОDn$ŭ8nԿgp  r1]QjJ[]]+ 瞦KRJ+Xe#(ͪm9j֦AEA72v*DVp)IB/GإM(t689;\D/]_v]+Nb:*"|DM x+},\-W&3mj#^O h-9q iQo "Tq8U&[!׆8ѡU>heh:wǃ򜁊K RyG>n4#ǥ` A>j}׈h݆'Â̡֎>To(ˤnt)G#UxHC8 j.TvV`fBMmHsss49N|iOwC0`(q Tc6GpF4y{.o!K <'֨}ɰ`w`-OLN.i.F5Jй~yfpۙbZf.qۭȪW"aL^̑Imxl)$m%׍RKJ@)kEvf__$_1D >)~"+MA-`12^Ǵ.SOT;8IͲG"Xo OD#_pEɃÖsN4(ΣY4=8 RtZ<ɘ;ID׬-z6IcZ 7)-:e0_fޝ6@9 ÊU?(s]Ud$_Y_ASNyҲ-iḄ7%Tم"%1^nU+u1- B|9.B$q#"0MbJ3TCDy"=ny}ިԀa.r-b 0/w m3A{XD˜ki2OE @jIeJ```3Mw_@yy"߭3Qώ@沔)0`x'uNͿIőZ12 HTѽ[.<\Inʭ:ipŸRl! `,;0#ʖl_`iuqY^fLYr{xp)ð⟧4x2\Α z um1$t7a8,,Q1Cp.yђ E{/&Eflq1BLk2qQ.K*"!6nkn<L:当 [192ï8Kjy;(CC[.s5@V>gBbˠ&5ܚ} JkǩMpFspf-KU^`\CWuٲSfG؈[>ky$׮iUH k7tӱJѝZ3{I#gV .A zeUOђ{PK0o{>y?z DߣL2Kna0f@WBTH!.& Z, RM|rPVF}oJDQ ЅSҡl]lwcUoϮl+Y~v(v8b B LI6$Wٚ:Viή2N?n(7^,h| (Nr<@{-xUwkS $CMJTF?dQWqrX3S \r}I,{b^ Sl+:#l "OngK}`봽\ ;3lbA )ٴaL3E`>{$]uwHô[ 1/bܝzfL 2QnSa;/C8 9H-LrT< ko+xf5Έ3>|Q,a蟎S@6P tgcVM)o<$7vvBF׵(-+\! _,&b˙)sE2Qbj7٤PKH?S.Y8e ԽF_"#QkYt r>T|ΈN/aoro/3]n +twNWCqkmxU g@8̀+9؏utE%inc$)4rI_O}mSO&׶ČiiyxPFͫ h@< {,(ŴsO L?SwX8a>f4nr1V#۞C|52TyndU_ 1e{Dt1$Ae`H9V{s!Em񖻾S'b 9aw{k}47^HkSU`)~N7 (Spi<(2afB4 ԍMS2X':7(%yIu>~6oBNk B[i`C$Ǿ9:@t|6 h0 P t}id\J}Z$Z*uګvtɕ2Բ HF[LJ1X_TW[EЀjl~l8jwoYg,MBeMd2/§,"YǮl=#f$e2ň{?>??͌>>>~Nq%\/6s0_vJ݁x𡝠șO5 C\ި>pN&a p~3 1M@ӶNY3tԵkp$uMh2Xhd,/b.3qN˗KDz9UqYX)F8ZT:r2 -h ]k  x^˹ypQ^NkԖRʵ vnPj\ԜK!+(!pRVojM_}HX>k`^ LJHaeX7t>rw;sK޿-ZD3/Zfh.TSn=Wh<z 1} FmK\5<P^/{ ʃ!aBL1rx*mQJ I|X}򁘾ԋ% A}݋I>1eu +z= <%.7Wyb)!oVYЩ3aD W~?~2ct_F5Raio͂@G"DF{ sM:uǟھ?5C=ÎY!rj2[PQg?s!I.hCO /:&k· [-h3LѢ?~T2U?䖿gCSsG}{zqBxo整CC,dA<! SMɏ~$4ink7 7mwjמ.?ꂟ?Tx' #;ɷ0g8KB^"z̚8BBOlS{~#!r>ss*/oڮBw/s*ekFiN mi}Yp_rץ _/xmzPрW-#h7/y*,P>C 0RaÞe7maLa3_?ĪDuI>;#rFv.6h ѝ]z HCzS09nI_W;%9B?"lngz1-ma #d*  kz^W"5GFbk#EnP4+ DGaWUn5Kn}A\O:kן̩Eó͒P ja3BL!ɳ8ؼ;YԻ1 ^svyRGkl{%'?>ɩkF8sDYV1zRg!qeTiW|9<[lzy Q֍볥/{;s_c N }t`C|[%:I8^yǹyS>@^f"Ѐ -4:k?=N7UQ3ghӐ{#aaqLu@I@e2`L|=`PJ@ꖩXKL)U74"$ybiq2|K ]YA㈩p[e7 t?}I__I2ΚG;Z/!L?dlťX6{TA #O1jZ'͋ j;4JO7/zNxl X{g5ƙ]KShBy³Q<;Ŋ:}'+qͽD\D /h4{+NRaC_!'}{h7VRKh'wܴشAUntި x3Ah\s+?a3|5ĎUg\h?\c$2őC|o >Ig< (Lmݢ|^Ϛ7gαy.]gRW^t9': 4< ܯ[q<6ODi?/BZ䫤˹CuxSP{ 1= “ #]b7MdKbCԌ[ldgxsym'Kh*&9O('K<0yW\/WPSRw215)ޗOe-mS =Y0P}3d:?#%_ƬpXwئr-SȐ!2PG6%^ MP6yѿyBL1`z$ڢ mQ&`4z$Ѿ2͑"Nm(LWr2R#)rpDm/V>]RMl4&[DHDVC(G^Tj2L|jsg\rur_W]]>-.&8> {02Z 5 g]#,1 M ܨp")s$d|8=y\F"D_:\9S#PKYBB9jڰղVg/N! uW6̏ :<_=6a͕~@e r /9PTͥ)-3cOv!0C*ޯi>Sv79WtLIl~Kl40zK>D!#?{'@p_Ϛv۹ :m }5;@&6kl(?#Y!` j,HM]sD#vOiVr]Kh^l(\y&iF EҥzhH Ǧ-VD'xWAGCz^ =0ELk5օǭ,c DL}zZ@rSԱ1'LM~u~{ +ztj'χ5,@dق6Qj`B"Vh#uOθΓz.cN ʞ Hk+-f U>pCV?бkZ5! B b4Yᱛ #ɰ;tK+O q@ U^-sbBLva 9m't+s ` C0$kTpb  ́S*G(jwYj$am!ܑ &j }{}/>L)(Yc c.("vJYʭߛRN Sd$QK(LG3K/Y5@>>m C8@pOc[~ݫ0>+Og‰r^ZӰ5|O(1SsU9r D ;C,~E}8c)RFHMuwónW!S`kfG…]jc*mɜ|)Vr}h0~6BA!ɴP-~!:b <4D,c8@60#Fp++WraӫxV Zw64f CR+;L6_F#? / 8NX[a0 |5}EGA(}?6ڻ jtcekFj5~i" L3Np{6!5en aO6 `TQ134JXSh}Tp'n[F4j;*\ ma[_j8j|pL8FɎFDR3C@hKh=f2&"$ƹ .#R0?DQ3K;3K`q/UݮSӶg=+CJGS7(m~DZ֑#,2pb sZGNQLmoMs @SToH1N%*<%k5_!łs 3㥛6+Mn، d?:ՓrnEc}ꖢ f y(QoWs[za<[fGrxP@FD2((1Y|駇ybͅW=}|1SOnrlƳyɮvv𡎂i"TynInغl s귡>n^jbp<>M1S z`A׮].ӎ@[c~;TS{.\lxp YJrlATNMQq;g'e ODvy 3u6]r7E9G;rPU˞BlEJ.HU6YTBڶ`_J0c^G֞A=+CG!l~e{@,G.?*CH#;4'Hý#1-*Y] ½ଷ2/~AH2qrxsRU> 8F $Ѣ4-vY}%yf.uRX *?OLW̿^ aV0@(C}AMkgg@ A"Ԅzs$4X<ejD' LhB}3CѮ9Ҋkxcxa)5|G{gMv&@wfJő&NΜ[3~nCo[pzoʚ~>0e9$aT)'[j``,.:߱u9jX|PTw![&[As`18%wks?SBj)- $47#`Drɴ.&ږr^Hv?e=J>޽Or:pdqqdX,JSv a TŒ`?c+P|ݺWjl@^;90 ڸ^I/Z@"e)oΞok ){ PDE 쏰#[Ba^yEG"ΰPS&}RjR[ҲwTW=")=hz^&7O)d`$bf T|=uۆWH@cz0;٧]j{KI Ӷ/WkmS0}&ݼONҪG@ei+3N,N?M/YмP|!D-öz(\cTA<}W>O:ߏ]}?;cu_e)v6 e>;^ԓmh=>*] u MfY?L20~]PsdАčbe tûZ9~ƈ&OrIE)daeiHdX3èB gB0МTSnԀ{sVmύsu ul_FA O?ǖ9Dxtζϫ1gaAiTS xpV‰Sq@Eɋ_p~j!ZnjHE]2F0ht(eڿ_wl1IbzPM@7Zbb];znw%^)RB=.~oõ@AR#"t N+2ڳvu'x28 UgAL `ѮStMIV‹q"1_fH?z~\ "LIV+_@}Ƨ6,}~u E \ؤAW p󾦧Ar)0qJ~!CJK$Co68^^g?w='fԚroQvEAҖjVNI]5rPB~Ccܙ2P7taصuI82ldVY!!^j,o2dQP(ސMS]l>|pƪƺY힢i@^F6B "h SȄ1;*|g)+֫)fZĽKBta -ߜoq 2jK2 NCPѾ' rb)~RR9's.J[[0?b0::U󃱱V]j_:!0]v;~ҬcNULIS& 9cp- qdȎԡ}Hor{뱀}ȋFx28F'l&|~37ݑwer}i Kw,]x+$;: -n '&v`ic7nߋI;za!l(l9 LՎ:0\pّsZ7 fkLie+i5@T,ę'*h]sL9gH+yRhZ~`e)!Λi6+ {L?n#iA?('vC% NjbA[} ׿$F"gX4Jf0FS #a^tlj7UZ.D 8qlq,#`,=:VM+KO@z_he7㍲Fּ#eOwM+Qp$\b1ֿה\˱B=r(#Ql : Os=ļ$oM/+O4/ï'Vrg*OS/`3#®kb^#? \sdnQRَ: ;â!N3R6w'rSI]8nIږ&'?F>׵ޟys[%ɮ8[[b$cdSjnWeAZjSygֲ_6K.V}\S^ȭSĹ ?OJ4껱2!w C;!o4:=#7M]L-J^}@˕NsVo;f-+-g~z|,1=NYt\E" ^р6:I pLHP[~^t:gV&{vŻ=OLƾe&mo9y=i7s^7pqʨۣsU AYQݯDna{EؒIqW &eJܾ x7nxg]0}'KxW"|JJk|]/+}q*hw[Q sJvĴQj"~Q-~9~=z mߙե1!1^Y1::~ɣ yZȚ\s޶C'4W َf8Ĝ|L|Ȫo}q&xԌwx?EQA'.ߥոqCoZSF`/lqhl4.绔$ޕv3 ;ǔ D秐 9˦U7y;GG9=vƅf֘? K9fXݷrz]x?=C187O5;"3*}FgOKxaFɱ,nW<8zVA2ZoB4+ J?"~pP3?4|E"Wgxe wՕO~0Ҩ[y(UOs  dK _ ׬$Ys#>` /\5{ߏ6Էtn`qvv%e],t%s![Od4I$֥\-ֺ ^t,8I R<7gLkأ["z_tʀW7BPs NYkl2WORֽ_鐏OD,(in?>g=ԭVDw&޺{/Gxt@1|6ÍA:])ߚٲTPw쓷+=})\r1m? }15=&jxu|zݾ/v7O/Cd y pP)jljny>}*=%;;>bHg chi];u=,oYkoBdlʓ=ԗ߈V?]=<=7iv[Fq)>[Y,$$/؛CEeqz늢HInf .Ѭ21*׾nO kgb~4\*/=^nݢ-xGkb_vU?x?-q-lkiZlND% ﬈v8\,~fޒF.峭T|eWAǵ}Hov猞Njܬ2kA֊EA9;v]\[b{ۻJvw2[ֶjӦfDW|YfO/Ɋ =v|*mqj=*'rrݥĪ3yi܊vK5\,_eBE^#`F N|=ӄ^?ߓ`ٮ#Gn._eٲ369'tZ; _/zdcnn%L[G[!*هF(gNWvitF2s$ObuEk\'mCM= +Ӌg?眙sչs L?5|vɻc+N}Uτ|wA"]9lN5 W,qKF8ϭSql@+yKKn['}lUݭzerڵ/-&όQB_{rn?8%4ҶpS΢R_VĪ#slD ث,0s͐ZbDIӅ+ NV0dAo?]*}ͧsܗG5k򫂴 >?iY\NAuXS܄9r$܋Iy Zuy㄃&>ndnҺM17>2\ƪzKߑгfycX}[ccuppg /{ vҤ~*귬ހ#>_k]Ė x%׳wJ uUǏ֖|X<5oo}xtbqv2?Ưl91wPgfnWGF^9L>{Qb30Zsrx;6a`EB[gKQ ulveu}4{Y7'XDT^ܺeâ ss:UjH~"L͂ÎrWJhܧ3U#\ȘqDמ+.s.T4<^{xsg|m3;骻遴P /%3/:Ɲ8\*)~&/ouYWǽZtr=^ic r-`DqGAm=_$2LsRkZƯJ|876$ 6p!]m=Z֦^w=X潨$"yԵb\vlyK7WZovk .X\O;37պ}_岵&6x9>w; rpܦ^bU<3=" ןiǎ5Bj02PwׯqfhO$[QMc0&߿oyX0_P0X2Mw."ٔq۪wLײkم{%?d͹S6k倥K5=5[Z:vYmpnrG*R!ȭ}O/Rl`~-+ٕ28=G~^oz2 sFƷ\;5bCƯ 2)S֯QHVv0`BA8)gl&jJ["e"sW] nqkǹsYhqޜ;g/YC茢W/C3|j=5?/ Ot-Y5gYϷ%(m8co3O}rPF=U2,upm~~kݧS޾LTŨY!j~~ ,,ZD9`>=imٴ <*m'fw*+Jv,󭛼nҒ3}lm/~=xqf)S"V{R+nYUoGFϻ좸#Il8Kxt`ʉd^`_Aw Rl E#wWՖOSdYMᷦ붍Lj衄^Ԩ nف3l[WS-3v5Yř&X{xlNТ?6Rb9QlPϚ.-|prUI!}ݴObV *pXysoa)qi"=O.(8oF63PҒc Ѣ oŪ_WJܝ-}˶&f/ qw˳Q%Ol`S[D'Tـm\'L#I4:4jWz +#F4'''=O^ik;F=!rW@U~՞o;.SN_u-4 WSmlQG{Y Nu;xVW74cVhM JNaϸּkN轆O=:o6z_ZPUfIj<6vX|u}a;`SyO8O`w 4\AC=>Ejb{\_8Z ذ_'~> {X[18~mKlO(qWnh|M] 86z " " " " " jHI=" " "CD@D@D," " "1" " @;Y#D@D@Dc4D@D@vH@G" " h " " >ngD@D@@D@D@ }!" " H9 " "@:BD@D@>Fs@D@Dh'q; t " " }" " "Nv@D@D@D@D@D," " "1" " @;Y#D@ާ_~w]j__-9C  @X_*-q-u>˃sy2]|йV];ӹu:Wu}U_[Qk6g6}îu|bTFU:X]}RT~׽GU{*]X6jkf[uZVRWͱ?Ωʪ{sYeD@D782 4=kx4g:*uj5,׀nH3_u$wdK8 ~ K}}09!ؗQ h gU+<=U>xzV+50-3iNє``r!ϔ@?zFu heN+ԳtrpOmc4evGLoiwX'1:˜b1d`Cgs18mtl,<+;l>ǽ)ڞCK/-3toO |#E&ay3ʝ2c! ]uNOGZE9~0fock=ܷm0 h4GuݵV'[iۀNbt%a{{e:m*ظ1080c5]7 yv 7lfQݕ3k߱lPNLAA-T@ -!k :йQ_EFBJ"PlM}EC})]c>0J%>K~BH03tnַ[`}%h <9r ٴm_  Fָ,`td[0kϠbebшlJX7b}C!065L%6;⁇lC SbJVypg߮3|K'"1,!ǚb5r#|%P:U0A n-!XT9esc0^Pq(%FݡN 2N\B/[$ \cSBb0/bӟ(܅hڨal^FlbYA|1BaFc}JaW}}^|;ǑN,4@9l=bP Dc4D$~M8f#>پ(4eM==tuj}zfE&&\*q74=Ui2L<*fgKqM8)YYC'q#^YڣISJ1ʫzQ כTWW|OGw,Y#D塺.G;[R\_G{l lἍk8!"GFUmK 6Mx1ͱXK)^)}" !b`#$K=mVRB zxd46덄,8^`r+ }g0]CM%N;wlNjac $2].}%t>FD@9WN* ܾ.L;* !Uݤ)$B[9)4Hv}Ui1V*7pt%@B$%0γAB,$կ@,k,.ISh611Q)~"I|#16ϵT>idc llLSc~}ԇsgMXu(hq}`m|@a4I@(fQqwWjm̷)RhISwG_ g ^? Ӆ]3ǥ8?Vj] ~)l } k+XˠxlU0Q+(aɝD0ŚuRǺ}@@G clgϫzpb-EO@Ԇ8;fG3PJ_C^&\ ?nccLAloRׁ]ezKZ]ͱTDT1}JcCgքyȑ=؝RJ g_9Π a&Z$Ýu,(/#ď,1_`[}"7*#R `,֔ V: #v T1.SI6*˃U[e7S{*Y<j6Y+<cvWƥIb%8MM]B_Bِ&cJÔ`MH ѹYiiFCLX 1QjwGW>Uީg("\Lw 5z}̂)20l$8Ҿ*2܈A+`ͣT]W'0P[A6cBO|vU8Y5R_w-2_f99DC5':Ď;z1Jqa~4;Ǟx7 JcjBD=R,W{W݅31̤'ՈK z9>t])t3WE;h(3~0ȇsΤ Ƭ;֘٩Ku/'{cyE[1vQkt?$*U.|҆ďc&RĔKe}n$U>/'|', BU؎4,~(IV @Kޕ#a(D/ i؀1Df%;HF6b2HHwVfye@6/yIFޜ؆<7V;owk{llǛRkU:UuWOU=?2ٯH6`4TŖy`MߴZpHˁv(?μOVfvG~Qu-?f,x+hl"o^y>^홑H6^Iou6 ~\d?^GROJM_aYȺ~nHC3ju]Կ+-4)؏ q5经ǻh0@+qPuKò3[#;~{1gr^ǪWy+o}]ۄu`o5DBQȑG`\5ָX׵bO=:_8}|vkw)JZ>K>՘VAe?n\8:x`|-DWE˶YHZq;3PK>tCێ q-gi)mT0ڰ23,7﹭|_zb꺝3_{;˴`KUbLUpvB@Q}i騘 X.`tl?Y "SۃLKُo3_Ƕ4vŏz1=4qNZh,_J~sXYr˓gx( ?ηTm0ʶS#Xcfxv'u%3eZ_kh}?쇛1KbKxSV ^nXq+$gB'a٤D#--L?|^ڋmX S÷!`Ez=:P)ؓx8Zx~L{{`wo4fb0k\sf0x-8HekAgzfoV_gQx\3D+x+(/yʱZG Ż:g`Kϯ瑩cT5ܺͰaeN #kllT4ļ4Mh1:vވHjaӶ-c0b Y-Qqjd#W`q#:l_G?`O#5-o׀oBgmLZ g~Yg'lѴh؎/u_cy[``Ob^q~?uwܬDۇֳ# Z/7l LMS4}e~2(lҞ~%:c+hKc X )eu~+aQ.*/q/} _؟xvZ֫Zq>U="s XW[/yvڷ¦Tu08&9 `0`ŏkwxG]'+,!{czHPN+Xb/Fguo__ ȥTd`r|=bZǑ 5Mo;i;Tt`C/}]Z6zkJkeLG>m%Nj>r\|mmЅKȷ[KpKt^75B_t;8&W[_ta7nx5}G^P)v'|^Ck gGEǏ5m yf& }N跽5-_,"d#-_LSiρs$QA{*h`GM|ePیԲg>!{uqz%u=9?E`T%G?J}_7oң6s~cڏ?:RB ~l*A `؏+7`{m/ppUP=?vϝǰ~\G(lbkb*8p;6:y| yΘL%KL M!W568>$X|c2qa(7/%0zk_ӣ_650jC%!/_JS${+Q rR5;Qe(Ae!馉=8`! yպyZ4:&T-N:FƵޫsC # !vÏwG# `e#@ K\х2>N~>FsP;RWZ2=WҺ5|7ɑ&y^J:d߉߫PSuXd0dxL:Ԧ侒K*KIr5T55\ӥ\$JgXޖCR]*l\+oו+6>;rs} u 7kV9WJ}=kX>K?o쓯 rl?*R A? LE\Unšܕ#Z|Qzz̺(u5#ONKgJYH1 K~іFA AlCc١[N[g:6xzs2M; ֠<;֜g/MBΎRtrawAۮ7t|Aqʞl6_$c|D~严\2JYkJ\=]|/L1x'#m( ǝ{o:2W̲~,1ldž8z碻'OKɏA KdLT.ǎ)MY*=:+y<7>H|w۾O W\L0Iag._U[i1ڪq]1H  r|EWڿX6#$'|➏?A ~Z]('A `0 A'I `0 A@gA `0 OÏ &A `0 gÏr2Z A `0< ?~28T A `0  ?~6hi0 A d0lR1 A `x60ӊ&?-LA #CdqbV7b0鴌k=h[9?xmO,MA %ɣ¤jwDSsMG ?~:`R5 2D`F%s5䳜A煀O<$^`vS &UA ,# $Ïw,[ܦ1 S_Iytv"P?,=?}u}a:Wzǻ<9o¤j0 .31"/W.Q\r+55/!?95lCyw?~\ ٍGFkxB9ؐ#cN T ~\#IMw3_R揫oVߪYI[n>^U^#3mW8U$e(x^{uPڛU I6\[su|A[rXԗ$OǍryQ {I^Uw嚄>Jϒk{+kou AQ}-2o`&jǏ Y|͟aA cf|^,ȉb؏ݲfrU6*WYTyJl=?G]_uFǛ˸|XƯXcQ|({z]9-U,Pu*<S %3 K,W^]tG-UnV! .U*^<-o%:mb_SiC”:U7kGe1z!azW`LG̬ǁi0X'xJ;0^YQޞ6ء>*}'9cu!Tr,YQx.,+e{{#SexP\2$Ӣ&Ju!s 1_Jy-MFX8dzL6+|_ &˂OK ), 41yX&?NZѳ%~zѥuO{ s,vq%Ll:Чe7zҧv:me*|+V#ztߑj}GW:}3ͱRKfS~~os[«ǖx>9}G:"JV+lpo: '0F>~7~1]]rj:mGYy6>:$k&VNZd=a ӫg]ӑˇ?Wwd蕎Hxr9]Ɠ3@_he3KCʤfߑuM}٣t#^y3:.ѹl9@mWul1J"}+/Lzi{@ꄸtU3=Jv?~{>z|Q3_hN2F J߂WmbPg˅;#Gs ˧9ie&ǧF{B?]im\]':DS ز/ՏA{kcPM~<1,_1oºslq4thx6.&@pw*ji"D@mza*DYs7+ \Mm801 NNG ): 9?tRܙ|fyF׾#֬f-0_,Jǫz[OƢ˗*߼θap:2̦#?F֝lYw.<ꟲ3̍.]Ly8BìYmAym\7sɦ#,^yYZ#({Yu:}Pt:PӑW柱 zn"UIl:vYCL(G Eú'w!o_fz. 8%g3(Bʦ>,I3Xt45x=vw6?ODDj"ί҉DD zdXguD_Z7D_X bX K>F2mQ*K*EO3X TBFe.^!d ̕s5HԚKjhV}A`W2 P2('jߜjHO{k_f~%-'[7ϱlqgn#K񕬣 jNW)?>۷e//̘ޞ/W'fe_qz+9v,ve 6Ybydu*q`鷥#ME`iJaz`޴ rɗ,6xTkzujHbS,b5'^7=^BO ='tkS^ږLfԛfd yO}CڰXsxQkq㺵g+^Wiت~5iY<2]=5R28[aPzb0l}RckȪk N:~NtC_~9<ʐ&$<{]a|>zӂ/R"L?zFLe18SUgq0ֹaFQw䭒VaHAVC~9Baݑ}C4lVWpR;ڟuH;t'Yخ #2UnW%)SwY>,iӬc57*4fJH/>QE+8"=*]6ʸ^[z+LXhK駙zf٭S>>5ymivʗt.s.2&r.yzZH:ƫ ȏ' +֔bKXtl*Y^VRmė֬ yx~ߑ@01Cg#,+,΃cdSk=slC8VdShRǪ~OZG|c :=[KSӕ|&+>QI`@1Nʦ|%K_ͱk FOq)gw,\8D+oڥ@M_ΦKqR3k,WC(kLT=k"_>\+~̰okܚ̌2A+&Ǔ矠L65ST>Hx4WSvזm]K4^OƓRdwrsx,J?KwٺǰoJ6{XTq|Y7]a-MǓK)k;(œ@(_ ,xR6VoDVԍ`BՎMj%NǰSJxPQjJDz; O<Ϫ^a(ԝ5+1(_;ahدU\T_Mɳ9ۥ9~ҥ5u3Z!:n'TyyDYueY؎+dਅb'EVhl`DD-D _W6]ZnUrزQZ݂) cE?ڙ z,1hc1*)5Mu1Qc IYdfhav:Ǩ ìо==t$بGJs>c{8JM؏rVt.Jrgm~0O=8S3}Fq|.m?|J՝ᷦ_a͹"M?W-8c?awaLla~rcܟIFc.xz̡GL y'41jʿғu&f`i*].ESyܢx*vz|SKqtm;1}FkmNJQnVk<;g%uަD6NٓU*M3CwLxDW?mw2T>Mj&z\$چCɻ]_aQU3X<2[ɟza1u'jKˆ3~ ?|2?ZAya?3W}dzimaq)۩j9nS,.` (t4Y;%<[pQRpݤn8=uX+YajGn))S+;y۹]~ܥuěpUxLzl V`6}+ߛ!'! e>o؄}ȕ*C y`?&F<ڏͥ]#?, 'ÖˈH~3?oX)S6n[x7/ K%-V:٣b?:\7'>otyMǞ^ر4RXڜ)cqrhkҪ{+˲_ uxC !usNVq+jr>EA\a=Ꭓ13}w~O5SV|&oف,=<~igSrQlqyVh},wz=lfUlTco9>p ?ǍLT*aȺ2egBb6QYX;7TgӚe؈i2e<2b؏iS;²0-]Ǒ S}x1J5v eSҺ㹘@edߒz|8۫kLݶ&\XC?6k"gYѯD~u:WGE!ݽlj먕.!"pH3ڊešWUB~uDyf1$Ug}7N{ DV=dpRTt[icP5<{+ >[DO?,m:nX23-a&ZxZɖeUτrYF(}|PEaͮ;> /L<=Et['lVܮnB޲SWa}mrQq~aZ8/ +yja[y=ώs)3xZ|׫f{|ZnghŅ&ZSi~QIjJV`?fk~Ç"YCA.RbDZba &;\0!}Yp,'G⑌8lzӚffvԑeckʿeF(GkufL3]e'8$p]x0ObKsY%el"W-㟜agMs! ut[1}j*eV9SEf= >W~Lc7ѱo WX儽K^W[C`BfÊ= }ggGƔ[ u'w8?H,~l&:+ %&]ugVu\]:{qZN%=BM;R tH@bW(8;acHwN tQ pŠHM灣f3 7WS;+S-Ib?zߢp%F'D_yCX9~sT)b.Fv̏;<1L%W9٠eTzJCm$5|eL.` vrKw*[sX=>`,N+;,yu 2cqaUшӅ(nPgZ;GkXݱ3-O"Wp[x Fִp$+3c?>ʚ:au #ǔ_2}X g,ZiiL/0忑>=f+YB.ΖC#RQ@s5y`_ws1ѣUXz?X^1ͼؓM bzc&# \uYa?\1yv))Mj\MS:eal /ȬD cRwٟKzR$ts(yکW2-؊}o+ϪKy~D3[cY=-fF\Yv'ٖs=}=6fs*׊'TnvqeQ+{M59aqWBȅPXQ!פ5RȍP)@ aA~k y"#.K$cD؈y"#eΩU]UӨBn{wo:չ7Uˤg6ǔK:@!A'ޯ0ʷ ˺ 'tÀO'7>n0d\Go"};d/}bojcؒ/=S{mh] o-c0kTְf3<%K⮏_aFdD^ojq+ۻ`喋"߉=,rfi9m'[bbH rŸc3=Ӆa]Kx{i}Lj |RVwQnW0l(f& V&DzR1L2|_Q,F2V١SFyj8ϑk_A[Չxw TguY&Z#Ao|kP:TjF,ۈ:6]ѶyqSYkIfHRJX6`V}ѿ1er?pk>o%2={>zoNT[ٓAsʹ_+'3zGfVG.V)0'|K`;5[][GFo}`aZ& wXc_+ľv)Uj\n]-G:?fˑ+zf`%²x{mb_"nhҒu>j6ݣ4qQ/dܰX╌F +0PZ#~m eR xWتGq86}n[^wu.{'TQ.9#sJ}+\K;PQ]e^OIqz$FGo2ݖ3"Kt擣/y OTgLV|}x:zWӛۅҒ4X|;svB`KImx/&GԿ;>%ma뷞^ viqXn]fz(kմĜ6):EQ' x)OEc)~EQލ: "?vrTđ,4[-kI~DxL={^`Js䏩ޟrK^=nW `P~ZO`j~3ܹuUYt͞Q6Qe|U'؎s|S[//c6TIgw'ʵb%{tϫxDew,]@7/nkL_8fL VYE^<U%僤-dላ8cf)]-d.~&[MMj;yNs%ƽmѫEMu-0Fظ̴wpm$cD`G.0&[58g赼^J[䳹(_)ѨVbĠUX+q'shJ k^vSD.ugg6J^7mC*Ͻ{ |l3=1_?̭Ư]R.oG.ɗyn1G8қē\S5]%|(= 4O|糟exw$-]^n+A^=_EqZfX:ci# ='3ޝ7Rm_q J;%h'Xi_T_ "Dk;CʵQWb DK}cW8c'?3/,~oX+?XCYv-ZokYD~ӬS}J{Xc{L99 cWj+bZq=J>n fR]<)źU^[K>돵Isg2rJ{?{ߜ|(:Y%O N^/Mic<٪Cg.VB^J&?K'JQ?f =e빘-G툼G8 x2#ʆ VlW}׺Fi)v~ț0 Idݳd7kafzzʢR1gs[˗?춰.50F/=?ụ̈́'27cdϮ Gzb1}e9Fk?i~nj{N7ɺe-֌ZXiW=*xR P^rƴg^O.%ROmG0j+\0N YnWtMIwM-,~K:C=`<$N]=Ego0_}uV}O:G.-C܎s>5S/tH97f7}j<97B藕=ߐyiQHGhH=Ɠ$.NbGGs#$ЂgSL. wagG(rs*gf##p :xuYLLgzXݤqc]lkK3ɧF4ᓁ,O{N $8T9X\ׇYbgq[]DXO2|oӮ>h5J2hhsh{m)3d1]"/һ{-y^@ ύx|iz&Xz#-O{ui_P3gxQa_Xe=̕q6Y%|r쟦3SAf Z8X~pLsRLV."8Go8ⱢyUls }`۳}2?_= ׵2z*mz{Yؽz<4pُ:3}[>N'}=w!|D^?6ZC׶4jaΥ19~dV0!)~8&n ~dK[C@fٵ#|:EY;,灱$GImiļqo0R?Y ~V٦&m.Ɩ]8s~uKmE6WK%P=wPyg8*X'Wm7v g|F|V-F>KKK{##LО;])\R%F.2%[> פ}uv^|~B"qר6ov[q\9ٲE-RpaU.kPGmzQ0L+tEK4w<د1.sCֈj oK_/ߝhIr\U>+l鎱aJY0@]h{ʹ FdҊI[I"3%gUi$KF?u޶y\|g=Yɕp[#Z?Kz^q?,0\cq>89>t1ү7=3)eFN>XZ o **B+K_H[^3[|].tP 1e`(=̀?BQpqg '˜yXG,g)*#0 6osǓ|i}m;YPuĎ< `%x[t~;qXyc1sȏOI d%b-uB˝xӪ8+̫+nvGb?{'۵f #}Lڿ.oT_C'e463<8ǃ [ |&Jo #HҘfƓq߸|i[v3z1)(21÷0cJ~c +(,=-?vW25^k%ֺ=~9rzZhwRloq ԽGO%~G[Aړ |v)6%e&7mKmˡo!~y؎̥I:=ܻIrԩ*j* &a'=(U+PVYS ۬1<ۻni; j<ۥ|pܵ#菷iIwf 6(ƼpaU,&G)¢eqE)/z;{srFޞu|?8qVy eqکAp+Z1g@C +ǿ0&MDz2n>|3cqtqb[,Z;]fQ.Oj)o71%HIՒT|)d3][C\2~3U82bw᭠(1v썹n>.:a.= ƹ7ÜC3-^g8VQGY댁ne3|pTR-8XضyΉ7wӘ6kvӆᏝ1X7h^.væcyr\n^AcyWl^ytE[3w ,0fzjAM$V_;< Vt Cc`-V?ފ~z8bie~[ENo6hoYFӋud' \2OV#]Yڮ=ح0 RWoT)ƶw7WoK_7'>}XlMUo&%G g|o5aqcOrVV?O@oǽOH_lW[YޛԵwmo{00QEX<*=aZ"~[BVC&LB1>TaZ1b/!n?1vHe`p H{:Tasqұq.s0OӘ*<VvA}Fb8A7v 8v;6-0pu'2,#dnׅV?go3ǙĝFfV#.Wf9,F=96;:Z-Gv/|Ճ:ivVc3~OA܉iΦ3іcT?nhQ9ׯ۱;c11<Ǽ'ٿ>`gJ#)=<{F[+l%%uy\rm 'Z%|R5t+9c)k{oj604>(5[91_ԵM,=\*a2 \s?1^CQ]͸ayhKle )⻱^|{9[KKo#[[G~71w{\z2V>SlX'>ؖk=^Lu#EXu [JKx(Ҝ}vTHt#ZD$ӯ~vF;wzϼrGp8*GQ,ǥn_Hɷv>I?QL8g29qq U?sHY-[GW\RQA)ڰƫ4>/X24>&oX^&iyx~qqGO;C?=gFbd\Y+8EeYȟz?9enh{:i&o#b?u&lg&aTȼg?;gRs|f] ׾|pbXw65,GXO::'x2N, Li  U;n>ɻ xwy#=?Z]~ϿLZL-Me],.ʥZ?l%p/WGd̃;&R*hDV-5o!Kwbz1Ɇ@= p/womQ{ㆵdkD~v5c?:p.-VZny+ q3t#*>׍lIJ2p,)̥{?ZGbfx K|mK\0AO}{ U,N7}/BKڵˬZC0 C0 !\\K?M|S*cUorb1WN۬uQy,Gx٧ _\9mڦWg¼䈵,W.,[nX7 s ?GL=#mƑGn=?te,vf]KSoҳW!`!`A 7qY2x|++VZ41[ "7n +u"Q +xUFDS˽׆1zq)|/5٧\I-deϘ/#2lafu-(_K:aG#"`*g[K(k99k^$ 2_Q00 C0  @*as%YmXkx3XAjXąy-XeM +-U=G}wM,nUH0`[ѥ ?NRjԼ\~1m_>~LM!`!`![W5Zo[pcxG[AΘm@^̫aYуuJW'r%Ծkx!gY2g'Uwyɵ cBeŬک:vo)@g-~Eo v0 C0 xBy ۍӘDjhQZ@83wv5 OHhue΀CFϫylWҦ74,"<1 ,|zQTGZ x-_>Ĉ3ljyC0 C~# +h:Jy1ﶘWC2lEzp ^Zz+" zhDLp#MX+ƙCvY~y\9!lضQ̄K碁"<]g%Gӿ4 d9s`Pך+6 C0 CzŸ9J5fKx;XRF[ OFqx5{ GMoo||罫(b}091$ rPdc^`TNq7ŵ䪎s9y]2<;P>XYFOIY^Q6GQ^6wnuE+c3y-YnRYZ^;}ʗ+vî1G0 C0 C`)sbO͟[r>naoe<[-7*Vn m 2eY5 ~FW^ޫ6.grys Q;^ƩK1|xCvref@>֓k-}❂1hruZ<ӫ;u衦&WH y]k!`# TNW WVoKo[k\J.,r\ƺ\L>onװ]OƒLYP"8O^\^L?L.zXfE?ec>S~z|Dz/%V=XٴeAT螜KEʡ h*(,:c قDa9`|iQ\Xu-r60?/-y|)-juq^HǕ%r⥕qd6S^ŭ;*㼻:! +ϼ=y-M+{,W6vUVCp`y^#ܷ'7c 7x@!`! ÁizD,KvQίÃ'18&(S~kikkef=`q^ zn ҹ-e,%ZKLI׫.:?}Ae^lR.S】һ:s[WzNʠ2y2/#OZ~KZ,A_lcC0 Cx֡}?ӺH*wPP>!թ~s& Owj7OŜpm\俤;_0OOH/i5mh165O_5|P6RLxSI<"\@W姲DA~< /}1x15!`!PHm[4w\ 3~\:Vc. UzU^.},W//.LoT?Ww|*zvbj>vH0 C0 ?n>eDe'u2x'5ن!`!`Vc!`!`N"`Nk C0 C0 L_C0 C0 DDd!`!`f[!`!`;;6 C0 C7>3} C0 C0vw]m!`!Po}\o5f!`!`$f$&0 C0 C0j5 C0 CI>ItM!`!`@!`q՘k!`!}lC0 C0 zCz10 C0 C`'ص}׮]o`}l]~~/℞] l3Xփq?\mw'm'^<~DCqω?ƱV+_#ֿ?^D_N ܏.C{eh/UeM?`ݰ.Չ/L'se؃u+7X5omv׮|5ZX4bu 7Xkx+Ez_4Bw?t[Wv/V~]γ}pu骷qryzZ=]fp +`Ph+@Ǯ`$\#V O!X,^* 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ Normal5CJ_HmH sH tH :@: $ Heading 1$@&5>*4@4 % Heading 2$@&<@< & Heading 3$@&^@@@  Heading 4$@&^58@8  Heading 5$@&5@@@  Heading 6$@&^>*DA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List 8B@8 Body Text$a$CJ@P@@ Body Text 2$a$5CJ4 @4 Footer  9r .)@!. Page NumberHC@2H 'Body Text Indentx^RRBR Body Text Indent 2dx^4>@R4 Title$a$>*tH 0J@b0 Subtitle>*(W`q( Strong5<Q@< Body Text 3$a$CJH@H  Balloon TextCJOJQJ^JaJ6U`6 KX! Hyperlink >*B*phFV`F @FollowedHyperlink >*B*ph`d B'`B ,cComment ReferenceCJaJ8@8 (,c Comment TextCJ>j@> ,cComment Subject\4@4 VGHeader  !bob 9+Default 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH DZ@D 8H Plain Text!5CJOJQJ^Jj#j wu> Table Grid7:V"0"VY@2V |M Document Map#-D M CJOJQJ^J<oA< 5Heading 1 Char>*CJ<oQ< 5Heading 2 Char5CJ<oa< 5Heading 3 Char5CJJoqJ 5Body Text Indent Char5CJ>o> 5Comment Text Char5D@D 5 List Paragraph )^m$PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] 5GcNh]^_bcdeimop5GcNh ,*Tޖ TTgguuuuuuuuuuuuuuuuuuuuuuuuuuuuuuux$ ^ Q * *V<suXW[,"k v!!"4##O$7%%&&'z( ))\*)++,,f-E. //K0013*589<?AD_FNI(KxM Q=SVYZ\]_`+b!ckejoJpsou.xz~ɂم2Ɠٙ/K۬(2=6q Er7Bpr^}ml   %.5:BGMTUZ^_`bcdfhmqsvxy{~@ 0#)!/48N99w:::;;=<~<=A;BDGI$JLLNNNOOOnPPQQ&SUUEVVWZaflUopppq,rNrrCs{s|ss#tmtttttCuouuu5vmvvwwww+xAx~xxyyyy} ~ ~~~QR 0 ݇߈E PS:Ɠ|4k} ^~>xYn7a %2?JS[9_: ="h|~&   !"#$&'()*+,-/012346789;<=>?@ACDEFHIJKLNOPQRSVWXY[\]aegijklnoprtuwz|}?[`| $8BXgq !+HR]|'0Rlt3=[q +5@]gq2:_qzad#,KZc ) E P [     B U _  0 ; \ q {   9 p t   : J T v 7S[}(1Y/Xs|%0NYd-6Smv/9\#/Yu -=Gg&CKw"x7@Jl 6FRw Hen3CMs:CNs8ALhq}"<CMyL{  8 O Y { !!$!B!M!X!t!!!!!!!!""8"A"]"u"~"""""# #*#C#L#l#z######$ $'$C$J$n$$$$$$$$$ %%%;%^%f%%%%%%%&"&-&F&Y&c&&&&&&& ''!'@'K'U't'''''''((J(t({(((((().)F)O)s)))))))* *F*\*c*******+3+=+\++++++,,K,,,-///0O012Z24>557/8s8888<c<<wEEFIsJJQQRCSSSSTTTUnU~UU VV]VVVWDWqWX X&XXX*ZuZZ![l[[]j]] ^S^^ʃ5~Oukjӗެ)v>ϱ4eyF]"kq A)NG@wXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXV]_iprx!!h: r/X"$A?Picture 1#" `?B S  ?#T[8L;,"TqyB#ATp8z4$TX _Hlt79210862 _Hlt299629455 _Hlt79206689 _Hlt299629368 _Hlt79210957 _Hlt352143798 _Hlt299629374 _Hlt300600983 _Hlt299629377 _Hlt300600999 _Hlt299629381 _Hlt300601013 _Hlt79203170 _Hlt79203171 _Hlt299629386 _Hlt300601027 _Hlt299629389 _Hlt300601037 _Hlt299629395 _Hlt300601051 _Hlt300601161 _Hlt300601082 _Hlt300601096 _Hlt299629407 _Hlt299629470 _Hlt300601173 _Hlt352143002 _Hlt300601185 _Hlt299629478 _Hlt352143008 _Hlt299629482 _Hlt300601195 _Hlt299629485 _Hlt300601205 _Hlt299629488 _Hlt300601227 _Hlt300601239 _Hlt299629490 _Hlt352143028 _Hlt352143022 _Hlt299629493 _Hlt352143026 _Hlt352143018 _Hlt352143024 _Hlt300601249 _Hlt299629497 _Hlt300601261 _Hlt300601271 _Hlt352143038 _Hlt299629501 _Hlt221598793 _Hlt299629505 _Hlt352143044 _Hlt352143101 _Hlt352143111 _Hlt299629508 _Hlt299629512 _Hlt300601352 _Hlt300601369 _Hlt299629517 _Hlt303679966 _Hlt299629521 _Hlt202067997 _Hlt299629525 _Hlt300601396 _Hlt352143135 _Hlt299629529 _Hlt299629535 _Hlt300601425 _Hlt299629540 _Hlt300601442 _Hlt299629544 _Hlt352143145 _Hlt300601460 _Hlt299629549 _Hlt300601491 _Hlt352143329 _Hlt221598651 _Hlt300601535 _Hlt299629555 _Hlt300667882 _Hlt221598686 _Hlt300601510 _Hlt300672289 _Hlt300668201 _Hlt300601570 _Hlt221598817 _Hlt299629559 _Hlt79203925 _Hlt79203964 _Hlt299629564 _Hlt299629569 _Hlt171918151 _Hlt352143336 _Hlt300601611 _Hlt299629574 _Hlt300601629 _Hlt202067927 _Hlt202067928 _Hlt299629581 _Hlt300601670 _Hlt151186821 _Hlt151186682 _Hlt151186765 _Hlt202068290 _Hlt202068291 _Hlt299629586 _Hlt151186878 _Hlt299629607 _Hlt299629591 _Hlt299629616 _Hlt300601701 _Hlt79204034 _Hlt300601901 _Hlt79204078 _Hlt322419760 _Hlt300601720 _Hlt300601758 _Hlt300672335 _Hlt299629624 _Hlt299629652 _Hlt352143389 _Hlt79204054 _Hlt299629700 _Hlt300601991 _Hlt300601879 _Hlt300602026 _Hlt299629678 _Hlt352143399 _Hlt300602080 _Hlt352143406 _Hlt300602143 _Hlt299629681 _Hlt300601887 _Hlt300602169 _Hlt300602046 _Hlt322419325 _Hlt322419326 _Hlt300602280 _Hlt300602157 _Hlt299629687 _Hlt300602307 _Hlt300602358 _Hlt299629735 _Hlt352143792 _Hlt300602297 _Hlt300602387 _Hlt300602378 _Hlt352143438 _Hlt300602448 _Hlt300602443 _Hlt300602515 _Hlt300602538 _Hlt300602626 _Hlt300602602 _Hlt352143417 _Hlt300602526 _Hlt79204811 _Hlt202075303 _Hlt352143525 _Hlt79204765 _Hlt300602615 _Hlt352143483 _Hlt300602694 _Hlt352143464 _Hlt300602801 _Hlt300602911 _Hlt79204834 _Hlt352143541 _Hlt79204849 _Hlt352143548 _Hlt297108367 _Hlt297108368 _Hlt300603033 _Hlt352143555 _Hlt352143594 _Hlt352143565 _Hlt300603281 _Hlt300603202 _Hlt352143572 _Hlt352143586 _Hlt352143610 _Hlt352143618 _Hlt352143624 _Hlt300672283 _Hlt300672284 _Hlt300603828 _Hlt352143668 _Hlt352143633 _Hlt300603701 _Hlt352143678 _Hlt300603775 _Hlt300604075 _Hlt300603921 _Hlt352143694 _Hlt300603939 _Hlt352143702 _Hlt352143708 _Hlt352143713 _Hlt300604127 _Hlt352143725 _Hlt352143733 _Hlt352143743 _Hlt300672443 _Hlt79211068 _Hlt352143806 _Hlt352143815 _Hlt352143822 _Hlt252439369 _Hlt352143877 _Hlt352143831 _Hlt357595639 _Hlt352143840 _Hlt357595323 _Hlt357595324 _Hlt352143848 _Hlt352143903 _Hlt357595540 _Hlt352143861 _Hlt352143888 _Hlt352143933 _Hlt300604144 _Hlt221616347 _Hlt221616660 _Hlt221616661 _Hlt300747797 _Hlt300747798 _Hlt300747813 _Hlt300747814 _Hlt79211108 _Hlt300747831 _Hlt300748200 _Hlt300751458 _Hlt300748274 _Hlt300748218 _Hlt300751299 _Hlt300751300 _Hlt300751329 _Hlt300748292 _Hlt300748293 _Hlt300751473 _Hlt300748318 _Hlt300748250 _Hlt79211183 _Hlt79206857 _Hlt79211226 _Hlt252452830 _Hlt252452831 _Hlt300748462 _Hlt300748518 _Hlt300748568 _Hlt79207714 _Hlt300748618 _Hlt79208885 _Hlt221598317 _Hlt221602182 _Hlt221602183 _Hlt303679960 _Hlt303679961 _Hlt221598469 _Hlt221598762 _Hlt352144023 _Hlt352143994 _Hlt352143982 _Hlt352143969 _Hlt352143959 _Hlt352143947 _Hlt303679909 _Hlt303679910 _Hlt303679928 _Hlt303679929 _Hlt303679906 _Hlt303679907 _Hlt227994325 _Hlt227994326 _Hlt303679915 _Hlt303679916 _Hlt300748708 _Hlt303680022 _Hlt303680023 _Hlt303680316 _Hlt303680317 _Hlt303679912 _Hlt303679913 _Hlt303680313 _Hlt303680314 _Hlt303680028 _Hlt303680029gastrointestinalantacidsantispasmodicsmotility _Hlt389552477 _Hlt389552478 _Hlt389551124 _Hlt389551125 _Hlt389552484 _Hlt389552485 _Hlt389551111 _Hlt389551112 _Hlt389552369 _Hlt389552370ulcerh2proton _Hlt352148898 _Hlt352148899 _Hlt352148936 _Hlt352148937 _Hlt352148995 _Hlt352148996 _Hlt352149011 _Hlt352149012 _Hlt350811787 _Hlt350811788antidiarrhoeals chronicbowel laxatives bulkforming stimulantfaecalosmoticbowelcleansing _Hlt350854319 _Hlt350856100 _Hlt350856101laxativepolicy haemorrhoid intestinal_CARDIOVASCULAR_SYSTEMpositiveinotropes dieuretics thiazidesloopdieureticspotassiumsparingcombinationdieureticsosmoticdieureticsantiarrhythmics _Hlt351991972 betablockers _Hlt351991294 _Hlt351991295 _Hlt351991427drugsaffectingrenin vasodilatorcentrallyacting alphablockers angiotensin antiotensinIInitratescalciumchannelblockers Ivabradine _Hlt352142130 _Hlt352142131 _Hlt352142168 _Hlt352142169 _Hlt390678240 _Hlt390678241 _Hlt351992137 _Hlt351992138potassiumchannelsympathomimeticsanticoagulants _Hlt351992163 _Hlt351992164 _Hlt351991391 _Hlt352142300 _Hlt352142301 _Hlt352142353 _Hlt352142354 _Hlt352142404 _Hlt352142405 _Hlt351993080 _Hlt351993081 _Hlt352142478 _Hlt352142479 _Hlt351993045antiplateletdrugs _Hlt351993160 _Hlt351993161 _Hlt351993276 _Hlt351993277clopidogrelprescribingFibrinolyticdrugsAntifibrinolyticdrugs Lipidlowering AnionexchangeFibratesStatinsfishoils otheragents_2._CARDIOVASCULAR_SYSTEMrespiratorysystembronchodilatorsselectivebeta2shortactingbeta2Antimuscarinicsa TheophyllinecombinationbronchodilatorsinhalerdevicesinhaledcorticosteroidsmanagementacuteasthmaLeukotriencereceptormanagementacuteasthma2managementchronicasthma _Hlt350854552 _Hlt350854553 _Hlt350856287 _Hlt350856288 _Hlt350932364 _Hlt350932365managementofcopd _Hlt350932328 _Hlt350932329 _Hlt350854707 _Hlt350854708 _Hlt350854801 _Hlt350854802solutionsnebulisationantihistaminesantihistamines2respiratorystimulantsoxygen mucolytics _Hlt350854890 _Hlt350854891aromaticinhalationscoughpreparationscentralnervoussystem hypnoticsdrugspsychoses _Hlt352142766 _Hlt352142767 _Hlt350932505 _Hlt350932506 _Hlt350856433 _Hlt350856434 _Hlt350854960 _Hlt350854961antidepressants nauseavertigo _Hlt389126794 _Hlt389126795 _Hlt389126232 _Hlt389126233 _Hlt389126269 _Hlt389126270 _Hlt389552512 _Hlt389126582 _Hlt389126583algorithmnausea analgesics _Hlt303680120 _Hlt303680121 _Hlt303680163 _Hlt221595918 _Hlt221595919 _Hlt221598869 _Hlt221595904 _Hlt221595905 _Hlt221595984 _Hlt221595985 _Hlt221616693 _Hlt221616694 Painladdernonopoidopoidprophylaxismigraineantiepileptics parkinsonism reliefhiccupdrugssubstancedependence _Hlt350855057 _Hlt350855058 _Hlt350856451 _Hlt350856452managenentalcohol infections antibiotivs _Hlt221616355 _Hlt221596111 _Hlt221596112 _Hlt352142887 _Hlt352156753 _Hlt352156754 _Hlt352142896 _Hlt352156684 _Hlt352156685 _Hlt350856456 _Hlt350856457 _Hlt350855151 _Hlt350855152 endocrine drugsdiabetes _Hlt350932723 _Hlt350855299 _Hlt350855300 _Hlt350856505 _Hlt350856506 _Hlt350856512 _Hlt350856513 _Hlt350855860 _Hlt350855861 _Hlt350856519 _Hlt350856520 _Hlt350932819 _Hlt350856659 _Hlt350856660 _Hlt350856577 _Hlt350856578 _Hlt350855597 _Hlt350855598 _Hlt350856651 _Hlt350856652 _Hlt350856664 _Hlt350856665 _Hlt350855663 _Hlt350855664 _Hlt350855671 _Hlt350855672 hypoglycaemiathyroidcorticosteroids2pituitaryhormones drugsbone urinarytractvaginalantiinfective genitourinary!malignantdiseaseimmunosuppression cytotoxicimmunosuppressants sexhormonesnutritionbloodanaemiasfluidselectrolyesintravenousnutritionenteralnutritionmineralsvitaminsmusculoskeletaldrugsrheumaticnsaidscorticosteroidinjections drugsgoutneuromusculardisordersdrugsenhanceneuromuscularskeletelmusclerelaxantsnocturnallegcrampstopicalantirheumaticsdrugsactingeye antiinfectivecorticosteroids3 mydriaticsglaucomamiscteardeficiencyearnosedrugsear antiinflam removalwax drugsnose nasalallergu nasalstaphydrigsoropharynx ulcerationfungalinfections oralhygienedrymouthskin emollient _Hlt352152516 _Hlt352152517 _Hlt352152462 _Hlt352152463topicalantipruriticstopicalcorticosteroids sunscreensantiinfectiveskinantibacterials antifungals2 antivirals2 scableslice disinfectantswoundmanagement immunological$_14._IMMUNOLOGICAL_PRODUCTS_AND VACC anaesthesia_15._ANAESTHESIAintravenousanaesthesiainhalationalanaesthesiaantimuscarinics2sedative anxiolyticsnonopoidanalgesicsopoidanalgesicsmusclerelaxantsanticholinesterases antanonistsmalignanthyperthermialocalanaestheticsRR5577]bMMN"[j#1ikn14bdd'hj&4=T   H I I I I K L         H K M O Q R ' ( ( . . f g k      E ] A D C  myagmp"SS#Z"hm*|;twym ##&(f(((((((U**++v++ ,C,C,D,D,J,J,K,K,K,K,,,,,,,,,,,,- -R--// 0 0+0+0.0.0.0.0000121255@8@88888939i9u99G:{:3;r<u<u<<.AjAAAABC+CZDDDEF|J|JJJJLL!MjMOPPQQQQQQQQRR*SSSS'U'UUUVV|Z|ZZZZZ[[t]t]^ cfgg=gbggh3h3hOhghhEm4puvx{TׂÍÍōōɝ8<dSPPڭ4Pkklmmnppqqss7VQQ[[a 6TTUU""RnXc|"r }Y~ Fe''QqXSSZZ1c1Ka}9N)U@@@@@@@@@ @ @ @ @ @@@@@@@@@@@@@@@@@@@ @!@"@#@$@%@&@'@(@)@*@+@,@-@.@/@0@1@2@3@4@5@6@7@8@9@:@;@<@=@>@?@@@A@B@C@D@E@F@G@H@I@J@K@L@M@N@O@P@Q@R@S@T@U@V@W@X@Y@Z@[@\@]@^@_@`@a@b@c@d@e@f@g@h@i@j@k@l@m@n@o@p@q@r@s@t@u@v@w@x@y@z@{@|@}@~@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ @ @ @ @ @@@@@@@@@@@@@@@@@@@ !"#$@%@&@'@(@)@*@+@,@-@./40@1@2@3@5@6@7@8@9@:@;<=>?@ABC@D@E@FGHIJKLMNOPQR@ST@U@V@WXYZ[\]^_`@a@b@c@d@e@f@g@himj@k@l@n@o@p@q@r@s@t@u@v@w@x@yz@{@|@}@~@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@      !"#$%&'()*+,-./012345678=9@:@;@<@>?@ABCDEFGIHKJLMNOPQRSTUVWSS6688^cNNO#\k$2jlo25cee(ik'5> U    I J J J J L M           I L N P R S ( ) ) / / g h l      F ^ B E D !nzbhnq#TT$[#in+}<uxzn ##&(g(((((((V**,+w++,D,D,E,E,K,K,,,,,,,,,,,,,,,,-)-a--//!0!0,0,0/0/0/0/000222255N6A8A888889K9t999`::V;s<v<v<<GAAAAB BCGCpDDDE"F}J}JJJKLLPMMOPPQQQQQQQQ6RRSSST(U(UUUVV}Z}ZZZZZ[[u]u]._2cfg.gFgigg h3h_hhh[mApuvx́2ÍÍččƍƍ'JK o^QQNjİllmnnoqqrrtt{/+F:zRR\\  7UUVV##b={:; 3pQ{ &Y;p $bTT[[zG{=VrPiGiPa  * T  T[|01@@,,-//Q03345667t8u89::<<<<<=j=l=????=@B@@@@@@@@AAA BBB#B$B7B9BCBaBtBBBC&CGCPCCCsD}DDDDDDDDEE EEEE"E6EAEiEF~FFFFFFFFFFFF7GAGCGMGGGGGGGGGGGGGGGHHHHH(HLHSHHHHHI I*I4IIIIJJJJJJKK%K2K;KLLLLLMMMMMPMXMMMTOXOOOOPP PJPRPSP]P_PePPPPPPPPPQQ'R.R6R@RARKRRRRRRRRRSTTTTTToUpU{U}UVVVVFW XXY"YYY*ZZZ [[[ \\s\|\\\]]^^^^^^_ _bbbb c,c3c?cEcHcddeeaejeeeeeffffffff.g;gFgQgUg`ggggggg hh#h&hkl]l_lalllmlsltl~lnnnnnnn oxoooooooooo%jԗ՗ȫެw3^mu(/8@A &,-4!1<MYaj9.ZeWa q|9FGQY^ EH                          ! " # $ % & \ [ Z * + , - . / 0 = 2 3 4 5 6 7 8 9 : ; < ) > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y ] ^ _ ` a b c d e f g h i j k l m n o p q ",-,4,A,R0v0;:?:;;;<_=b=9BQBDDuEwE7PCPPPRRRRYYYY[_]_lbrbBnknmnnn ooo#q6q8q?qssz.z2zEzFz[z^z{z}}}}}}}}}}}~]bqz| 8b'6RZzڻ-1|ns333333333333333333333333333333333333333333333333T  T[|0"K,,---////Q000457t889<<QCCCCDD'D+DYDYDwEFIJPPPP~Q~QQRRRSTToU~UVVVVEW&XX![[]]QR5jԗȫ,7\fެwy> ^lqANGVXQb Kac}((jT  T[|0"K,,---////Q000457t889<<QCCCCDD'D+DYDYDwEFIJPPPP~Q~QQRRRSTToU~UVVVVEW&XX![[]]QR5jԗȫ,7\fެwy> ^lqANGVX((.oXϺo+mr}{ĘCL-p'@>]Y  :4 bu F? `<J r q6-Y|DS (g  \] x3$taL$L{]](@,g+KS+> x 37!nY(6qaDQBA\DaCeJnxFD;?Fێ1@J XOOz)U2Rjz`/TήP"U 0 y`6tDbvQc5Aff1Bc0,l%l 6 m66(vXn qjV@rRyG@HE|   ^`o(^`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........ ^`o(^`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........HH^H`o(-h^`OJ QJ o(hHh^`OJQJ^Jo(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJ QJ o(hH \^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........ hh^h`OJQJo(h  ^ `OJ QJ o(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh| | ^| `OJQJo(hHhLL^L`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hH ^`o(^`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........ hh^h`OJQJo(h^`OJ QJ o(hHh^`OJQJ^Jo(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJ QJ o(hH^`OJQJo(hHh^`OJQJo(hHp^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hHh^`5OJQJo(hHh SS^S`hH.h #L#^#`LhH.h   ^ `hH.h   ^ `hH.h L^`LhH.h cc^c`hH.h 33^3`hH.h L^`LhH. hh^h`OJQJo(\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........h^`OJ QJ o(hHh  ^ `OJQJ^Jo(hHoh  ^ `OJ QJ o(hHhxx^x`OJQJo(hHhHH^H`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHhh^h`5o() ^`o(^`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........hh^h`o(hh^h`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJ QJ o(hHXX^X`o(XX^X`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........h ^`5hH.h SS^S`hH.h #L#^#`LhH.h   ^ `hH.h   ^ `hH.h L^`LhH.h cc^c`hH.h 33^3`hH.h L^`LhH.hh^h`o(. ^`o(^`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........^`o(-  ^ `o() ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.0^`0o(.\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... Donnelly Gillian (RBQ) LHCH2Microsoft Office Word@@,`k)@Ԝ@Ԝ-B%d' http://www.npc.nhs.uk/merec/pain/musculo/merec_extra_no30.phpGIR{OYhttps://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=101896i!http://www.mhra.gov.uk/PrintPreview/DSUArticlePage/CON300404?DynamicListQuery=dDocType%20%3cmatches%3e%20%60Publication%60%20%20%3cAND%3e%20%20xSecondLevel%20%3cmatches%3e%20%60Safety%20Guidance%60%20%20%3cAND%3e%20%20xThirdLevel%20%3cmatches%3e%20%60Medicines%60%20%20%3cAND%3e%20%20xFourthLevel%20%3cmatches%3e%20%60Drug%20Safety%20Update%60%20%3cand%3e%20%20xNHSNetOnly%20%3cmatches%3e%20%60No%60c^http://nww.staffintranet.lhch.nhs.uk/library/departments՜.+,D՜.+,\ hp  The Cardiothoracic Centre' GASTRO-INTESTINAL SYSTEM Title^ 8@ _PID_HLINKSA^q|yhttp://nww.staffintranet.lhch.nhs.uk/library/departments/support_services/pharmacy/wound_dressing_formulary_march_09.docfay7http://www.nrls.npsa.nhs.uk/resources/?entryid45=59876okv;http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdff"s<http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdfj!p<http://www.nice.org.uk/nicemedia/live/13670/58205/58205.pdfj,m<http://www.nice.org.uk/nicemedia/live/11482/32518/32518.pdf-jmhttp://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Insulin policy v 4 3 Nov 2012.pdfq$g;http://www.nice.org.uk/nicemedia/pdf/TA168fullguidance.pdfl!d<http://www.nice.org.uk/nicemedia/live/12060/42040/42040.pdfoashttp://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Antimicrobial Policy 3.1 April 2012.pdfm$^<http://www.nice.org.uk/nicemedia/live/11809/35940/35940.pdf V[:http://ctcnt20/policy/81/Acute Pain Current June 2011.pdfi!Xhttp://www.mhra.gov.uk/PrintPreview/DSUArticlePage/CON300404?DynamicListQuery=dDocType%20%3cmatches%3e%20%60Publication%60%20%20%3cAND%3e%20%20xSecondLevel%20%3cmatches%3e%20%60Safety%20Guidance%60%20%20%3cAND%3e%20%20xThirdLevel%20%3cmatches%3e%20%60Medicines%60%20%20%3cAND%3e%20%20xFourthLevel%20%3cmatches%3e%20%60Drug%20Safety%20Update%60%20%3cand%3e%20%20xNHSNetOnly%20%3cmatches%3e%20%60No%60Y+Uzhttp://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Lithium Therapy Protocol Current June 2011.pdfl R<http://www.nice.org.uk/nicemedia/live/13969/61603/61603.pdfc"O<http://www.nice.org.uk/nicemedia/live/13649/57889/57889.pdfm$L<http://www.nice.org.uk/nicemedia/live/11809/35940/35940.pdf!?Ihttp://www.nice.org.uk/` F<http://www.nice.org.uk/nicemedia/live/11945/40099/40099.pdf\EC!http://www.brit-thoracic.org.uk/&@<http://www.cmcsn.nhs.uk//fileuploads/NSTEACS_Guidelines.pdfa.=<http://www.nice.org.uk/nicemedia/live/13588/56819/56819.pdfk%:<http://www.nice.org.uk/nicemedia/live/12324/45849/45849.pdfj'7<http://www.nice.org.uk/nicemedia/live/13513/55411/55411.pdf:4vhttp://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/EP Anticoagulation Guidelines Mar 2013.pdflG1{http://nww.staffintranet.lhch.nhs.uk/Library/Corporate/policies_procedures/Anticoagulation Policy Version 5 0 Mar 2013.pdf/support_services/pharmacy/woundcareformulary/wound dressing formulary july 2011.xlslocalanaestheticsmalignanthyperthermiaf} antanonists`anticholinesteraseszbmusclerelaxantsjnopoidanalgesicsnvnonopoidanalgesicsf| anxiolytics sedative\antimuscarinics2vinhalationalanaesthesiavxintravenousanaesthesiaF_15._ANAESTHESIAm|%_14._IMMUNOLOGICAL_PRODUCTS_AND VACCffwoundmanagementdisinfectantsdk scableslice}| antivirals2K antifungals2trantibacterialsantiinfectiveskinscalpub sunscreensnltopicalcorticosteroidstopicalantipruritics emollientskin drymouthd` oralhygienefungalinfectionso ulcerationdadrigsoropharynxuz nasalstaphy  nasalallergu  drugsnosedd removalwax{h antiinflam drugsearx|earnosereteardeficiency misc glaucomawp} mydriatics Vzcorticosteroids3wantiinfectivevntdrugsactingeyeqtopicalantirheumaticsmonnocturnallegcrampsl}kskeletelmusclerelaxantshdrugsenhanceneuromuscularlneneuromusculardisorders b drugsgout_corticosteroidinjectionski\nsaidswxYdrugsrheumaticwhVmusculoskeletalS vitaminsP mineralsMenteralnutritionJintravenousnutritionGfluidselectrolyes D anaemiaswuAnutritionbloodgu> sexhormones}y;immunosuppressants8 cytotoxic 5"malignantdiseaseimmunosuppression 2genitourinary/vaginalantiinfective, urinarytract ) drugsbone &pituitaryhormones W#corticosteroids2bs thyroid hypoglycaemiagoralantibiotic insulinsdrugsdiabetes  endocrineVJAhttp://ctcnt20/policy/81/Antimicrobial Current February 2010.pdfkc  infectionsmanagenentalcoholdrugssubstancedependence reliefhiccupjnantimuscarinics dopaminergics parkinsonismkqantiepilepticsbvprophylaxismigraineopoid  nonopoidtx Painladderw} analgesics|algorithmnausea|algorithmnauseanauseavertigoyvantidepressantsxtdrugspsychoses hypnoticscentralnervoussystemcoughpreparationspaaromaticinhalationsuy mucolyticssqoxygenrespiratorystimulantscjantihistamines2solutionsnebulisationmanagementofcopdl)managementacuteasthma2 Leukotriencereceptorlainhaledcorticosteroidsvhinhalerdevices{mcombinationbronchodilators Theophylline\antimuscarinics2t&selectivebeta2fzbronchodilatorsrespiratorysystem|a otheragents fishoilsGuidelinesforstatins{nStatins FibratesAnionexchangelipidloweringAntifibrinolyticdrugsFibrinolyticdrugskk~clopidogrelprescribing{antiplateletdrugsw~xanticoagulantsusympathomimeticsrpotassiumchannelpyo Ivabradine|nlcalciumchannelblockersi nitratesfantiotensinIItc angiotensin`alphablockers`g]centrallyactingyiZ vasodilatorgsWdrugsaffectingreninT betablockers~gQantiarrhythmicsNosmoticdieureticsKcombinationdieureticsHpotassiumsparingg|EloopdieureticsB thiazidesdc? dieuretics<positiveinotropesLV9_CARDIOVASCULAR_SYSTEMf}6 intestinal3 haemorrhoidxh0managementimpactedis-laxativepolicyil*bowelcleansingvu'osmoticbn$faecal! stimulantsr bulkforming  laxatives chronicbowell}antidiarrhoealsphprotonh2h2  ulcer  motilitymqantispasmodics antacidsgastrointestinalPropertiesUCompObj%rstoreItem ds:itemID="{6BB423D5-2D96-427F-9099-0B8FC89D51CE}" xmlns:ds="http://schemas.openxmlformats.org/officeDocument/2006/customXml">  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q`^``o(....... ^`o(........h^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJ QJ o(hH\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........0^`0o(.\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........$ $ ^$ `o(-\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........hh^h`o( hh^h`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........\^`\o(\^`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........\^`\o(X\X^X`\o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........hh^h`. hh^h`OJQJo(. qE|g+vXnyffP"U6 m1@J\]r%luc0,lcDaCY(6DQBAx3$ y` <XOOCp'@S+xFDY U2R@rr} 3oXϺL$/T?F]]( :qF?g 0-Y|Db..                                             `                          \                  s>h7@%z;[(+B JnW^9`gb vgNf]h#Jg* 7 hM ^m.5Wi # 8I 8 c n  sr ' | Q DqW ,c.- CPf R`lvV{ kLqD*"02q(c6]X>I$h45z&9+<|CM 6p KX!#!]#Fh#;$R%&+&-(5(c(r)!)b)f)+H8+>+,6,bk,*-O.Ak.</./ 171]R1d_1&P4e4jH5I 6 6B6D607Jt7;8zE8N8^O8.9^9#:W:g:2/;w;;4<,=2>wu>v>|>d?)@A B/BjBDCD-vDvD\F`FFpF GBGp>GAtG8HXH IqIJXEJB$K L|M N14N@NNNONvNOIOKOPPsQRR]R^RXzR4Sr/S IS5TtCTVT4nT#UV]W.vWX!X8uYcZ_9Z>ZleZ~Z7*[2\IF\O\]]f]^|J_v` `HC`i`haa>cJc7f@Kf"jfi=gWgugVyg&iPqi jj8jGejsjj(l1l rlsl2wmSn= oIolpbpvp1qVqZoqE=roHrMrxr t_ tNt)htE6vRvdvWiv>wxn@xYynkyzipzH}J~J~VL 9Cx-V-R1vj)+Pf0_27U`w"(HPZ7KNM$Qiji%K<vB}w5R\Qn 6b"!adh9h^ efii,2Z.zLWyny(;WdxMVc2ir(~ZT!yK$UwW2pe[$ =[h.epu6d{v qWE -tQrW~@+d: INoP $Yv80@tw"$z\BgacIydU/0q?A@k}p4`~}@m$8Y@ XYq/s$bAiwLQ(W2`+=I9B`c .A>+?k88hoJ$!OP `.ceDwJ?Xk c?^#8\^4tEqVYF40Vb,VG_ksT jjBr{K2*x+B0fEV1UvCZd6zy3 )_>i?W\=_Ra `mrw@@Unknown G*Ax Times New Roman5Symbol3. *Cx Arial=Arial BoldC Frutiger-BoldAZapfDingbatsE Frutiger-Light5. .[`)Tahoma?= *Cx Courier New;WingdingsA$BCambria Math"1h^)G^)G'B%d-B%d-!24'' 2qHX?b2! xx GASTRO-INTESTINAL SYSTEMjcrawDonnelly Gillian (RBQ) LHCH.                           ! " # $ % & ' ( ) * + , -